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2Abstract
It has been known for some years now that histone deacetylase (HDAC) inhibition exerts a 
variety o f effects on cellular proliferation and apoptosis. The potential for use of inhibitors 
of HDAC in the field of cancer therapy has now been realised; the first drug of this class 
recently being approved for use.1 Structurally, a great variety of molecules have been shown 
to be capable of producing an inhibitory effect, through mechanisms elucidated by 
crystallographic studies of the inhibitor-bound enzyme. Despite the diversity of these 
compounds, several structural features common to most o f the known inhibitors can be 
identified, including a moiety capable o f binding a zinc ion present at the enzymes active 
site. A great number of the known inhibitors bear a hydroxamic acid group for this reason, 
despite the reportedly unfavourable characteristics of this functionality in vivo}  This thesis 
focuses on the synthesis of novel inhibitors of HDAC, attempts to develop non- 
hydroxamate inhibitors and biological evaluation of the HDAC inhibitory capability of 
compounds synthesised within this group.
A series of compounds bearing aryloxyalkanoic acid hydroxyamide motifs were synthesised 
following the identification of this class of compounds as potent HDAC inhibitors. 
Systematic variation of these molecules allowed optimisation of their activity in isolated 
enzyme inhibition assays and in human cancer cell line cytotoxicity assays.
Attempts to identify novel zinc-binding groups capable o f replacing the hydroxamic acid 
motif were possible through use of the structure o f a known potent inhibitor and substitution 
o f the motif with a variety of structures proposed to provide the same role. A further group 
o f novel hydroxamate inhibitors were synthesised based on the simple structure of a known 
inhibitor. Diversification of the structure and substitution of bio-isosteres led to 
enhancement of inhibitory activity. Finally, a selection o f novel compounds synthesised 
within this group were evaluated for their effect on cell cycle, cell protein expression and 
isolated HDAC inhibition.
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1 Introduction
1.1 Objectives
This thesis focuses on inhibitors of histone deacetylase enzymes, and their potential for use 
as anti-cancer drugs. Observed effects of compounds of this class on cellular proliferation 
and apoptosis have led to their identification as a promising new target for cancer therapy. 
The field is already bearing fruit, with the first histone deacetylase inhibitor recently having 
successfully completed clinical trials and being approved for use in the United States.1 This 
chapter commences with an overview of cancer and the role of the enzymes in question, and 
proceeds to a review of currently known inhibitors.
1.2 Cancer: The Disease
Cancer is the broad term used to describe the diseases that result from unregulated cellular 
proliferation. When cells cease to be controlled by the regulatory circuits that bring order to 
‘normal’ cell growth they can acquire the ability to form neoplastic tissue masses, referred 
to as tumours. If further loss of regulation occurs, tumour cells may also attain the ability to 
invade remote sites in the body, to metastasise, forming secondary tumours where the cells 
are deposited by the vascular and or endocrine systems. Not all neoplastic tissue is 
cancerous; tumours may be benign or malignant. Whilst both arise from a loss of control of 
cellular proliferation, benign tumours, such as warts, retain control of differentiation and 
may not transfer to different parts of the body.
Malignant neoplastic tissue will commonly display five key characteristics: increased rate of 
proliferation, development of pleomorphisms (mixtures of differently differentiated cell 
types), disturbance of cellular arrangement, invasion of adjacent tissues and formation of 
secondary tumours or metastases. In some instances ‘normal’ cells display all of these 
characteristics, such as the implantation of a fertilised egg in the uterine wall, however these
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events are tightly controlled. Although the development of cancers may appear rapid due to 
the exponential growth of tumours, formation o f a tumour from a single cell may take 
decades.
The original tissue type in which a cancer develops gives the disease its name, for example, 
carcinoma for epithelial tissue, sarcoma for connective tissue or lymphoma for lymphatic 
cells. It has been suggested that in order to generate the common characteristics of all 
cancers there are six essential alterations in cell physiology that must occur.2 These 
combined alterations, irrespective of how they arise, are necessary and sufficient to dictate 
malignant growth. These changes that must occur for a cell to become transformed are: self 
sufficiency from growth signals, resistance to growth-inhibition signals, evasion of 
programmed cell death (apoptosis), unlimited replication potential, sustained angiogenesis 
and tissue invasion and metastasis.
1.3 Requirements for Cancer
We shall now look in more detail at the mechanisms by which the six key alterations 
mentioned above may be effected.
1.3.1 Self Sufficiency in Growth Signals
It is possible for a cell to become self sufficient in growth signals in three ways: (i) excess 
production of growth factors (GFs), (ii) aberrant activity of the cell surface receptors for 
these signals or (iii) of the complex signal transduction pathways for these stimuli.2
The effect of most GFs is regulated under normal conditions through their expression by 
one tissue type to act on another. If a cell is able to produce a GF that stimulates itself, it 
may become independent of the supply from other tissues. An alternative to self-expression 
of GFs could be over expression of the cell surface receptor for that GF, allowing the cell to 
become hyper sensitive to normal GF concentrations. Finally, over expression or activity of 
any of the proteins in the pathway that transmits the extracellular signal may lead to the 
same effect.
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1.3.2 Resistance to Growth-Inhibition Signals
Normal inhibition of growth can be mediated through proteins that block entry into new 
phases of the cell cycle. Two such proteins, the products of the retinoblastoma (Rb) and 
TP53 tumour-suppressor genes, are the proteins pRb and p53. Until the correct level growth 
signals have been reached, pRb will prevent progression of the cell cycle. Activation of p53 
by cellular stress (such as DNA damage) also acts to prevent potential replication of 
damaged cells. Mutations or deletions of the TP53 gene occur in 50% of all cancers.3 It is 
not surprising, with these crucial roles, that loss of activity of either of these proteins can 
have dramatic effects on the control of proliferation.
1.3.3 Evasion of Apoptosis
It is a crucial ability of most, if not all animal cells, to be able to undergo a process of 
controlled suicide - apoptosis. Apoptosis can be triggered as a result of cellular stress such 
as DNA damage (in this case mediated through the activity of p53). Through this process a 
single cell could be sacrificed on detection of DNA damage as a means of preventing 
propagation of any potential mutations. In contrast to necrotic cell death, apoptosis is a 
highly ordered process. Once initiated, the cell begins to shrink as the cytoskeleton and 
organelles are degraded. The nucleus fragments as chromatin is broken down and eventually 
the cell breaks into separate vesicles which are phagocytosed by neighbouring cells.
Upregulation of anti-apoptotic genes and loss of activity of pro-apoptotic factors (including 
p53) have been identified in several cancers as a way of avoiding this barrier to tumour 
formation.
1.3.4 Immortalisation
In the event of a cell escaping the normal proliferation control and avoiding apoptosis, its 
potential for tumour formation is still limited. Under normal circumstances, cells are not 
able to continue dividing indefinitely: observation of human cells in culture has shown that 
typically a cell is capable of only 60 to 70 divisions. The method by which a cell ages, or 
senesces, has been identified as shortening of chromosome ends with each round of cell 
division. The end of a normal chromosome consists of a six base sequence, TTAGG,
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repeated several thousand times forming a structure known as a telomere, protecting against 
unwanted fusion of chromosome ends. Under normal circumstances the shortening 
telomeres of an ageing cell are interpreted by p53 as DNA damage, leading to apoptosis. 
Almost all tumours avoid this process and achieve an unlimited replicative potential by 
actively maintaining telomeres through the aberrant activity of telomerase -  an enzyme 
capable o f extending the hexanucleotide repeats.
1.3.5 Sustained Angiogenesis
In order for a small collection of cancer cells to develop into a tumour greater than one or 
two millimetres in diameter the cells must increase the supply of oxygen and nutrients. This 
is achieved through vascularisation of the tumour by invasion of new endothelial cells 
towards the tumour to produce new capillaries. Angiogenesis -  the process of new blood 
vessel growth -  is tightly controlled, and this restriction must be bypassed if the tumour is to 
continue to expand. The process can be viewed as having four stages:
(i) Initiation -  “angiogenic switch”2 triggered by action of pro-angiogenic factors. 
This can be either by tumour cells directly, or by surrounding cells as stimulated 
by the anaerobic environment created by the tumour.
(ii) Progression -  degradation and remodelling of the extracellular matrix to promote 
survival.
(iii) Differentiation -  attraction of endothelial cells and re-establishment of cell-cell 
contacts to form the luminal structure.
(iv) Maturation into functional blood vessels.
In addition to providing the necessary oxygen and nutrient supply, vascularisation of a 
tumour allows release of cancer cells into the circulatory system, providing a possible route 
to metastasis.
1.3.6 Tissue Invasion and Metastasis
The formation of secondary tumours is a part of the development of most cancers, and it is 
these metastases that are responsible for the vast majority o f human cancer deaths. 
Migration of tumour cells into body cavity fluid, the vascular or the lymphatic system 
provides a mechanism of colonising distant sites in the body. The frequency of metastasis is
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very low -  invading tumour cells must contend with the normal immune response and the 
process itself is extremely inefficient. For metastatic tumour to develop, ten key steps must 
be achieved: progressive growth of the primary tumour, penetration of the basement 
membrane, vascularisation, entry of tumour cells into vasculature, migration and survival in 
lymph or blood, arrest in distant capillary bed, exit o f vasculature and disruption by 
mechanical expansion, migration to parenchyma of new organ and progressive growth from 
one cell to over lxlO9 cells.
These six capabilities provide the basic requirements for a tumour cell to transform and 
fully develop the disease. Several genes have been mentioned which are commonly found to 
be abnormally overactive or inactive (oncogenes and tumour-suppressor genes respectively) 
and these genes have traditionally been the focus of studies on genetic mutations that 
produce cancer. It is now known, however, that 50% of the mutated genes that cause 
inherited forms of cancer can be silenced by epigenetic mechanisms.4 An explanation of 
epigenetic control of gene expression and its implications shall follow.
1.4 Histones, Chromatin and the Availability of Genes
It is hardly necessary to state that an enormous amount of information is required in order to 
produce a living human entity. The human genome is currently thought to contain 20- 
25,000 protein coding genes, encoded by 2.85 billion nucleotides.5 This information in its 
entirety is stored within the nucleus of virtually every cell of the organism. It is not 
surprising, therefore, that an astoundingly complex system exists for not only storage of this 
information, but for retrieval of the coding necessary at any given time and place.
1.4.1 The Role of the Histone
Fully extended, the longest human DNA molecules would reach over 8 cm in length -  a fact 
that demonstrates the achievement of normal DNA condensation. Nuclear DNA in its 
chromosomal conformation, termed chromatin, exists in a protein-DNA complex of 
approximately equal proportions by weight. O f these proteins, histones constitute the vast 
majority and are involved at the first level of DNA organisation. Histones are small, basic
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proteins consisting of -25%  lysine and arginine residues which, through their protonated 
side-chains, provide a means of interaction with the negatively charged phosphate backbone 
of the DNA double helix.6 O f the five main types of histones; H I, H2A, H2B, H3 and H4, 
all but HI are required for nucleosome formation. The nucleosome is the basic repeating 
unit of chromatin and consists of a core histone-octamer, consisting of two copies each of 
histones H2A, H2B, H3 and H4, which provide a spool for DNA to coil around. The DNA 
passes around this core 1.65 times,7 with linker regions between nucleosomes producing a 
‘beads-on-a-string’ effect (figure l .l) .8 With the aid of histone HI (an example of a Tinker 
histone’, so called because of its interaction with the linking DNA regions), this structure 
coils on itself to form a 30 nm fibre. The fibre is then arranged in loops radiating from a 
central protein scaffold, to produce the recognisable chromosome structure. The extent of 
chromosomal condensation is not fixed, and the maximum density occurs during the 
metaphase of a cell’s mitotic division, when the largest chromosome is reduced to -10  pm 
in length. In this extreme conformation there is no access for the transcriptional apparatus to 
DNA, and so this ultra efficient form of packaging is not adopted during interphase.
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Although it is not possible for chromosomes to be fully condensed all o f the time, it is also 
not necessary for an entire chromosome to be accessible for transcription, even during 
interphase. Every human cell (excluding erythrocytes) contains at least one copy of the 
genome in its entirety, however, not all genes are required for expression in any single cell. 
A cell’s identity, and therefore its role, is defined by expression o f a specific combination o f 
genes, and so not only is it unnecessary to have transcriptional access to every gene, it is 
potentially dangerous. This is highlighted by the effects o f aberrant expression o f oncogenes,
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the products of which are often required only in embryonic development, or, conversely, the 
repression of tumour suppressor genes such as p53 and pRb (discussed in the previous 
section). It is becoming increasingly clear that post-translational modification of histone 
proteins has profound effects on the conformation of chromosomal DNA, and therefore, a 
cell’s expression profile. On a large scale, regions of the chromosome may be rendered 
accessible or inaccessible through epigenetic events. Epigenetic events can be defined as 
‘reversible but heritable changes in gene expression, produced without alteration of the 
DNA sequence.’9 They include DNA methylation and histone modification, and allow 
differentiation of cell types when essentially all cells contain the same information - the 
genome. Formation of transcriptionally unavailable heterochromatin is a complex process, 
requiring the activity o f histone-modifying enzymes, chromatin-remodeling proteins, DNA 
methyl transferases and RNA-directed silencing complexes in addition to other architectural 
proteins.10 With such a broad range of control mechanisms, it is sadly not within the scope 
of this thesis to consider them all, and it is the post-translational modification of histones 
that will provide the focus from here on.
1.4.2 Histone Post-Translational Modifications
The high proportion of lysine and arginine residues in these proteins render histones 
particularly susceptible to a variety of post-translational modifications. The extent of these 
modifications vary, but include acetylation of lysine residues by histone acetyltransferases 
(HATs), methylation of lysine and arginine residues by histone methyltransferases (HMTs), 
serine phosphorylation by serine kinases, ubiquitination by ubiquitin ligases, poly ADP- 
ribosylation by poly ADP-ribose polymerase and sumoylation of lysine by the small 
ubiquitin-like modifier (SUMO). It should be noted that all known covalent histone 
modifications are reversible, and the enzymes responsible for attachment and removal of the 
modifying groups are often present at the same time.7 These competing reactions are 
achieved through the action of enzymes such as histone deacetylases (HDACs) (scheme 1.1), 
methylases, phosphatases and proteases.
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Scheme 1.1. Opposing actions of histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) on lysine acetylation.
There are three key ways in which histone modifications are thought to affect chromatin 
structure; first, modifications such as lysine acetylation and methylation alter the charge of 
the amino acid residue (scheme 1.1), thereby altering its electrostatic interaction with the 
negatively charged phosphate backbone of the DNA. This original hypothesis would 
suggest that the degree of acetylation of lysine residues would produce a cumulative effect 
to bring about large conformational changes. Second, modification can affect the 
recruitment of DNA binding factors, thereby indirectly eliciting an effect. This is analogous 
to the effect of phosphorylation on many protein-protein interactions and implies, for 
example, that acetylation of a single specific residue could create a new binding surface 
sufficient to recruit another protein.11 One protein structure capable of responding to this is 
the bromo domain, which recognises acetylated lysine residues. This domain has been
identified through sequence analysis as being potentially present in more than 72 human
12proteins. Consideration of this mode of action has led to the hypothesis of an epigenetic 
code,13 whereby individual modifications or combinations thereof (in conjunction with 
DNA methylation) mediate a variety of nuclear functions through their sequence-specific 
recognition by specific domains contained in effector proteins.14 The third possible 
mechanism is through modification affecting nucleosome-nucleosome interactions, and 
therefore, higher order chromatin structure.7
Of the modifications described above, acetylation is the best characterised -  several families 
of proteins have been identified as histone acetyltransferases (HATs) each displaying 
different specificities.14 Many proteins identified as possessing HAT activity had been
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previously known as transcriptional regulators, with diverse functions such as control of cell 
cycle, differentiation and apoptosis.12 A characteristic of this group of enzymes is that they 
function as transcriptional co-activators, binding to DNA-binding proteins (as opposed to 
directly binding DNA itself). On recruitment to promoter regions by these DNA-binding 
proteins, HATs are then able to exert their catalytic effects as components of large, multi­
subunit complexes.15 The enzymes catalyse the acetyl coenzyme A-dependent acetylation of 
the s-amino groups of lysine residues (scheme 1.1). Unsurprisingly, considering their key 
roles in cellular processes, aberrant activity of HATs has been observed in cancer.12 
Traditionally, the stable hyperacetylation of histones has been considered a characteristic of 
transcriptionally active genes, however it is now though possible that rapid turnover of 
acetylation/deacetylation could be more important for transcription.11 Histones are not the 
only substrates of these enzymes, and other targets include general transcription factors and 
nuclear proteins,16 further complicating a precise description of their role.
1.5 The Histone Deacetylases
The four classes of mammalian proteins that have so far been identified as possessing 
HDAC activity are distinguished by their structural homology to yeast HDACs.17 Class I are 
most closely related to the S. cerivisiae transcriptional regulator Rpd3 (reduced potassium 
dependency) and includes HDACs 1, 2, 3 and 8. Members of class II, including HDACs 4, 5, 
6, 7, 9 and 10, are homologous to yeast deacetylase Hdal. The sole member of class IV is 
HDAC11, which does not have sufficient sequence similarity to be considered a member of 
class I or II. All of these enzymes contain a highly conserved catalytic domain, however the 
members of class II are typically two to three times larger in size than the class I proteins.18 
The third class of HDACs, the sirtuins (related to yeast transcriptional repressor Sir2) are 
evolutionarily distinct, requiring the presence of NAD+ as a cofactor for enzymatic activity. 
Class III HDAC’s alternative mechanism of action allows them to remain unaffected by the 
majority of HDAC inhibitors currently under development, and so this class will not be 
included in the following discussion.
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HDACs function almost exclusively in multi-protein complexes; most recombinantly 
expressed HDACs (with the exception of HDAC8) will not function in the absence of other 
cofactors.19 The complexes generally include proteins which influence recruitment, DNA- 
binding and chromatin re-modelling. Further cellular regulation of HDAC activity exists at 
the levels of gene expression, proteolytic processing and post-translational modification.
Active HDACs 1 and 2 are localised exclusively to the nucleus and have been identified in 
three different protein complexes: Sin3, NuRD (nucleosome remodelling and deacetylating, 
also known as Mi2) and CoREST.18 Recombinantly expressed versions of these two 
enzymes are inactive alone and require the other members of the complex for DNA-binding, 
recruitment and modulation of deacetylase activity. Both HDACs 1 and 2 interact with the 
previously mentioned tumour-suppressor protein pRb.20 HDAC3 is capable of leaving the 
nucleus owing to its possession of both nuclear localisation signal (NLS) and nuclear export 
signal (NES) sequences. HDAC8 is present in the nucleus, however only in very low 
abundance.
Class II HDACs are more able to shuttle between the nucleus and cytoplasm; HDACs 4, 5 
and 7 are exported from the nucleus on phosphorylation.19 HDAC6 is found predominantly 
in the cytoplasm and is thought to play a role in cell motility owing to its activity as a 
tubulin deacetylase.
The first structural information on histone deacetylases came from crystallographic studies 
of a HDAC homologue, HDLP, from the hyperthermophilic bacterium Aquifex aeolicus 21 
The enzyme shares 35.2% homology with human HDAC1, and in addition to the pure 
enzyme, crystal structures of HDLP complexed with the HDAC inhibitors trichostatin A 
(TSA) and suberoylanilide hydroxamic acid (SAHA) (figure 1.3) were elucidated, 
suggesting mechanistic information on the enzyme-catalysed reaction (figure 1.2), which 
shows characteristic elements of both metallo- and serine-proteases. The crystal structure 
showed a tubular pocket approximately 11 A deep and -4.5 A across at its narrowest point, 
where the aromatic rings of two phenylalanine residues face each other across the tunnel.
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Figure 1.2. Proposed mechanism for deacetylation of acetylated Lys by HDLP. Active site residues 
(and HDAC1 counterparts) are labelled.21
The pocket is lined with hydrophobic and aromatic residues, with a zinc ion and water 
molecule present near the base o f the cavity. No deacetylase activity was seen without 
incubation o f the purified enzyme with zinc chloride (or a cobalt substitute) showing the ion 
is a necessary component o f the catalytic site. A charge-relay system that is characteristic o f 
serine proteases is present in the pocket: two histidines (H I32 and H 131, figure 1.2) each 
hydrogen-bond with an aspartic acid residue (D173 and D166 respectively), thereby 
polarising the imidazole ring and increasing its basicity. The lower o f  these two histidine 
residues, H 131, hydrogen-bonds with the water molecule, which is also bonding with the 
zinc ion. Another structural feature o f the enzyme is a second cavity adjacent to the pocket. 
The cavity is composed o f hydrophobic residues and its function is not clear.
The crystal structure o f the enzyme bound to the highly potent hydroxamic acid inhibitor 
TSA (figure 1.3) shows the aliphatic chain penetrating the pocket, projecting the 
hydroxamic acid moiety into the proximity o f the zinc ion and making numerous contacts 
with the hydrophobic residues lining the tube. The length o f the chain allows coordination 
o f the hydroxamic acid with the zinc ion and also interaction o f the aromatic ring with 
residues at the pocket entrance, as shown schematically in figure 1.4.
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Figure 1.3. Structures of HDAC inhibitors trichostatin A (TSA) and suberoylanilide hydroxam ic acid 
(SAHA).
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Figure 1.4. Schematic representation of HDLP-TSA interactions (HDLP residues are labelled in red 
with HDAC1 counterparts indicated in b lack).21
Coordination o f the carbonyl and hydroxyl oxygens o f the hydroxamic acid result in a 
pentavalent zinc ion, showing similarities with the binding o f hydroxamic acids to zinc 
metalloproteases such as MMP-1.~~ Binding o f SAHA is in a similar fashion, however, 
several structural differences may help to explain SAHA’s significantly lower inhibitory 
capacity. The unbranched aliphatic chain o f SAHA fits the pocket less well and is more 
flexible than the TSA chain, resulting in fewer van der Waals interactions with residues 
lining the pocket. Also, the phenyl group o f SAHA has a lower electron density, suggesting 
it packs less well at the cap region.
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Further structural information has been elucidated on human HDACs by the publication 
(simultaneously by two separate groups) of crystal structures of HDAC8 complexed with a 
variety of hydroxamic acid inhibitors.23,24 Based on the structure of the bound hydroxamic 
acid, Somoza et al. propose a mechanism of acetylated lysine binding (figure 1.5) that is 
similar to that proposed by Finnin et al. given in figure 1.2.
A H143
D183
D176
H142
H143
D176
H142
Figure 1.5. A. Schematic representation of binding of a hydroxamic acid with human HDAC8. B. 
Proposed binding of acetyl Lys and water.24
With the current understanding of the structure and mechanism of histone deacetylases thus 
summarised, it is useful to take a step back and review the basic principles of enzyme 
kinetics before moving on to discussion of the wide variety of HDAC inhibitors under 
development.
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1.6 Enzyme Inhibition
At the most fundamental level, enzymes reduce the free energy (AG) required for chemical 
reaction by providing an alternative pathway to the uncatalysed reaction with a lower 
energy transition state (figure 1.6). The Gibbs free energy o f activation, denoted as AG*, is 
the increase in energy required to convert the substrate to the high energy transition state.
(Dc
LLI
CD Transition State
Substrate
Product
Reaction Coordinate
Transition Statecn
i  L
AG'
LL
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Reaction Coordinate
Figure 1.6. Free energy profiles of A: an uncatalysed reaction and B: a catalysed reaction.25
The overall rate of an enzyme catalysed reaction is described as its velocity, and the initial 
velocity, Vo, produced before consumption of 10% of the substrate (S) is the maximum 
value (figure 1.7). The velocity then begins to decrease as substrate concentration ([5]) 
decreases and product concentration ([P]) increases. The rate is typically dependent on three 
key factors: [5], temperature and pH. Increasing [S] will increase reaction rate until [5] 
reaches the enzymes saturation point, at which point increasing [5] will no longer increase 
the rate, and the reaction becomes dependent on enzyme concentration [E\. The enzyme will 
operate at an optimum temperature, typically close to 37 °C. Reaction rate will tend to 
increase fairly steadily until the optimum temperature is reached then drop rapidly when 
exceeded owing to denaturating of the protein. Similarly, an enzyme will have an optimum 
pH range.
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Figure 1.7. Rate of formation of product in a typical enzyme catalysed reaction (initial velocity, V0l 
indicated).
The process involved in an enzyme catalysed reaction can be described by the Michaelis- 
Menten model: binding of the enzyme (E) with substrate (S) to form complex ES  and 
breaking down of this complex to give either free enzyme and product (P) or the reverse 
reaction to give E  and S  (scheme 1.2). The rates of these reactions are described as k+\, k+ 2, 
and k.\ respectively and the overall reaction is considered irreversible as conversion of P  to 
back to ES is assumed to be at an insignificant rate.
k+\
E + S  -  ES
k. 1
Scheme 1.2. Stages of enzyme catalysed reactions.
There are two stages at which the kinetics of a reaction can be studied: (i) the pre-steady 
state, which concerns the very first round of reaction on contact of E  with S  and (ii) the 
steady-state. The steady-state concerns turnover of multiple rounds of reaction when 5 in 
present in excess, and so this is the case over the majority of the course of a reaction 
provided it is not inhibited by formation of P. Under these conditions the concentration of 
ES ([£*S]) remains constant and it is possible to describe the relationship between [S], Vo, 
maximum velocity (Vmax) and a constant, Km, derived from the rate constants shown in 
scheme 1.2.
K 2
 ►  E + P
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Calculation of V0 at a range of values for [5], as in figure 1.8, shows that Vq is directly 
proportional to [S] at low concentrations, whereas at high [5], it tends towards a maximum 
value (Vmax).
max
oo<u>
TO
C
[S]
Figure 1.8. Relationship between [S] and VQ.
Finally, these terms are combined in the Michaelis-Menten equation:
Vmax. [6 ]
V0 = ---------------------
K m + [S]
Equation 1.1. Michaelis-Menten
As Fmax is only achieved at an infinite substrate concentration it is not possible to determine 
this factor from the hyperbolic plot of [S'] against V0 (figure 1.8). Manipulation of the data to 
produce a double reciprocal plot, known as the Lineweaver-Burke plot (equation 1.2, figure 
1.9), allows calculation of Vmax from experimental values.
1 1 ATin 1
 =   +    • _______
Vo Vmax Vmax [S]
Equation 1.2. Double reciprocal of the Michaelis-Menten equation.
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Slope = KJV r
Intercept = -1/Km
Intercept = 1/Vr
1/[S]
Figure 1.9. Lineweaver-Burk Plot allowing calculation of Vmax and Km.
Information about the mechanism of an enzyme inhibitor may be obtained by study of 
enzyme kinetics in this way. Any compound that reduces the rate of an enzyme catalysed 
reaction can be called an inhibitor, and these compounds can be divided into two main 
groups; reversible and irreversible inhibitors. Irreversible inhibitors cause permanent loss of 
activity, generally by covalently bonding to the enzymes active site. Reversible inhibitors 
have traditionally been divided into three sub-classes: (i) non-competitive, when the degree 
of inhibition is unaffected by change in [5], (ii) competitive, when inhibition is reduced by 
increasing [5] and (iii) un-competitive, where the reverse is true, and inhibition increases 
with increasing [S'].26 Lineweaver-Burk plots of reactions in the presence of these types of 
inhibitors show characteristic differences (figure 1.10).
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Figure 1.10. Comparison of Lineweaver-Burk plots in the presence of classical non-competitive, 
competitive and un-competitive inhibitors.
With the background topics including the molecular basis of cancer, histone 
acetylation/deacetylation, HD AC structure and enzyme kinetics now reviewed, the focus of 
this introduction now comes to the use of HDAC inhibitors as therapeutic agents. Before 
considering in detail the wide ranging structural characteristics of current HDAC inhibitors 
an overview of the biochemical effects of this class of compounds shall be given.
1.7 Cellular Effects of HDAC Inhibition
By considering the six characteristic requirements for development of cancer (self 
sufficiency in growth signals, resistance to growth inhibition signals, evasion of apoptosis, 
immortalisation, sustained angiogenesis and invasion and metastasis, discussed in chapter 
1.3) the complex anti-tumour action of HDAC inhibitors can be begun to be understood. As 
has previously been mentioned, the balanced actions of HATs and HDACs in their 
respective acetylation and deacetylation of various proteins plays a key role in regulation of 
transcription. Gene profiling studies have shown that treatment of cells with HDAC 
inhibitors leads to alteration in expression of 2-5% of expressed genes in malignant cells,27 
with similar proportions of these genes being activated and repressed. It is important to note
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that among this small percentage of genes are key regulators of all six properties required 
for cancer, some of which are listed in table 1.1.28
Oncogenes Down-Regulated by HDAC Inhibitors
TGF(3 Regulator of cell proliferation and differentiation
Thioredoxin Cytokine capable of inhibiting apoptosis
Telomerase Prevents telomer erosion
VEGF Angiogenic factor
cyclins A, B and D Cell cycle regulators
Tumour-Suppressor Genes Activated by HDAC Inhibitors
p53 Pro-apoptotic
Fas/FasL Pro-apoptotic
p2^ WAF1/Cip1 Cell cycle regulator
p27Kip1 Cell cycle regulator
Table 1.1. Some tumour-associated proteins transcriptionally affected by HDAC inhibitors.28
It has been suggested that the reason for only a relatively small subset of genes to be 
affected by the induced global increase in histone acetylation is due to the effect this change 
has on histone and DNA methylation, which exerts a dominant effect over histone 
acetylation. A summary of the currently understood functions of HDAC inhibitors in 
cancer therapy is given in table 1.2.
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Inhibition of Cell Proliferation
Augmentation of nuclear receptor response driving terminal cell differentiation 
Reversal of repression by fusion transcription factors or over-expressed repressors 
Induction of p21, G1 arrest and cellular differentiation
Re-activation of silenced tumour suppressor genes in combination with DNA methyltransferase 
inhibitors
Suppression of telomerase gene expression 
Induction of Apoptosis
Activation of mitochondria-dependent apoptosis
Activation and/or sensitization of death-receptor mediated killing
Mitotic dysfunction, aberrant chromosomal segregation and DNA damage
Induction of topoisomerase II may alter sensitivity to DNA-damaging agents
Inhibition of Cancer Cell Migration, Invasion and Metastasis
Activation of suppressors of invasion and metastasis including TIMP1, KAI1 and RhoB
Suppression of promoters of migration, invasion and metastasis including TGF(31, MTA1 and 
MMP2_____________________________________________________________________________________
Inhibition of Tumour-Driven Angiogenesis
Activation of suppressors including p53
Suppression of promoters including VEGF, VEGF receptor 1 and 2 and MMP2
Other Mechanisms
Alteration of microtubule function
Induction of MHC antigens on cell surface to augment immune response 
Suppression of IL-2-mediated gene expression
Table 1.2. Summary of HDAC inhibitors’ effects in cancer therapy.29,27
1.8 Known Inhibitors of Histone Deacetylase
Having now discussed the biological effects of HDAC inhibitors, the attention shall now 
turn to a review and classification of current molecules known to inhibit the enzyme. Many 
apparently structurally-diverse compounds fall within this field, however it is almost always 
possible to describe inhibitors with respect to a common pharmacophore model based on the
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crystallographic studies of Finnin et al.21 (discussed in chapter 1.5). The model divides 
inhibitors into three sections: a zinc-binding domain, a spacer domain and a capping domain 
(figure 1 .1 1 )
N r "
c A
Aromatic cap
I
•OH
y Spacer
Zn-binding group
Zn 2 +
Figure 1.11. Pharmacophore model for HDAC inhibitors using TSA as an example.
It has been established that many chemical moieties are capable of functioning as the zinc- 
binding group, the most commonly used being a hydroxamic acid. The other known 
categories of inhibitors, including benzamides, carboxylates and macrocycles, will be 
discussed presently. The spacer region may take the form of saturated or unsaturated alkyl 
chains, or cyclic linkers and the cap regions are commonly hydrophobic, aromatic groups, 
however another major class of inhibitors contain macrocyclic domains. Much of the work 
done in establishing this pharmacophore is summarised in the excellent review by Miller et
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al.30 We shall commence the review with the hydroxamate inhibitors as this class provides 
the greatest number of examples.
1.8.1 Straight-Chain Hydroxamic Acids
The straight-chain class includes the compounds trichostatin A (TSA) and suberoylanilide 
hydroxamic acid (SAHA), both of which were utilised in the elucidation of HDAC catalytic 
mechanism (described in chapter 1.5). The structures of some potent compounds of this 
class are given in figure 1 . 1 2 .
NHOH
Trichostatin A  (TSA)
o
NHOH
Suberoylanilide hydroxamic add  
(SAHA)
NHOH
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Figure 1.12 Examples of straight chain hydroxamate inhibitors.
The potent natural product TSA, isolated from Streptomyces hygroscopicus, was first 
identified as a non-competitive HDAC inhibitor by Yoshida and co-workers in 1990, with
• 31Ki = 3.4 nM. As has previously been mentioned, the structurally related, unsaturated 
SAHA has a significantly lower inhibitory capacity, with activity at low micromolar 
concentrations. Extensive work has been carried out to identify the structural requirements 
for TSA’s potency. Synthesis of the un-natural 0S)-TSA showed this enantiomer to be
* • 33inactive. Hybrid structures blending elements of these two compounds in the form of
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amide TSA-analogues show the importance of TSA’s unique chain (figure 1.13).34 The fully 
saturated analogue la shows an IC5o one tenth of the parent compound, methyl-substitution 
on the chain of lb reduces activity by a further half and unsaturation (lc) effectively 
destroys the inhibitory activity.
HDAC IC50 (nM) HDAC IC50 (nM)
NHOH
NHOH
12187NHOH NHOH
Figure 1.13. Amide analogues of TSA.
Compound la also featured in a structure-activity relationship (SAR) study of cap groups 
on the unsaturated amide analogue by Remiszewski et al. in 2002 (figure 1.14).35
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Figure 1.14. Further amide analogues of TSA. 35
This study identified the longer chain length of six methylene units as being the optimal 
length in this case, the potency being markedly increased by inclusion of the 4-N,N- 
dimethyl cap (2i). Non-amide compound 2g, with a longer chain than that of TSA, 
displayed a 20-fold reduction in potency. A-Methylation of the amide group (2k) reduced 
activity, however, annulation in the form of phthalimide 21 produced an improvement 
compared with 2a.
Another study centering on this class of inverted-amide SAHA analogues investigated the 
effect of heterocycles in the cap region, with a particular emphasis on indoles.36 The
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inclusion of electron-rich aromatic groups including indoles and a benzofuran showed 
remarkable effects on activity.
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Figure 1.15. Development of indole amide SAHA analogues 3 6
Substitution of a pyrrole group for the phenyl group of SAHA in 3b (figure 1.15) was found 
to be favourable and extension of this moiety into an indole functionality produced a ten­
fold increase in activity. Attachment in the 2-position of 3c led to an IC50 approaching the 
single-figure nanomolar range.
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Departing from the amide-linked cap regions, inclusion of ketone 2g in Remiszewski’s 
series (figure 1.14) leads conveniently to further work around this unsaturated, unsubstituted 
analogue of TSA. The following series by Woo and co-workers (published shortly after 
Remiszewski’s series of figure 1.14), given in figure 1.16, includes the structure 2g and 
provides an extensive study on the chain length and cap region o f this compound.37 The 
study identifies the six-methylene linker to be the optimal length, with the most potent 
compounds possessing highly hydrophobic naphthyl or biphenyl cap groups. The methoxy- 
substituted phenyl cap groups of compounds 4h and 4i indicate that substitution in the 2- 
position of the former is detrimental, whereas the 4-position produces a favourable effect. 
Replacement of the ketone with an oxime appears to be well tolerated (4n and 4o), as is 
methylene 4p. Removal of the group altogether does not significantly affect potency, 
implying a degree of freedom in the pharmacophore at this point.
Substitution adjacent to the hydroxamic acid, as with the methyl group of 4u, dramatically 
reduces the inhibitory capacity -  a point seemingly confirmed in a recent study on the effect 
of substitution of SAHA in this position. The study showed inclusion of any group, ranging 
in bulk from methyl to benzyl, in this position significantly reduced activity.38
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Figure 1.16. SAR of straight-chain analogues of TSA.37
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A series of straight chain, polyunsaturated analogues of TSA synthesised by the Marson
heteroatom at the join between chain and cap, as with the highly potent 4v and 4w above 
(figure 1.16). The examples given in figure 1.17 indicate that with the unsaturated, carbon- 
only linker a much shorter chain is tolerated than in the previous series (figure 1.16). The 
unsaturated chain of 5d reduces activity by a factor o f ten, and whilst para-chloro 
substitution is tolerated in 5b, the j9«m-dimethylamino group of 5c greatly reduces activity. 
It may be surmised that the shorter chain of these compounds does not allow the amine to sit 
in the same position at the top of the enzymes active site as is occupied by the 
corresponding group in TSA. Additional bulk in the chain has little effect in the chloro 
example 5e, but greatly improves activity with amine 5 f  (although still considerably less 
active than 5e).
Figure 1.17. Polyunsaturated straight chain analogues of TSA .39
Conformationally constrained analogues of TSA were recently reported by Charrier and co­
depicted in figure 1.18 all retained moderate to good inhibitory activity, the indanone 
proving superior in the unsubstituted examples 6 a and 6 b. Substitution on the phenyl ring
group39 showed that good potency could be achieved with a shorter chain possessing no
l-DACICso (nM) hCACICso (nftfy
o o
NHOH
279
NHOH
2580
o o
NHOH
252
NHOH
302
o o
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1700
NHOH
788
workers as potent inhibitors.40 The tetralone, 6 a, and three indanone analogues 6 b-d
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increased activity, with the direct TSA analogue, bearing a dimethylamino moiety, 6d, 
showing the greatest activity with a sub-micromolar IC50 in H661 cell assays.
HDAC IC50 HDAC IC**, (pIVQ
o  o
1.65
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1.5
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NHOH
Figure 1.18. Rigid analogues of TSA .40
It should be noted that although the imposed rigidity at the joining region between cap and 
chain is tolerated in this case, albeit at some reduction in potency, the chain of TSA is 
already considerably restricted in its conformations owing to its unsaturation (despite 
potential rotation arising from 1,3-allyl steric clashO. If the rigid chain of TSA does confer 
favourable attributes when the molecule is docking in the pocket of the enzymes active site, 
it might be suggested that SAHA, with its fully saturated chain, would be an appropriate 
target for this type of conformational analysis. It may be the case that increasing the rigidity 
of the chain of SAHA in this way would produce more favourable effects.
The capacity of the attachment point of cap and chain to tolerate diverse chemical entities is 
further confirmed by a series of potent aromatic sulfur-linked compounds (figure 1.19), 
synthesised by the Marson group.41
NHOH
NHOH
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Figure 1.19. Aromatic sulfide analogues of TSA and SAHA. 4 1
Almost all of the aromatic sulfur-linked inhibitors depicted in figure 1.19 showed lower 
IC50S than SAHA, compounds 7b and 7c indicated that increase in oxidation state of the 
sulfur to sulfoxide and sulfone respectively increased potency. This was not the case with 
unsaturated compounds 7k and 7n, which retained approximately the same activity.
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An aromatic thiol structurally related to the above series (figure 1.19) was recently 
synthesised by Kim et al.42 The 2-naphthylthiol analogue of SAHA, 8, (figure 1.20) proved 
to be a potent inhibitor in vitro. Additionally, sulfoxide 7g was effective in vivo, exhibiting 
stronger potency than SAHA in xenograft mice tumour models.
NHOH
Figure 1.20. 2-Naphthylthiol SAHA analogue.42
Uracil-based thiols have been synthesised by Mai and co-workers 43 The unsubstituted 
uracil cap o f compound 9a (figure 1.21) showed a modest inhibitory capacity and the cap 
region was optimised, producing low nanomolar inhibition, by inclusion of benzyl or phenyl 
groups in 9d and 9e respectively.
SAHA
I-D2IC5 0  (nl\/Q
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Figure 1.21. Uracil-based hydroxamates.43
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A solitary example of an aryl ether linked straight chain hydroxamic acid inhibitor was 
reported by Dai and co-workers (10, figure 1.22), this simple example showed modest 
activity in isolated HDAC assays.44 The biaryl analogue 11, reported the same year by 
Wada and co-workers, showed greatly improved activity.
NHOH
Figure 1.22. Aryl ether straight chain hydroxamates.44,45
Previous work within the Marson group greatly enhanced the potential of this motif by 
introducing /7-substitution. A lead compound in bearing a 4-amino group substituted with 
pyridyl and methyl moieties (12, figure 1.23) showed an IC50 of 15 nM and the simple 
naphthyl group of 13 produced exceptional potency 46
NHOH
Figure 1.23. Additional aryl ethers.46
In addition to his work on indole amide hydroxamic acids (figure 1.15), Dai et al. have 
demonstrated it to be possible to include an aromatic connecting unit in place of the linear 
amide, ketone or sulfur examples reviewed thus far. Exchange of SAHA’s amide linker for 
oxazole or thiazole moieties (figure 1.24) significantly raised the activity of the inhibitors 44 
Potency in this series was further enhanced with substitution on the phenyl ring, p-methoxy 
and p-bromo analogues of 14a lowering the IC50S to 2 nM and 3 nM respectively.
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Figure 1.24. HDAC inhibitors incorporating aromatic connection units. 44
A one-off, related compound, containing a thiazole ring in the cap region (this time
HDAC IC50 0.7 nM  
15
Figure 1.25. A thiazole-containing inhibitor.47
The potential of the framework of 15 to form the basis of a drug-like molecule has been 
explored in greater detail by Suzuki et al. whose analogous compound (discussed later) 
replaces the hydroxamic acid moiety with, initially, a simple thiol.48
retaining the amide linker) was synthesised and tested by Glaser and co-workers as part of a 
structurally diverse series of inhibitors.47 Retention of the amide connecting unit in 15 
(figure 1.25) resulted in exceptional potency in in vitro assays.
o
NHOH
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The somewhat unique structure of the previously depicted tubacin (figure 1.12) was 
identified from a mass screen of a diversity-oriented synthesis library by Schreiber and co­
workers.49 This vast study also identified a total of 617 small molecule inhibitors of HDAC.
As shall been seen to a greater extent later with macrocyclic inhibitors, the cap region of 
these compounds is not restricted to linearly linked aromatic groups. A series of 
phenylalanine-based SAHA analogues produced by Jung and co-workers demonstrated the 
potency of bifurcated caps. Figure 1.26 gives a selection of compounds identified as most 
potent in cell-based assays. As has been demonstrated in other systems, the biphenyl motif 
of 16d provided good activity, with the aliphatic valine derivative, naphthyl and thienyl 
compounds 16e, 16g and 16h all displaying low micromolar values.
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Figure 1.26. Phenylalanine-based SAHA analogues
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In an extensive study also involving compounds possessing the bifurcated cap region, this 
time with derivatives of aminosuberic acid, Kahnberg and co-workers synthesised and 
evaluated over 50 novel inhibitors.50 This study not only identified many potently cytotoxic 
compounds in assays with MM96L human melanoma cells, but it also sought to identify 
compounds that showed selectivity for toxicity to cancer cells over untransformed neonatal 
foreskin fibroblasts (NFF) cells. Comparison of the IC50 values from assays with each of 
these cell types individually were used to give a qualitative selectivity index (SI). The most 
cytotoxic and selective structures from this study are given in figure 1.27. Six compounds 
were found to have IC50 20-80 nM, activity comparable to that of TSA. The series focuses 
heavily on aromatic substituents of the parent amino acid, with minimal flexibility linking at 
positions Ri and R2. Compounds bearing linkers of two or more carbon atoms between the 
carbonyl and aromatic group (not featured here) showed reduced potency. The most potent 
compounds, 17k-m, contained the rigid and bulky 8-aminoquinoline substituent in the R2 
position, and exchange of this group for a benzyl moiety resulted in a 2-80 fold loss of 
potency. It was noted that the ten-fold increase in potency of the (Z^)-enantiomer 17b over 
(5)-17a was consistent with the predicted molecular modelling study which indicated 
greater H-bonding and van der Waals interactions with the enzyme for this enantiomer. It is 
therefore suggested from this that the unnatural D-amino acids may prove to be more potent 
than the L-forms.
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Figure 1.27. Novel aminosuberic acid-based inhibitors compared in assays against normal NNF 
cells versus MM96L melanoma cells.a Selectivity index.50
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A recent communication reporting a similar series of aromatic derivatives of aminosuberic 
acid, which included other similar structures to those in the series described above, also 
identified this framework as being potent in HDAC1 assays and SC9 murine 
erythroleukaemia cell cytotoxicity assays.51 This series reduced flexibility in the cap group 
still further by including aniline substituents where benzylamine had been used above. The 
most potent cell kill achieved from the compounds of figure 1.28 was of low nanomolar 
potency, by compounds bearing a combination of phenyl and quinolyl groups (18c and 18e).
NHOH
\
R?
O'
18a 1 2 .1 /7 3  18b 1 1 .1 /2 5 0  18c 1 0 /3 3  18d 1 8 /1 0 2
18e 9 .4 /4 3  18f 4 /3 6 7  18g 4 2 /1 6 5  18h 14 .5 /39
18i 3 .5 /9 0  1 ^  1 .3 /7 5 6  18k 5 4 /1 0 7  1 8 1 7 .7 /1 1 0
18m 9 3 /1 0 3 9  18n 1 2 0 /3 4 2 3  18o 5 1 .3 /3 7 4  18p 4 8 /4 1 2
Values shewn for IC^o HDAC1 /  IC50 SC9 (nM)
Figure 1.28. Aminosuberic acid derivatives.
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Additional flexibility of the R1 group was seen to dramatically reduce potency (18m), 
however inclusion of a benzyl ester at R2 did not reduce the activity to such a great extent in 
most cases (18d, 18h and 181).
Other inhibitors bearing bifurcated cap regions related to the class of compounds described 
above, but based on malonamide branch points, have also been investigated. As the 
previously reported structures are not straight-chain, hydroxamic acid inhibitors they shall 
be discussed in later sections. However, additional compounds that do fall into this category 
have been synthesised as part of this thesis and will be discussed in the appropriate chapter.
1.8.2 Hydroxamic Acids Bearing Cyclic Linker Domains
The discovery that cyclic groups could be tolerated in the linker regions of inhibitors came 
with development of the so-called second generation of hybrid polar compounds.52 Included 
in this class was the previously discussed SAHA and m-carboxycinnamic acid bis 
hydroxamide (CBHA). Although it may seem surprising that a bulky benzene ring may 
provide a suitable replacement for an alkyl chain, comparison with the linker of TSA shows 
good overlap with this highly effective scaffold (figure 1.29).
o  o
NHOH
| TSA
o  o
H O H N ^^jj^
CBHA
Figure 1.29. Similarity of TSA and CBHA linkers.51
An early example of cyclic-linker hydroxamic acid inhibitors came from Jung in 1999.53 
Comparison of the activity of the two compounds 19 and 20, figure 1.30, indicates a
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dramatic influence on activity produced by the positioning of the cyclic group in the chain. 
This dramatic difference may indicate that different conformations are being adopted by 
these two molecules, which prevent 20 from binding well to the active site.
HD2 ICgo (nM)
NHOH
NHOH
Figure 1.30. Amide analogues of TSA .53
The potent benzylic hydroxamic acid 19 is the same overall length as its analogue 20, which 
should theoretically allow the same contacts of the cap groups with the top of the enzymes 
active site, however, placing the methylene unit of the chain before the phenyl ring (20) 
instead of after results in what is effectively a total loss of activity. These two compounds 
were the only cyclic-linker inhibitors evaluated in this study but further work making use of 
the linker unit o f 19 has been carried out by Maeda and co-workers. They produced a short 
series of benzylic hydroxamic acids with varied aromatic capping groups that showed good 
activity in isolated enzyme assays and were able to optimise the cap to give low single 
figure micromolar inhibition in HCT116 cell assays (figure 1.31).54
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NHOH
IC50
HDAC HCT116 
(nM) (|JV9
HDAC HCT116 
(nIVO (|jM)
\
2 1 a
2 1 b
MezN
2 1 c
H2N
HQ
\
\
2 1  d
2 1  e
44 0.7
830 9.7
>10,000 80.4
39 3.9
21f
2 1 g
2 1  h
2 1 iMeO'
26 3.8
TSA
SAHA
43 3.6
240 3.2
830 8.2
>10,000 36.1
3 0.5
263 6.3
Figure 1.31. /V-Hydroxybenzamide HDAC inhibitors.54
Although the most potent compound in this series was naphthyl analogue 21a, it was the 
more water-soluble amine 2 1 d which was selected for further evaluation in the form of a 
murine tumour model, showing promising results.
Benzylic hydroxamic acids bearing shorter linker units than those above have also been 
shown to be effective by Chen and co-workers.55 The phenylbutyrate based compound
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HTBP (figure 1.32) was identified in a screen of short chain fatty acids tethered with Zn- 
chelating motifs.
NHOH
iCsotmv* ICso(nM)
o
HTPB
2 2 a
2 2 b
2 2 c
44
25
98
34
2 2 d
2 2 e
22f
o
o
68
16
84
Figure 1.32. Phenybutyrate-derived HDAC inhibitors. 55
The phenylbutyrate moiety was further optimised on the basis of computer docking models 
to shorter, bulkier 3-methyl-2-phenylbutanoyl 22e. The (7?)-enantiomer 22f showed a 
significantly reduced activity, as was the case with 2-phenylbutanoyl compounds 22c and 
22d. This property was consistent with the computer predicted binding energies for the 
different enantiomers.
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Work on optimisation of the cyclic linker of a class of sulfonamide-containing hydroxamic 
acids was carried out by Lavoie and co-workers (figure 1.33).56
■Cso(HV*
X  R  HDAC1 HCT116
TSA 0.005 1
23a (-) H 0.9 2
23b C H , H 1 22
23c (Ofefe H 0.1 2
23d (CH2)3 H 1 8
23e H 0.2 3
23f V ^ | A H 2 15
23g v V H 17 >50
23h
23i
Figure 1.33. Sulfonamide-containing compounds.
The optimum linker between aryl group and hydroxamic acid was identified as two carbon 
units, with little difference on this scale between the saturated dihydrocinnamic acid-type 
23c and unsaturated cinnamic acid-type 23e. Reduction or increase of this separation in 23a, 
23b and 23d reduced activity significantly in this series. Introduction of alkyl substituents to
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the chain was also not favourable for activity, it was, however, better tolerated in the N- 
methyl analogue 23i. As has been shown by comparison of TSA with CBHA, the cinnamic 
acid group provides excellent analogy with the substituted, unsaturated chain of TSA, and 
this group has been shown repeatedly to be an excellent linker. This study further optimised 
the unsaturated chain analogue 23e by substitution in the aryl cap group, identifying the 4- 
chloro and 4-methoxy analogues as substantially more active inhibitors.
This optimisation of the aromatic cap was continued in later work to include polycyclic 
moieties.57 As is consistent with previously described work, the biphenyl (24e) and naphthyl 
(24f) groups proved suitable units for capping the structure (figure 1.34). Analogues in this 
series bearing the reverse order of sulfonamide units (NHS02) were also evaluated and 
found to give comparable activity to those shown.
1 Introduction 53
NHOH
R  HDAC1 IC50 (mM) R  HDAC1 IC ^  (pM)
Figure 1.34. Further cinnamyl-based sulfonamides.
Significant attention has been given to cyclic linker units containing pyrrole functions, with 
examples being reported by Massa in 1990.58 Massa and Mai have continued work on these 
compounds, reporting a series of pyrrole-containing inhibitors of moderate activity in 
2001.59 Later work by the same groups was able to improve activity of this class of 
compounds by increasing separation of the aryl cap from the pyrrole by inclusion of alkyl 
chains of various lengths.60 Building on the information gained in this study on the benefit 
of a separating group between pyrrole and cap, work was continued with an unsaturated
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linker.61 These compounds proved to be highly selective inhibitors for class II HDACs 
(figure 1.35).
R1 R2 HD2 ICsq (pA/$ R1 R2 HD2ICso (pM)
OMe
SAHA 0.05
Figure 1.35. Unsaturated linker pyrrole inhibitors.61
The potent inhibitor NVP-LAQ824 (now in phase II clinical trials) (figure 1.36) was the 
optimised product of an SAR study stemming from the identification of compound 26 in a 
high-throughput screen of the Novartis compound archive.62
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NHOH
ICgo (nM|
NHOH
I C 5 0  (nM)
26 HDAC 150 
HCT116 50
NVP-LAQ824 HDAC 32  
HCT116 10
Figure 1.36. Optimisation of hit compound 26 to NVP-LAQ824.62
A series of benzyl hydroxamate analogues of NVP-LAQ824, with variation of the 
heterocycle in the cap region was produced by Nagaoka and co-workers, however, all 
examples showed substantially lower activities than the cinnamoyl NVP-LAQ824.63 The 
direct benzyl analogue (27) of NVP-LAQ824 was reported as having an isolated enzyme 
IC50 with more than a ten-fold reduction in potency, and with 30,000 times lower activity in 
the HCT116 assay (figure 1.37). It may be suggested from these observed effects that the 
shorter chain of 27 does not allow the same contacts to be made by the cap group with the 
opening of the enzyme active site.
o h  o
NHOH
HN
ICso(mM)
27 HDAC 0.5
HCT116 32
Figure 1.37. Benzyl hydroxamate analogue of NVP-LAQ824.63
It was shown by Shinji and co-workers in 2005 that a phthaloyl group is also capable of 
being tolerated in linker region.64 The unsaturated general structure shown in figure 1.38 
was determined as being preferable to an unsaturated linker or direct attachment of the 
hydroxamic acid to the aromatic ring. It was determined that an additional unsaturated
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linker attaching an aryl group to the phthaloyl nitrogen was optimal, the unsubstituted two- 
carbon linker of 28b showing greatest potency in this series.
o
r - n  
o
R  ECgo (nM) R (nM)
NHOH
SAHA 230
28a
28b
28cMe
MeO 28d
\
\
\
\
2080
177
474
186
2090
28f Me
28g Me
28h c e n
28e
\
28i "^oBn
250
291
3790
763
Figure 1.38. Phthalimide based inhibitors. 6 4
In a similar vein to the phthalimide series above, an isoindolinone linker was identified by 
Miyachi and co-workers.65 The //-benzyl analogue 29a (figure 1.39) showed moderate 
activity against HDAC1 and 6, with ten-fold selectivity for HDAC4.
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NHOH
_____________»C5o(nl\fl_________
R  HDAC1 HDAC4 HDAC6
16 29 53
250 20 230
230 180 990
220 98 750
92 56 280
3300 2100 15,000
Figure 1.39. Isoindolinone inhibitors.65
The first instance of benzo[b]thiophene-linked HDAC inhibitors was recently reported, with 
compounds in this series displaying sub-micromolar activity against SC9 murine 
erythroleukaemia cells (figure 1.40).66 Of the chiral amide examples 30f and 30g, the S- 
enantiomer 30f showed approximately a three-fold greater activity.
TSA
29a
\
\
29b
29c
29d
29e
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R'
f
NHOH
IC50
HDAC1 SC9  
(nM) (pM)
I C 5 0
HDAC1 SC9  
(nM) (|jM)
MeO.
55 111
30a o
NA  60
30b o
o
30c
o
30d
o
30e
A
A
A
2.08
10 0.22
20 0.23
20 0.21
A 2 0
30i
o 30j
0.14
0.53
0.16
128 0.46
10 0.19
Figure 1.40. Benzo[b]thiophene inhibitors 66
Insertion of a 8 -lactam into the otherwise straight, aliphatic chains of compounds 31a-d, 
figure 1.41, resulted in inhibitors approaching the potency of SAHA .67 It was also noted that, 
in addition to HDAC inhibition, these compounds inhibited production o f pro-inflammatory 
agents tumour necrosis factor a (TNFa) and nitric oxide (NO), although again, to a lesser 
extent than SAHA.
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n o  o
n HDAC IC50 (mM)
31a 1 0.67
31b 2 0.35
31c 3 0.27
31 d 4 0.13
SAHA 0.11
Figure 1.41. 5-Lactam-based HDAC inhibitors.67
1.8.3 Benzamides
Having covered the broad category of hydroxamate inhibitors we shall now review the 
known inhibitors in the benzamide class. The class typically displays lower potency than the 
corresponding hydroxamic acids. It is also a common trait of this class to display relatively 
poor potency in isolated enzyme assays whilst maintaining good potency in anti­
proliferation assays. For example, many benzamides are only active at micromolar 
concentrations in isolated enzyme assays and have anti-proliferation activity at similar 
concentrations. This low specific activity may suggest that HDAC inhibition is not the only 
mode of action of benzamides in effecting their cytotoxic response, or that hydroxamates 
suffer from a reduction in expected potency on moving from isolated enzyme to cell-based 
assays.
An early study which established some of the key structural necessities for this class 
identified the 2-aminobenzanilide MS-275 (figure 1.42).68 The study clearly demonstrated 
the requirement of a coordinating heteroatom (in this case -N H 2 or -OH) in the 2-position, 
with re-location to the 3- or 4-positions eliminating activity. Additional bulk on the ring in 
the form of methyl, methoxy or chloro groups is not tolerated in the 3- or 4- positions (32f-i), 
but seems to be allowed in the 5-position (32j-m).
1 Introduction 60
o
A
H
N.
O
R, Rz Rj R4 HEACICsoGjA/D
MS-275 Nhfe H H H 4.8
32a H H H H > 1 0 0
32b H NH2 H H > 1 0 0
32c H H NHz H > 1 0 0
32d NHAc H H H > 1 0 0
32e OH H H H 2 .2
32f NH2 ci-h H H > 1 0 0
32g NH2 H CH3 H > 1 0 0
32h NH2 H OCH3 H 44
32i NHz H a H 40
32j NB? H H CH3 2 .8
32k NH2 H H o c i-h 4.6
321 NHz H H a 7.7
32m
TSA
NH2 H H F 6 .0
0.0046
Figure 1.42. Identification of the 2-aminobenzamide moiety in development of MS-275.68
With the 2-aminobenzanilide group generally adopted as the Zn-binding group of choice in 
this class, further experimentation has focused on the linking and capping regions. The 
linker groups tend to contain cyclic groups as opposed to straight aliphatic chains. The 
direct analogue of SAHA being 50 times less active in isolated enzyme assays (discussed 
later) . 69 A series of cinnamoyl-type benzamide containing a sulfonamide group was 
synthesised as part of a previously discussed hydroxamic acid series (figure 1 .3 4 ) . 57
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The compounds of figure 1.43 are the most potent of the series. Dimethoxy analogue 33b 
showed only modest HDAC1 inhibition, but inhibited HCT116 proliferation at I pM. Again, 
compounds bearing a biphenyl cap group displayed the lowest enzyme IC50S, the order of 
the sulfonamide bearing little influence.
Ar
ICgofcJVO
X-Y  HDAC1 H A  Ac HCT116 T24
Me.
33a
33b
MeO'
Ph
33c
Me.
33d
MeO,
33e
MeO'
Ph
33f
SOjNH 3
SQ 2 NH 4
SQ>NH 1
NHSO2 2
NHSQ> 3
NHSO2 1
10
15 15 >36
3.5 6 .5
7.5
N.T. N.T.
Figure 1.43. Sulfonamide-containing benzamides.57
The promising drug-candidate MGCD0103 (figure 1.44) was discovered by Methylgene to 
bear more favourable biological properties than MS-275. By directly replacing the 
carbamate of MS-275 with a more stable aminopyrimidine ring, the two oxygen atoms are 
exchanged for nitrogen but their positions remain the same.
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MGCD0103
Figure 1.44. MGCD0103: Improved analogue of MS-275.
A later study by Methylgene, referred to in figure 1.45, identifies several benzamides active 
at sub-micromolar concentrations. The cinnamyl compounds 3 4 a -e  were found to be less 
potent than the benzyl variants 34 f-j. The appreciable activity o f p-methoxy analogue 3 4 f  
was not improved by increased flexibility of the cap in 3 4 g . The same appeared true for 
translocation of the cap amine group (cf. 3 4 i and 3 4 j)  with cellular assays.
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Figure 1.45. Amine-linked benzamides.70
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Analogues of MS-275 bearing short-chain fatty acid cap groups have also been synthesised, 
demonstrating comparable activities to the parent compound in enzyme assays (figure 
1.46).71 The highly flexible aromatic cap of 35c provided best potency from these 
compounds.
mACiCgoGJV*
Figure 1.46. Short-chain fatty acids.
Hydroxyethyl compounds bearing structural resemblance to NVP-LAQ824 (figure 1.36) 
have shown moderate activity.63 Variation of the aromatic cap groups in figure 1.47 had 
little effect on potency with these compounds unlike in the case of hydroxamic acid NVQ- 
LAQ824, which required the presence of an indole cap group for cellular activity.
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Ar N
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ICgotMlVO
HDAC HCT116
36a
36b
36c
3.7
2.4
3.1
4 .7
4 .5
4 .6
Figure 1.47. Hydroxyethyl amines. 6 3
1 .8 .4 . C a r b o x y la te s
A small number of short-chain fatty acids are known as relatively feeble inhibitors of 
HDACs, with activity typically in the millimolar range (figure 1.48).28
ONa OH
o o
ONa o^ ^o
o o
Sodium
butyrate Valproic add
Sodium AN-9
phenyl butyrate (pivaloyloxymethyl butyrate)
Figure 1.48. Carboxylate inhibitors.
Despite the low activity of this class of inhibitor some examples are still being clinically 
investigated, partly owing to the fact that they have already passed safety testing for other 
clinical uses.
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1 .8 .5 . M a c r o c y c lic  In h ib ito rs
This heading shall include both cyclic peptides and related hybrid compounds. Compounds 
of this class generally demonstrate very good activity, however, the disulfide-bridged 
compound FK228 (figure 1.49) is the only member of this group currently in clinical trials. 
The bridged 16-membered ring structure of this compound does not immediately resemble 
the generalised formula followed by the previously discussed inhibitors. Work by Furumai72 
elucidating the mode of action of FK228 demonstrated that the native compound in fact acts 
as a prodrug, and the active structure is the reduced form, 37, which provides a free thiol 
moiety which could be capable of co-ordinating to the enzyme’s active site.
Figure 1.49. FK228 prodrug and its active form.72
Depicted in figure 1.50 are the structures of some analogous cyclic tetrapeptide inhibitors. 
All show similarly substituted peptidic cap regions, with saturated straight-chain linkers. 
Trapoxin B is an example of an irreversible HDAC inhibitor; reaction of the terminal 
epoxide with the enzymes active site covalently binds the inhibitor (possibly the 
nucleophilic histidine residue on Lewis acid activation of the epoxide by zinc), permanently 
blocking activity. CHAP31 is the reversible analogue of this compound, bearing the 
common hydroxamic acid Zn-coordinating group. The naturally occurring apicidin 
demonstrates the potency conferred by the cyclic peptide cap group. The compound is 
active at low nanomolar concentrations even though it does not bear a group capable of 
strong coordination with the enzymes Zn ion. The recently reported compound 3 8  bears a 
trifluoromethylketone moiety, 73 a group known to act as a coordinating group through the
FK228 37
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carbonyl. The trifluoromethylketone functionality, although capable of conferring good 
activity, has been deemed to be unsuitable for in vivo use owing to its ready metabolism to 
the inactive alcohol.
HN.
NH HN'
Trapoxin B
Apiddin
Figure 1.50. Cyclic tetrapeptides.
o
HN. NHOH
NH HN
CHAP31
CF'HN.
HN.
NH HN
NH HN'
OMe
38
The compounds 39 and 40 (figure 1.51) could have been included with other straight-chain 
hydroxamic acid inhibitors, however, they have been included here as hybrids, blurring the 
boundaries between the classifications. Peptide-mimic 39 showed low nanomolar inhibition 
for mixed HDACs and approximately a ten-fold selectivity for HDAC1 over HDAC8 .74 The 
benzodiazepine 40 is an interesting example of a peptide-mimetic, but gave more modest 
potency, displaying low micromolar activity in H661 cell assays.75
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MeO.
NHAc
'OH
39
Figure 1.51. Cyclic peptide mimics. 7 4 , 7 5
'OH
40
1.8.6. Miscellaneous Zinc-Binding Groups
Having discussed examples of the most commonly used zinc-binding groups present in 
HDAC inhibitors some attention must now fall on work that has sought to identify new 
alternatives to these groups. As has been mentioned before, the hydroxamic acid group 
generally provides excellent activity but suffers in vivo from rapid metabolism and poor 
bioavailability. The benzamide functionality does not suffer these drawbacks, but generally 
confers considerably lower activity. Figure 1.52 summarises the examples of new Zn- 
binding groups that can be readily compared in efficacy owing to their possession of the 
same linking and cap groups -  in this case, the unsaturated chain and anilide groups of 
SAHA.
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Figure 1.52. SAHA analogues with Zn-binding groups. 
a Ref76; b ref77; c ref69; d ref48; e ref78; f ref79; 9 ref80; h ref45; 1 ref81.
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It is noted that, as previously mentioned, the benzamide analogue 41b shows essentially no 
activity compared with its hydroxamate analogue SAHA.69 The most promising alternative 
groups appear to be those containing a sulfur atom for coordination. The simple thiol 4 1 c  
appears to be an improvement on the hydroxamate, with acetylation (4Id) greatly 
attenuating activity. The sulfur atom in potent mercaptoamide 4 1 e  cannot be replaced with 
oxygen (4 1 g ) ,78,79 but removal of the nitrogen to give mercaptoketone 4 1 k  improves activity 
further.79 In this case, acetylation of the sulfur, in 411, is not only tolerated but produces a 
favourable effect. The only other example of sub-micromolar activity is from a-ketoamide 
4 1 u , however it was determined that this functionality is also readily metabolised to the 
alcohol in vivo.45 Substitution of SAHA’s carbonyl oxygen for sulfur in 4 1 f  and the 
subsequent loss of activity may indicate that the acidity of the hydroxamic acid group is 
necessary for its high activity.
The direct thiol analogue of SAHA (4 1 c) has been the subject of considerable study by 
Suzuki and co-workers. First identified in 2004, it was optimised in the cap region by 
substitution of various aromatic groups (figure 1.53) .48
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Ar ICsotMN* Ar ICso(MM)
41c
0.21
0.11
0.072
Figure 1.53. Optimisation of thiol SAHA analogue. 48
42c
\  0.075
42d
0.17
The cap group of 4 2 d  (the hydroxamic acid analogue of which, 15, (figure 1.25) was 
described by Glaser) was selected for further study, resulting in the pro-drug form 43  (figure
1.59), which performed at low micromolar concentrations against a panel of cancer cell
lines 82
42d 43
Figure 1.54. Thiol inhibitor and enhanced performance pro-drug. 82
As part of the study that discovered a-ketoamide 4 1 u  (figure 1.52), biphenyl compounds 
4 4 a -f  were also synthesised (figure 1.55). The a-ketoester 4 4 d  also showed very promising
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activity but proved unstable. Using the same general structure, Vasudevan and co-workers 
synthesised a series of heterocyclic ketones.83 The most active of these compounds (44g-i) 
showed low micromolar potency.
R HDAC ICgo (MM) R HDAC IG*, (|JVD
o
44a3 0.02
ox
44b3 \ " cf3 2.9
44c3 3 7
o
44cf o.062
o
44c3 \  y  0.11
o
Figure 1.55. Further Zn-binding groups. 
a Ref45; b ref83.
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2 The Oxygen Series
The initial study of this project consisted of the synthesis of a series of potential HDAC 
inhibitors containing a common aryloxyalkanoic acid hydroxyamide motif1 -  more easily 
referred to as the oxygen series.
2.1 Synthesis
The general form of this series was selected by beginning from the structure of trichostatin 
A (TSA) and the frequently observed mechanical formula of Zn-binding group -  linker -  
capping group (discussed previously). When considering the mode o f attachment of the 
alkyl chain to the aromatic cap, it was noted that a benzyl ketone is present in TSA -  
previous work has shown that this may be replaced with a variety of functional groups, 
including a sulfoxide, thioether or aromatic ether without harming inhibitory activity. The 
structurally most simple example phenyl ether 10 showed some promise ,2 with moderate 
inhibitory activity. Biphenyl analogue 11 showed a greater than ten-fold increase in activity 
(figure 2 .1 ) .3
NHOH NHOH
Figure 2.1. Known arylether hydroxamates.
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Further work within this group focusing on development o f this framework had led to the 
identification of compounds 12 and 13 (figure 2.2) as extremely potent in isolated enzyme 
assays.
NHOH
Figure 2.2. Previously synthesised oxygen series compounds.
Despite the excellent activity of 12 and 13, performance in cellular assays remained modest. 
It was from this starting point that the oxygen series study began, with the aim of 
developing the identified active framework to improve cellular activity o f this class of 
compounds. It was decided that the series designed to explore the potential o f this template 
should contain a terminal A-hydroxyamide, a saturated alkyl chain linking to an aromatic 
group capable of expedient diversification. With this decided, it was noted that the p-amino 
group of 12 would retain the structural analogy to TSA and provide a point for variation 
from its dimethylamine (figure 2.3).
TSA General structure for oxygen series
Figure 2.3. Structural basis of the oxygen series.
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For this arrangement the key intermediate amines 51 -53  could be readily reached from the 
commercially available 4-nitrophenol and alkyl bromides (4 5 -4 7 ). A Williamson ether 
synthesis, with caesium carbonate and refluxing in DMF, gave the various ethers (4 8 -5 0 )  
(scheme 2.1). The chain length o f the initial alkyl bromide was the first point of variation 
for the structure-activity relationship study, but the chain always contained a terminal ester 
ready for later conversion to the hydroxamic acid. TSA possesses a linker seven carbons in 
length, so oxygen series variants with six, seven and eight carbon linkers were synthesised 
to determine the optimum length. Both the ethyl-6 -bromohexanoate (4 5 ) and ethyl-7- 
bromoheptanoate (46 ) starting materials (scheme 2.1) were commercially available. The 
known ester methyl-8 -bromooctanoate (47 )4 was easily obtained in from the commercially 
available acid (54 ) by refluxing in 4% conc. H2SO4 in methanol (scheme 2.2), basic work­
up providing the pure compound.
With the ether link installed in excellent yield, reduction o f the nitro group by catalytic 
hydrogenolysis using 5% palladium on carbon provided the aromatic amine in good to 
excellent yield and requiring no further purification after removal o f catalyst by filtration.
o
Br
OR
Q?N
n R
46 1 Et
46 2 Et
47 3 Me
OR
n R
48 1 B  85%
49 2 B  90%
50 3 Me 97%
H2N
51
52
53
OR
n R
1 Et 83%
2 Et 62%
3 Me 95%
(a) 4-Nitrophenol, CS2 CO3, DMF; reflux; (b) 5 % Pd/C, BOH
Scheme 2.1. Synthesis of intermediate amines 51-53.
4 % c. EbS04/Me0H; reflux
Scheme 2.2. Synthesis of methyl-8-bromooctanoate.
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The direct analogue of TSA, possessing the dimethylamino cap (R 1=R2=Me), was a logical 
compound to begin the series. The intermediate amine (52) provided a straightforward point 
for divergence of structure at the cap region through alkylation or acylation, the 
dimethylamino compound being available through double reductive alkylation of amine 52 
(scheme 2.3). A solution of aqueous formaldehyde, sodium cyanoborohydride and catalytic 
acetic acid gave the ester 55 in good yield.
OEt HCHO (37 % aq solution)
NaCNBHs, AcOH(cat.), MeCN 
69%
OEt
Scheme 2.3. Dimethylamine 55.
A standard procedure was employed with all compounds of this series for the conversion of 
the ethyl esters (or methyl ester, in the case of 47) into the corresponding hydroxamic acids. 
Moderate to poor yields of the hydroxamic acids were obtained from the addition of 
methanolic solutions of hydroxylamine and potassium hydroxide to solutions of the esters in 
THF with stirring typically for at least one day. Purification of these highly polar 
compounds was initially problematic. Extremely poor recovery was experienced with 
column chromatography, and poor solubility in organic solvents eliminated the possibility 
of recrystallisation in most cases. The insoluble nature of the compounds was eventually 
utilised through the repeated trituration of the hydroxamic acids in various solvents to wash 
out any impurities and provide analytically pure material.
The amines 51-53 provided very few restrictions on possible functionalisation of our cap 
group, leaving us with a wide range of possibilities. Investigation into the SAR of another 
HDAC inhibitor, NVP-LAQ824 had shown inclusion of an indole group to be necessary for 
cellular activity (figure 2.4, discussed in the introduction) , 5 and although there is little
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structural similarity between NVP-LAQ824 and our series, it seemed an interesting point to 
investigate.
NHOH
HN IC5 0  (nM)
NVP-LAQ824 HDAC 32 
HCT116 10
Figure 2.4. Indole-containing compound NVP-LAQ824.5
Acylation of amine 52 with indole-3-acetic acid using the coupling system of EDCI, HOBT 
and NMM as base in DMF proceeded in good yield, as did reaction with indole-3-propionic 
acid under the same conditions to produce the more flexibly linked analogue (57 and 58 
respectively, scheme 2.4). The six-carbon and eight-carbon chain analogues were acylated 
under the same conditions in excellent yield (56 and 59 respectively). These esters, after 
recrystallisation from ethanol were converted to the hydroxamic acids in the standard 
manner.
n R
51 1 B
52 2 B
53 3 Me
OR OR
85%
78%
79%
82%
(a) 56, 57, 58; x=1: lndde-3-acetic add, EDC.HQ, HOBT, NMVI, DMF; 58; x=2: i ndole-3-propionic 
add, EDC.HQ, HOBT, NMVf DIVF.
Scheme 2.4. Acylation of amines 51-53.
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Compound 60, the amine analogue of amide 57, was not available from the reduction of 57 
with borane-THF complex or sodium borohydride under standard conditions. Reduction of a 
similar amide using sodium borohydride in the presence of acetic acid had been reported, 5 
and this approach proved successful with warming to 45 °C and stirring for 17 h (scheme 
2.5). The modest yield in this reaction appeared to be due, at least in part, to the unwanted 
reduction of the ester to a small extent.
OEt
HN
53%
c
(a)(i) AcOH, NaBKj, THF; (ii) 57, THF, 45 °C.
Scheme 2.5. Reduction of amide 57.
Derivatization of the series continued with attachment of a pyridine moiety to the cap region, 
the lead compound 12 warranting further investigation of this system. The secondary amine 
61 (scheme 2.6) was the product of a reductive alkylation o f primary amine 52 with 4- 
pyridinecarboxaldehyde. The imine formed from mixing the aldehyde and amine in 
methanol was reduced by addition of sodium cyanoborohydride and zinc chloride to give 61 
in good yield.
An indole was incorporated by acylation with indole-3-acetic acid or indole-3-propionic 
acid to give compounds 62 and 63 respectively. Initial attempts to carry out this acylation 
under the conditions used for 56-59, using EDCI.HC1/HOBT, were unsuccessful - as were 
attempts using BOP. An excellent yield, however, resulted from the use of isobutyl 
chloroformate to activate the acid, with A-methylmorpholine in THF. The more flexibly- 
linked compound 63 was converted to the hydroxamic acid in the usual way, however, the 
shorter 62 proved problematic. The reaction in this case proceeded as expected, but the 
crude product after work-up was a viscous oil. Purification by column chromatography was
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unsuccessful owing to the extremely polar and insoluble nature o f the compound, and as 
recrystallisation or washing of the product was not an option this compound remained un­
purified and so is not included in this series.
OEt
62 1 44%
63 2 85%
(a) (i) 4-Pyridinecarboxaldehyde, MeOH; (ii) NaCNBFb, ZnCI2; (b) n=V. 3-indoleacetic add, NMM, 
isobutyl chloroformate, THF; n=2: 3-inddepropionic add, NMM, isobutyl chloroformate, THF.
Scheme 2.6. Reductive alkylation and acylation of amine 52.
The amide 63 was seen as a useful potential stepping stone to a tertiary amine analogue. It 
was hoped that selective reduction of the amide carbonyl would provide the amine analogue 
64, ready for conversion to the hydroxamic acid (scheme 2.7). Unfortunately, attempts at 
reduction with BH3.THF or the previously successful use of sodium borohydride in the 
presence of acetic acid proved fruitless.
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OEt BH3 THF
or
NaBKt, AcOH, THF
O B
64
Scheme 2.7. Attempted selective reduction of amide.
It was decided, therefore, that the more vigorous reduction with lithium aluminium hydride 
would be required, followed by re-oxidation of the resultant alcohol 65 (scheme 2.8).
OEt OH
U A IH 4, THF
9 9 %
63
6667
Scheme 2.8. Reduction and attempted re-oxidation.
Whilst the aggressive reduction proceeded in excellent yield, oxidation was less successful. 
Attempts were made to reach the acid directly using ruthenium (III) chloride, PDC in DMF
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and TEMPO, all without success. Further unsuccessful attempts to reach the aldehyde as an 
intermediate were made using PDC in dichloromethane or PCC in dichloromethane.
Returning to the intermediate primary amine 52, an alternative attachment of an indole 
group was possible from reductive amination of indole-5-carboxaldehyde to give 68 
(scheme 2.9). The highly functionalised analogue 69 was selected with the aim of 
improving water solubility, as an analogue that retained the pyridyl group. In these cases, 
substitution of sodium borohydride for the cyanoborohydride -  zinc chloride system was 
found to be preferential. Both esters were then converted to the hydroxamic acids.
69
OH
(a)(i) Pyridoxal hydrochloride, Bt3 N, MeOH; (ii) NaBH,;
(b)(i) Indde-5-cartx)xaldehyde, MeOH; (ii) NaBFb
Scheme 2.9. Additional reductive alkylations.
Another interesting compound (71) was available through 0-alkylation o f 5-hydroxyindole 
(70) in the place of 4-nitrophenol (scheme 2.9). It was observed that inclusion of the 
potentially desirable indole moiety in this fashion provided an annulated analogue which 
fitted perfectly with the general structure planned for this series as it retained the 4- 
aminophenyl structure. Only one step was required to reach the target ester, ready for
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hydroxamation -  the Williamson ether synthesis with 5-hydroxyindole and ethyl-7- 
bromoheptanoate providing an acceptable yield of the ester under standard conditions 
(scheme 2.10).
OH
70
Ethyl 7-brorrDheptanoate
CS2CO3, DMF; reflux 
60%
O B
Scheme 2.10. Alkylation of 5-hydroxyindole.
With a range of groups now installed in the cap region, a final study into any effects of 
electron-withdrawing substituents on the benzene ring was desired. Fluorine atoms present 
at the 2- or 3-position on the ring will exert an influence on the electron densities of the 
aromatic amine and ether linkages, and so may influence the biological stability o f the 
compound. With the commercial availability of both 2- and 3-fluoro-4-nitrophenol no 
change in synthetic route was necessary. Both compounds successfully underwent the 
Williamson ether synthesis and catalytic hydrogenolysis in high to excellent yields (scheme 
2 .11).
OEt
OjN
OEt C
72
73
Ri R2
F H 79 % 
H F 74 %
t-ysi
74
75
Ri R2
F H 89 % 
H F 95 %
(a) R1-F: 2-Ruoro-4-nitrophenol, CS2CO3, DMF; reflux; F^=F: 3-fluoro4-nitrophenol, Cs^CCh, DMF; reflux;
(b) ht, 5 % Pd/C, BOH
Scheme 2.11. Incorporation of electron-withdrawing substituents on the benzene ring.
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The amines 74 and 75 underwent acylation under the conditions previously used to provide 
the analogues 76 and 77 in excellent yield (scheme 2.12).
v W r
Ri R2
74 F H
75 H F
Scheme 2.12. Acylation of fluoro analogues.
2.2 Results
Conversion of all esters to the hydroxamic acids under the conditions previously described 
provided a systematically varied range of compounds with which to begin our analysis of 
histone deacetylase inhibition. Un-optimised yields for the final conversion of esters to 
hydroxamic acids along with results from the isolated enzyme assay are given in table 2.1.
76
77
Ri r 2
F H
H F 83%
(i) lndole-3-acetic add, EDC.HQ, 
HOBt, NMM, DMF
(ii) Rj=F: 74; R*=F: 75
Qttrr0B5 o
H
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NHOH
R n Yield IQ*, (nM) n Yield IC5 0  (nl\/&
78
79
HN
80
HN
H
81
HN
H
82
o
HM
N'
83
6 38% 18.8 ±6.0 6 39% 16.0 ±5.0
5 59% 50 ± Z1
6 36% 1Z8±5.2
7 42% 22.4 ±9.0
6 28% 13.1 ±5.0
6 77% 23.5 ±9.0
HN
6 69% 6.2 ±3.5
85
H
86 NH
87
6 81% 16.4 ±8.0
6 59% 14.3 ±5.7
OH
88
OH
6  59% 2Z 0±1Z 0
6  6 6  % 3.6 ± 1.8
89
Table 2.1. Hydroxamic acids of the oxygen series with percentage yields and HDAC IC50 values.
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Biological evaluation of most of these compounds was carried out by Alao and Vigushin at 
Imperial College and some others by Joel at St. Bartholomew’s Hospital, London. All 
compounds of the oxygen series proved to be potent, low nanomolar inhibitors of histone 
deacetylase in isolated enzyme assays.
The 4-dimethylamino cap group of 78 (analogous to that of TSA) showed excellent activity, 
being dramatically more active than the known unsubstituted analogue 10 (figure 2.1). 
Comparison of the three indolylacetamide compounds 79-81 showed that the seven-carbon 
chain length provided optimal activity in this case, although six and eight-carbon chains 
were tolerated reasonably well. Fluorination o f the aryl ring in the 3-position (82) showed 
no change in activity, however, in the 2-position (83) a moderate reduction in potency was 
observed. Increasing flexibility of the attached indole group with 84 did not appear to affect 
activity, and somewhat surprisingly, increasing the aromatic character o f the cap by 
inclusion of the pyridyl group of 86 did not improve activity.
Reduction o f the amide to secondary amine 85 would also allow greater flexibility in 
addition to changing potential interactions at the cap region, this compound showing greater 
potency than the corresponding amide 80. The alternative attachment of the indole group in 
amine 87, with reduced flexibility and changed position o f the indole-amine still showed 
excellent activity. The more polar cap group of 88 was tolerated, but did not increase 
activity. It was the simple indole 89, which retains the 4-amino function (as with TSA 
analogue 78) but with the addition of a fused ring, that showed the greatest potency of this 
series.
Antiproliferation assays were also carried out on compounds 85 and 89 with two cancer cell 
lines. With HeLa cells, both compounds gave an IC 50 of 7 pM, and with MCF-7 cells 
compound 85 again showed an IC 50 of 7 pM and 89 5 pM.
Work in this series produced some very promising results in the form of excellent activity in 
the isolated enzyme assay. The general structure was clearly a suitable basis for 
development of compounds with high affinity for the enzyme, and it was indeed possible to
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identify one compound in particular which displayed not only excellent activity, but was 
synthetically simple to make and structurally very efficient. The indole 89 appeared to be an 
ideal candidate for further development, but the trend that was observed with the series with 
respect to cellular activity was unsatisfactory. TSA gives nanomolar activity in the isolated 
cell assay and this transfers to still nanomolar activity in cell-based assays. The oxygen 
series developed compounds with activities in the same range as TSA, but this did not track 
in results from cellular assays. The trend observed was of reduction in potency to 
micromolar figures, the best activity achieved being 5pM in one cell line. With this trend 
still being observed despite our efforts to optimise the series, it was felt that a problem was 
likely to lie with the general aryl-ether structure when it came to cellular penetration. No 
further development of this series was carried out, but it is possible that were the cap-group 
development undertaken here to be transferred to a different linker-structure, improvements 
in cellular activity may be achieved.
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Work in this chapter focuses on the exploration of new zinc-binding moieties. The 
development initially began utilising the frame of the known potent inhibitor MGCD0103 
(figure 3.1).
W iVa> *w  „  L s  m - S  h . *  m
s
MGCD0103 90 91 92 93 94  95
Figure 3.1. Exploration of new potential Zn-binding groups.
Whilst the hydroxamic acid moiety present in many HDAC inhibitors provides an excellent 
zinc-binding functionality, its presence in a drug can lead to undesired characteristics such 
as low oral bio-availability and short half-life in vivo} With this in mind, there is a clear 
need to discover alternative groups capable of chelating the Zn2+ ion with high affinity and 
which do not produce the undesired physiological affects of hydroxamic acids. By 
considering the mode in which the heteroatoms coordinate the metal ion, it seems plausible 
that amino heterocycles (90-95) could provide suitable alternatives (figure 3.2).
3 Cyclic-Linker Non-Hydroxamates 96
o
o
Hydroxamic add benzamde 91
Figure 3.2. Suggested potential mode of binding of new end groups.
The imidazole group has been shown to function as a zinc-binding group when incorporated 
in inhibitors o f the enzyme famesyl transferase, which also utilises a zinc ion at the active 
site f With this in mind, an additional, structurally simple, example o f an imidazole- 
containing compound, 96, was synthesised (figure 3.3).
Figure 3.3. Additional imidazole-containing target compound.
Additional targets 97 and 98 were also desired for evaluation o f  the novel end groups, 
however, despite synthetic effort towards these compounds the final products were 
unfortunately not reached (figure 3.4).
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98
HO
Figure 3.4. Additional planned targets.
Although synthesis of hydroxymethylimidazole 98 was not completed, synthesis of 
interesting intermediate compounds suggested another possible zinc-binding group. It 
seemed surprising that no examples of compounds bearing the amidoxime functionality o f 
99 (figure 3.5) had been previously reported when considering the similarity to a 
hydroxamic acid. This compound was duly synthesised and evaluated. In addition to the 
MGCD0103 target a small number of synthetically simple amidoximes were also 
synthesised.
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NOH
NOH
Figure 3.5. Amidoxime compounds.
A final example of this class was synthesised in an attempt to directly compare the activity 
of the amidoxime group with that of a hydroxamic acid. The direct amidoxime analogue of 
SAHA (104, figure 3.6) was selected for this purpose and shall be included here for the 
purpose of comparison with other amidoximes despite it not containing a cyclic linker.
NHOH
NOH
Figure 3.6. Amidoxime analogue of SAHA.
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3.1 Synthesis
As the many of the compounds in this chapter are structurally based on MGCD0103, it was 
necessary to have a sample of the original compound for comparison o f biological 
properties. The patented route of Methylgene to this compound was followed without 
difficulty (scheme 3.1).
HQ. l-feN
OMe
105
73%
i-ysi n
OMe 6 0 %
NH2
o
MGCD0103
OMe
107 o
93%
OH
66%
108
(a) Pyrazde cartooxamidine.HQ, DIPEA DIVF; 5 h, r.t.; (b), 110, ‘PrOH; 20 h, reflux; (c) LiOH, 
THF, MeOH, FfeQ 1 d, r.t.; (d) 1, 2-Phenylenediamne, BOP, Et3 N, DMF; 1 d, r.t.
Scheme 3.1. Synthesis of MGCD0103.
Guanidine 106 was the product of stirring a solution of commercially available amine 105 
and pyrazole carboxamidine hydrochloride with an amine base in DMF at room temperature. 
Condensation of 106 with 110 (produced in one step from 3-acetylpyridine (109) by 
refluxing in dimethylformamide dimethylacetal, scheme 3.2) gave the aminopyrimidine 107, 
requiring only trituration with ethyl acetate for purification.
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Drrethylfcxmamide dimethylacetal
Scheme 3.2. MGCD0103 intermediate.
A likely mechanism for the formation of the aminopyrimidine ring involving the early 
irreversible loss of volatile methylamine is given in scheme 3.3.
Scheme 3.3. Proposed mechanism of ring formation for 107
The final compound was obtained by hydrolysis of methyl ester 107 under standard 
conditions and acylation of 1,2-phenylenediamine with the resultant acid 108, using BOP as 
an activating agent. With a control sample of MGCD0103 now in hand, it was possible to 
utilise intermediate acid 108 for acylation of the amines required for the novel groups of 
targets 90-95.
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3.1 .1  P rep a ra tio n  o f  A m in es
The first target was the direct sulfur analogue, 95 , of the parent compound. It again 
appeared surprising that this group had not been evaluated before, especially when the 
excellent activity of other thiol-based inhibitors is considered.4 The 2-amino substituted 
group, used in so many inhibitors, was identified during the development of inhibitor MS- 
275, and during this development the 2-hydroxy analogue was also identified as having 
excellent activity (discussed in the introduction).5
Direct acylation of 2-aminothiophenol (1 1 1 ) with 108 was not attempted owing to the 
probability of forming the benzothiazole (scheme 3.4).6
o
SH DIPEA
111
R
Scheme 3.4. Likely formation of benzothiazoles.6
It was therefore deemed necessary to protect the thiol before coupling the amine. The 
method of Noveron et al.7 was followed, trityl protection occurring on sulfur under highly 
acidic conditions with triphenylmethanol (scheme 3.5).
SH STrt
111 112
Scheme 3.5. Trityl protection of aminothiophenol.
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H2N. N ^ N  n  n2N Sx H2N n
T  vnh r  >  Y  > Y
N = y  N ^ nX S —^
s
113 114 115 116
Figure 3.7. Commercially available amino heterocycles.
The heterocyclic amines required for targets 90-93 are all commercially available (figure 
3.7). Aminomethylimidazole 119 required for analogue 94 was not commercially available 
and was prepared as the dihydrochloride salt in two steps from imidazole according to the 
procedure of Bastiaansen et al. (scheme 3.6).8
Bz Bz / i
a  D N .2HCI
GY "N 23% N N 56% N NH2
Bz
117 118 119
(a) Benzoyl chloride, Et3 N; 2 h, CfC-r.t.; (b) MeOH, 'PrOH (sat0* with HQ); 4  h, reflux.
Scheme 3.6. Synthesis of aminomethylimidazole intermediate.
Proposed mechanisms for the formation of 118 and 119 are given in scheme 3.7.
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MeOH
HQ, reflux
Scheme 3.7. Proposed mechanisms for formation of 118 and 119.
The heterocyclic amine required for target 97 was the 1,2,5-thiadiazole-3,4-diamine 123 
(scheme 3.8). Synthesis of the diamine has been reported via the bicyclic compound 122. 
This is formed from reaction of diamidoxime 121 with freshly prepared sulfur dichloride. 
This precursor was, in this case, prepared from aqueous glyoxal (120) and hydroxylamine 
with aqueous sodium hydroxide (scheme 3.8).
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C° —  " T ™ — t f r %  —  ^ >O 19% 35% V ^ N  7 4  % N
120 121 122 123
(a) NH2OH.Ha, NaOH, h^O; 5h, 0 to 95 °C; (b) S a 2, DIVF; 0 to 55 °C, 14 h;
(c) 3 M NH4OH; 100 °C, 10 rrin.
Scheme 3.8. Preparation of I^.S-thiadiazole-S^-diamine.
Whilst the yield of the initial step9 in this sequence is poor, starting materials are cheap and 
easily handled; this is as opposed to alternate routes utilising the gaseous and highly toxic 
cyanogen in place of glyoxal, which itself must be prepared from a cyanide metal salt. 
Conversion of 121 into heterocycle 122 is also a less than ideal reaction -  sulfur dichloride 
is not commercially available on less than an industrial scale, and so must be generated from 
the more stable sulfur monochloride and chlorine gas. The low boiling fraction of SCI2 is 
then distilled as a cherry red, noxious liquid and used immediately in reaction with 121 
according to the procedure of Komin et al.10 Thorough studies on compound 122 in the 
same paper show that efficient hydrolysis to target diamine 123 is possible by heating in the 
presence of ammonium hydroxide, without which, any sulfur dioxide generated in the 
reaction leads to over hydrolysis of 122 to glyoxime and elemental sulfur.
Having prepared the required amines, coupling with the acid 108 was carried out. Examples 
90-94 utilised EDCI.HC1/HOBT coupling agents in place of BOP in order to ease isolation. 
Purification of MGCD0103 involved removal o f solvent from the reaction and column 
chromatography of the crude mixture. The targets synthesised here proved to be extremely 
insoluble, rendering column chromatography out o f the question. With the water soluble by­
products of the EDCI/HOBT system, the products could be precipitated from the reaction 
mixture by addition of copious amounts of water. This method afforded good yields for the 
above examples (scheme 3.9).
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OH
amines 113-116,119, DMF; 
18 h, r.t.
HOBT, EDO.HQ, IMVM
H
N.
R
O O
S
90 91 92 93 94
Yield: 50% 61 % 62 % 49 % 36%
Scheme 3.9. Coupling of amino heterocycles.
The trityl protected 2-aminothiophenol (112) failed to react under these conditions, possibly 
due to the steric bulk of the trityl group. In light of this, the more reactive acid chloride was 
employed. Initial attempts at the new coupling involved formation of the acid chloride 
through refluxing in thionyl chloride and were not successful. As it was suspected that the 
conditions for acyl chloride formation were perhaps unnecessarily harsh, the reaction was 
tried again using oxalyl chloride with catalytic DMF at room temperature. Despite a 
reaction time of 2 d for the coupling, this method did furnish the protected intermediate 124, 
which was readily deprotected with trifluoroacetic acid and triethylsilane to give the target 
thiol 95 (scheme 3.10). Whilst microanalytical evidence identified the product of this 
reaction as free thiol 95, later analysis by mass spectrometry and repeat of microanalysis 
demonstrated that decomposition to the benzothiazole 125 had occurred.
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OH
26%
a
44%  b
(a)(i) Qxalyl chloride, cat. DMF, DCM; 3 h, r.t.; (Ii) trityl 2-aminothiophenol, CHa3; 2 d, r.t.;
(b) triethylsilane, TFA, DCM; 10 rnin, r.t.
Scheme 3.10. Synthesis of 2-aminothiophenol analogue.
Unfortunately, coupling of the 1,2,5-thiadiazoIe-3,4-diamine 123 was unsuccessful under all 
the conditions described above, in each case no reaction occurring.
In addition to assessing imidazole 94, it was desired that an additional example o f an 
aminomethylimidazole-containing compound be synthesised. This particular group has been 
utilised as a zinc-binding group in inhibitors of another zinc-containing enzyme, famesyl 
transferase.2
The benzylamine-linked compound 96 was available in three simple steps from 4- 
nitrobenzaldehyde, 126 (scheme 3.11). Reductive amination with 3-aminoquinoline 
proceeded in excellent yield, requiring only hydrogenolysis of the nitro group (127), then 
another reductive amination, this time with 4(5)-imidazole carboxaldehyde.
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N.
a b
^  76% 5 9 %
126 127 NO, 128 NH2
31 % c
N
H HM—{/
N
96
(a)(i) 3-Anrtnoquinoline, cat. AcOH, MeOH; 18 h, r.t.; (ii) NaBH*; 1h, r.t.; (b) 5% Pd/C, EtOH;
18 h, r.t.; (c)(i) 4(5)-irridazole carboxaldehyde, cat. AcOH, MeOH; 1 h, r.t.; (ii) NaBH*; 3 d, r.t.
Scheme 3.11. Additional imidazole Zn-binding group.
Despite the structural diversity present in the above compound’s proposed zinc-binding 
moieties all compounds failed to produce any significant effect in an in vitro HDAC 
inhibition screening assay carried out at standard 5 pM concentrations.
3.1.2 Hydroxymethylimidazole Cap Group
Efforts towards synthesis of target 98 (figure 3.4) were reliant on the possibility of 
converting an amidine group into the desired imidazole. An example of this reaction, 
utilising a procedure of Thurkauf and co-workers11, was carried out making use of 
dihydroxyacetone dimer (DHAD) and ammonium chloride in ammonium hydroxide to 
convert benzamidine 129 to the bicyclic 130, albeit in poor yield (scheme 3.12).
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NH
129
DHAD, NH4CI, NH4OH
80  °C, 30 rrin 
1 3 % 130 HO
Scheme 3.12. Trial formation of hydroxymethylbenzimidazole.
A proposed mechanism for the formation of 130 is given in scheme 3.13.
OH
OH
HO
OH
NH
OH
HVOH
OH
OH 130
Scheme 3.13. Proposed mechanism for formation of 130.
In the literature example the benzamidine was formed from a nitrile by reaction with lithium 
hexamethyldisilazide (LHMDS), therefore it was proposed that our target might be reached 
from a benzonitrile precursor analogous to acid 108 above.
With the reaction known to work in this simple context, work began on production of the 
necessary nitrile precursor 133 (scheme 3.14). It was found that the same experimental 
procedures as for the original MGCD0103 could be used, merely substituting the methyl-4- 
(aminomethyl)benzoate for commercially available 4-(aminomethyl)benzonitrile (131).
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HQ. HhN
CN 78 %
NH
ii
H2N N
CN 6 4 %
131 132
CN
133
(a) Pyrazole carboxaridine.HQ, DIPEA, DMF; 7  h, r.t.; (b), 110, 'PrOH; 18 h, reflux.
Scheme 3.14. Synthesis of intermediate nitrile.
The nitrile was now ready for conversion to the amidine, and hence heterocycle formation. 
The first method attempted was similar to that of Eisen and Kapon, which, as described 
above, involved formation of a complex with LHMDS followed by acid hydrolysis.12 
Unfortunately this reaction proved problematic, and reaction of either the free amine 133 or 
the Boc protected analogue 135 did not result in an isolable, pure product (scheme 3.15). 
The original procedure utilised aqueous HC1 for hydrolysis, but this was not successful in 
the present case. As the product of hydrolysis appeared to be extremely hygroscopic, 
attempts were made using ethanolic HC1 or TFA, both of which gave similarly unsuccessful 
results.
CN
133
9 0 %
Boc
CN
NHj
136
(a)(i) LHMDS, THF; (ii) acid; (b) Boc^O, DMAP (cat), pyridine, 4  d, r.t.
Scheme 3.15. Attempted formation of benzamidine.
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3 .1 .3  A m id o x im es
During the attempted synthesis of the hydroxymethylimidazole 98, it was noted that the 
reaction of a nitrile group with hydroxylamine would result in formation of an amidoxime, a 
structure closely related to that of hydroxamic acids. It is known that the (Z)-amidoxime is 
the favoured isomer in cases without A-substitution,13 and their coordination with metal ions 
has been studied.14 Amidoximes have also been used as metal coordinators in quantitative 
analysis.15 The similarity of this group to a hydroxamic acid, combined with the fact that no 
example of this class of compound had been reported in the field o f HD AC inhibitors 
suggested that it might be an interesting group to assess.
It was found that the direct amidoxime-analogue of MGCD0103, 99, was available in 
excellent yield with easy purification by recrystallisation by reaction of hydroxylamine with 
intermediate benzonitrile 133 (scheme 3.16).
N ^O H .H C l, DIEA, MeOH
CN 7 5 %
133 99 OH
Scheme 3.16. Amidoxime analogue of MGCD0103.
Further examples of amidoximes were desired to rapidly assess the suitability of this group 
as a hydroxamic acid-substitute. The four examples 100-103 (figure 3.5) were selected as a 
sub-series of simple compounds possessing structures that would be likely to be potent in 
the case of hydroxamic acid inhibitors.
Amides 137 and 138 were synthesised in three steps from 4-cyanobenzoic acid (136) by 
coupling with aniline and 3-aminoquinoline respectively (via the acid chloride), followed by 
conversion of the nitrile into amidoxime under the same conditions as above (scheme 3.17).
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HO'
84% 137
CN
41 %
71 %
N'
CN
138
47%
N'
H
100 NOH
N'
H
102 NOH
(a) (i) SO a2; 1 h, 90 °C; (ii) aniline, pyridine, DCM; 1 h, 0°C; (aii) (i) SOCI2; 1 h, 90 °C; 
(ii) 3 -ani noquinoline, pyridine, DCM; 2 h, 0°C; (b) NhbOHHQ, DIEA, MeOH; 18 h, r.t.
Scheme 3.17. Synthesis of amide-linked amidoximes.
The more flexibly-linked amine 101 was the product of the reductive amination of 4- 
cyanobenzaldehyde (139) and conversion of the nitrile 140 into the amidoxime. Formation 
of the un-isolated imine by mixing the aldehyde and aniline in methanol was assisted by 
addition of catalytic acetic acid, and was reduced with sodium borohydride (scheme 3.18).
cy '
CN 56%
139
N'
CN
140
33%
N'
H
NOH101
(a)(i) Aniline, MeOH, cat. AoOH; 24 h, r.t.; (ii) NaBH*; 18 h, r.t.;
(b) NH2OH.HCI, DIEA, MeOH; 3d, r.t.
Scheme 3.18. Amine-linked amidoxime.
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Finally, reaction of benzoyl chloride with 4-(aminomethyl)benzonitrile (131) provided the 
more flexible amide 141 in excellent yield, amidoxime formation proceeding under the 
standard conditions (scheme 3.19).
o o
NOH
131 141 103
(a) Benzoyl chloride, B 3N, DCM; 3 h, 0°C; (b) NB>OH.HCl, DIEA, MeOH; 20 h, r.t.
Scheme 3.19. Extended amide-linked amidoxime.
The amidoximes thus far synthesized were subjected to the standard in vitro HDAC 
inhibition screening. Unfortunately, none of the above examples displayed any significant 
activity at concentrations of 5 juM. Despite these results, it was felt that one final example of 
this class should be synthesized in order to compare directly with a known straight-chain 
hydroxamic acid.
3.1.4 Amidoxime SAHA analogue
The route initially selected for synthesis of amidoxime analogue of SAHA 104 was based 
on the oxidation of amine 142 to nitrile 143 (scheme 3.20). In a procedure reported by Chen 
et al.16 a variety of amines including 7-aminoheptanoic acid (which was thought to provide 
good analogy for 8-aminooctanoic acid required in this case) were converted to the nitrile in 
80 % yield under very mild conditions, using trichloroisocyanuric acid (TCCA) and 
catalytic TEMPO. Unfortunately, treatment of amine 142 with these reagents under a 
variety of conditions, including adjusting the temperature to 0, 5, 10 or 20 °C, increasing the 
catalyst from 1 mol% to 10 mol% and even addition of base to deprotonate the acid, all 
resulted in rapid formation of an unwanted product in quantitative yield.
3 Cyclic-Linker Non-Hydroxamates 113
(a) TCCA cat. TEMPO, DCM; 2-7h, 0-10 °C
Scheme 3.20. Proposed route to amidoxime SAHA analogue.
With convenient oxidation of the amine ruled out as a route to the nitrile, the alternative 
alkylation of an alkyl bromide with a cyanide salt was investigated (scheme 3.21).
(a) 2M LiOH, MeOH; 18h, r.t; (b) NaCN, K2 CO3, hfeO, 18h, reflux.
Figure 3.21. Alternative route to nitrile 143.
Bromoacid 145 was not commercially available and so was given by the hydrolysis of the 
ethyl ester according to the procedure of Suzuki et al.,17 and although this extra step is 
undesirable, it proceeds in excellent yield. The alkylation of 6-bromohexanoic acid is 
reported by Schultz18 in good yield on the scale o f 100 g, however, a small scale run of this 
reaction resulted in poor yield (by NMR) of 143 and so it was thought that this would be 
improved by derivatization of the carboxylic acid before alkylation (scheme 3.22)
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NOH
(a) 2M LiOH, M0 OH; 18h r.t.; (b)(i) SOCt2; 1h, 70 °C; (ii) aniline, pyridine, DCM; 2h, 0 °C;
(c) KCN, BOH; 18h, 75 °C; (d) 1M NH2OH, MeOH; 4  d, r.t.
Scheme 3.22. Final route to amidoxime 104.
Coupling of acid 145 with aniline proceeded in good yield via the acid chloride, and it was 
seen that amide 146 did indeed undergo the alkylation step in excellent yield. Whilst this 
sequence is not as convenient as that depicted in scheme 3.21 with respect to ease of 
derivatization of the amide group, it was deemed preferable under these circumstances to 
the use of excessive amounts of cyanide salts in a low yielding step.
Conversion of the alkyl nitrile group of 147 into the amidoxime occurred far less readily 
than with the previous aromatic examples. Under all conditions trialled the reaction 
proceeded slowly and did not run to completion. Efforts to increase the rate of reaction 
attempted to adapt the procedure of Gissot et al. for formation of O-benzyl hydroxamates 
from esters.19 In this case, the O-protected hydroxylamine is deprotonated with lithium 
hexamethyldisilazide then the ester is added, giving the protected hydroxamate in excellent 
yield within ten minutes. This procedure was unsuccessful when applied to reaction with the 
nitrile (to give the O-benzyl amidoxime) in place of the ester, and it has been reported that 
O-alkyl amidoximes are in fact known to be unstable.15 Other conditions experimented with 
to optimise this reaction included use of free hydroxylamine or the hydrochloride salt with 
various bases (DIPEA, Na2C0 3 , KOH, or no base) in water, methanol, ethanol or 
dimethylformamide. The best yields were obtained by stirring the nitrile in a 1 M
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methanolic solution of hydroxylamine for 4 d. Although this reaction did not go to 
completion, stirring for longer periods led to decomposition of the product, and after 4 d any 
remaining unreacted starting material was recovered by column chromatography.
The final compound was subjected to the standard screening assay at 5 pM concentration 
and was found to be inactive. It was concluded that, after this result combined with the 
negative results from the previous amidoximes, this group was unfortunately not a suitable 
substitute for a hydroxamic acid zinc-binding group, and our investigation in this area was 
closed.
Efforts in this chapter to develop potent new non-hydroxamate HDAC inhibitors as 
potential anti-cancer drugs were deemed unsuccessful on the basis o f poor activity in cell- 
based assay screens. This lack of activity was un-surprising in some cases, with poor 
solubilities being noted during synthesis. It was, however, disappointing to not see some 
significant activity from the range of new groups tested, given the wide range of groups 
known to act as substitutes for hydroxamic acids (discussed in the introduction). It should 
also be noted that, because of funding constraints on the screening process, compounds 
were required to have shown an appreciable activity in cell-based assays before any further 
analysis could be carried out. This single concentration-point assay provided little 
information for direction of further development. It is possible that if  the compounds of this 
chapter were subjected to an isolated enzyme assay, some information may be obtained that 
could allow further development o f this work. The isolated enzyme assay would also be of 
particular interest in the case of the amidoxime compounds in determining the requirements 
for replacement hydroxamates. The similarity of amidoximes to hydroxamic acids could 
prove a useful tool in elucidating the binding requirements of inhibitors if  it were possible to 
compare directly the isolated enzyme activity of these analogues. As it remains we are 
unable to say whether the observed poor activity is due to poor HDAC-binding or just a 
result of poor cellular penetration.
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4 Analogues of SAHA
The work described in this chapter covers the synthesis o f various novel hydroxamic acids 
bearing structural relationships to suberoylanilide hydroxamic acid (SAHA) (figure 4.1). 
The well established hydroxamic acid zinc-binding group was utilised in each of the 
following examples, with efforts to improve inhibitory activity focusing on developing the 
structurally simple linker (148) and cap region (149-155) of SAHA.
The piperidyl linker of compound 148 was proposed as a potential improvement on a 
saturated alkyl chain as it would provide more bulk to fill the pocket of the enzyme’s active 
site. Inclusion of an amine in the linker would improve solubility o f the compound and 
simplify synthesis. Carboxylic acid 149 and alcohol 150 provide increased bulk in the cap 
region, whilst also potentially greatly improving water solubility. Benzimidazole 151 was 
synthesised to asses the suitability of the fused system as a substitute for the anilide moiety 
of SAHA, and addition of the group in 152 greatly increases aromatic bulk in the cap. 
Inclusion of an ester with the benzimidazole of 153 was also carried out to increase bulk and 
potentially behave as a pro-drug by hydrolysis to the acid. Finally, piperidinones 154 and 
155 retain good structural analogy to SAHA whilst increasing the area covered by the cap.
In order to compare the biological activity of these compounds a sample of the parent 
compound was also required, and so laboratory work in this series began with a literature 
synthesis of SAHA.
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SAHA
NHOH
N
NHOH
O148
NHOH
OH 149 HO'
NHOH
150
NHOH
NHOH
HN151 152
NHOH
153
ISHOH NHOH
Figure 4.1. Novel hydroxamic acids based on SAHA.
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4.1 Suberoylanilide Hydroxamic Acid
Several syntheses of SAHA have been reported and the procedure of Mai et al.1 was 
selected in this case (scheme 4.1).
PhHN79%
NHOH
PhHN' PhHN'
(a) AC2 Q 1h, reflux; (b) aniline, THF; 45 rrin, r.t.; (c) ethyl cNoroformate, THF; 20 rnin, 0 °C; 
(d) NKpOH, MeOH; 20 rrin, r.t.
Scheme 4.1. Synthesis of SAHA .1
Suberic acid was converted to its anhydride by refluxing in acetic anhydride for 1 h, this 
transformation allowing selective reaction of one acid group simply by opening of the 
anhydride 157 with aniline in THF. The acid 158 is itself not active to attack of 
hydroxylamine, therefore prior conversion to the mixed anhydride by reaction with ethyl 
chloroformate is necessary, this is however generated in situ, without requiring isolation.
Whilst this route provides a quick and high-yielding synthesis of SAHA, it should be noted 
that difficulties were encountered, particularly in the separation of the final product from 
un-reacted acid 158 by recrystallisation.
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4.2 Piperidyl SAHA Analogue
A reason that is commonly proposed for the lower activity of SAHA when compared with 
TSA is the high flexibility of the unsaturated chain of SAHA. The more rigid, unsaturated 
chain of TSA, along with its bulkier protruding methyl groups provide a more snug fit in 
this space.2 This observation led to the proposal of the piperidyl compound 1 4 8  (figure 4.1) 
as a potential improvement on the simple alkyl chain by providing more conformational 
constraint in addition to improved solubility.
An analogue of SAHA (1 6 0 ) previously synthesised by this group had demonstrated the 
benefit to activity of bifurcation of the cap region in the form of a second anilide group (un­
published results) (figure 4.2). With this knowledge, an additional piperidyl target also 
bearing the di-anilide cap (1 6 1 ) was proposed.
NHOHNHOH
SAHA
PhI
O
OEt
161
Figure 4.2. SAHA, previously synthesised bifurcated analogue and proposed piperidyl target.
4.2 .1  M o n o -a n ilid e  A n a lo g u e
The direct route to mono-anilide 148, given in scheme 4.2, began from commercially 
available isonipecotic acid (1 6 2 ). Protection of the amine with a Boc group allowed trouble-
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free coupling of the acid 163 with aniline using EDCI/HOBt. Monitoring the deprotection of 
the amine with TFA in dichloromethane via TLC indicated that the reaction proceeded 
rapidly as might be expected, however, the uninspiring yield of 68% is likely to be due to 
the reluctance of amine 165 to be extracted from the aqueous phase in the work-up. 
Extraction with ethyl acetate showed small amounts of amine by TLC, and although it is 
likely that the yield could be improved with further extraction, a compromise was met after 
10 washes.
o
HO'
HO'
NH 8 4 %
162 163
NHOH
42%
°  .H2O.HCI
148
o
68%
N'
o
164
N. OEt
O
166
68%
6 7 %
o
165
NH
(a) KjCQs, B0 C2O, water, THF; 4  h, r.t.; (b) HOBT, EDCI.HCl, NMVl, aniline, DIVF; 18 h, r.t.; (c) DCM-TFA 1:1; 
17 h, r.t.; (d) ethyl acrylate, BOH; 4 d, r.t.; (e) NB>OH, KOH, THF, MeOH, 18 h, r.t.
Scheme 4.2. Synthesis of mono-anilide piperidyl analogue.
The spacer region was completed by conjugate addition o f piperidine 165 to ethyl acrylate. 
The reaction proceed slowly at room temperature in ethanol providing an acceptable yield 
of ester 166 after four days, however, it may be possible to improve this by extending the 
reaction time or heating. Separation of the product by column chromatography was easily 
achieved, providing the crystalline ester. Conversion to the hydroxamic acid was achieved 
by treatment with methanolic hydroxylamine and potassium hydroxide in THF at room
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temperature. After neutralisation with HC1 the crude product was recrystallised from 5% 
methanol-acetonitrile to afford the product as the hydrochloride salt monohydrate 148.
4.2.2 Di-anilide Analogue
The synthetic route proposed to the di-anilide 161 could potentially also provide an 
alternative route to the mono-anilide 148. This approach involves formation of the 
piperidine ring in the third step by dialkylation of di-tert-buXy\ malonate (scheme 4.3).
no'
HO .NH
167
Ph
HO'
94%
HO
Ph'
OEt
O172
HQ
OEt
168 o
Br
39%
B r '
N O B
OEt
51 %
O
171
169 o
54%
O& i
Bu*a.
OEt
o
170
(a) Ethyl acrylate, EtOH; 7 d, r.t.; (b) NBS, PPhj, DCM; (c) (i) di-Tbutyl malonate, NaH (1.5 eq), DIVF; (ii) 
169; (iii) NaH (1.5 eq); 70 °C, 18 h; (d) TEA, DCM; 20 h, r.t; (e)(i) SOa2; (ii) PhNhfe, pyridine, DCM; 3 h, r.t.
Scheme 4.3. Route to di-anilide.
Selective hydrolysis of the tert-butyl esters of 170 would then provide an interesting diacid 
(171) which could potentially be decarboxylated (173), or coupled with one equivalent of 
aniline leaving a free carboxylic acid for further derivatization (174, scheme 4.6).
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R
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C X . O H
PhHN
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O
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Scheme 4.4. Potential derivatives available from di-acid 171.
Initially, the Michael addition of ethanolamine (167) to ethyl acrylate was carried out under 
the same conditions as for addition of piperidine 165 (scheme 4.3), viz, in ethanolic solution 
at room temperature. Whilst this did furnish the addition product 168 in excellent yield, 
reaction was sluggish, requiring seven days. The reaction time was subsequently reduced to 
5 h by heating to 120 °C whilst retaining an excellent yield. Isolation of di-bromide 169 
after conversion with triphenylphosphine and 7V-bromosuccinimide was hampered by the 
presence of two equivalents of the unwanted triphenylphosphine oxide side-product, 
possibly contributing to the modest yield. Formation of the piperidine ring of 170 was then 
carried out in two stages by deprotonation of di-ter/-butyl malonate with two successive 
portions of sodium hydride with cautious heating in DMF. Attempts to improve the yield for 
the alkylation by using the potentially more reactive di-mesylate in place o f di-bromide 169 
was unsuccessful as the only product isolated from the reaction of di-alcohol 168 with 
methanesulfonyl chloride appeared to be the self-reacted morpholine.
From ester 170 was provided di-acid 171 by cleavage in TFA-DCM. Preparation of the di­
amide derivative 172 proceeded well through formation of the di-acyl chloride with thionyl 
chloride, then coupling with two equivalents of aniline. This method of coupling was found
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to be preferable to the use of EDCI/HOBt, which provided only a poor yield with longer 
reaction time.
Unfortunately, the synthesis o f this di-anilide analogue was not continued beyond this point 
as results from biological testing of initial target 148 were received, showing no significant 
activity in cell viability assays. This information led us to believe that the piperidyl spacer is 
not a tolerable alternative to the alkyl chain of SAHA, and this line o f investigation was 
therefore discontinued.
4.3 Malonamide-Based Compounds
This section incorporates the unsymmetrical, malonamide-derived compounds 149, 150, 
152 and 153, and also, owing to its role in the development of the series, symmetrical 
benzimidazole 151. Synthesis of this compound was based on that of SAHA, utilising the 
suberic anhydride intermediate 157 (scheme 4.5).
OH
o
175
29%  
over 2 steps
HQ2C \  f  CQ>H
83%
156 157
NHOH OEt
61 %
o o
151 176
(a) AC2 O; 2h, reflux; (b) 1,2-phenylenediamne, THF; 20 rrin, r.t.; (c) 4%aDnc.H2S04/Et0H 
16 h, reflux; (e) NFfeOHCaq), 1M KOH/MeOH, THF; 6 h, r.t.
Scheme 4.5. Synthesis of benzimidazole SAHA analogue.
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The amino-acid intermediate 175 was not isolated, as dehydration to form the 
benzimidazole and esterification was possible in one step. Reflux in 4% concentrated 
sulfuric acid in ethanol gave the more easily purified ester 176, which was converted to the 
corresponding hydroxamic acid with aqueous hydroxylamine and methanolic potassium 
hydroxide. It should be noted that, whilst the formation o f the benzimidazole under these 
harsh conditions was not a significant problem in this case, much milder methods are 
possible from reaction of phenylenediamine with aldehydes in the presence of oxidising 
agents such as hypervalent iodine.3
The three anilide-containing compounds 149, 150 and 152 were all derived from malonic 
acid via the intermediate amide-ester 179 (scheme 4.6). Mono-esterification was carried out 
in excellent yield with tert-butyl alcohol according to the procedure o f Melman et al., using 
DCC as a coupling agent.4 Acylation of aniline with the resultant acid 178 was carried out 
with three different methods; initially, EDCI.HC1 and HOBt coupling reagents were used, 
giving the product in 63% yield and requiring no purification after aqueous work-up. On 
repetition of the synthesis, DCC was substituted for the EDCI.HCl/HOBt system to provide 
a more economically viable route for use on larger scale. The reaction proceeded well, 
improving the yield to 77%, however, as the by-product of this reaction is not water soluble, 
purification by column chromatography was required. Finally, activation of the acid in the 
form of the acid chloride provided an excellent yield and easy purification, capable of use 
on a large scale.
(a) Bn'OH, DCC, MeCN; 2 h, r.t.; (b)(i) oxalyl chloride, DMF (cat), DCM; 2 h, 40 °C; (ii) PhNH2, DMAP, 
DCM; 2 h, r.t.; (c)(i) NaH, THF, 20 min, r.t.; (ii) ethyl 6 -bromohexanoate; 18 h, 70 °C.
177 178 179 180
Scheme 4.6. Synthesis of alkylmalonamide ester intermediate.
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It proved possible to alkylate the intermediate malonamide ester 179 under standard 
conditions despite the reduced acidity of the methylene group compared with that of a 
malonate ester. Deprotonation with sodium hydride in tetrahydrofuran was followed by 
alkylation with ethyl 6 -bromohexanoate at reflux in excellent yield. It was envisaged that 
the synthesis of these compounds would initially aim at producing racemic material. Any 
racemic compounds that showed promising activity would then be targeted for asymmetric 
synthesis or chiral resolution in order to assess any difference in activity between 
enantiomers. Separation of the product from unreacted starting material was difficult to 
achieve completely by column chromatography, however, pure material could be obtained 
with subsequent recrystallisation from diethyl ether-petroleum ether.
Synthesis of the acid-containing compound 149 was first attempted by selective hydrolysis 
of the ter/-butyl ester with trifluoroacetic acid (intermediate 182, scheme 4.8), then 
conversion of the ethyl ester to hydroxamic acid. Whilst this route did provide the target 
compound, it proved extremely difficult to isolate the pure product from the highly polar 
starting material. It was therefore decided to attempt conversion of the ethyl ester of 180 to 
the hydroxamic acid in the presence of the tert-butyl ester (scheme 4.7). Reaction proceeded 
rapidly to give the hydroxamic acid precursor 181, which was purified by column 
chromatography before hydrolysis of the tert-butyl ester to give the final compound.
2 9 %
a
NHOH
NHOH
HO O 1 4 9
(a) NH2OH(aq), t M KOH/MeOH, THF; 45 min, r.t.; (b) TFA, DCM; 1h, r.t.
Scheme 4.7. Synthesis of acid 149.
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The hydroxymethyl analogue 150 was seen to be available through hydrolysis of the tert- 
butyl ester, selective reduction of the resultant acid 182 and conversion to the hydroxamic 
acid (scheme 4.8). Hydrolysis proceeded in excellent yield, however, reduction of the acid 
proved more troublesome. Initially it was envisaged that reduction with borane would be 
suitably selective for the carboxylic acid; reaction with up to two equivalents of BH3.THF 
produced no reaction, but increasing to five equivalents resulted in additional reduction of 
the amide. It was possible to reduce the acid in the presence o f the amide and ester by 
formation of the mixed anhydride with ethyl chloroformate, followed by reduction with 
sodium borohydride, adapting the procedure of Polla et al.5
NHOH
(a) TFA, DCM; 6  h, r.t.; (b)(i) ethyl chloroformate, Et3N, THF; 30 min, 0 °C; (ii) NaBH4, MeOH; 1.5 h, 10 °C; 
(c) NH2OH(aq), 1 M KOH/MeOH, THF;
Scheme 4.8. Hydroxymethyl analogue.
The intermediate acid 182 provided a route to many potential targets bearing two different 
aromatic groups in the cap region. A compound of particular interest was the hybrid 
combination of SAHA with our benzimidazole analogue 151, in the form of benzimidazole- 
containing anilide 152. The synthesis involved coupling of the acid with 1,2- 
phenyl enediamine followed by dehydrative cyclization of the free amino group on the 
amide carbonyl under acidic conditions (in the same manner as with benzimidazole 176,
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scheme 4.5). In practice, it was found that yields in the coupling step were improved by use 
of a mono-protected 1,2-diamine 185 (scheme 4.9).
Nhfc Boc^O, THF
7 6 %
NB>
BocHN.
184 185
Scheme 4.9. Mono-protection of i,2-phenylenediamine.
Acylation of the free amino group of 185 with acid 182 using EDCI.HC1 and HOBt 
coupling gave amide 186 in good yield (scheme 4.10). It was then possible to deprotect the 
amine and form the benzimidazole in one step by warming in trifluoroacetic acid. Attempts 
to convert the ester of 187 directly to the hydroxamic acid resulted in difficulties in 
purification of the product. Column chromatography and preparative TLC proved 
ineffective owing to strong adherence of the compound to silica gel, and recrystallisation 
from various solvents also failed to remove by-products. It was therefore decided to protect 
the NH group of the benzimidazole in an effort to reduce the polarity of the product 
hydroxamate, potentially allowing separation by column chromatography. Boc-protection to 
give 188 proceeded very slowly, after 4 d only yielding 35% of the protected product. It was, 
however, possible to recover 45% of the starting material from this reaction. Subjection of 
the product to the standard hydroxamation conditions of aqueous hydroxylamine and 
methanolic potassium hydroxide resulted in spontaneous deprotection of the amine. This 
effect was observed by TLC comparison and is presumably due to the high concentration of 
hydroxylamine (10 equivalents) in the reaction. Despite this deprotection, the reaction 
proceeded cleanly and the final product (152) purified by recrystallisation from ethanol.
x
z
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OEt Ph OEt
6 6 %
HNHO'
186182 BocHN
5  75 % H
HN
187
3 5%
HN '  N
NHOH
50 % BocN '  N
OEt
(a) 185, EDC.HCI, HOBT, Et3N, DMF; 18 h, r.t.; (b) TFA, DCM; 2 h, reflux;
(c) Boc20 ,  THF; 4 d, r.t.; (d) NH2OH(aq) 1M KOH/MeOH, THF; 6  h, r.t.
Scheme 4.10. Route to benzimidazole analogue.
The hybrid, asymmetric benzimidazole 153 was available using the same methodologies 
developed with the previous compounds of this class. Acylation of 1,2-phenylenediamine 
with the tert-butyl malonate 178 using DCC coupling agent proceeded rapidly in moderate 
yield (scheme 4.11). Subsequent dehydration to form the benzimidazole ring occurred on 
heating 189 in glacial acetic acid in quantitative yield. An initial attempt at alkylation of this 
compound under the same conditions used for previous malonamide and malonate examples 
resulted in A-alkylation only. The NH group was therefore protected, allowing alkylation on 
carbon to give 192 in modest yield. Conversion to the hydroxamic acid also resulted in 
deprotection of the amine, as seen with previously (152, scheme 4.10).
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BirO
NH
189
9 6 %
Bu'O
190
NHOH
BukD' 153
67%
97 % Boc
Bu‘0 '
191
3 3 %
OEt
Boc
192
(a) 1,2-Phenylenediamine, DCC, MeCN; 20 min, r.t.; (b) AcOH; 1 h, 90 °C; (c) B0 C2O, THF; 3 d, r.t.;
(d)(i) NaH, THF; 30 min, r.t.; (ii) ethyl 6 -bromohexanoate; 18 h, 60 °C; (e)NH2OH(aq) 1M KOH/MeOH, 
THF; 30 min, r.t.
Scheme 4.11. Functionalised benzimidazole analogue.
4.4 Piperidinone Analogues
This class of compounds retains the general structure of SAHA, including the alkyl spacer, 
but introduces some rigidity in the cap region. Formation of piperidinone rings is commonly 
carried out with malonic esters under harsh, basic conditions. This would not be possible in 
our case as the compound would be required to contain an alkyl ester for subsequent 
conversion to the hydroxamic acid. After attempts involving several different methods of 
activating the malonyl carboxylic acids to nucleophilic attack, an acceptable method for 
formation o f the ring was found, and the synthesis is given in scheme 4.12.
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NHOH
(a)(i) NaH, THF; 30 min, r.t.; (ii) ethyl 6 -bromohexanoate; 16 h, 85 °C; (b) TFA, DCM; 24 h, r.t.; 
(c) 2,4,6-trichlorophenol, POCI3; 5 h, 100 °C; (d) benzamidine, DCM; 1 h, 40 °C;
(e) NH2OH(aq), 1M KOH/MeOH, THF; 2h, r.t.
Scheme 4.12. Synthesis of piperidinone 154.
Alkylation of di-/er?-butyl malonate was carried out under established conditions, with 
sodium hydride in tetrahydrofuran. The two tert-butyl esters o f 194 were selectively 
hydrolysed with trifluoroacetic acid to give di-acid 195 in excellent yield. Attempts at 
formation of the piperidinone via formation of the di-acyl chloride or activation of the 
carboxylic acids via formation of the mixed anhydride with ethyl chloroformate both failed 
to give the desired product on treatment with benzamidine. The transformation was 
eventually completed through the di-2,4,6-trichlorophenol ester 196, formed by refluxing 
the acid 195 with 2,4,6-trichlorophenol in phosphorus oxychloride,6 which reacted rapidly 
and cleanly with the amidine, the products poor solubility allowing purification by washing 
with ethanol. Presumably the trichlorophenol ester provided the correct level of activity to
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allow reaction with the amidine but avoid formation o f unwanted side-products. The ethyl 
ester of 197 was then converted to the hydroxamic acid 154 with aqueous hydroxylamine 
and methanolic potassium hydroxide solution.
It was thought possible that it may be able to reduce the number of steps to this ester 
intermediate (196) by directly alkylating the bis-trichlorophenyl malonate 198. This ester 
was available from reaction of malonic acid with the phenol under the same conditions as 
above,6 however, attempts to alkylate were unsuccessful (scheme 4.13). In light of the 
undesired result of this reaction, it is noted that deprotonation of 198 could readily result in 
elimination of a TCP group to form a highly reactive ketene intermediate.
ci ci
o- -OH
Cr
I 77 %
OH
177
Cl
O; O
198
ci
Cl
o. o
OEt
196
Cl
(a) 2,4,6-Trichlorophenol, POCI3; 2.5h, 100 °C; (b)(i) NaH, THF; 30 min, r.t.; 
(ii) ethyl 6 -bromohexanoate; 18h, 75 °C
Scheme 4.13. Attempted alkylation of malonate ester.
The second piperidinone compound (155) required synthesis of the guanidine 201 before 
formation of the ring. The third nitrogen of the group was installed by addition of aniline to 
nitrile 200, requiring an extended period of heating in toluene and still only proceeding in 
very modest yield (scheme 4.14). Diethyl cyanamide (200) was prepared by the procedure
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of Keil and Hartmann through careful addition o f diethylamine to cyanogen bromide on
7ice.
a  l b\  N -------
N 75 % 15 %
199 200
(a) Dethylarrine, B 2Q  30 min, CPC; (b) aniline. HQ, PhMe; 3d, reflux.
Scheme 4.14. Synthesis of guanidine precursor.
With guanidine 201 now in hand, the pyrimidinone of 202 was formed from the previously 
synthesised TCP-precursor 196 (scheme 4.15). The reaction did not proceed as readily as 
with benzamidine, but a good yield was achieved by heating the two compounds neat for 5
o
min at 150 °C, according to the procedure of Gotthard et al. Hydroxamation followed under 
standard conditions to give the target compound 155. Unfortunately, the physical properties 
of the hydroxamic acid appear to be unsuitable for a drug molecule — no solid was obtained, 
it being unclear whether the product is an oil, or, as may be more likely, an extremely 
hygroscopic solid.
201
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ci
OEt
6 8 %
a
N N OH
J 202
51% b
OEt
Cl
NHOH
(a) 201; 5 min, 150 °C; (b) NH2OH(aq), 1 M KOH/MeOH, THF; 2 h, r.t.
Scheme 4.15. Synthesis of functionalised piperidinone.
The compounds synthesised in this series were subjected to a routine screen to biological 
activity. Screening was in the form of a cellular proliferation assay carried out at a standard 
5 pM concentration and was performed by Alexandra V. Stavropoulou at Imperial College 
London. The majority of compounds described here unfortunately did not show significant 
activity, however, the benzimidazole SAHA analogue 151 and hydroxymethyl analogue 150 
(figure 4.1) did show promising results. Further analysis was carried out on these 
compounds, respective IC50 values of 2.4 pM and 4.4 pM being determined. Full details of 
the analysis of these compounds is given in chapter 5, where explanations of methods used 
are also included.
The development of the series described here is in its early stages, but looks promising for 
further work. The versatility of the malonate-based compounds for development of further 
analogues is excellent, with alternative amides, amines, ethers, esters or heterocycles readily 
accessible from this structure (particularly indoles, bearing in mind the work of chapter 2 ). 
In addition to production of further analogues in this series, it would be necessary to 
consider evaluation of enantiomerically pure compounds. Having observed the activity of
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racemic compounds such as the promising alcohol 150, the analysis of activity of the pure 
enantiomers is now highly desirable. Work to consider in the immediate future could focus 
on racemic alcohol 150, which could be suitable for chiral resolution by formation of an 
ester with a chiral acid. The proximity of the alcohol to the chiral centre would potentially 
mean this is a viable method for separating the resultant diastereomers. An alternative 
would be an asymmetric synthesis, possibly involving an asymmetric aldol reaction.
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5 Biological Analysis
In addition to the biological evaluation of compounds synthesised for this thesis, which was 
carried out by collaborating groups, compounds previously synthesised (unpublished work) 
within this group were tested for biological effect. In these cases, evaluation took the form of 
cell protein and cell cycle analysis. Work was carried out at the Rayne Institute, King’s 
College London under the supervision of Dr N. S. B. Thomas. Protein analysis was carried out 
by SDS-PAGE and western blot and cell cycle analysis by flow cytometry on two human 
cancer cell lines, HCT116 (colon) and HeLa (cervical). An in vitro assay for histone 
deacetylase activity was also carried out.
Also discussed in this chapter are the results of the biological analysis of SAHA analogues 
150 and 151, as carried out by Alexandra V. Stavropoulou. The synthesis of these compounds 
was discussed in chapter 4.
5.1 SST4-4 and SST4-5
Novel histone deacetylase (HDAC) inhibitors SST4-4 and SST4-5 were assessed for 
biological function by whole cell protein analysis and cell cycle analysis. The pair of 
compounds are complex macrocycles, structurally analogous to the known inhibitor 
depsipeptide (also known as FK228). Although biological activity o f these compounds was 
lower than expected on the basis of structural analogy with depsipeptide, some differences in 
biological effect were observed between the compounds and between the cell lines.
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FK228
Figure 5.1 Structures of SST4-4, SST4-5 and FK228
5.1.1 Protein Analysis
Typical experiments for analysis of protein by western blot involved the incubation of cells for 
24 h in the presence of a range of concentrations of inhibitors. Controls and standards in the 
form of known inhibitors trichostatin A (TS A) and apicidin were always included in the assay. 
On completion of incubation, cells were harvested, samples fixed in SDS-lysis buffer and 
heated to 100 °C for 10 min before storage at -20 °C.
After SDS-PAGE and western blot, membranes were probed with antibodies to assess 
deacetylase activity and potential apoptosis. Anti hyperacetylated histone H4 is a marker for 
inhibition of class I HDACs which are most commonly localised to the nucleus. Class II 
HDACs are generally able to shuttle between the nucleus and cytoplasm, allowing detection of 
cytoplasmic substrates to provide an indication of class II inhibition. For this, anti acetylated 
a-tubulin was used as the marker. Anti PARP was employed as a marker for caspase-
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dependent apoptosis. Anti MAPK was used as an indication of protein loading for the 
electrophoresis.
Preliminary experiments at low nanomolar inhibitor concentrations showed little effect on 
levels of the probed proteins, therefore concentrations of SST4-4 and SST4-5 were increased 
to a maximum of 10 pM.
5.1.2 Results
Qualitative protein analysis after culturing HeLa cells with SST4-4 and SST4-5 at 
concentrations from 50 nM to 10 pM are shown in figure 5.2. Trichostatin A (TSA) and 
apicidin were included at concentrations of 1 pM and 100 nM respectively as controls.
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Figure 5.2. Accumulation of hyperacetylated H4 in HeLa cells on 24 h incubation with HDAC inhibitors 
as detected by western blot. Test compounds SST4-4 and SST4-5 were incubated at concentrations 
ranging from 50 nM to 10 pM. Detection of PARP and its respective cleavage product was used as an 
indication of apoptosis and MAPK expression was used as a loading control. Representative of n=2 
experiments.
Faint PARP cleavage products are seen in most lanes, however, no full-length PARP is present 
with SST4-4 at 10 pM (A, figure 5.2). This total loss of PARP at high concentrations of SST4-
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4 is consistent with high levels of apoptosis identified by flow cytometry (discussed later). In 
comparison with the DMSO control, distinct increases in levels of hyperacetylated H4 (B) are 
seen with apicidin, TSA and SST4-4 at 10 pM. A slight increase is also seen with SST4-5 at 
10 pM. Detection of MAPK as a protein-loading control (C) indicated that overloading may 
have occurred in the TSA and apicidin lanes, but all other cases appear approximately equal. 
Probing with anti acetylated a-tubulin showed no detectable levels of protein under all 
conditions (results not shown).
The results obtained from the protein analysis in HeLa cells indicate that SST4-4 is capable of 
increasing accumulation of hyperacetylated H4 when present in high concentrations. As 
indicated by the known inhibitors TSA and apicidin, this is the predicted result of HD AC 
inhibition. No inference can be made with respect to HDAC class specificity owing to 
extremely low levels of acetylated a-tubulin.
The same experiments were repeated in a second cell line. Figure 5.3 shows the effect of 
SST4-4 and SST4-5 on HCT116 cell protein levels. PARP cleavage products can be seen as a 
result of treatment with TSA at 1 pM, and faintly with SST4-4 at 10 pM. No significant 
increase in hyperacetylated H4 is seen for either test compounds up to 10 pM concentration. 
An increase in levels of acetylated a-tubulin is seen with TSA, and crucially, a distinct 
increase is seen with SST4-4 at 10 pM but not the analogue SST4-5 at this concentration.
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Figure 5.3. Accumulation of hyperacetylated H4 and acetylated a-tubulin in HCT116 cells on 24 h 
incubation with HDAC inhibitors as detected by western blot. Test compounds SST4-4 and SST4-5 
were incubated at concentrations ranging from 50 nM to 10 pM. Detection of PARP and its respective 
cleavage product was used as an indication of apoptosis and MAPK expression was used as a loading 
control. Representative of n=2 experiments.
These results indicate that SST4-4 is a weak inhibitor of class II HDACs in HCT116. It is not 
possible to say from these results whether this inhibition is specific to class II over class I from 
the comparison with hyperacetylated H4 accumulation. This is owing to high naturally 
occurring background levels of the protein in this cell line, making subtle changes in level 
hard to detect. There is no obvious effect on the protein levels assessed from treatment with 
the analogue SST4-5.
Further experiments were carried out with increased incubation time using HCT116 cells. In 
addition to 24 h, samples were taken at 48 h and 72 h to determine any possible delayed 
effects of treatment, and a final experiment to determine the effect of reduction of the internal 
disulfide bridge present in SST4-4 and SST4-5 was included. The functionality is also present
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in depsipeptide and studies have shown that it is the reduced form of the compound that is the 
active HDAC inhibitor.1 It has been demonstrated in the same study that the reduction will 
take place in the cellular environment, and that the product is rapidly metabolised. If this 
reduction is carried out artificially by the addition of dithiothreitol (DTT) the potency of the 
compound in cellular assays is greatly reduced, presumably due to decreased uptake and 
instability of the free di-thiol.
Increased incubation periods did not show any change in detected protein levels (figure 5.4). 
This may be expected from studies of the structurally analogous inhibitor depsipeptide, which 
has been reported to be rapidly metabolised in the cellular environment. Figure 5.4 also shows 
no detectable change in protein levels as a result of added DTT.
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Figure 5.4. Accumulation of hyperacetylated H4 on incubation of HCT116 cells for extended time 
periods (24, 48 and 72 h) in the presence of SST4-4 or SST4-5 at 10 pM. Incubation (24 h) in the 
presence of DTT showed no significant effect.
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5.1.3 Cell Cycle Analysis
Cell cycle analysis was carried out by flow cytometry. The technique allows identification of 
the cell cycle stage of individual cells by detection of protein and DNA levels. Treatment of 
cells to be sampled with a fluorescent dye that bind non-specifically to protein, and another for 
DNA allows quantification by detection of fluorescence from the respective tags on laser 
excitation. Detection is possible by passing a single-file stream of the labelled cells in front of 
the laser and as each cell passes, the resultant scattered light is recorded as an ‘event’. For 
each event, the relative level of both cell protein and DNA content is determined from light 
emitted by the respective tags, and the data plotted. After calibration of the cell cycle profile of 
the desired cell type, the populations of cells in each stage of the cell cycle can be determined 
from the characteristic proportions of DNA-to-protein levels. For example, from a sample of 
‘normally’ dividing cells, a band will be seen containing 2n equivalents of DNA -  these cells 
can be identified as residing in G0/G1 phase. Cells in G2/M, which are preparing to divide, 
contain 4n equivalents of DNA and higher total protein levels. Those cells possessing DNA 
and protein levels between these groups are assigned to S phase, and those with levels below 
that of G0/G1 are designated to be undergoing apoptosis (figure 5.5).
G0/G1a)
O
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0 1023
2n 4n
Cellular DNA C ontent
Figure 5.5. Example of cell cycle data obtained from flow cytometry of normal HCT116 cells.
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Results from flow cytometry of HeLa cells incubated for 24 h with SST4-4 are shown in 
figure 5.6. Figures are given for the percentage of cells in the samples taken at each stage of 
the cell cycle (G0/G1, S or G2/M) and those undergoing apoptosis. Displayed here are the 
results for the control sample, a DMSO control, TSA and apicidin standards and SST4-4 at 50 
nM, 500 nM, 5 pM and 10 pM.
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Figure 5.6. Apoptosis in HeLa cells induced by SST4-4. Cell cycle analysis by flow cytometry of HeLa 
cells cultured for 24 h with SST4-4 at concentrations up to 10 pM.
The effect of TSA on the cell cycle can be clearly seen with a reduction of cells in G0/G1 and 
a dramatic increase of those undergoing apoptosis. Concentrations of SST4-4 up to 5 pM 
show no significant difference in cell cycle profile from the controls, however at 10 pM there 
is a very pronounced drop in cells in G0/G1 accompanied by a massive increase in apoptosis. 
This observed high level of apoptosis is consistent with the loss of PARP (identified by
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western blot, figure 5.1) from cells cultured in this concentration of SST4-4. The result also 
highlights the clear difference between the effects of SST4-4 and SST4-5 on HeLa cells 
(figure 5.7). The cell cycle profile of HeLa cells treated with the same concentration range of 
SST4-5 is shown in figure 5.7. The internal standards TSA and apicidin can again be seen to 
exert a consistent effect on the profile. As with SST4-4, SST4-5 shows no significant change 
in cell cycle profile up to 5 pM, however, unlike SST4-4, at 10 pM there is only a very modest 
increase in apoptosis.
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Figure 5.7. No significant change in cell cycle profile of HeLa cells cultured for 24 h with SST4-5 at 
concentrations up to 10 pM.
These results, in addition to results of protein analysis, show a clear difference in activity 
between analogues SST4-4 and SST4-5, with SST4-4 producing accumulation of 
hyperacetylated H4 and high levels of apoptosis at 10 pM but little or no effect by SST4-5 at 
the same concentration.
5 Biological Analysis 148
As may have been expected from the limited effects of both compounds on HCT116 cells, no 
dramatic changes in cell cycle profile were observed on culturing the cells for 24 h with 
concentrations up to 10 pM. Figure 5.8 demonstrates the pronounced effect of TSA on the 
cells, producing a massive decrease in cells in G0/G1 along with increase in apoptosis at 1 pM 
concentration. Apicidin shows no great increase in apoptosis, but does produce an 
accumulation of cells in the G2/M stage. SST4-4 does not show any significant effect on cell 
cycle at any concentration.
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Figure 5.8. No significant change in cell cycle profile of HCT116 cells cultured for 24 h with SST4-4 at 
concentrations up to 10 pM.
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Similar profiles are obtained from 24 h incubation of HCT116 cells with SST4-5 (figure 5.9).
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Figure 5.9. No significant change in cell cycle profile o f HCT116 cells cultured for 24 h with SST4-4 at 
concentrations up to 10 pM.
With little effect observed on the cell cycle o f HCT116 cells cultured with even 10 pM 
concentrations of these compounds, experiments were carried out over extended periods to 
determine any delayed effects. Figure 5.10 shows the effect of single concentration 10 pM 
doses over 24 h, 48 h and 72 h. In addition to the extended time periods, the influence of the 
reducing agent DTT with 24 h culture was determined.
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Figure 5.10. Increase in induction of apoptosis in HCT116 cells on extended incubation with SST4-4 
but not SST4-5 at 10 pM. Samples were taken for flow cytometry at 24, 48 and 72 h. Some increased 
levels of apoptosis are also seen on incubation of SST4-4 in the presence of DTT for 24 h.
As was expected, neither SST4-4 or SST4-5 produced a pronounced effect over 24 h, however, 
prolonged exposure to SST4-4 did increase levels of apoptosis. Incubation with added DTT 
did appear to significantly decrease the population of cells residing in G0/G1, with a slight 
increase in apoptotic cells over 24 h incubation in the absence of DTT.
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5.2 SS581 and BM577
The two compounds SS581 and BM577 were tested together because of their structural 
relationship (figure 5.11). Both are analogues of the known macrocylic inhibitor apicidin (see 
introduction, section 1.8.5). Protein and cell cycle analysis was carried out as for SST4-4 and 
SST4-5 and an additional in vitro HDAC inhibition assay was also performed. Despite the 
structural similarities with apicidin, neither SS581 nor BM577 displayed any activity as 
HDAC inhibitors and produced no change in cell cycle of the two cell lines tested.
Figure 5.11. Structures of SS581 and BM577 compared with apicidin.
Figure 5.12 shows that cellular levels of hyperacetylated H4 were not increased by either 
compound up to concentrations of 100 pM. The failure to detect any PARP cleavage product
SS581 BM577
Apicidin
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indicated that apoptosis was not being induced -  this was confirmed by the results of cell cycle 
analysis.
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Figure 5.12. Accumulation of hypercetylated H4 in HCT116 and HeLa cells on 24 h incubation with 
HDAC inhibitors as detected by western blot. Test compounds SS581 and BM577 were incubated at 
concentrations ranging from 10 pM to 100 pM. Detection of PARP and its respective cleavage product 
was used as an indication of apoptosis and MAPK expression was used as a loading control. 
Representative of n=2 experiments.
Results of cell cycle analysis on incubation of both cell lines with each compound up to 
concentrations of 100 pM for 24 h indicated no effect (figures 5.13 and 5.14).
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Figure 5.13. Influence of SS581 and BM577 on HCT116 cells after 24 h incubation. No discernable 
effect is seen on incubation with test compounds up to 100 pM concentration.
1564
5 Biological Analysis__________________________________________ 154
SS581, BM 577 HeLa
75-
70-
65-
60'
5S
=  50' 
5
« 45J 
° 4 0 -
05
«  35- 
|  30- 
|  25- 
20-  
15- 
10-
CJi Control 
tz a  DMSO 
nm  TSA, 500 nM 
CTia Apicidin, 250 nM 
C HSS571, 10 pM 
O i  SS571, 50 pM 
CHI SS571, 100 pM 
C a  BM577, 10 pM 
HM BM577, 50 pM 
C0BM 577, 100 pM
_ofl nnjliflfln
G0/G1 S G2/M
Cell Cycle Stage
A p o p to s is
Figure 5.14. Influence of SS571 and BM577 on HeLa cells after 24 h incubation. No discernable effect 
is seen on incubation with test compounds up to 100 pM concentration.
A final test of these compounds was carried out in the form of an isolated HDAC-inhibition 
assay. This would allow detection of any capability to act as HDAC inhibitors that may not 
have been observable in the cellular assays owing to reasons such as metabolism to an inactive 
form. The assay selected was the commercially available Fluor de Lys™  (AK500, BIOMOL) 
system (figure 5.15).
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Figure 5.15. Schematic representation of Fluor de Lys assay. Deacetylation of the substrate sensitizes 
it to the developer, which then generates a fluorophore. The fluorophore is excited with 360 nm light 
and the emitted 460 nm light is detected on a fluorometric plate reader.
An initial experiment was carried with concentrations of SS581 and BM577 up to 500 nM, 
which displayed no inhibitory activity. The experiment was repeated, increasing 
concentrations to a maximum of 50 pM (figure 5.16). A control was included in the form of 
TSA (10 nM), which reduced HDAC activity to below 40 %. The two test compounds still 
failed to produce any inhibitory effect.
The reasons for the inactivity of this pair of compounds can not be known for certain, but it 
may be suggested that, although the cyclic tetra-peptide cap regions bear similarity to that of 
apicidin, the methyl ester end-group is not present in apicidin. It should also be noted that the 
aliphatic chain of SS581 is one unit longer than that o f apicidin. It may be the case that despite 
the strong structural homology to the cap of the potent inhibitor, this new end-group does not 
function in a zinc-binding capacity and or, that the linker region of the compounds are not 
suitable for effective enzyme binding.
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Figure 5.16. Isolated HDAC inhibition assay. Assays were carried out using an HDAC fluorescent 
activity kit (AK500, BIOMOL). Results are typical of n=2 experiments.
5.3 SAHA Analogues 150 and 151
The synthesis of the two SAHA analogues 150 and 151 (figure 5.17) was discussed in chapter 
4. As was described, the compounds were selected for further analysis after displaying 
promising activity in the compound screen. Analysis of these compounds was carried out by 
Alexandra V. Stavropoulou.
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NHOHNHOH
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Figure 5.17. Structures of novel HDAC inhibitors 150 and 151 compared with SAHA.
The employed method for determination of inhibitor effects on cell proliferation was the SRB 
(sulphorhodamine B) assay. The assay involves incubation of a human cancer cell line (in this 
case MCF-7) with the test compounds in the presence of the aminoxanthine dye (SRB), which 
is taken up by the cells. Cell numbers may then be determined after the incubation period by 
colourimetric methods, intensity of colour being correlated to cell number after residual 
medium is washed away and remaining cells are lysed to release the absorbed dye. The results 
of the initial screening assay of the above compounds are shown in figure 5.18, along with 
TSA and a control. It can be seen that, at the same concentration as SAHA, both compounds 
appear to result in a greater reduction in cell proliferation at time periods over 24 h.
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Figure 5.18. SRB anti-proliferation assay of compounds 150 and 151. Compounds screened at 5 pM 
showed comparable activity to SAHA at the same concentration and to TSA at 1 pM. Proliferation 
determined at 0, 24, 48 and 72 h.
With the identification of 150 and 151 in the above screen, a follow-up proliferation assay was 
carried out at a range of concentrations to determine the IC50 values (figure 5.19). Results o f 
this assay were used to calculate respective IC50 values o f 4.4 pM  and 2.4 p.M for 150 and 151.
150
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Figure 5.19. Effect of increasing concentration of 150 and 151 on MCF-7 proliferation (SRB assay).
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Finally, the compounds were subjected to cell cycle analysis by flow cytometry (as described 
above). The results given in figure 5.20 show that treatment of MCF-7 cells with either 150 or 
151 led to significant increases in apoptosis levels. It should also be noted that the compounds 
also induced cell cycle arrest, as demonstrated by the accumulation of cells in the G2/M phase.
In conclusion, biological analysis of previously synthesized compounds SST4-4, SST4-5, 
SS581 and BM577 and analysis by Alexandra V. Stavropoulou o f 150 and 151 has identified 
potent cytotoxic and cytostatic anti-cancer activity from some o f these compounds. Stark 
differences in biological activity were observed between epimers SST4-4 and SST4-5, 
apparently arising from inversion of a single chiral centre (possibly resulting in poor binding 
interaction of the non-natural isomer with the enzyme’s surface). O f the two cell-lines tested, a 
more significant effect was noted in HeLa cells over HCT116, with increased levels of 
hyperacetylated H4 and apoptosis being observed.
Novel cyclic tetrapeptides SS581 and BM577 failed to display any significant activity as 
inhibitors of HDAC or on cell cycle despite their structural similarity to known inhibitors. 
This lack of activity could be due to a number of factors, possibly including non-optimum 
chain length of the linker regions and or poor binding capabilities of the end groups.
Promising activity was observed in compounds synthesized in chapter 4. Substitution of the 
anilide moiety of SAHA for the bioisosteric benzimidazole group of 151 resulted in an 
increase in activity. It is also likely that this substitution would improve the metabolic stability 
of the compound in vitro. The introduction of a hydroxymethyl group to the cap region of 150 
was also well tolerated, leading to a moderate increase in activity. This modification markedly 
improved the solubility of the compound, which would be expected to improve its 
pharmacokinetic properties as a drug. The identification of these two profitable changes to the 
basic structure of SAHA provides a point of focus for further research, in particular with the 
synthesis of the hybrid combination of these features in a hydroxymethyl, benzimidazole 
analogue.
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Figure 5.20. Cell cycle analysis of MCF-7 cells by flow cytometry after incubation with test compounds 
150 and 151 at various concentrations for 48 h.
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5.4 Experimental
5.4.1 Solutions and Buffers
Cell lysis Buffer 25 mM Tris-HCl pH 7.8, 2mM DTT, 1% Triton X-100, 10% v/v  
glycerol
lx  PBS lxPBS tablet was dissolved in 200 ml dH20
10% SDS 50 g SDS dissolved in 500 ml o f  H20
Propidium Iodide 1 mg/ml
Fluorescein Isothiocyanate(FITC) 1 pg/ml
SDS loading buffer 4% SDS, 0.1 M Tris pH 8.9. 2 mM EDTA. 0.1% and 
bromophenol blue
RNAse A 10 mg/ml in dH20
5.4.2 Tissue culture
Human cancer cell lines (HCT116 and HeLa) were maintained and propagated in 75 mL tissue 
culture flasks. Cells were split on reaching 80 % confluency by aspiration of media, washing 
with PBS and detachment with trypsin (0.1 mL). Cells were suspended in fresh Dulbecco’s 
Minimal Essential Medium (DMEM) containing 10 % fetal calf serum (FCS) (20 mL) and 5 
mL aliquots added to fresh tissue culture flasks containing 50 mL DMEM. For incubation with 
inhibitors, cells (1.8xl05) were seeded in 24-well plates containing 5 mL DMEM and 
incubated for 24 h. The desired concentration of test compound was then added as a solution 
in DMSO, and the sample typically incubated for a further 24 h.
5.4.3 Protein Analysis
Samples were collected after the incubation period as follows. The medium (500 pL) was 
aspirated and collected in a 1.5 mL microcentrifuge tube. The cells were washed with PBS 
(100 pL), detached with trypsin (80 pL) and the wells washed with further PBS (100 pL). 
Cells of the combined washings and media were counted and samples separated for protein 
and cell cycle analysis. The respective samples were centrifuged (300 g, 8  min), The 
supernatant was carefully removed and discarded. Cell pellets allocated for protein analysis 
were gently disaggregated. Cells were lysed by addition of SDS (2X) loading buffer to give a 
concentration of 2xl04 cells/pL and the samples heated to 100 °C for 5 min. Samples could 
then be stored indefinitely at -20 °C. Before separation by SDS-polyacrylamide gel 
electrophoresis (PAGE), samples were re-heated to 100 °C to fully denature proteins, 
centrifuged to collect any evaporated water, re-mixed and centrifuged briefly.
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For SDS-PAGE analysis, 4-12% NuPage Bis-Tris precast gels were used. Sample volumes of 
1 0  pi were loaded into each well and a potential of 160 volts was applied to the apparatus for 1 
hour. As an indication of molecular weight, Novagen chromophore-conjugated protein 
markers were separated on the same gel.
Western blotting was carried out after separation by SDS-PAGE. The gel was placed on a 
nitrocellulose membrane (Hybond-C), pieces of 3mm paper placed over the reverse side of the 
gel and over the membrane and the combined layers placed in a cassette between cotton pads 
saturated with 20 % methanol-Tris-glycine. Proteins were transferred from the gel to the 
membrane by application of an electric current (160 mA, 25 V) across the cassette for 90 min. 
The membrane was then carefully removed from the cassette and blocked for 1 h in a solution 
of dried, skimmed milk (Marvel) in PBS-0.05 % Tween20, then rinsed in PBS-Tween.
For the detection of acetylated a-tubulin, membranes were incubated overnight at 4 °C in a 
1:4000 dilution of an anti-acetylated a-tubulin monoclonal antibody in 1 % dried, skimmed 
milk in PBS 0.05 %-Tween. Anti-hyperacetylated histone H4 rabbit (1:10,000 dilution), anti- 
PARP mouse (1:1000) and anti-MAPK rabbit (1:1000) antibodies were used in the same way. 
Membranes were subsequently washed with PBS-0.05 % Tween ( 3 x 5  min) Incubation with 
the secondary antibody followed for 1 hour at a 1 : 2 0 0 0  dilution of either anti-rabbit or anti­
mouse Horse Radish Peroxidase (HRP) conjugated antibody in 1% (w/v) dried skimmed milk 
diluted in PBS-0.05% Tween. Membranes were again washed in PBS-0.05 % Tween ( 3 x 5  
min) and bound antibodies detected with a chemiluminescence detection product (ECL-plus). 
After incubation for 5 minutes at RT with ECL-plus the membranes were wrapped in clear 
plastic membrane (Saran wrap) and exposed to photosensitive film.
5.4.4 Cell Cycle Analysis
Samples of pelleted cells collected as described in section 5.4.3. The pellets were gently 
disaggregated then fixed by addition of 70 % ice-cold ethanol with vortexing. Samples could 
then be stored indefinitely at -20 °C.
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For analysis, fixed sample were centrifuged (400 g, 10 min) and the supernatant (70 % ethanol) 
removed by inverting the tubes. Cells were then re-suspended in a staining solution (500 pL) 
consisting of propidium iodide (PI, for DNA staining) (400 pL), fluorescein isothiocyanate 
(FITC, for protein staining) (50 pL) and RNAase A (500 pL) made up to 10 mL in ddf^O.
The stained cells were analysed by flow cytometry (Beckton-Dickinson, FACScan) with FITC 
(total cell protein content, proportional to cell size) on FL-1 and PI (DNA content) on FL-2. 
Cell cycle stages were then assigned according to cell size and DNA content.
5.4.5 Histone Deacetylase Inhibition Assay
The HDAC inhibition assay was carried out in a 96-well plate with a fluorescence activity 
drug discovery kit (AK500, BIOMOL). The sample compounds at various concentrations 
were diluted in the assay buffer (10 pL), then a source of HDAC enzymes from HeLa nuclear 
extract (15 pL) added. The solutions were allowed to equilibrate at 25 °C for 15 min, then the 
Fluor de Lys substrate (25 pL) added and the plate incubated at 25 °C for 10 min. The reaction 
was stopped after this time by addition of Fluor de Lys developer (50 pL) including TSA at a 
final concentration of 1 pM. After developing for 15 min at 25 °C the fluorescence of the 
wells was measured on a fluorometric plate reader with excitation at 360 nM and detection at 
460 nM. The percentage of deacetylase activity was calculated from the readings corrected to 
the control wells containing no inhibitor ( 1 0 0  % activity) and no enzyme ( 0  % activity).
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6 Experimental
Melting points were determined on a microscope hot-stage Electrothermal 9100 apparatus, 
and are uncorrected. Infra-red (IR) spectra were recorded on a Perkin-Elmer PE-983 
spectrophotometer; absorptions are quoted in wavenumbers (vmax in cm '1). *H NMR spectra 
were recorded on a Bruker AC300 (300 MHz) spectrometer; data reported in parts per 
million (5). Coupling constants (J) are given in Hertz (Hz). The following abbreviations are 
used in signal assignments: singlet (s), broad singlet (br s), doublet (d), triplet (t), quartet 
(q), and multiplet (m). 13C NMR spectra were obtained using Bruker AMX300 (75 MHz), 
Bruker AMX 400 (100 MHz) and Bruker AMX 500 (125 MHz) spectrometers and are 
recorded in parts per million (5) with CHCI3 as an internal standard. Mass spectra were 
recorded on a VG7070H mass spectrometer with Finigan Incos II data system at University 
College London. Thin-layer chromatography was performed on Merck 0.2 mm aluminium- 
backed silica gel 60 F254 plates and visualised by ultra violet light or an alkaline potassium 
permanganate spray with subsequent heating. Evaporation refers to the removal o f solvent 
under reduced pressure. Glassware, syringes and needles for moisture-sensitive reactions 
were pre-dried in an oven (130 °C). Temperatures below 0 °C were obtained from various 
mixtures of water, freezing salt and ice, acetone and ice, acetone and dry ice or liquid 
nitrogen.
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6.1 The Oxygen Series
Methyl 8-bromooctanoate (47)1
o
A solution of 8 -bromooctanoic acid (1.50 g, 6.72 mmol) in 4 % cH2S 04-methanol (65 mL) 
was heated to 50 °C for 3 h. On cooling to room temperature the solvent was removed in 
vacuo and the colourless oil dissolved in ethyl acetate (30 mL). The solution was washed 
with saturated aqueous sodium hydrogen carbonate solution ( 2 x 3 0  mL), water (20 mL) and 
brine (20 mL) then dried over MgS04. The solvent was evaporated to leave a pale yellow 
oil (1.50 g, 94 %) requiring no purification; 'H-NMR (CDCI3, 300 MHz) 5 3.55 (3H, s, 
CH3), 3.30 (2H, m, BrC7/2), 2.19 (2H, t, .7=7.4 Hz, CH2COO), 1.73 (2H, m, BrCH2CH2), 
1.53 (2H, m, C772CH2COO), 1.34-1.21 (6 H, m, BrCH2CH2C //2, BrCH2CH2CH2C7/2, 
C772CH2CH2COO); 13C-NMR (CDC13, 75 MHz) 5 173.87 (COO), 51.30 (CH3), 33.85 
(CH2COO), 28.82 (CH2CH2CH2COO), 28.31 BrCH2CH2CH2CH2), 27.87 (BrCH2CH2CH2), 
24.71 (CH2CH2COO).
Ethyl 6-(4-nitrophenoxy)hexanoate (48)
o
A mixture of 4-nitrophenol (935 mg, 6.72 mmol), ethyl 6 -bromohexanoate (1.80 g, 8.07 
mmol) and caesium carbonate (2.63 g, 8.07 mmol) in dimethylformamide (35 mL) was 
refluxed at 150 °C for 20 h. On cooling to room temperature water (50 mL) was added and 
the aqueous solution extracted with ethyl acetate (3 x 20 mL) and the combined organics 
washed with 1 M sodium hydroxide (20 mL), water (2 x 20 mL) and brine (20 mL). The 
organic phase was dried over M gS04 and evaporated to leave a pale yellow solid which was 
recrystallised from diethyl ether-petroleum ether (40 - 60) to give the product (1.83 g, 97 %) 
as pale yellow crystals, mp 68-70 °C; IR (KBr, thin film) (cm 1) 2949, 1728, 1498, 1267. 
1 H-NMR (C D C I3 ,  300 MHz) 5 8.13 (2H, d, .7=9.3 Hz, 3, 5-aryl), 6.89 (2H, d, 7=9.3 Hz, 2, 6 - 
aryl), 4.09 (2H, q, 7=7.1 Hz, OC772CH3), 4.01 (2H, t, 7=6.4 Hz, OC772CH2), 2.30 (2H, t,
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.7=7.3 Hz, CH2COO), 1.81 (2H, m, OCH2CH2), 1.66 (2H, m, C //2CH2COO), 1.53 (2H, m, 
OCH2CH2CH2), 1 .2 1  (3H, t, .7=7.1 Hz, CH2C //3); 13C-NMR (CDC13, 75 MHz) 5 173.47 
(COO), 164.13 ( 1-aryl), 141.30 (4-aryl), 125.85 (3, 5-aryl), 114.38 (2, 6 -aryl), 68.52 
(OCH2CH2), 60.26 (OCH2CH3), 34.11 (CH2COO), 28.65 (OCH2CH2), 25.48 
(OCH2CH2CH2), 24.58 (CH2CH2COO), 14.23 (CH2CH3). Anal. Calcd for ChH^NOs C, 
59.78; H, 8.81; N, 4.98. Found: C, 59.42; H, 6.80; N, 4.90.
Ethyl 7-(4-nitrophenoxy)heptanoate (49)
Q?N
To a stirred solution of 4-nitrophenol (2.97 g, 21.4 mmol) in dimethylformamide (12 mL) 
was added cesium carbonate (8.34 g, 25.6 mmol) followed by ethyl-7-bromoheptanoate 
(6.08g, 25.6 mmol). The mixture was heated to reflux for 18 h then allowed to cool to room 
temperature. Water (50 mL) was added and the aqueous solution extracted with ethyl 
acetate (2 x 40 mL). The yellow organic phase was washed with 1 M sodium hydroxide 
solution (50 mL) and water (2 x 50 mL) before drying (MgSCL). The solvent was removed 
in vacuo to yield a low melting solid which was recrystallised from ethanol to give the title 
compound (5.33 g, 85 %) as white needles, mp 31-32 °C; 'H-NMR (CDC13, 300 MHz) 8  
8.15 (2H, d, .7=9.2 Hz, 3, 5-aryl), 6.90 (2H, d, .7=9.2 Hz, 2, 6 -aryl), 4.09 (2H, q, .7=7.1 Hz, 
OC772CH3), 4.01 (2H, t, .7=6.4 Hz, OC772CH2), 2.28 (2H, t, .7=7.4 Hz, CH2COO), 1.80 (2H, 
m, 0CH 2C772), 1.63 (2H, m, C772CH2COO), 1.49-1.34 (4H, m, OCH2CH2C772, 
C772CH2CH2C 0 0 ), 1.22 (3H, t, .7=7.1 Hz, CH2C/73); 13C-NMR (CDC13, 75 MHz) 8  173.67 
(COO), 164.18 ( 1 -aryl), 141.33 (4-aryl), 125.90 (3, 5-aryl), 114.39 (2 , 6 -aryl), 68.70 
(OCH2CH2), 60.24 (OCH2CH3), 34.19 (CH2COO), 28.77 (CH2CH2CH2COO, OCH2CH2), 
25.62 (OCH2CH2CH2), 24.79 (CH2CH2COO), 14.26 (CH2CH3).
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Methyl 8-(4-nitrophenoxy)octanoate (50)
o
A mixture of 4-nitrophenol (694 mg, 4.99 mmol), methyl 8 -bromooctanoate (1.42 g, 5.99 
mmol) and caesium carbonate (1.95 g, 5.99 mmol) in dimethylformamide (30 mL) was 
refluxed at 150 °C for 20 h. On cooling to room temperature, water (50 mL) was added, and 
the aqueous solution extracted with ethyl acetate (3 x 20 mL) and the combined organics 
washed with 1 M sodium hydroxide (20 mL), water (2 x 20 mL) and brine (20 mL). The 
organic phase was dried over MgS0 4  and evaporated to leave a pale yellow solid which was 
recrystallised from diethyl ether-petroleum ether (40 - 60) to give the product (1.33 g, 90 %) 
as yellow crystals, mp 71-72 °C; IR (KBr, thin film) (cm'1) 2930, 1732, 1499, 1337, 1265. 
1 H-NMR (CDC13, 300 MHz) 6  8.15 (2H, m, 3, 5-aryl), 6.91 (2H, m, 2, 6 -aryl), 4.01 (2H, t, 
J= 6.5 Hz, OC//2CH2), 3.63, (3H, s, CH3), 2.28 (2H, t, J=7.4 Hz, CH2COO), 1.77 (2H, m, 
OCH2C //2), 1.61 (2 H, m, C //2CH2COO), 1.47-1.32 (6 H, m, OCH2CH 2CH2, 
OCH2CH2CH2C//2, C //2CH2CH2COO); 13C-NMR (CDCI3, 75 MHz) 6  174.16 (COO),
164.21 ( 1 -aryl), 141.27 (4-aryl), 125.87 (3, 5-aryl), 114.38 (2 , 6 -aryl), 68.78 (OCH2CH2), 
51.45 (CH3), 33.97 (CH2COO), 28.97 (OCH2CH2), 28.91 (CH2CH2CH2CH2COO), 28.87 
(CH2CH2CH2COO), 25.71 (OCH2CH2CH2), 24.80 (CH2CH2COO). Anal. Calcd for 
C ,5H2 ,N0 5  C, 61.00; H, 7.17; N, 4.74. Found: C, 60.96; H, 7.22; N, 4.71.
Ethyl 6-(4-aminophenoxy)hexanoate (51)
o
To a stirred solution o f ethyl 6-(4-nitrophenoxy)hexanoate (48) (1.67 g, 5.94 mmol) in 
ethanol (30 mL), was added 5 % palladium on carbon (20 mg) under nitrogen. The system 
was evacuated and replaced with hydrogen at atmospheric pressure. After stirring for 36 h 
the catalyst was removed and the solvent removed in vacuo to yield a red oil (1.42 g, 95 %) 
which required no further purification; IR (KBr, thin film) (cm'1) 3362, 2937, 1732, 1512, 
1236. ‘H-NMR (CDC13, 300 MHz) 6  6.72 (2H, m, 2, 6 -aryl), 6.59 (2H, m, 3, 5-aryl), 4.10
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(2H, q, .7=7.1 Hz, OC772CH3), 3.85 (2H, t, .7=6.6 Hz, OC7/2CH2), 2.30 (2H, t, .7=7.2 Hz, 
CH2COO), 1.75-1.61 (4H, m, OCH2C772, C7/2CH2COO), 1.46 (2H, m, OCH2CH2C772), 1.23 
(3H, t, 7=7.1 Hz, CH2C/7)); 13C-NMR (CDC13i 75 MHz) 5 173.67 (COO), 152.09 (1-aryl), 
140.09 (4-aryl), 116.34 (3, 5-aryl), 115.62 (2 , 6 -aryl), 68.31 (OCH2CH2), 60.23 
(OCH2CH3), 34.26 (CH2COO), 29.10 (OCH2CH2), 25.67 (OCH2CH2CH2), 24.75 
(CH2CH2COO), 14.26 (CH2CH3). LRMS (El) m/z 251 (M+, 35 %), 206 (13 %), 143 (32 %), 
109 (100 %). HRMS calcd for C 14H21NO3 251.15214. Found: 251.15197.
Ethyl 7-(4-aminophenoxy)heptanoate (52)
H2N
To a stirred solution of ethyl 7-(4-nitrophenoxy)heptanoate (49) (1.80 g, 6.1 mmol) in 
ethanol (20 mL), was added 5 % palladium on carbon (15 mg) under nitrogen. The system 
was evacuated and replaced with hydrogen at atmospheric pressure. After stirring for 4 h, 
the catalyst was removed and the solvent removed in vacuo to yield a pale brown solid 
which was recrystallised from ethanol to give the title compound (1.34 g, 83 %) as white 
flakes, mp 47-48 °C; ’H-NMR (CDC13, 300 MHz) 5 6.67 (4H, m, aryl), 4.12 (2H, q, .7=7.1 
Hz, OC//2CH3), 3.85 (2H, t, 7=6.5 Hz, OC7/2CH2), 3.26 (2 H, s, NH2), 2.29 (2 H, t, 7=7.5 Hz, 
CH2COO), 1.75-1.61 (4H, m, OCH2C //2, C/72CH2COO), 1.48-1.36 (4H, m, OCH2CH2C//2, 
OCH2CH2CH2C//2), 1-24 (3H, t, 7=7.1 Hz, CH2C/73); ,3C-NMR (CDC13, 75 MHz) 5 173.82 
(COO), 152.29 (1-aryl), 139.82 (4-aryl), 116.44 (3, 5-aryl), 115.65 (2, 6 -aryl), 68.51 
(OCH2CH2), 60.21 (OCH2CH3), 34.30 (CH2COO), 29.25 (OCH2CH2), 28.91 
(OCH2CH2CH2CH2), 25.77 (OCH2CH2CH2), 24.91 (CH2CH2COO), 14.27 (CH2CH3). Anal. 
Calcd for Ci5H23N0 3  C, 67.90; H, 8.74; N, 5.28. Found: C, 67.81; H, 8.79; N, 5.30.
Methyl 8-(4-aminophenoxy)octanoate (53)
o
To a stirred solution of methyl 8-(4-nitrophenoxy)octanoate (50) (1.24 g, 4.20 mmol) in 
ethanol (30 mL), was added 5 % palladium on carbon (15 mg) under nitrogen. The system
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was evacuated and replaced with hydrogen at atmospheric pressure. After stirring for 36 h, 
the catalyst was removed and the solvent evaporated to yield a red oil (0.69 g, 62 %); *H- 
NMR (CDCI3, 300 MHz) 5 6.73 (2H, m, 2, 6 -aryl), 6.59 (2H, m, 3, 5-aryl), 3.85 (2H, t, 
J= 6.5 Hz, OC//2CH2), 3.65, (3H, s, CH3), 3.32 (2H, brs, NH2), 2.30 (2H, t, J=1A Hz, 
CH2COO), 1.74-1.60 (4H, m, OCH2CH2, C //2CH2COO), 1.45-1.31 (6 H, m, OCH2CH2C //2, 
OCH2CH2CH2C //2, C //2CH2CH2COO); 13C-NMR (CDCI3, 75 MHz) 6  174.28 (COO), 
152.24 ( 1 -aryl), 139.93 (4-aryl), 116.39 (3, 5-aryl), 115.64 (2 , 6 -aryl), 68.58 (OCH2CH2), 
51.47 (CH3), 34.07 (CH2COO), 29.36 (OCH2CH2), 29.07 (CH2CH2CH2CH2COO, 
CH2CH2CH2COO), 25.91 (OCH2CH2CH2), 24.89 (CH2CH2COO). LRMS (El) m/z 265 (M+, 
6 6  %), 235 ( 8  %), 109 (100 %). HRMS calcd for C 15H23NO3 265.16778. Found: 265.16738.
Ethyl 7-(4-(dimethylamino)phenoxy)heptanoate (55)
To a solution of ethyl 7-(4-aminophenoxy)heptanoate (52) (300 mg, 1.13 mmol), 
formaldehyde (0.55 mL of a 37 % aqueous solution, 6.78 mmol) and sodium 
cyanoborohydride (106 mg, 1.70 mmol) in acetonitrile (10 mL) was added acetic acid (34 
mg, 0.57 mmol) and the solution stirred for 18 h. A further aliquot of acetic acid (34 mg, 
0.57 mmol) was then added and stirring continued for 1 d. The reaction was quenched with 
water (10 mL) and the solution extracted with ethyl acetate (10 mL). The organic phase was 
washed with saturated aqueous sodium hydrogen carbonate solution (10 mL) and brine (10 
mL) before drying over MgS(>4 . The solvent was removed in vacuo and the crude yellow oil 
purified by column chromatography (hexane-ethyl acetate, 4:1) to give the title compound 
(230 mg, 69 %) as a pale yellow oil; IR (KBr, thin film) (c m 1) 2937, 1734, 1514, 1244. *H- 
NMR (CDCI3, 300 MHz) 5 6 . 8 8  (2H, m, 2, 6 -aryl), 6.73 (2H, m, 3, 5-aryl), 4.13 (2H, q, 
J=1.2 Hz, OC//2CH3), 3.89 (2 H, t, J=6.5 Hz, OCH2), 2.85 (6 H, s, N(CH3)2), 2.30 (2 H, t, 
J=1A Hz, CH2COO), 1.78-1.63 (4H, m, OCH2CH2, CH2CH2COO), 1.48-1.38 (4H, m, 
OCH2CH2C //2, OCH2CH2CH2C//2), 1.25 (3H, t, J=12 Hz, CH2C //3); 13C-NMR (CDC13, 75 
MHz) 6  173.25 (COO), 151.45 (1-aryl), 145.73 (4-aryl), 115.47 (2, 6 -aryl), 114.87 (3, 5- 
aryl), 68.48 (OCH2CH2), 60.17 (OCH2CH3), 41.81 (N(CH3)2), 34.29 (CH2COO), 29.30
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(OCH2CH2), 28.93 (CH2CH2CH2COO), 25.80 (OCH2CH2CH2), 24.93 (CH2CH2COO),
14.28 (CH2CH3). LRMS (El) m/z 293 (M+, 100 %), 248 (14 %), 136 (95 %), 108 (38 %). 
HRMS calcd fo rC |7H27N 0 3293.19908. Found: 293.19859.
Ethyl 6-(4-(2-(l//-indol-3-yI)acetamido)phenoxy)hexanoate (56)
3-Indole acetic acid (0.99 g, 5.64 mmol) was dissolved in dimethyl formamide (55 mL) and 
1 -hydroxybenzotriazole (0.94 g, 6.98 mmol), l-(3-dimethylaminopropyl)-3-ethyl 
carbodiimide hydrochloride (1.18, 6.18 mmol) and 7V-methyl morpholine (1.25 g, 12.35 
mmol) added successively and the solution stirred at room temperature for 30 min. To the 
solution was added ethyl 6-(4-aminophenoxy)hexanoate (51) (1.35 g, 5.37 mmol) in 
dimethyl formamide (4 mL) and the solution stirred for 21 h. The reaction was quenched by 
the addition of 1 M HC1 and the resultant suspension extracted with ethyl acetate (4 x 20 
mL). The combined organics were washed with saturated aqueous sodium hydrogen 
carbonate solution (40 mL), water (2 x 40 mL) and brine (40 mL). The solvent was removed 
in vacuo to yield an off-white solid which was recrystallised from ethanol to give the title 
compound (1.86 g, 85 %) as white crystals, 114-116 °C; IR (KBr, thin film) (cm’1) 3412, 
2939, 1732, 1649, 1510. 'H-NMR (CDC13, 300 MHz) 5 8.75 (1H, s, NH), 7.61 (1H, d, 7=7.8 
Hz, 5-indolyl), 7.47 (1H, s, NH), 7.40 (1H, d, 7=8.0 Hz, 8 -indolyl), 7.27-7.13 (5H, m, 7- 
indolyl, 3, 5-aryl, 6 , 2-indolyl), 6.75 (2H, d, 7=9.0 Hz, 2, 6 -aryl), 4.12 (2H, q, 7=7.1 Hz, 
OC//2CH3), 3.86 (4H, m, OC//2CH2, C //2CONH), 2.32 (2H, t, 7=7.4 Hz, CH2COO), 1.77-
1.65 (4H, m, OCH2CH2, CH2CH2COO), 1.48 (2H, m, C //2CH2CH2COO), 1.25 (3H, t, 
7=7.2 Hz, CH2CH3); ,3C-NMR (CDC13, 75 MHz) 5 173.79 (COO), 169.90 (CONH), 155.97 
(1 -aryl), 136.56 (9-indolyl), 130.61 (4-aryl), 126.95 (4-indolyl), 124.16 (2-indolyl), 122.66 
(6 -indolyl), 122.09 (3, 5-aryl), 120.20 (7-indolyl), 118.62 (5-indolyl), 114.66 (2, 6 -aryl), 
111.66 (8 -indolyl), 108.45, (3-indolyl), 67.90 (OCH2CH2), 60.32 (OCH2CH3), 34.28 
(OOCCH2, CH2CONH), 28.93 (OCH2CH2), 25.63 (OCH2CH2CH2), 24.73 (CH2CH2COO),
14.28 (CH2CH3). Anal. Calcd for C24H28N20 4  C, 71.57; H, 6.91; N, 6 .8 6 . Found: C, 70.42; 
H, 6.80; N, 6 .8 6 .
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Ethyl 7-(4-(2-(l//-indoI-3-yl)acetamido)phenoxy)heptanoate (57)
H
3-Indole acetic acid (0.52 g, 2.95 mmol) was dissolved in dimethyl formamide ( 8  mL) and 
1-hydroxybenzotriazole (0.49 g, 3.65 mmol), l-(3-dimethylaminopropyl)-3-ethyl 
carbodiimide hydrochloride (0.62, 3.23 mmol) and A-methyl morpholine (0.72 mL, 6.46 
mmol) added successively at 0 °C. To the solution was added ethyl 7-(4- 
aminophenoxy)heptanoate (52) (1.0 g, 3.77 mmol) in dimethyl formamide (4 mL) and the 
solution stirred for 16 h. The reaction was quenched by the addition of 1 M HC1 (15 mL) 
and the resultant solution extracted with ethyl acetate (2 x 20 mL). The combined organics 
were washed with 5 % aqueous sodium hydrogen carbonate solution (20 mL) and brine (20 
mL) before drying (MgS0 4 ). The solvent was removed in vacuo to yield an off-white solid 
which was recrystallised from ethanol to give the title compound (0.95 g, 78 %) as white 
crystals, mp 107-108 °C; IR (KBr, thin film) (cm'1) 3409, 2939, 1720, 1649, 1510. ’H-NMR 
(CDC13, 300 MHz) 5 8.58 (1H, s, NH), 7.61 (1H, d, 7=7.8 Hz, 5-indolyl), 7.41 (2H, d, 7=8.0 
Hz, Ar), 7.21 (4H, m, 8 , 2, 7, 6 -indolyl), 6.75 (2H, d, 7=8.8 Hz, 2, 6 -aryl), 4.12 (2H, q, 
7=7.1 Hz, OC//2CH3), 3.87 (4H, m, OC//2CH2, C //2CONH), 2.30 (2H, t, 7=7.5 Hz, 
CH2COO), 1.87 (2H, m, OCH2C //2), 1.68 (2H, m, C //2CH2COO), 1.40 (4H, m,
OCH2CH2CH2, CH2CH2CH2COO), 1.24 (3H, t, 7=7.1 Hz, CH2CH3); 13C-NMR (CDCI3, 75 
MHz) 8  173.87 (COO), 169.76 (CONH), 156.02 (1-aryl), 136.52 (9-indolyl), 130.54 (4- 
aryl), 126.53 (4-indolyl), 124.10 (2-indolyl), 122.75 (6 -indolyl), 122.03 (3, 5-aryl), 120.29 
(7-indolyl), 118.66 (5-indolyl), 114.66 (2, 6 -aryl), 111.61 (8 -indolyl), 108.58, (3-indolyl), 
68.08 (OCH2CH2), 60.27 (OCH2CH3), 34.29 (OOCCH2CH2, CH2CONH), 29.07 
(OCH2CH2), 28.87 (OCH2CH2CH2CH2), 25.72 (OCH2CH2CH2), 24.88 (CH2CH2COO),
14.28 (CH2CH3). Anal. Calcd for C25H3oN20 4  C, 71.07; H, 7.16; N, 6.63. Found: C, 70.93; 
H, 7.22; N, 6.56.
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Methyl 8-(4-(2-(l//-indol-3-yl)acetamido)phenoxy)octanoate (59)
H
3-Indole acetic acid (0.44 g, 2.95 mmol) was dissolved in dimethyl formamide (25 mL) and 
1-hydroxybenzotriazole (0.42 g, 3.08 mmol), l-(3-dimethylaminopropyl)-3-ethyl 
carbodiimide hydrochloride (0.52, 2.73 mmol) and A-methyl morpholine (0.55 g, 5.45 
mmol) added successively and the resultant solution stirred at room temperature for 30 min. 
To the solution was added methyl 8-(4-aminophenoxy)octanoate (53) (0.63 g, 2.37 mmol) 
in dimethyl formamide (4 mL) and the solution stirred for 21 h. The reaction was quenched 
by the addition of 1 M HC1 and the resultant suspension extracted with ethyl acetate (1 x 20 
mL, 3 x 10 mL). The combined organics were washed with saturated aqueous sodium 
hydrogen carbonate solution (25 mL), water (2 x 25 mL) and brine (20 mL). The solvent 
was removed in vacuo to yield a pale pink solid which was recrystallised from ethyl acetate- 
petroleum ether (40 - 60) to give the title compound (0.82 g, 82 %) as white crystals, mp 
133-134 "C; IR (KBr, thin film) (cm 1) 3416, 2941, 1738, 1651. 'H-NMR (CDC13, 300 
MHz) 5 8.61 (1H, brs, NH), 7.62 (1H, d, .7=7.8 Hz, 5-indolyl), 7.41 (2H, m, 8 -indolyl, NH), 
7.20 (5H, m, 7-indolyl, 3, 5-aryl, 6 , 2-indolyl), 6.75 (2H, d, J= 9.0 Hz, 2, 6 -aryl), 3.86 (4H, 
m, OC//2CH2,C //2CONH), 3.66 (3H, s, CH3), 2.30 (2H, t, .7=7.4 Hz, CH2COO), 1.77-1.60 
(4H, m, 0CH 2C7/2, C772CH2C 00), 1.44-1.32 (6 H, m, OCH2CH2C772, OCH2CH2CH2C772, 
C772CH2CH2C 00); 13C-NMR (CDC13, 75 MHz) 6  174.35 (COO), 169.74 (CONH), 156.03 
(1-aryl), 136.53 (9-indoIyl), 130.55 (4-aryl), 126.94 (4-indolyl), 124.08 (2-indolyl), 122.73 
(6 -indolyl), 122.03 (3, 5-aryl), 120.27 (7-indolyl), 118.65 (5-indolyl), 114.67 (2, 6 -aryl), 
111.61 (8 -indolyl), 108.59, (3-indolyl), 68.16 (OCH2CH2), 51.51 (CH3), 34.32
(CH2CONH), 34.08 (OOCCH2CH2), 29.17 (OCH2CH2), 29.04 (CH2CH2CH2CH2COO, 
CH2CH2CH2COO), 25.84 (OCH2CH2CH2), 24.87 (CH2CH2COO). Anal. Calcd for 
C25H30N2O4 C, 71.07; H, 7.16; N, 6.63. Found: C, 70.88; H, 7.21; N, 6.58.
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Ethyl 7-(4-(3-(lJ/-indol-3-yl)propanamido)phenoxy)heptanoate (58)
3 -Indolepropionic acid (449 mg, 2.37 mmol) was dissolved in dimethyl formamide (9 mL) 
and 1-hydroxybenzotriazole (397 mg, 2.94 mmol), l-(3-dimethylaminopropyl)-3-ethyl 
carbodiimide hydrochloride (498 mg, 2.60 mmol) and TV-methyl morpholine (526 mg, 5.20 
mmol) added successively at 0 °C. To the solution was added ethyl 7-(4- 
aminophenoxy)heptanoate (52) (600 mg, 2.26 mmol) in dimethyl formamide (5 mL) and the 
solution stirred for 16 h. The reaction was quenched by the addition of 1 M HC1 ( 8  mL) and 
the resultant solution extracted with ethyl acetate (2 x 20 mL). The combined organics were 
washed with 5 % aqueous sodium hydrogen carbonate solution (20 mL) and brine (20 mL) 
before drying (MgS0 4 ). The solvent was removed in vacuo to yield a cream coloured solid 
which was recrystallised from ethyl acetate-petroleum ether (40 - 60) to give the title 
compound (0.78 g, 79 %) as white crystals, mp 110-111 °C; IR (KBr, thin film) (cm '1) 3408, 
3304, 2934, 1732, 1655, 1510. 1H-NMR (CDCI3, 300 MHz) 6  8.31 (1H, brs, NH) 7.58 (1H, 
d, .7=7.7 Hz, 5-indolyl), 7.51 (1H, s, NH), 7.28 (3H, m, 3, 5-aryl, 8 -indolyl), 7.18-7.09 (2H, 
m, 7, 6 -indolyl), 6 . 8 6  (1H, d, J=0.7 Hz, 2-indolyl), 6.76 (2H, d, 7=8.9 Hz, 2, 6 -aryl), 4.13 
(2H, q, 7=7.1 Hz, OC//2CH3), 3.85 (2H, t, 7=6.5 Hz, OC772CH2), 3.14 (2H, t, 7=7.4 Hz, 
C7/2CH2CONH), 2.66 (2H, t, 7=7.4 Hz, C7/2CONH), 2.31 (2H, t, 7=7.4 Hz, CH2COO), 
1.76-1.62 (4H, m, OCH2C7/2, C7/2CH2COO), 1.40 (4H, m, OCH2CH2C7/2,
C7/2CH2CH2COO), 1.26 (3H, t, 7=7.1 Hz, CH2CH3); 13C-NMR (CDC13, 75 MHz) 5 173.88 
(COO), 171.02 (CONH), 155.87 (1-aryl), 136.38 (9-indolyl), 130.80 (4-aryl), 127.05 (4- 
indolyl), 122.07 (2-indolyl), 122.01 (3, 5-aryl), 121.88 (6 -indolyl), 119.39 (7-indolyl),
118.65 (5-indolyl), 114.70 (2, 6 -aryl, 8 -indolyl), 11 1.34 (3-indolyl), 68.10 (OCH2CH2),
60.28 (OCH2CH3), 38.13 (CH2CONH), 34.30 (CH2COO), 29.08 (OCH2CH2), 28.87 
(CH2CH2CH2COO), 25.73 (OCH2CH2CH2), 24.89 (CH2CH2COO), 21.31 
(CH2CH2CONH)), 14.28 (CH2CH3). Anal. Calcd for C26H32N20 4 C, 71.53; H, 7.39; N, 
6.42. Found: C, 71.53; H, 7.39; N, 6.42.
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Ethyl 7-(4-(2-(li/-indoI-3-yI)ethylamino)phenoxy)heptanoate (60)
H
A solution of acetic acid (1.99 g, 33.1 mmol) in tetrahydrofuran (5 mL) was added dropwise 
to a stirred suspension of sodium borohydride (1.25 g, 33.1 mmol) in tetrahydrofuran (30 
mL). After stirring for 2 h, a solution of ethyl 7-(4-(2-(l//-indol-3- 
yl)acetamido)phenoxy)heptanoate (57) (1.40 g, 3.31 mmol) in tetrahydrofuran (10 mL) was 
added dropwise, and the suspension warmed to 45 °C and stirred for 17 h. On cooling to 
room temperature, the reaction was quenched with brine (20 mL) and extracted with ethyl 
acetate (3 x 20 mL). The combined organics were washed with water (2 x 20 mL) and brine 
(20 mL), then dried (MgS0 4 ). The solvent was removed in vacuo and the colourless oil 
purified by column chromatography (ethyl acetate-petroleum ether (40 - 60), 1:1) to give the 
product (0.72 g, 53 %) as a white crystalline solid, mp 76-77 °C; IR (KBr, thin film) (cm'1) 
3393,2937, 1730, 1512, 1231. 'H-NMR (CDC13, 300 MHz) 5 8.06 (1H, brs, NH), 7.63 (1H, 
d, 7=7.9 Hz, 5-indolyl), 7.37 (1H, d, .7=8.1 Hz, 8 -indolyl), 7.21 (1H, ddd, 7=1.1, 7.1, 8.1 Hz, 
7-indolyl), 7.13 (1H, ddd, 7=1.1, 7.1, 8.1 Hz, 6 -indolyl), 7.04 (1H, d, 7= 2.3 Hz, 2-indolyl), 
6.77 (2H, d, 7= 8.9 Hz, 3, 5-aryl) 6.58 (2H, d, 7= 8.9 Hz, 2, 6 -aryl), 4.13 (2H, q, 7=7.1 Hz, 
OC//2CH3), 3.88 (2H, t, 7=6.5 Hz, OC//2CH2), 3.43 (2H, t, 7=6.8 Hz, C //2NH), 3.08 (2H, t, 
7=6.8 Hz, C //2CH2NH), 2.31 (2H, t, 7=7.5 Hz, CH2COO), 1.69 (4H, m, OCH2C//2, 
CH2CH2COO), 1.41 (4H, m, OCH2CH2CH2, CH2CH2CH2COO), 1.26 (3H, t, 7=7.1 Hz, 
CH2CH3); I3C-NMR (CDC13, 75 MHz) 5 173.85 (COO), 151.57 (1-aryl), 142.47 (4-aryl),
136.42 (9-indolyl), 127.47 (4-indolyl), 122.17 (2-indolyl), 122.05 (6 -indolyl), 119.43 (7- 
indolyl), 118.85 (5-indolyl), 115.82 (3, 5-aryl), 114.40 (2, 6 -aryl), 113.53 (8 -indolyl),
111.21 (3-indolyl), 68.65 (OCH2CH2), 60.22 (OCH2CH3), 44.98 (CH2NH), 34.33 
(CH2COO), 29.30 (OCH2CH2), 28.93 (CH2CH2CH2COO), 25.79 (CH2CH2NH), 25.20 
(CH2CH2COO), 24.93 (OCH2CH2CH2), 14.28 (CH2CH3). Anal. Calcd for C25H32N20 3 C, 
73.50; H, 7.90; N, 6 .8 6 . Found: C, 73.25; H, 7.93; N, 6 .8 8 .
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Ethyl 7-(4-(pyridin-4-ylmethylamino)phenoxy)heptanoate (61)
To a solution of ethyl 7-(4-aminophenoxy)heptanoate (52) (1.17 g, 4.43 mmol), in methanol 
(80 mL) was added 4-pyridine carboxaldehyde (0.56 mL, 4.43 mmol) and the solution 
stirred at room temperature for 2 h, during which time a yellow precipitate formed. The 
suspension was cooled to 0 °C and sodium cyanoborohydride (0.56 g, 8 . 8 6  mmol) and zinc 
chloride (0.6 g, 4.43 mmol) added. The reaction was allowed to warm to room temperature 
and was stirred for a further 2 h. Water (5 mL) was added and the solvent removed in vacuo. 
The residue was dissolved in ethyl acetate and was washed with saturated aqueous sodium 
hydrogen carbonate solution (2 x 20 mL) and brine (20 mL) then dried (MgSC>4). The 
solvent was removed in vacuo to yield a pale orange solid which was recrystallised from 
isopropanol to give the title compound (1.14 g, 72 %) as pale yellow crystals, mp 98-99 °C; 
IR (KBr, thin film) (cm'1) 3371, 2935, 1714, 1518, 1231. 'H-NMR (CDC13, 300 MHz) 6
8.51 (2H, m, 2, 6 -pyridyl), 7.27 (2H, m, 3, 5-pyridyl), 6.73 (2H, d, 7=8.8 Hz, 2, 6 -aryl),
6.50 (2H, d, .7=8.8 Hz, 3, 5-aryl), 4.30 (2H, s, CH2NH), 4.10 (2H, q, 7=7.1 Hz, C //2CH3), 
3.84 (2H, t, 7=6.4 Hz, OC7/2CH2), 2.28 (2H, t, 7=7.5 Hz, CH2COO), 1.74-1.60 (4H, m, 
OCH2C772, CH2CH2COO), 1.44-1.33 (4H, m, OCH2CH2C7/2, OCH2CH2CH2C//2), 1.23 
(3H, t, 7=7.1 Hz, CH2C //3); 13C-NMR (CDC13, 75 MHz) 6  173.80 (COO), 151.88 (1-aryl),
149.91 (2, 6 -pyridyl), 149.42 (4-pyridyl), 141.57 (4-aryl), 122.19 (3, 5-pyridyl), 115.75 (3,
5-aryl), 114.08 (2, 6 -aryl), 68.50 (OCH2CH2), 60.21 (OCH2CH3), 47.91 (CH2NH), 34.28 
(CH2COO), 29.24 (OCH2CH2), 28.90 (OCH2CH2CH2CH2), 25.76 (OCH2CH2CH2), 24.90 
(CH2CH2COO), 14.27 (CH2CH3). Anal. Calcd for C21H28N20 3 C, 70.76; H, 7.92; N, 7.86. 
Found: C, 70.50; H, 7.94; N, 7.84.
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7-{4-[(2-l//-Indo!-3-yl-acetyl)-pyridin-4-yImethyI-ammoJ-phenoxy}-heptanoic acid 
ethyl ester (63)
3-Indoleacetic acid (100 mg, 0.56 mmol) was dissolved in dry dichloromethane (12 mL) 
and to the solution was added triethylamine (135 mg 1.34 mmol). The solution was cooled 
to -20 °C and isobutyl chloroformate (110 mg, 0.84 mmol) added dropwise. After stirring 
for 15 min at -20 °C, 7-{4-[(pyridin-4-ylmethyl)-amino]-phenoxy}-heptanoic acid ethyl 
ester (61) (200 mg, 0.56 mmol) was added and the reaction allowed to warm to room 
temperature for 3 h. The solvent was removed in vacuo and the residue dissolved in ethyl 
acetate (10 mL) then washed with 10 % aqueous citric acid ( 2 x 1 0  mL), saturated aqueous 
sodium hydrogen carbonate solution ( 2 x 1 0  mL) and brine (10 mL). The organic phase was 
dried (MgS0 4 ) and the solvent removed in vacuo to give the crude product as a brown oil 
which was purified by column chromatography (ethyl acetate- 1 % acetic acid) to yield the 
title compound (127 mg, 44 %) as a pale yellow oil; ’H-NMR (CDCI3, 300 MHz) 5 8.85 
(1H, s, NH), 8.47 (2H, brs, Ar), 7.39 -  6.57 (11H, m, Ar), 4.84 (2H, s, CH2N), 4.11 (2H, q, 
7=7.1 Hz, OCN2CH3) 3.90 (2H, t, 7=6.4 Hz, O C//2CH2), 3.64 (2H, s, NCOCH2), 2.31 (2H, 
t, 7=7.4 Hz, CH2COO), 1.77 (2H, m, OCH2CH2), 1.66 (2H, m, CH2CH2COO) 1.43 (4H, m, 
OCH2CH2CH2, CH2CH2CH2COO) 1.24 (3H, t, 7=7.1 Hz, CH2CH 3); 13C-NMR (CDC13, 75 
MHz) 5 173.84 (COO), 172.28 (CON), 158.70 (1-aryl), 149.66 (Ar), 146.79 (Ar), 136.14 
(Ar), 134.85 (Ar), 129.20 (Ar), 127.18 (Ar), 123.31 (Ar), 121.80 (Ar), 119.22 (5-indolyl),
118.81 (7-indolyl), 115.26 (2, 6 -aryl), 111.23 (3-indolyl), 108.88 (8 -indolyl), 68.09 
(OCH2CH2), 60.29 (OCH2CH3), 52.63 (CH2N) 34.25 (OOCCH2CH2), 31.16 (CH2CON),
28.97 (OCH2CH2), 28.83 (OCH2CH2CH2CH2 ), 25.73 (OCH2CH2CH2), 24.86
(CH2CH2COO), 14.28 (CH2CH3). LRMS (Cl) m/z 514 (M+H, 50 %), 457 (29 %), 306 (23 
%), 154 (100 %). HRMS (M+H) calcd for C31H35N3O4 514.27057. Found: 514.26977.
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Ethyl 7-(4-(3-(l//-indol-3-yl)-iV-(pyridin-4- 
ylmethyl)propanamido)phenoxy)heptanoate (63)
NH
3-Indolepropionic acid (441 mg, 2.33 mmol) was dissolved in THF (23 mL) at 0 °C and to 
the solution was added TV-methyl morpholine (236 mg, 2.33 mmol) and isobutyl 
chloroformate (318 mg, 2.33 mmol). After stirring for 30 min at room temperature, ethyl 7- 
(4 -(pyridin-4 -ylmethylamino)phenoxy)heptanoate (61) (830 mg, 2.33 mmol) was added and 
stirring continued for 16 h. Water (15 mL) was added and the aqueous phase extracted with 
ethyl acetate ( 2 x 1 0  mL). The combined organics were washed with 10 % aqueous citric 
acid (20 mL), saturated aqueous sodium hydrogen carbonate solution (20 mL) and brine (20 
mL). The organic phase was dried (MgSCli) and the solvent removed in vacuo to give the 
crude product as a yellow oil which was purified by column chromatography ( 2 0  % 
petroleum ether (40 - 60)-ethyl acetate increasing to 5 % methanol-ethyl acetate) to yield the 
title compound (1.05 g, 85 %) as a yellow oil; IR (KBr, thin film) (cm 1) 3306, 2936, 1732, 
1651, 1510, 1248. “H-NMR (CDCfi, 300 MHz) 5 9.15 (1H, s, NH), 8.45 (2H, d, 7=5.2 Hz, 
2, 6 -pyridyl), 7.33 (2H, m, 5, 8 -indolyl), 7.13 (1H, m, indolyl), 7.01 (3H, m, 3, 5-pyridyl, 
indolyl), 6.92 (1H, d, 7=2.0 Hz, 2-indolyl), 6.62 (4H, m, aryl), 4.79 (2H, s, CH2N), 4.12 
(2H, q, 7=7.2 Hz, OC//2CH3), 3.84 (2H, t, 7=6.3 Hz, OC7fiCH2), 3.11 (2H, t, 7=7.3 Hz, 
NCOCH2CH2), 2.53 (2H, t, 7=7.4 Hz, NCOCH2), 2.30 (2H, t, 7=7.4 Hz, CH2COO), 1.76-
1.62 (4H, m, OCH2C //2,C7/2CH2COO), 1.41 (4H, m, OCH2CH2CH2, C //2CH2CH2COO),
1.23 (3H, t, 7=7.1 Hz, CH2C //3); 13C-NMR (CDCfi, 75 MHz) 5 173.83 (COO), 173.58 
(CON), 158.57 (1-aryl), 149.64 (2, 6 -pyridyl), 146.78 (4-pyridyl), 136.44 (9-indolyl),
134.58 (4-aryl), 129.05 (2, 6 -aryl), 127.25 (4-indolyl), 123.37 (3, 5-pyridyl), 122.25 (2- 
indolyl), 121.71 (6 -indolyl), 118.98 (5-indolyl), 118.84 (7-indolyl), 115.21 (3, 5-aryl),
114.60 (3-indolyl), 111.27 (8 -indolyl), 68.01 (OCH2CH2), 60.28 (OCH2CH3), 52.36 
(CH2N), 34.81 (CH2CON), 34.26 (CH2COO), 28.97 (OCH2CH2), 28.83 (OCH2CH2CH2CH2 
), 25.73 (OCH2CH2CH2), 24.86 (CH2CH2COO), 21.55 (NCOCH2CH2), 14.28 (CH2CH3).
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LRMS (Cl) m/z 528 (M+H, 54 %), 419 (25 %), 287 (32 %), 154 (100 %). HRMS (M+H) 
calcd for C32H37N3O4 528.28622. Found: 528.28636.
7-(4-{[3-(Indol-3-yl)-propyl]-pyridin-4-ylmethyl-amino}-phenoxy)-heptan-l-ol (65)
To a suspension of lithium aluminium hydride (0.66 g, 17.4 mmol) in dry tetrahydrofuran 
(40 mL) at 0 °C was added a solution of 7-{4-[(3-l//-indol-3-yl-propionyl)-pyridin-4- 
ylmethyl-amino]-phenoxy}-heptanoic acid ethyl ester (63) (2.30 g, 4.36 mmol) in dry 
tetrahydrofuran (5 mL) dropwise. The solution was allowed to warm to room temperature 
and stirred for 4 h then quenched with water (0.7 mL), 15 % aqueous sodium hydroxide 
solution (0.7 mL) and water (2.1 mL). The suspension was filtered through celite and the 
precipitate washed with ethyl acetate. The solvent was removed in vacuo and the crude oil 
purified by column chromatography (3 % methanol, 1 % triethylamine, 96 % ethyl acetate) 
to give the title compound (2.05 g, 99 %) as a colourless oil; IR (KBr, thin film) (cm'1) 
3261, 2934, 1512, 1240, 1217. ‘H-NMR (CDC13, 300 MHz) 6  8.79 (1H, s, NH), 8.46 (2H, 
dd, 7=1.5 Hz, 7=4.6 Hz, 2, 6 -pyridyl), 7.56 (1H, d, J = l.l  Hz, indolyl), 7.32 (1H, d, 7=8.0 
Hz, indolyl), 7.14 (4H, m, Ar), 6.91 (1H, d, 7=2.1 Hz, 2-indolyl), 6.75 (2H, d, 7=9.1 Hz, 2,
6 -aryl), 6.57 (2H, d, 7=9.1 Hz, 3, 5-aryl), 4.38 (2H, s, CH2N), 3.86 (2H, t, 7=6.5 Hz, 
OC//2CH2), 3.63 (2H, t, 7=6.6 Hz, C //2OH), 3.38 (2H, t, 7=7.1 Hz, NC772CH2), 2.95 (1H, br 
s, OH), 2.80 (2H, t, 7=7.3 Hz, NCH2CH2C //2), 2.06 (2H, m, NCH2C i/2CH2) 1.73 (2H, m, 
OCH2C//2), 1.58 (2H, m, CH2CH2OH) 1.43 (6 H, m, C //2C //2C //2CH2CH2OH); ,3C-NMR 
(CDCI3, 75 MHz) 5 151.35 (1-aryl), 149.59 (2, 6 -pyridyl), 142.73 (4-pyridyl), 136.57 (4- 
aryl), 127.41 (4-indolyl), 122.28 (3, 5-pyridyl), 121.81 (indolyl), 121.52 (indolyl), 119.03 
(indolyl), 118.78 (indolyl), 115.67 (Ar), 115.37 (indolyl), 114.78 (3, 5-aryl), 111.32 (8 - 
indolyl), 68.60 (OCH2), 62.69 CH2OH), 55.03 (pyridine-CH2N), 52.16 (CH2CH2N), 32.79 
(CH2CH2OH), 29.41 (OCH2CH2), 29.26 (CH2CH2CH2CH2OH), 27.50 (CH2CH2N), 26.11 
(CH2CH2CH2OH), 25.82 (OCH2CH2CH2), 22.70 (indole-CH2). LRMS (Cl) m/z 471 (M+,
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100 %), 380 (22 %), 327 (46 %), 250 (19 %). HRMS (M+H) calcd for C29H35N30 2 
472.29639. Found: 472.29496.
Ethyl 7-(4-((l//-indol-5-yl)methyIamino)phenoxy)heptanoate (68)
H
A solution of ethyl 7-(4-aminophenoxy)heptanoate (52) (683 mg, 2.57 mmol) and indole-5- 
carboxaldehyde (374 mg, 2.57 mmol) in methanol (35 mL) was stirred for 30 min. The 
orange solution was then cooled to 0 °C and sodium borohydride (243 mg, 6.43 mmol) 
added portion-wise. After stirring for a further 1 h the solvent was removed in vacuo and 
replaced with ethyl acetate (20 mL) then the solution washed with water (2 x 20 mL) and 
brine (20 mL). The organic phase was dried (M gS04) and evaporated to leave an 
orange/brown solid which was recrystallised from ethanol to give the product (675 mg, 
67 %) as orange crystals, mp 87-89 °C; IR (KBr, thin film) (cm"1) 3408, 2936, 1720, 1510, 
1232. !H-NMR (CDCI3, 300 MHz) 5 8.49 (1H, s, NH), 7.66 (1H, s, 5-indolyl), 7.32 (1H, d, 
7=8.3 Hz, 8 -indolyl), 7.24 (1H, dd, 7=1.3, 8.4 Hz, 7-indolyl), 7.15 (1H, t, 7=2.7 Hz, 2- 
indolyl), 6.79 (2H, d, 7=8.8 Hz, 2, 6 -aryl), 6.67 (2H, d, 7=8.9 Hz, 3, 5-aryl), 6.53 (1H, m, 3- 
indolyl), 4.36 (2H, s, C //2NH), 4.19 (2H, q, 7=7.1 Hz, O C//2CH3), 3.91 (2H, t, 7=6.5 Hz, 
OC//2CH2), 2.35 (2H, t, 7=7.4 Hz, CH2COO), 1.82-1.67 (4H, m, OCH2CH2, CH2CH2COO), 
1.47 (4H, m, OCH2CH2CH2, C //2CH2CH2COO), 1.30 (3H, t, 7=7.1 Hz, CH2CH3); 13C- 
NMR (CDC13, 75 MHz) 5 174.03 (COO), 151.51 (1-aryl), 142.91 (4-aryl), 135.27 (9- 
indolyl), 130.84 (6 -indolyl), 128.09 (4-indolyl), 124.89 (2-indolyl), 122.15 (7-indolyl),
119.81 (5-indolyl), 115.89 (2, 6 -aryl), 114.22 (3, 5-aryl), 111.30 (8 -indolyl), 102.36 (3- 
indolyl), 68.72 (OCH2CH2), 60.34 (CH2CH3), 49.92 (CH2NH), 34.38 (CH2COO), 29.35 
(OCH2CH2), 28.97 (CH2CH2CH2COO), 25.83 (OCH2CH2CH2), 24.99 (CH2CH2COO), 
14.34 (CH2CH3). Anal. Calcd for C24H30N2O3 C, 73.07; H, 7.66; N, 7.10. Found: C, 72.67; 
H, 7.71; N, 6.98.
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Ethyl 7-(4-((3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4- 
yl)methylamino)phenoxy)heptanoate (69)
To a stirred solution of ethyl 7-(4-aminophenoxy)heptanoate (52) (300 mg, 1.13 mmol) in 
methanol (12 mL) was added pyridoxal hydrochloride (230 mg, 1.13 mmol) and 
triethylamine (114 mg, 1.13 mmol). After stirring for 30 min sodium borohydride (107 mg, 
2.83 mmol) was added portionwise to the yellow suspension and the resultant solution 
stirred for a further 20 min. The solvent was removed in vacuo to leave a light-brown solid 
which was recrystallised from ethyl acetate-petroleum ether (40 - 60) to yield the title 
compound (362 mg, 77 %) as white crystals, mp 134-135 °C; IR (KBr, thin film) (cm'1) 
3277, 2860, 1736, 1514, 1242. 'H-NMR (CDC13, 300 MHz) 5 7.69 (1H, s, 6 -pyridyl), 6.77 
(4H, m, 2, 3, 5, 6 -aryl), 4.58 (2H, s, C //2OH), 4.49 (2H, s, C //2NH), 4.11 (2H, q, 7=7.1 Hz, 
OC//2CH3), 3.86 (2H, t, 7=6.5 Hz, OC//2CH2), 2.39 (3H, s, Ar-CH3), 2.29 (2H, t, 7=7.4 Hz, 
CH2COO), 1.76-1.61 (4H, m, OCH2CH2, CH2CH2COO), 1.41 (4H, m, OCH2CH2CH2, 
C/72CH2CH2COO), 1.24 (3H, t, 7=7.1 Hz, CH2CH3); ,3C-NMR (CDC13, 75 MHz) 5 173.83 
(COO), 154.55 (3-pyridyl), 152.31 (2-pyridyl), 147.85 (1-aryl), 139.74 (6 -pyridyl), 139.31 
(4-pyridyl), 131.65 (4-aryl), 128.63 (5-pyridyl), 118.15 (3, 5-aryl), 115.53 (2, 6 -aryl), 68.31 
(OCH2CH2), 60.72 (CH2OH), 60.24 (OCH2CH3), 45.88 (CH2NH), 34.28 (CH2COO), 29.12 
(OCH2CH2), 28.87 (CH2CH2CH2COO), 25.73 (OCH2CH2CH2), 24.87 (CH2CH2COO),
18.67 (Ar-CH3), 14.26 (CH2CH3). Anal. Calcd for C23H32N20 5 C, 66.32; H, 7.74; N, 6.73. 
Found: C, 65.96; H, 7.77; N, 6.84.
Ethyl 7-(l//-indol-5-yloxy)heptanoate (71)
To a solution of 5-hydroxyindole (1.47 g, 11.04 mmol) in dimethylformamide (40 mL) was 
added caesium carbonate (4.32 mg, 13.25 mmol) and ethyl-7-bromoheptanoate (3.14 g, 
13.25 mmol) and the resultant mixture heated to 120 °C for 18 h. Water (35 mL) was added
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and the solution extracted with ethyl acetate (1 x 40 mL, 3 x 20 mL). The combined extracts 
were washed with water (2 x 30 mL) and brine (30 mL) then dried over MgSC>4 and 
evaporated. The brown oil was purified by column chromatography (petroleum ether (40 - 
60)-ethyl acetate, 3:1) to give a pale yellow solid which was recrystallised from diethyl 
ether-petroleum ether (40 - 60) to give the product (1.90 g, 60 %) as a white, crystalline 
solid, mp 64 °C; IR (KBr, thin film) (cm'1) 3377, 2937, 1717, 1456, 1225. *H-NMR (CDCfi, 
300 MHz) 5 8.28 (1H, s, NH), 7.25 (1H, d, J= 8 . 6  Hz, 8 -indolyl), 7.14 (2H, m, 2, 5-indolyl), 
6 .8 8  (1H, dd, J=2A, 8 .8  Hz, 7-indolyl), 6.48 (1H, ddd, J= 0.9, 2.0, 3.0 Hz, 3-indolyl), 4.19 
(2H, q, 7=7.0 Hz, OC//2CH3), 4.01 (2H, t, J= 6.5 Hz, OCH2CH2), 2.35 (2H, t, 7=7.4 Hz, 
CH2COO), 1.83 (2H, m, OCH2C //2), L70 (2H, m, C //2CH2COO), 1.55-1.42 (4H, m, 
OCH2CH2C//2, C //2CH2CH2COO), 1.28 (3H, t, 7=7.1 Hz, CH2C //3); ,3C-NMR (CDC13, 75 
MHz) 5 174.03 (COO), 153.54 (6 -indolyl), 131.09 (4-indolyl), 128.33 (9-indolyl), 124.98 
(2-indolyl), 112.85 (8 -indolyl), 111.76 (7-indolyl), 103.52 (3-indolyl), 102.18 (5-indolyl), 
62.72 (OCH2CH2), 60.32 (CH2CH3), 34.38 (CH2COO), 29.36 (OCH2CH2), 28.98 
(CH2CH2CH2COO), 25.89 (OCH2CH2CH2), 24.99 (CH2CH2COO), 14.31 (CH2CH3). 
Anal.Calcd for C 17H23N0 3 C, 70.56; H, 8.01; N, 4.84. Found: C, 70.37; H, 8.08; N, 4.77.
Ethyl 7-(2-fluoro-4-nitrophenoxy)heptanoate (72)
F
To a stirred solution of 2-fluoro-4-nitrophenol (500 mg, 3.18 mmol) in dimethylformamide 
(30 mL) was added cesium carbonate (1.24 g, 3.82 mmol) followed by ethyl-7- 
bromoheptanoate (0.90 g, 3.82 mmol). The mixture was heated to 130 °C for 20 h then 
allowed to cool to room temperature. Water (40 mL) was added and the aqueous solution 
extracted with ethyl acetate (2 x 30 mL, 2 x 1 5  mL). The combined yellow organics were 
washed with 1 M sodium hydroxide solution (30 mL), water (2 x 30 mL) and brine before 
drying (MgSd*). The solvent was removed in vacuo to yield a yellow oil which was 
purified by column chromatography (petroleum ether (40 - 60)-ethyl acetate, 4:1) to give a 
pale yellow solid. The solid was recrystallised from diethyl ether-petroleum ether (40 - 60) 
to yield the title compound (0.79 g, 79 %) as pale yellow crystals, mp 40-42 °C; IR (KBr,
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thin film) (cm'1) 2941, 1732, 1524, 1346, 1286. 'H-NMR (CDC13, 300 MHz) 5 7.99 (1H, 
ddd, > 1 .5 , 2.7, 9.0 Hz, 5-aryl), 7.92 (1H, dd, > 2 .7 , 10.7 Hz, 3-aryl), 6.99 (1H, dd, > 8 .1 ,
9.0 Hz, 6 -aryl), 4.08 (4H, m, OC//2CH3, OC//2CH2), 2.27 (2H, t, > 7 .4  Hz, CH2COO), 1.84 
(2H, m, OCH2Ci/2), 1.63 (2H, m, C //2CH2COO), 1.51-1.37 (4H, m, OCH2CH2C//2, 
CH2CH2CH2COO), 1.21 (3H, t, > 7 .1  Hz, CH2C //3); 13C-NMR (CDC13, 75 MHz) 5 173.62 
(COO), 152.99 (d, J Cf=10.6 H z , 1-aryl), 151.19 (d, J Cf=251.1 Hz, 2-aryl), 140.57 (d, 
J Cf=7.3 H z, 4-aryl), 120.91 (d, J Cf=3.1 H z , 5-aryl), 112.85 (6 -aryl), 112.17 (d, J Cf=22.9 
Hz, 3-aryl), 69.70 (OCH2CH2), 60.20 (OCH2CH3), 34.13 (CH2COO), 28.69 (OCH2CH2),
28.65 (CH2CH2CH2COO), 25.49 (OCH2CH2CH2), 24.74 (CH2CH2COO), 14.21 (CH2CH3). 
Anal. Calcd for Ci5H20FNO5 C, 57.50; H, 6.43; N, 4.47. Found: C, 57.47; H, 6.47; N, 4.32.
Ethyl 7-(3-fluoro-4-nitrophenoxy)heptanoate (73)
To a stirred solution of 3-fluoro-4-nitrophenol (400 mg, 2.55 mmol) in dimethylformamide 
(25 mL) was added cesium carbonate (980 mg, 3.06 mmol) followed by ethyl-7- 
bromoheptanoate (720 mg, 3.06 mmol). The mixture was heated to 120 °C for 5 h then 
allowed to cool to room temperature. Water (40 mL) was added and the aqueous solution 
extracted with ethyl acetate (3 x 20 mL). The combined yellow organics were washed with 
1 M sodium hydroxide solution (30 mL), water (2 x 30 mL) and brine before drying 
(MgSO^. The solvent was removed in vacuo to yield a yellow oil which was purified by 
column chromatography (petroleum ether (40 - 60)-ethyl acetate, 4:1) to give the product 
(594 mg, 74 %) as a pale yellow oil; ’H-NMR (CDC13, 300 MHz) 8  8.02 (1H, m, 5-aryl),
6.69 (2H, m, 2, 6 -aryl), 4.05 (4H, m, OC//2CH3, OC//2CH2), 2.27 (2H, t, > 7 .4  Hz, 
CH2COO), 1.79 (2H, m, OCH2CH2\  1.62 (2H, m, C //2CH2COO), 1.42 (4H, m, 
OCH2CH2C//2, C //2CH2CH2COO), 1.21 (3H, t, > 7 .2  Hz, CH2CH3); ,3C-NMR (CDC13, 75 
MHz) 5 173 .62  (COO), 1 6 4 .90  (d, J Cr= 1 1 .3  Hz, 4-aryl), 1 5 7 .4 7  (d, J CF= 2 6 3 .3  Hz, 3-aryl), 
130.46 (1-aryl), 127.84 (5-aryl), 110.75 (6 -aryl), 103.48 (d, J Cf=24.0 H z, 2-aryl), 69.22 
(OCH2CH2), 60.21 (OCH2CH3), 34.13 (CH2COO), 28.69 (OCH2CH2), 28.58 
(CH2CH2CH2COO), 25.52 (OCH2CH2CH2), 24.74 (CH2CH2COO), 14.22 (CH2CH3). LRMS
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(Cl) m/z 314 (M+H, 82 %), 284 (28 %), 268 (100 %), 238 (28 %), 158 (39 %). HRMS calcd 
for C15H20FNO5 (M+H) 314.14037. Found: 314.13936.
Ethyl 7-(4-amino-2-fluorophenoxy)heptanoate (74)
F
To a stirred solution of ethyl 7-(2-fluoro-4-nitrophenoxy)heptanoate (72) (500 mg, 1.60 
mmol) in ethanol (16 mL), was added 5 % palladium on carbon (15 mg) under nitrogen. The 
system was evacuated and replaced with hydrogen at atmospheric pressure. After stirring
which was purified by column chromatography (petroleum ether (40 - 60)-ethyl acetate, 4:1 
increasing to 2:1) to give the product (403 mg, 89 %) as a light brown oil; IR (KBr, thin 
film) (cm'1) 3371, 2937, 1724, 1518, 1263. ’H-NMR (CDC13, 300 MHz) 6  6.71 (1H, t, .7=8.9
1.73-1.54 (4H, m, OCH2CH2, CH2CH2COO), 1.43-1.31 (4H, m, OCH2CH2C7/2, 
C772CH2CH2COO), 1.19 (3H, t, 7=7.1 Hz, CH2C //3). 13C-NMR (CDC13, 75 MHz) 5 173.62 
(COO), 153.75 (d, J Cf=244.7 H z , 2-aryl), 141.50 (d, 7CF=9.4 H z , 4-aryl), 139.19 (d, 
J Cf=1 1.3 Hz, 1-aryl), 117.87 (d, 7CF=2.7 H z, 6 -aryl), 110.25 (d, 7CF=3.0 H z , 5-aryl), 103.95 
(d, Jcf=21.6 H z, 3-aryl), 70.80 (OCH2CH2), 60.14 (OCH2CH3), 34.19 (CH2COO), 29.23 
(OCH2CH2), 28.80 (CH2CH2CH2COO), 25.57 (OCH2CH2CH2), 24.83 (CH2CH2COO),
14.13 (CH2CH3). Anal. Calcd for C 15H22FN 03 C, 63.58; H, 7.83; N, 4.94. Found: C, 63.70; 
H, 7.89; N, 4.93.
Ethyl 7-(4-amino-3-fluorophenoxy)heptanoate (75)
To a stirred solution of ethyl 7-(3-fluoro-4-nitrophenoxy)heptanoate (73) (595 mg, 1.90 
mmol) in ethanol (19 mL), was added 5 % palladium on carbon (20 mg) under nitrogen. The 
system was evacuated and replaced with hydrogen at atmospheric pressure. After stirring
for 4 h, the catalyst was removed and the solvent removed in vacuo to yield a red/brown oil
Hz, 6 -aryl), 6.38 (1H, d, .7=12.8 Hz, 5-aryl), 6.29 (1H, d, 7=8.5 Hz, 3-aryl), 4.06 (2H, q, 
7=7.1 Hz, OC772CH3), 3.85 (2H, t, 7=6.4 Hz, OC7/2CH2), 2.24 (2H, t, 7=7.4 Hz, CH2COO),
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for 4  h, the catalyst was removed and the solvent removed in vacuo to yield a red/brown oil 
which was purified by column chromatography (petroleum ether (40 - 60)-ethyl acetate, 4:1 
increasing to 2:1) to give the product (511 mg, 95 %) as a red oil; *H-NMR (CDCI3, 300 
MHz) 5 6.55 (3H, m, 2, 5, 6 -aryl), 4.07 (2H, q, 7=7.1 Hz, O C//2CH3), 3.78 (2H, t, 7= 6.5 Hz, 
OC//2CH2), 3.44 (2H, s, NH2), 2.25 (2H, t, J=1.4 Hz, CH2COO), 1.72-1.57 (4H, m, 
OCH2C//2, C //2CH2COO), 1.36 (4H, m, OCH2CH2C //2 , C //2CH2CH2COO), 1.20 (3H, t, 
7=7.1 Hz, CH2C//3); I3C-NMR (CDCI3, 75 MHz) 5 173.69 (COO), 151.91 (d, 7CF=238.9 
Hz, 3-aryl), 152.09 (d, 7CF=9.4 H z , 1-aryl), 127.80 (d, 7CF=13.6 H z , 4-aryl), 117.53 (d, 
7cf=4.8 H z, 5-aryl), 110.48 (d, Jcf=2.8 H z, 6 -aryl), 102.90 (d, 7CF=22.1 H z, 2-aryl), 68.53 
(OCH2CH2), 60.15 (OCH2CH3), 34.19 (CH2COO), 29.06 (OCH2CH2), 28.82 
(CH2CH2CH2COO), 25.68 (OCH2CH2CH2), 24.84 (CH2CH2COO), 14.21 (CH2CH3). LRMS 
(Cl) m/z 284 (M+H, 63 %), 283 (100 %), 157 (12 %), 127 (37 %). HRMS calcd for 
C 15H22FN0 3 284.16565. Found: 284.16688.
Ethyl 7-(4-(2-(lH-indol-3-yl)acetamido)-2-fluorophenoxy)heptanoate (76)
3-Indole acetic acid (449 mg, 2.56 mmol) was dissolved in dimethyl formamide (24 mL) 
and 1-hydroxybenzotriazole (429 g, 3.17 mmol), l-(3-dimethylaminopropyl)-3-ethyl 
carbodiimide hydrochloride (538 mg, 2.81 mmol) and JV-methyl morpholine (568 mg, 5.61 
mmol) added successively and the solution stirred at room temperature for 20 min. To the 
solution was added ethyl 7-(4-amino-2-fluorophenoxy)heptanoate (74) (691 mg, 2.44 
mmol) in dimethyl formamide (4 mL) and the solution stirred for 16 h. The reaction was 
quenched by the addition of 1 M HC1 and the resultant suspension extracted with ethyl 
acetate (3 x 20 mL). The combined organics were washed with saturated aqueous sodium 
hydrogen carbonate solution (30 mL), water (2 x 20 mL) and brine (30 mL) before drying 
(MgS(>4). The solvent was removed in vacuo to yield a brown solid which was 
recrystallised from ethanol to give the title compound (1.02 g, 94 %), mp 107-109 °C; IR 
(KBr, thin film) (cm'1) 3319, 2936, 1738, 1661, 1375, 1269. 'H-NMR (CDC13, 300 MHz) 5
8.87 (1H, s, NH), 7.76 (1H, s, NH), 7.58 (1H, d, 7=7.8 Hz, 5-indolyl), 7.37 (1H, d, 7=8.1
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Hz, 8 -indolyl), 7.31 (1H, m, 3-aryl), 7.22 (1H, t, 7=7.3 Hz, 6 -indolyl), 7.13 (2H, m, 2- 
indolyl, 5-aryl), 6.92 (1H, d, 7=8.8 Hz, 6 -aryl), 6.76 (1H, m, 7-indolyl), 4.13 (2H, q, 7=7.1 
Hz, OCi/2CH3), 3.91 (2H, t, 7=6.5 Hz OC//2CH2), 3.84 (2H, s, CH2CONH), 2.30 (2H, t, 
7=7.4 Hz, CH2COO), 1.78-1.64 (4H, m, OCH2C //2, C //2CH2COO), 1.41 (4H, m, 
OCH2CH2GH2, CH2CH2CH2COO), 1.25 (3H, t, 7=7.1 Hz, CH2CH3); 13C-NMR (CDC13, 75 
MHz) 6  174.04 (COO), 170.29 (CONH), 152.31 (d, 7CF=243.8 Hz, 1-aryl), 136.52 (9- 
indolyl), 131.17 (d, 7CF=11.3 Hz, 4-aryl), 126.92 (4-indolyl), 124.18 (d, 7CF=12.0 Hz, 5- 
aryl), 122.53 (6 -indolyl), 120.06 (2-indolyl), 118.47 (5-indolyl), 116.50 (6 -aryl), 115.18 (7- 
indolyl), 111.74 (8 -indolyl), 109.48 (d, 7CF=22.5 Hz, 3-aryl), 108.02 (3-indolyl), 69.74 
(OCH2CH2), 60.35 (OCH2CH3), 34.30 (OOCCH2CH2, CH2CONH), 29.03 (OCH2CH2), 
28.82 (OCH2CH2CH2CH2), 25.59 (OCH2CH2CH2), 24.87 (CH2CH2COO), 14.27 (CH2CH3). 
Anal. Calcd for C25H29FN20 4 C, 68.16; H, 6.64; N, 6.36. Found: C, 68.06; H, 6.73; N, 6.32.
Ethyl 7-(4-(2-(lH-indol-3-yl)acetamido)-3-fluorophenoxy)heptanoate (77)
3-Indole acetic acid (0.71 g, 4.08 mmol) was dissolved in dimethyl formamide (38 mL) and
1-hydroxybenzotriazole (0.68 g, 5.04 mmol), l-(3-dimethylaminopropyl)-3-ethyl 
carbodiimide hydrochloride (0.85 g, 4.46 mmol) and A-methyl morpholine (0.90 g, 8.92 
mmol) added successively and the solution stirred at room temperature for 20 min. To the 
solution was added ethyl 7-(4-amino-3-fluorophenoxy)heptanoate (75) (1.10 g, 3.88 mmol) 
and the solution stirred for 24 h. The reaction was quenched by the addition of 1 M HC1 and 
the resultant suspension extracted with ethyl acetate (4 x 20 mL). The combined organics 
were washed with saturated aqueous sodium hydrogen carbonate solution (30 mL), water (2 
x 20 mL) and brine (30 mL) before drying (M gS04). The solvent was removed in vacuo to 
yield a red oil which solidified on cooling and was recrystallised from ethanol to give the 
title compound (1.42 g, 83 %), mp 94-96 °C; IR (KBr) (c m 1) 3053, 2988, 1421, 1258, 898.
1 H-NMR (CDC13, 300 MHz) 5 8.96 (1H, s, NH), 7.92 (1H, t, 7=9.0 Hz, 5-aryl), 7.61 (2H, m, 
5-indolyl, NH), 7.37 (1H, d, 7=8.0 Hz, 8 -indolyl), 7.19 (3H, m, 6 , 7, 2-indolyl), 6.56 (2H, 
m, 2, 6 -aryl), 4.15 (2H, q, 7=7.2 Hz, OC//2CH3), 3.90 (2H, s, C //2CONH), 3.80 (2H, t,
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J= 6.4 Hz OC//2CH2), 2.31 (2H, t, J= 7.4 Hz, CH2COO), 1.68 (4H, m, OCH2CH2, 
C //2CH2COO), 1.42 (4H, m, OCH2CH2C//2, C //2CH2CH2COO), 1.26 (3H, t, J=1A Hz, 
CH2CH3); 13C-NMR (CDCI3, 75 MHz) 6  173.95 (COO), 170.26 (CONH), 156.19 (d, 
yCF=10.4 Hz, 1-aryl), 154.06 (d, Jcf=244.9 H z , 3-aryl), 136.90 (9-indolyl), 126.94 (4- 
indolyl), 124.20 (2-indolyl), 123.91 (5-aryl), 122.52 (6 -indolyl), 120.01 (7-indolyl), 118.64 
(4-aryl), 118.56 (5-indolyl), 111.68 (8 -indolyl), 109.91 (d, J Cf=2.1 H z, 6 -aryl), 108.08 (3- 
indolyl), 102.12 (d, J Cf=22.7 H z , 2 -aryl), 68.32 (OCH2CH2), 60.33 (OCH2CH3), 34.28 
(OOCCH2CH2, CH2CONH), 28.90 (OCH2CH2), 28.83 (OCH2CH2CH2CH2), 25.66 
(OCH2CH2CH2), 24.87 (CH2CH2COO), 14.28 (CH2CH3). Anal. Calcd for C25H29FN2O4 C, 
68.16; H, 6.64; N, 6.36. Found: C, 68.23; H, 6 .6 6 ; N, 6.40.
7-(4-(Dimethylamino)phenoxy)-Ar-hydroxyheptanamide (78)
NHOH
To a solution of ethyl 7-(4-(dimethylamino)phenoxy)heptanoate (52) (1.04 g, 3.54 mmol) in 
tetrahydrofuran (10 mL) at 0 °C was added a 1M solution of hydroxylamine in methanol 
(35.4 mL, 35.4 mmol) dropwise, followed by a 1M solution of potassium hydroxide in 
methanol (7.09 mL, 7.09 mmol) dropwise. The reaction was allowed to warm to room 
temperature and stirred for 2 d. After cooling to 0 °C, water (20 mL) was added and the 
acidity of the solution adjusted to pH6  by addition o f 1M HC1. The solution was extracted 
ethyl acetate (3 x 30 mL) and 10% methanol-ethyl acetate (2 x 20 mL). The combined 
organics were dried (MgSC^) and evaporated to leave an off-white solid which was 
recrystallised from methanol to give the product (377 mg, 38 %) as off-white crystals, mp 
105-107 °C; IR (KBr) (cm 1) 3188, 2934, 1624, 1514, 1259. 1H-NMR ((CD3)2SO, 300 
MHz) 8  8.69 (1H, brs, NH), 6.77 (2H, m, 2, 6 -aryl), 6 . 6 8  (2H, m, 3, 5-aryl), 3.82 (2H, t, 
J= 6 .2 , OCH2), 2.76 (6 H, s, N(CH3)2), 1.94 (2 H, t, J=7.2, CH2CO), 1.62 (2H, m, OCH2C//2), 
1.51-1.23 (6 H, m, C //2CH2CO, OCH2CH2C //2, C //2CH2CH2CO); 13C-NMR ((CD3)2SO, 75 
MHz) 8  169.10 (CO), 150.59 (1-aryl), 145.26 (4-aryl), 115.12 (2, 6 -aryl), 114.28 (3, 5-aryl),
67.69 (OCH2), 41.12 (N(CH3)2), 32.15 (CH2CO), 28.69 (OCH2CH2), 28.30
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(CH2CH2CH2CO), 25.23 (CH2CH2CO), 25.02 (OCH2CH2CH2). Anal.Calcd for Ci5H24N20 3 
C, 64.26; H, 8.63; N, 9.99. Found: C, 64.34; H, 8.84; N, 9.95.
6-(4-(2-(l/Z-IndoI-3-yI)acetamido)phenoxy)-7V-hydroxyhexanamide (79)
H
To a solution of ethyl 6-(4-(2-(l//-indol-3-yl)acetamido)phenoxy)hexanoate (56) (900 mg, 
2.20 mmol) in tetrahydrofuran ( 6  mL) at 0 °C were added a 1M solution of hydroxylamine 
in methanol (22 mL) and a 1M solution of KOH in methanol (4.4 mL) dropwise. The white 
suspension was stirred for 3 d at room temperature then water (20 mL) added. The white 
precipitate was collected by filtration and washed with cold methanol to give the product 
(383 mg, 59 %) as a white powder, mp 204 °C dec.; IR (KBr) (cm '1) 3385, 2937, 1661, 
1512, 1244, 723. ‘H-NMR ((CD3)2SO, 300 MHz) 6  7.61 (1H, d, 7= 7.8 Hz, 5-indolyl), 7.51 
(2H, d, .7=9.1 Hz, 3, 5-aryl), 7.35 (1H, d, 7= 8.0 Hz, 8 -indolyl), 7.24 (1H, s, 2-indolyl), 7.06 
(1H, ddd, .7=1.2, 7.1, 8.1 Hz, 7-indolyl), 6.96 (1H, ddd, 7=1.1, 7.1, 7.9 Hz, 6 -indolyl), 6.82 
(2H, d, 7=9.1 Hz, 2, 6 -aryl), 3.83 (2H, t, 7=6.4 Hz, OC7/2CH2), 3.69 (2H, s, C772CONH),
1.91 (2H, t, 7=7.2 Hz, C7/2CONHOH), 1.67-1.46 (4H, m, OCH2C772, C772CH2CONHOH),
1.33 (2H, m, C772CH2CH2CONHOH); 13C-NMR ((CD3)2SO, 75 MHz) 6  169.19 (CONH),
167.97 (CONHOH), 154.39 (1-aryl), 136.09 (9-indolyl), 132.49 (4-aryl), 127.20 (4-indolyl), 
123.80 (2-indolyl), 120.82 (6 -indolyl), 120.53 (3, 5-aryl), 118.66 (7-indolyl), 118.23 (5- 
indolyl), 114.25 (2, 6 -aryl), 111.30 (8 -indolyl), 108.67, (3-indolyl), 67.44 (OCH2CH2),
33.60 (OOCCH2CH2, CH2CONH), 28.56 (OCH2CH2), 25.47 (CH2CH2CONHOH), 25.34 
(OCH2CH2CH2). Anal. Calcd for C22H25N30 4 C, 66.82; H, 6.37; N, 10.73. Found: C, 66.63; 
H, 6.34; N, 10.52.
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7-(4-(2-(l//-IndoI-3-yl)acetamido)phenoxy)-J/V-hydroxyheptanamide (80)
NHOH 
H
To a solution of 7 ethyl 7-(4-(2-(l//-indol-3-yl)acetamido)phenoxy)heptanoate (57) (1.00 g, 
2.37 mmol) in tetrahydrofuran ( 8  mL) at 0 °C was added a 1M solution of hydroxyl amine in 
methanol (23.7 mL, 23.7 mmol) dropwise, followed by a 1M solution of potassium 
hydroxide in methanol (4.7 mL, 4.7 mmol) dropwise. The reaction was allowed to warm to 
room temperature and stirred for 2 d. After cooling to 0 °C, water (30 mL) was added to the 
white suspension and the acidity adjusted to pH6  by addition of 1M HC1. The solution was 
extracted ethyl acetate (1 x 50 mL, 2 x 30 mL) and 10% methanol-ethyl acetate (2 x 30 mL). 
The combined organics were evaporated to leave an off-white solid which was repeatedly 
triturated (petroleum ether (40 - 60)-ethyl acetate, 4:1) to give the product (349 mg, 36 %) 
as an off-white powder, mp 155-158 °C; IR (KBr) (cm*1) 3378, 2935, 1663, 1512, 1244, 
741. 1 H-NMR ((CD3)2SO, 300 MHz) 5 10.89 (1H, brs, NH), 10.32 (1H, brs, OH), 9.92 (1H, 
brs, NH), 8.65 (1H, brs, NH), 7.59 (1H, d, 7= 7.8 Hz, 5-indolyl), 7.48 (2H, d, 7=9.1 Hz, 3, 5- 
aryl), 7.34 (1H, d, 7=8.0 Hz, 8 -indolyl), 7.23 (1H, d, 7=2.2 Hz, 2-indolyl), 7.06 (1H, ddd, 
7=1.2, 7.1, 8.1, 7-indolyl), 6.97 (1H, ddd, 7=1.1, 7.1, 7.9 Hz, 5-indolyl), 6.84 (2H, d, 7=9.1 
Hz, 2, 6 -aryl), 3.88 (2H, t, 7=6.4 Hz, OCH2), 3.67 (2H, s, CJ72C=ONH), 1.93 (2H, t, 7=7.3 
Hz, CH2CONHOH), 1.65 (2H, m, OCH2C //2), 1.49 (2H, m, CH2CH2CONHOH), 1.40-1.23 
(4H, m, OCH2CH2CH2, C7/2CH2CH2CONHOH); l3C-NMR ((CD3)2SO, 75 MHz) 5 169.13 
(CONHOH), 169.06 (CONH), 154.42 (1-aryl), 136.05 (9-indolyl), 132.41 (4-aryl), 127.17 
(4-indolyl), 123.76 (2-indolyl), 120.90 (6 -indolyl), 120.54 (3, 5-aryl), 118.63 (7-indolyl),
118.29 (5-indolyl), 114.32 (2, 6 -aryl), 111.29 (8 -indolyl), 108.67 (3-indolyl), 67.41 (OCH2),
33.62 (CH2CONH), 32.15 (CH2CONHOH), 28.55 (OCH2CH2), 28.28 
(CH2CH2CH2CONHOH), 25.19 (CH2CH2CONHOH), 25.01 (OCH2CH2CH2). Anal.Calcd 
for C23H27N30 4 C, 67.46; H, 6.65; N, 10.26. Found: C, 67.24; H, 6.62; N, 9.99.
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8-(4-(2-(l//-Indol-3-yl)acetamido)phenoxy)-7V-hydroxyoctanamide (81)
To a suspension of methyl 8-(4-(2-(l//-indol-3-yl)acetamido)phenoxy)octanoate (59) (750 
mg, 1.78 mmol) in tetrahydrofuran (5 mL) at 0 °C were added a 1M solution of 
hydroxylamine in methanol (17.8 mL) and a 1M solution of KOH in methanol (3.6 mL) 
dropwise. The white suspension was stirred for 3 d at room temperature then water (50 mL) 
added and the suspension neutralised by the addition o f 2M HC1. The aqueous phase was 
extracted with ethyl acetate (1 x 90 mL, 3 x 1 5  mL) and the combined extracts washed with 
brine then the solvent removed in vacuo. The crude product was triturated with 1:1 ethyl 
acetate-petroleum ether (40 - 60) and washed with cold methanol to give the title compound 
(316 mg, 42 %) as an off-white powder, mp 164-165 °C; IR (KBr) (c m 1) 3381, 3308, 2936, 
1661, 1514, 1244. 1H-NMR ((CD3)2SO, 300 MHz) 6  8.74 (1H, s, NH), 7.64 (1H, d, 7= 7.8 
Hz, 5-indolyl), 7.55 (2H, d, 7= 9.0 Hz, 3, 5-aryl), 7.35 (1H, d, 7= 8.0 Hz, 8 -indolyl), 7.27 
(1H, d, 7=2.0 Hz, 2-indolyl), 7.05 (1H, m, 7-indolyl), 6.96 (1H, m, 6 -indolyl), 6.83 (2H, d, 
7=9.0 Hz, 2, 6 -aryl), 3.87 (2H, t, 7=6.3 Hz, OC//2CH2), 3.43 (2H, s, C //2CONH), 1.95 (2H, 
t, 7=7.2 Hz, C //2CONHOH), 1.64 (2H, m, OCH2CH2), 1.50 (2H, m, C //2CH2CONHOH), 
1.35-1.26 (6 H, m, OCH2CH2CH2, OCH2CH2CH2C //2, C //2CH2CH2CONHOH); 13C-NMR 
((CD3)2SO, 75 MHz) 5 169.22 (CONH), 169.14 (CONHOH), 154.35 (1-aryl), 136.03 (9- 
indolyl), 132.56 (4-aryl), 127.20 (4-indolyl), 123.80 (2-indolyl), 120.81 (6 -indolyl), 120.50 
(3, 5-aryl), 118.73 (7-indolyl), 118.21 (5-indolyl), 114.24 (2, 6 -aryl), 111.27 (8 -indolyl), 
108.73, (3-indolyl), 67.43 (OCH2CH2), 33.58 (CH2CONH), 32.16 (CH2CONHOH), 28.62 
(OCH2CH2), 28.42 (OCH2CH2CH2CH2, OCH2CH2CH2CH2CH2), 25.36 (OCH2CH2CH2),
25.00 (CH2CH2CONHOH). Anal. Calcd for C24H29N30 4  C, 68.06; H, 6.90; N, 9.92. Found: 
C, 67.94; H, 6.93; N, 9.80.
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7-(4-(2-(l//-Indol-3-yl)acetamido)-3-fluorophenoxy)-7V-hydroxyheptanamide (82)
°H
To a solution of ethyl 7-(4-(2-(l//-indol-3-yl)acetamido)-3-fluorophenoxy)heptanoate (77) 
(1.05 g, 2.38 mmol) in tetrahydrofuran (5 mL) at 0 °C were added a 1M solution of 
hydroxylamine in methanol (23.8 mL) and a 1M solution of KOH in methanol (4.8 mL) 
dropwise. After stirring for 2 d at room temperature water (50 mL) was added and the white 
precipitate collected by filtration. The precipitate was washed with cold methanol and dried 
in vacuo to give the product (0.78 g, 77 %) as a pale pink solid, mp 138-141 °C; IR (KBr) 
(cm 1) 3381, 3195, 2934, 1672, 1533, 1117. 1H-NMR ((CD3)2SO, 300 MHz) 5 9.64 (1H, 
brs, NH), 7.59 (2H, m, 5-indolyl, 5-aryl), 7.36 (1H, d, J -8 .0  Hz, 8 -indolyl), 7.26 (1H, s, 2- 
indolyl), 7.07 (1H, m, 7-indolyl), 7.01 (1H, m, 6 -indolyl), 6.87 (1H, dd, J= 2.6, 12.6 Hz, 6 - 
aryl), 6.71 (1H, dd, J=1.8, 8 .8  Hz, 2-aryl), 3.91 (2H, t, J=6.4 Hz OC//2CH2), 3.76 (2H, s, 
C //2CONH), 1.95 (2H, t, J=12 Hz, C //2CONHOH), 1.66 (2H, m, OCH20 7 2), 1.50 (2H, m, 
C //2CH2CONHOH), 1.42-1.27 (4H, m, OCH2CH2C //2, C //2CH2CH2CONHOH); 13C-NMR 
((CD3)2SO, 75 MHz) 5 169.84 (CONH), 169.06 (CONHOH), 156.31 (d, J CF=10.2 Hz, 1- 
aryl), 154.91 (d, J Cf=245.0 H z , 3-aryl), 136.07 (9-indolyl), 127.17 (4-indolyl), 125.86 (2- 
indolyl), 123.85 (5-aryl, 6 -indolyl), 120.93 (7-indolyl), 118.69 (4-aryl), 118.31 (5-indolyl), 
111.30 (8 -indolyl), 110.01 (d, 7Cf=2.2 H z , 6 -aryl), 108.50 (3-indolyl), 102.13 (d, J Cf=23.1 
Hz, 2-aryl), 67.90 (OCH2CH2), 32.89 (OOCCH2CH2) 32.15 (CH2CONH), 28.36 
(OCH2CH2), 28.23 (OCH2CH2CH2CH2), 25.12 (CH2CH2CONHOH), 25.00 
(OCH2CH2CH2). Anal. Calcd for C23H26FN30 4 C, 64.62; H, 6.13; N, 9.83. Found: C, 64.40; 
H, 6.14; N, 9.80.
7-(4-(2-(li/-IndoI-3-yI)acetamido)-2-fIuorophenoxy)WV-hydroxyheptanamide (83)
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To a solution of ethyl 7-(4-(2-(l//-indol-3-yl)acetamido)-2-fluorophenoxy)heptanoate (76) 
(0.53 g, 1.20 mmol) in tetrahydrofuran (3 mL) at 0 °C were added a 1M solution of 
hydroxyl amine in methanol (12.0 mL) and a 1M solution of KOH in methanol (2.4 mL) 
dropwise. After stirring for 2 d at room temperature water (50 mL) was added and the white 
precipitate collected by filtration. The white solid was washed with cold methanol and dried 
in vacuo to give the product (0.14 g, 28 %) as a white powder, mp 179-180 °C dec.; IR 
(KBr) (cm'1) 3377, 3307, 2937, 1661, 1518, 1223. ’H-NMR ((CD3)2SO, 300 MHz) 5 7.61 
(2H, m, Ar), 7.29 (3H, m, Ar), 7.00 (3H, m, Ar), 3.92 (2H, t, J= 6.5 Hz OC//2CH2), 3.70 
(2H, s, C7/2CONH), 1.87 (2H, t, J=7.2 Hz, CH2CONHOH), 1.64 (2H, m, OCH2C //2), 1.51-
1.24 (6H, m, C //2CH2CONHOH, OCH2CH2CH2, C //2CH2CH2CONHOH); ,3C-NMR 
((CD3)2SO, 75 MHz) 5 169.62 (CONH), 167.94 (CONHOH), 151.10 (d, J Cf=241.6 H z, 2- 
aryl), 141.87 (d, J Cf= 1 1-0 Hz, 1-aryl), 136.09 (9-indolyl), 133.12 (d, J Cf=9.6 H z H z , 4-aryl),
127.18 (4-indolyl), 123.89 (5-aryl), 120.81 (6-indolyl), 118.64 (2-indolyl), 118.23 (5- 
indolyl), 115.25 (6-aryl), 114.90 (7-indolyl), 111.31 (8-indolyl), 108.42 (3-indolyl), 107.47 
(d, J Cf=22.8 H z , 3-aryl), 68.91 (OCH2CH2), 33.59 (OOCCH2CH2) 32.89 (CH2CONH),
28.56 (OCH2CH2, OCH2CH2CH2CH2), 25.70 (CH2CH2CONHOH), 25.18 (OCH2CH2CH2). 
Anal. Calcd for C23H26FN30 4 C, 64.62; H, 6.13; N, 9.83. Found: C, 64.53; H, 6.06; N, 9.69.
7-(4-(3-(li7-Indol-3-yl)propanamido)phenoxy)-7V-hydroxyheptanamide (84)
NHOH
To a solution of ethyl 7-(4-(3-(l//-indol-3-yl)propanamido)phenoxy)heptanoate (58) (1.0 g,
2.29 mmol) in tetrahydrofuran (7 mL) at 0 °C was added a 1M solution o f hydroxyl amine in 
methanol (22.9 mL, 22.9 mmol) dropwise, followed by a 1M solution of potassium 
hydroxide in methanol (4.6 mL, 4.6 mmol) dropwise. The reaction was allowed to warm to 
room temperature and stirred for 2 d. After cooling to 0 °C, water (30 mL) was added to the 
white suspension and the acidity adjusted to pH6 by addition of 1M HC1. The solution was 
extracted ethyl acetate (1 x 50 mL, 2 x 30 mL) and 10% methanol-ethyl acetate (2 x 30 mL). 
The combined organics were evaporated to leave an off-white solid which was triturated 
(petroleum ether (40 - 60)-ethyl acetate, 4:1) to give the product (378 mg, 39 %) as an off-
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white powder, mp 149-150 °C; IR (KBr) (cm '1) 3418, 3285, 2928, 1653, 1510, 1244. ‘H- 
NMR ((CD3)2SO, 300 MHz) 5 10.76 (1H, s, NH), 10.33 (1H, s, OH), 9.75 (1H, s, NH), 8.67 
(1H, brs, NH), 7.56 (1H, d, 7= 7.8 Hz, 5-indolyl), 7.48 (2H, d, 7=9.1, 3, 5-aryl), 7.32 (1H, d, 
7=8.0 Hz, 8-indolyl), 7.12 (1H, d, 7=0.7 Hz, 2-indolyl), 7.06 (1H, m, 7-indolyl), 7.02 (1H, 
m, 6-indolyl), 6.84 (2H, d, 7= 9.1 Hz, 2, 6-aryl), 3.88 (2H, t, 7=6.4 Hz, OC//2CH2), 3.00 
(2H, t, 7=7.2 Hz, Gtf2CONH), 2.62 (2H, t, 7=7.2 Hz, C7/2CH2CONH), 1.94 (2H, t, 7=7.2 
Hz, CH2CONHOH), 1.66 (2H, m, OCH2Cf/2), 1.50 (2H, m, C //2CH2CONHOH), 1.40-1.27 
(4H, m, OCH2CH2CH2, C //2CH2CH2CONHOH); 13C-NMR ((CD3)2SO, 75 MHz) 6 170.38 
(CONH), 169.09 (CONHOH), 154.38 (1-aryl), 136.19 (9-indolyl), 132.37 (4-aryl), 126.99 
(4-indolyl), 122.08 (2-indolyl), 120.86 (6-indolyl), 120.55 (3, 5-aryl), 118.31 (7-indolyl),
118.10 (5-indolyl), 114.30 (2, 6-aryl), 113.70 (8-indolyl), 111.27 (3-indolyl), 67.42 
(OCH2CH2), 37.11 (CH2CONH), 32.16 (CH2CONHOH), 28.57 (OCH2CH2), 28.29 
(CH2CH2CH2CONHOH), 25.21 (CH2CH2CONHOH), 25.03 (OCH2CH2CH2), 20.84 
(CH2CH2CONH). Anal. Calcd for C24H29N30 4: C, 68.06; H, 6.90; N, 9.92. Found: C, 67.79;
H, 6.91; N, 9.74.
7-(4-(2-(l//-Indol-3-yl)ethyIamino)phenoxy)-Ar-hydroxyheptanamide (85)
NHOH 
H
To a solution of ethyl 7-(4-(2-(l//-indol-3-yl)ethylamino)phenoxy)heptanoate (57) (700 mg,
I.71 mmol) in tetrahydrofuran (5 mL) at 0 °C was added a 1M solution o f hydroxylamine in 
methanol (17.1 mL, 17.1 mmol) and a 1M solution o f KOH in methanol (3.43 mL, 3.43 
mmol) and the solution stirred for 1 d. Diethyl ether (20 mL) was added to the reaction and 
the white precipitate collected by filtration. The crude product was washed with water and 
10 % methanol-ethyl acetate to give a white powder (468 mg, 69 %), mp 104-106 °C; IR 
(KBr) (cm'1) 3391, 3223, 2934, 1616, 1514, 1244. 1 H-NMR ((CD3)2SO, 300 MHz) 5 10.94 
(1H, brs, NH), 7.54 (1H, d, 7=7.6 Hz, 5-indolyl), 7.38 (1H, d, 7=7.8 Hz, 8-indolyl), 7.21 
(1H, s, 2-indolyl), 7.03 (2H, m, 6, 7-indolyl), 6.71 (2H, d, 7=8.3 Hz, 2, 6-aryl), 6.56 (2H, d, 
7=8.3 Hz, 3, 5-aryl), 5.10 (1H, s, NH), 3.78 (2H, s, OC//2CH2), 3.26 (2H, s, C i/2NH), 2.96 
(2H, m, C //2CH2NH), 1.98 (2H, t, 7=6.7 Hz, CH2COO), 1.62-1.30 (8H, m, OCH2CH2,
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C//2CH2COO, OCH2CH2C //2, C //2CH2CH2COO). I3C-NMR ((CD3)2SO, 75 MHz) 5 168.93 
(CONHOH), 149.93 (1-aryl), 143.07 (4-aryl), 136.25 (9-indoIyl), 127.23 (4-indolyl), 122.71 
(2-indolyl), 120.81 (7-indolyl), 118.17 (8 , 6 -indolyl), 115.45 (2, 6 -aryl), 113.05 (3, 5-aryl),
112.13 (3-indolyl), 111.37 (5-indolyl), 67.83 (OCH2CH2), 44.67 (CH2NH), 32.32 
(CH2CONHOH), 28.82 (OCH2CH2), 28.41 (CH2CH2CH2COO), 25.32 (OCH2CH2CH2), 
25.19 (CH2CH2CONHOH), 24.86 (indole-CH2). Anal. Calcd for C23H29N 3O3 + VittiO C, 
68.81; H, 7.45; N, 10.47. Found: C, 68.71; H, 7.37; N, 10.26.
7-(4-(3-(l//-Indol-3-yl)-jV-(pyridin-4-ylmethyl)propanamido)phenoxy)-./V- 
hydroxyheptanamide (86)
NH
To a stirred solution of ethyl 7-(4-(2-(l//-indol-3-yl)-7V-(pyridin-4- 
ylmethyl)acetamido)phenoxy)heptanoate (63) (0.99 g, 1.88 mmol) in tetrahydrofuran (3 
mL) at 0 °C were added a 1M solution o f hydroxyl amine in methanol (18.8 mL) and a 1M 
solution of KOH in methanol (3.8 mL) dropwise. After stirring for 3 d at room temperature 
water (30 mL) was added and the white precipitate collected by filtration and recrystallised 
from methanol to give the product (783 mg, 81 %) as white crystals, mp 163-170 °C dec.; 
IR (KBr) (cm 1) 3215, 2936, 1665, 1512, 1256. 'H-NMR ((CD3)2SO, 300 MHz) 6  8 . 8 6  (1H, 
s, NH), 8.44 (2H, d, 7=5.4 Hz, 2, 6 -pyridyl), 7.36 (1H, d, 7=8.1 Hz, 8 -indolyl), 7.29 (1H, d, 
7=7.8 Hz, 5-indolyl), 7.08 (4H, m, 3, 5-pyridyl, 7, 2-indolyl), 6.91 (3H, m, 3, 5-aryl, 6 - 
indolyl), 6.77 (2H, d, 7=8.7 Hz, 2, 6 -aryl), 4.82 (2H, s, CH2N), 3.83 (2H, t, 7=5.7 Hz, 
OC//2CH2), 2.97 (2H, t, 7=7.2 Hz, NCOCH2C //2), 2.46 (2H, t, 7=7.7 Hz, NCOCH2), 1.97 
(2H, t, 7=7.1 Hz, C //2CONH), 1.62-1.49 (4H, m, OCH2C //2, C //2CH2CONH), 1.30 (4H, m, 
CH2CH2CH2CO, OCH2CH2C //2); l3C-NMR ((CD3)2SO, 75 MHz) 8  172.28 (CON), 169.15 
(CONH), 157.76 (1-aryl), 149.42 (2, 6 -pyridyl), 146.69 (4-pyridyl), 136.18 (9-indolyl),
134.56 (4-aryl), 129.02 (3, 5-aryl), 126.85 (4-indolyl), 122.65 (3, 5-pyridyl), 122.38 (6 - 
indolyl), 120.85 (2-indolyl), 118.21 (7-indolyl), 118.08 (5-indolyl), 114.88 (2, 6 -aryl),
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113.42 (3-indolyl), 111.31 (8 -indolyl), 67.46 (OCH2CH2), 51.37 (CH2N), 34.56 
(CH2CONH), 32.18 (CH2CONH), 28.44 (OCH2CH2), 28.26 (OCH2CH2CH2CH2), 25.18 
(OCH2CH2CH2), 25.03 (CH2CH2CONH), 20.96 (NCOCH2CH2). Anal. Calcd for 
C30H34N4O4 + ^H 20  C, 69.41; H, 6.70; N, 10.79. Found: C, 69.31; H, 6.77; N, 10.57.
7-(4-((l//-Indol-5-yl)methylamino)phenoxy)-Ar-hydroxyheptanamide (87)
NHOH 
H
To a solution of ethyl 7-(4-((l//-indol-5-yl)methylamino)phenoxy)heptanoate (6 8 ) (550 mg, 
1.39 mmol) in tetrahydrofuran (4 mL) at 0 °C were added a 1M solution of hydroxylamine 
in methanol (13.9 mL) and a 1M solution of KOH in methanol (2.8 mL) dropwise. The 
reaction was stirred for 7 d at room temperature then water (40 mL) added and the aqueous 
solution extracted with ethyl acetate (5 x 20 mL). The combined organics were washed with 
brine (30 mL) and dried (MgS0 4 ) then the solvent removed in vacuo. The crude product 
was purified by column chromatography (30 % ethyl acetate-petroleum ether (40 - 60) 
increasing to 5 % methanol-ethyl acetate) to give an orange oil which was triturated with 
diethyl ether to give the product (164 mg, 31 %) as a pale yellow powder, mp 99-102 °C; IR 
(KBr) (cm 1) 3416, 3261, 2930, 1663, 1514, 1242. 1H-NMR ((CD3)2SO, 300 MHz) 5 10.32 
(1H, brs, NH), 8 . 6 6  (1H, s, NH), 7.49 (1H, s, 5-indolyl), 7.30 (2H, m, 8 , 2-indolyl), 7.08 
(1H, d, 7=8.2 Hz, 7-indolyl), 6.64 (2H, d, 7=8.5 Hz, 2, 6 -aryl), 6.52 (2H, d, 7=8.7 Hz, 3, 5- 
aryl), 6.34 (1H, s, 3-indolyl), 5.68 (1H, s, NH), 4.22 (2H, s, C7f2NH), 3.76 (2H, t, 7=6.2 Hz, 
OCH2CH2), 1.92 (2H, t, 7=7.0 Hz, CH2CONH), 1.62-1.24 (8 H, m, OCH2CH2, 
CH2CH2COO, OCH2CH2C7/2, C //2CH2CH2COO); 13C-NMR ((CD3)2SO, 75 MHz) 8 169.08 
(COO), 149.82 (1-aryl), 143.12 (4-aryl), 134.94 (9-indolyl), 130.43 (6 -indolyl), 127.55 (4- 
indolyl), 125.30 (2-indolyl), 120.91 (7-indolyl), 118.47 (5-indolyl), 115.26 (2, 6 -aryl),
113.24 (3, 5-aryl), 111.07 (8 -indolyl), 100.76 (3-indolyl), 67.77 (OCH2CH2), 47.89 
(CH2NH), 32.16 (CH2CON), 28.75 (OCH2CH2), 28..31 (CH2CH2CH2CON), 25..25 
(OCH2CH2CH2), 25.03 (CH2CH2CON). Anal. Calcd for C22H27N30 3  + ^H 20  C, 68.46; H, 
7.18; N, 10.89. Found: C, 68.48; H, 7.03; N, 10.62.
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jV-Hydroxy-7-(4-((3-hydroxy-5-(hydroxymethyl)-2-methyIpyridin-4 
yl)methylamino)phenoxy)heptanamide (88)
.C l /NHOH
CH
To a solution of ethyl 7-(4-((3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4- 
yl)methylamino)phenoxy)heptanoate (69) (300 mg, 0.72 mmol) in tetrahydrofuran ( 8  mL) 
was added hydroxylamine (0.40 mL of a 50 % aqueous solution, 6.12 mmol) and 1M KOH 
in methanol (1.22 mL) at 0 °C. The solution was stirred for 3 h, then water ( 8  mL) followed 
by acidification with 1M HC1. The suspension was extracted with a 2:1 solution of 
chloroform-ethanol ( 2 x 1 0  mL) and the combined organics dried (MgSC>4). The solvent was 
removed in vacuo and the residue dried under high vacuum. The crude product was purified 
by column chromatography (5 % water-acetonitrile) followed by recrystallisation 
(acetonitrile-water) to yield the title compound (171 mg, 59 %) as white crystals, mp 159- 
161 °C; IR (KBr) (cm'1) 3252, 2943, 1670, 1514, 1244. 1H-NMR ((CD3)2SO, 300 MHz) 6
C//2CH2CONH, OCH2CH2CH2, C //2CH2CH2CONH); 13C-NMR ((CD3)2SO, 75 MHz) 5
169.21 (CONH), 151.61 (3-pyridyl), 145.56 (1-aryl), 141.89 (2-pyridyl), 139.03 (Ar),
129.98 (Ar), 115.21 (Ar), 67.69 (OCH2CH2), 58.90 (CH2OH), 41.34 (CH2NH), 32.12 
(CH2CONH), 28.61 (OCH2CH2), 28.24 (CH2CH2CH2CONH), 25.18 (OCH2CH2CH2), 24.99 
(CH2CH2CONH), 19.14 (Me). Anal. Calcd for C2 iH29N30 5 C, 62.51; H, 7.24; N, 10.41. 
Found: C, 62.50; H, 7.44; N, 10.42.
7-(l//-IndoI-5-yloxy)-A-hydroxyheptanamide (89)
To a solution of ethyl 7-(l//-indol-5-yloxy)heptanoate (71) (328 mg, 1.13 mmol) in 
tetrahydrofuran (3 mL) at 0 °C were added a 1M solution of hydroxylamine in methanol
7.88 (1H, s, 6 -pyridyl), 6.73 (2H, d, J= 9.1 Hz, 2, 6 -aryl), 6 . 6 6  (2H, d, J=9.1 Hz, 3, 5-aryl),
4.51 (2H, s, CH2OH), 4.28 (2H, s, C //2NH), 3.81 (2H, t, J= 6.4 Hz, O C//2CH3), 2.31 (3H, s, 
CH3), 1.93 (2H, t, J=13 Hz, CH2CONHOH), 1.61 (2H, m, OCH2CH2), 1.33 (6 H, m,
NHOH
H
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(11.3 mL) and a 1M solution of KOH in methanol (2.3 mL) dropwise. The solution was 
stirred for 3 d at room temperature then water (10 mL) added. The aqueous solution was 
extracted with ethyl acetate ( 5 x 1 5  mL) and the combined organics washed with brine (20 
mL) and dried (MgSO,*). The solvent was removed in vacuo to leave a viscous, purple oil 
which was purified by column chromatography (20 % ethyl acetate-petroleum ether (40 - 
60) increasing to 100 % ethyl acetate) to give the product (206 mg, 66 %) as an off-white 
crystalline solid, mp 119-122 °C; IR (KBr) (cm'1) 3400, 3184, 2939, 1666, 1585, 1225, 
1155. *H-NMR ((CD3)2SO, 300 MHz) 6 10.63 (2H, m, 2 NH), 9.02 (1H, brs, OH), 7.24 
(2H, m, 8, 2-indolyl), 6.96 (1H, s, 5-indolyl), 6.67 (1H, m, 7-indolyl), 6.30 (1H, s, 3- 
indolyl), 3.82 (2H, t, .7=6.3 Hz, OC/72CH2), 1.95 (2H, t, .7=6.9 Hz, CH2CONH), 1.60 (2H, 
m, OCH2C772), 1.46 (2H, m, C772CH2CONH), 1.26 (4H, m, OCH2CH2C772,
C772CH2CH2CONH); 13C-NMR ((CD3)2SO, 75 MHz) 5 170.31 (COO), 152.31 (6-indolyl),
130.88 (4-indolyl), 127.88 (9-indolyl), 125.62 (2-indolyl), 111.93 (8-indolyl), 111.59 (7- 
indolyl), 102.83 (3-indolyl), 100.90 (5-indolyl), 67.89 (OCH2CH2), 32.06 (CH2CONH), 
28.53 (OCH2CH2), 28.06 (CH2CH2CH2CONH), 25.11 (OCH2CH2CH2), 24.91 
(CH2CH2CONH). Anal.Calcd for C i5H20N2O3 C, 65.20; H, 7.30; N, 10.14. Found: C, 65.30; 
H, 7.37; N, 9.97.
6.2 Cyclic-Linker Non-Hydroxamates
Methyl 4-(guanidinomethyl)benzoate (106)
NH
O
To a suspension of methyl-4-(aminomethyl)benzoate hydrochloride (5.10 g, 25.29 mmol) in 
dimethylformamide (125 mL) was added 177-pyrazole-l-carboxamidine hydrochloride (4.08 
g, 27.28 mmol) and diispopropylethylamine (3.92 g, 30.35 mmol) in dimethylformamide 
(15 mL). The white suspension was stirred at room temperature for 5 h to give a clear 
solution. The solvent was removed in vacuo and the remaining slurry treated with 5 % 
aqueous sodium hydrogen carbonate solution (15 mL) to give a white suspension. The white
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precipitate was collected by filtration and washed with water and diethyl ether to give the 
product (3.82 g, 73 %) as a fine white powder, mp 158-160 °C; IR (cm'1) 3410, 2951, 1684, 
1274, 1109, 745. *H-NMR ((CD3)2SO, 300 MHz) 5 8.32 (4H, brs, NH, NH, NH2), 7.88 (2H, 
d, 7= 8.0 Hz, 2, 6-aryl), 7.37 (2H, d, 7=8.0 Hz, 3, 5-aryl), 4.32 (2H, s, CH2), 3.83 (3H, s, 
CH3); ,3C-NMR ((CD3)2SO, 75 MHz) 6 165.96 (CO), 157.69 (C(NH)NH2), 143.95 (4-aryl),
129.18 (2, 6-aryl), 128.29 (1-aryl), 127.02 (3, 5-aryl), 51.98 (CH3), 43.26 (CH2). LRMS 
(Cl) m/z 208 (M+H, 100 %), 194 (37 %), 166 (79 %), 151 (85 %).
(2?)-3-(DimethyIamino)-l-(pyridm-3-yl)prop-2-en-l-one (110)
o
3-Acetylpyridine (1 g, 8.25 mmol) was added to dimethylformamide dimethylacetal (2.89 g,
16.50 mmol) and the solution refluxed for 5 h. The reaction was then evaporated to dryness 
and the brown solid triturated with diethyl ether and filtered to give the product (0.95 g, 65 
%) as a yellow solid; IR (cm 1) 3055, 1637, 1575, 1065, 902. 'H-NMR (CDC13, 300 MHz) 5
8.98 (1H, d, 7=1.9 Hz, 2-pyridyl), 8.55 (1H, dd, 7=1.3, 4.7 Hz, 6-pyridyl), 8.07 (1H, td, 
7=1.5, 7.8 Hz, 4-pyridyl), 7.73 (1H, d, 7=12.3 Hz, C77NMe2), 7.24 (1H, dd, 7=4.8, 7.9 Hz, 
5-pyridyl), 5.57 (1H, d, 7=12.3 Hz, COCH), 3.06 (3H, s, CH3), 2.83 (3H, s, CH3). 13C-NMR 
(CDC13, 75 MHz) 6 186.22 (CO), 154.60 (6-pyridyl), 151.39 (2-pyridyl), 148.87 (CHN),
135.58 (3-pyridiyl), 134.93 (4-pyridyl), 123.20 (5-pyridyl), 91.74 (COCH), 45.15 (CH3), 
37.32 (CH3). LRMS (Cl) m/z 111 (M+H, 100 %), 159 (4 %), 134 (8 %), 98 (6 %).
Methyl 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoate (107)
OMe
A suspension of (£)-3-(dimethylamino)-l-(pyridin-3-yl)prop-2-en-l-one (110) (750 mg,
3.62 mmol) and methyl 4-(guanidinomethyl)benzoate (106) (532 mg, 3.02 mmol) in propan-
2-ol (9 mL) was refluxed for 20 h. The orange solution was evaporated to dryness and the
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yellow residue triturated with cold ethyl acetate then filtered to give the product (578 mg, 60 
%) as a tan solid, mp 151-153 °C; IR (cm'1) 3238, 1713, 1587, 1549, 1273, 1105, 707. *H- 
NMR ((CD3)2SO, 300 MHz) 5 9.18 (1H, d, 7=1.4 Hz, 2-pyridyl), 8.66 (1H, dd, 7=1.5, 4.8 
Hz, 6-pyridyl), 8.33 (1H, d, 7=4.9 Hz, 4-pyrimidine), 8.24 (1H, d, 7=8.0 Hz, 4-pyridyl), 7.99 
(2H, d, 7=8.3 Hz, 2, 6-aryl), 7.44 (2H, d, 7=8.1 Hz, 3, 5-aryl), 7.36 (1H, dd, 7=4.8. 7.0 Hz,
5-pyridyl), 7.00 (1H, d, 7=5.2 Hz, 5-pyrimidine), 6.05 (1H, brs, NH), 4.77 (2H, d, 7=6.1 Hz, 
CH2), 3.88 (3H, s, CH3). 13C-NMR ((CD3)2SO, 75 MHz) 8 166.91 (COOMe), 162.51 
(pyrimidine), 159.05 (4-pyrimidine), 151.32 (2-pyridyl), 148.50 (6-pyridyl), 144.73 (4-aryl), 
134.36 (4-pyridyl), 132.85 (3-pyridyl), 129.90 (2, 6-aryl), 129.06 (1-aryl), 127.01 (3, 5- 
aryl), 123.53 (4-pyridyl), 106.90 (5-pyrimidine), 52.57 (CH3), 45.21 (CH2). LRMS (Cl) m/z 
321 (M+H, 100 %), 201 (19 %), 177 (47 %), 151 (13 %).
4-((4-(Pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoic acid (108)
o
A suspension of methyl 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoate (107) 
(140 mg, 0.44 mmol) and lithium hydroxide monohydrate (22 mg, 0.53 mmol) in 
tetrahydrofuran (0.9 mL), water (0.45 mL) and methanol (0.9 mL) was stirred at room 
temperature for 1 d. The white suspension was acidified to pH 3 by addition of 2 M HC1 to 
give a pale yellow solution. The solvent was removed in vacuo and the pale yellow solid 
suspended in cold water (3 mL) then filtered and washed with cold water to give the product 
(126 mg, 93 %) as pale yellow solid; IR (cm 1) 3352, 3151, 3029, 1612, 1450, 1184, 796. 
1 H-NMR ((CD3)2SO, 300 MHz) 5 9.28.(1H, s, 2-pyridyl), 8.77 (1H, d, 7=4.1 Hz, 6-pyridyl),
8.60 (1H, 7=7.9 Hz, 4-pyridyl), 8.44 (1H, d, 7=5.0 Hz, 4-pyrimidyl), 8.11 (1H, brs, NH),
7.88 (2H, d, 7=8.2 Hz, 2, 6-aryl), 7.70 (1H, dd, 7=5.1, 7.6 Hz, 5-pyridyl), 7.47 (2H, d, 7=6.9 
Hz, 3, 5-aryl), 7.32 (1H, d, 7=5.2 Hz, 5-pyrimidyl), 4.65 (2H, s, CH2); 13C-NMR ((CD3)2SO, 
75 MHz) 5 167.14 (CO), 161.49 (2-pyrimidyl), 160.54 (6-pyrimidyl), 159.05 (4-pyrimidyl), 
148.55 (2-pyridyl), 145.47 (6-pyridyl, 4-aryl), 137.08 (4-pyridyl), 133.28 (3-pyridyl),
129.29 (2, 6-aryl), 129.09 (1-aryl), 127.07 (3, 5-aryl), 124.91 (5-pyridyl), 106.27 (5-
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pyrimidyl), 43.96 (CH2). LRMS (Cl) m/z 307 (M+H, 46 %), 263 (8 %), 173 (19 %), 82 (100 
%).
./V-(2-Aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamides
(MGCD0103)
A solution of 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoic acid (108) (300 mg, 
0.98 mmol), (benzotriazol-l-yloxy)tris(dimthylamino)phosphonium hexafluorophosphate 
(498 mg, 1.13 mmol), 1,2-phenylenediamine (212 mg, 1.96 mmol) and triethylamine (198 
mg, 1.96 mmol) in dimethylformamide (10 mL) was stirred at room temperature for 24 h. 
The solvent was removed in vacuo and the black residue purified by column 
chromatography (ethyl acetate, increasing to 5 % methanol-ethyl acetate) to give the 
product (256 mg, 66 %) as a tan solid, mp 183-185 °C; IR (c m 1) 3410, 3246, 1621, 1586, 
795. ‘H-NMR ((CD3)2SO, 300 MHz) 6 9.59 (1H, s, CONH), 9.24 (1H, s, 2-pyridyl), 8.67 
(1H, d, 7=3.7 Hz, 6-pyridyl), 8.40 (2H, m, 4-pyrimidyl, 4-pyridyl), 8.01 (1H, t, 7=6.2 Hz, 
NH), 7.92 (2H, d, 7=8.1 Hz, 2, 6-aryl), 7.48 (3H, m, 3, 5-aryl, 5-pyridyl), 7.25 (1H, d, 7=5.1 
Hz, 5-pyrimidyl), 7.14 (1H, d, 7=7.6 Hz, 6-aniliyl), 6.95 (1H, t, 7=7.0 Hz, 4-anilyl), 6.76 
(1H, d, 7=7.0 Hz, 3-anilyl), 6.57 (1H, t, 7=7.1 Hz, 5-anilyl), 4.87 (2H, s, NH2), 4.64 (2, d, 
7=5.9 Hz, CH2); b C-NMR ((CD3)2SO, 75 MHz) 5 165.20 (CO), 162.54 (2-pyrimidyl),
159.33 (4, 6-pyrimidyl), 151.19 (6-pyridyl), 147.95 (2-pyridyl), 144.11 (4-aryl), 143.02 (2- 
anilyl), 134.13 (4-pyridyl), 132.89 (1-aryl), 132.31 (3-pyridyl), 127.71 (2, 6-aryl), 126.84 
(3,5-aryl), 126.59 (4-anilyl), 126.39 (1-anilyl), 123.74 (5-pyridyl), 123.34 (6-anilyl), 116.26 
(5-anilyl), 116.10 (3-anilyl), 106.11 (4-pyrimidyl), 43.93 (CH2). LRMS (Cl) m/z 419 
(M+Na, 31 %), 397 (10 %), 329 (10 %), 289 (19 %), 176 (100 %). Anal.Calcd for 
C23H20N6O C, 69.68; H, 5.08; N, 21.20. Found: C, 69.40; H, 5.10; N, 20.97.
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4-((4-(Pyridin-3-yl)pyrimidin-2-yIaimno)methyl)-7V-(li/-l,2,4-triazoI-3-yl)benzamides
(90)
A solution of 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoic acid (108) (300 mg, 
0.98 mmol), 1-hydroxybenzotriazole (159 mg, 1.18 mmol), 1-(3-dimethyl aminopropyl)-3- 
ethyl carbodiimide (226 mg, 1.18 mmol), 3-amino-l,2,4-triazole (82 mg, 0.98 mmol) and N- 
methylmorpholine (218 mg, 2.16 mmol) in dimethylformamide (10 mL) was stirred at room 
temperature for 18 h. Water (20 mL) was added to the pale yellow solution and the white 
precipitate collected by filtration. The product was washed with water and methanol to give 
the title compound (181 mg, 50 %) as a white solid, mp 186 °C; IR (cm'1) 3396, 3312, 3134, 
1703, 1579, 931. ]H-NMR ((CD3)2SO, 300 MHz) 5 9.22 (1H, brs, 2-pyridyl), 8.67 (1H, brs,
6-pyridyl), 8.40 (2H, m, 4-pyrimidyl, 4-pyridyl), 8.01 (3H, m, 2, 6-aryl, NH), 7.68 (2H, s, 
NH, NH), 7.60 (1H, s, triazolyl), 7.50 (3H, m, 3, 5-aryl, 5-pyridyl), 7.26 (1H, d, J=1A Hz,
5-pyrimidyl), 4.66 (2H, d, J=5.4 Hz, CH2); 13C-NMR (CDC13, 75 MHz) 6 167.54 (CO),
162.30 (2-pyrimidyl), 159.40 (4, 6-pyrimidyl), 158.24 (3, 5-triazolyl), 151.21 (6-pyridyl), 
147.93 (2-pyridyl), 146.08 (4-aryl), 134.13 (4-pyridyl), 132.38 (3-pyridyl), 130.78 (1-aryl),
130.10 (2, 6-aryl), 126.45 (3, 5-aryl), 123.73 (5-pyridyl), 106.20 (4-pyrimidyl), 43.96 
(CH2). Anal.Calcd for C 19H16N80  + V2W2O C, 59.83; H, 4.49; N, 29.30. Found: C, 59.44; H, 
4.16; N, 29.48.
4-((4-(Pyridin-3-yl)pyrimidin-2-ylamino)methyl)-AL(l//-tetrazol-5-yl)benzamides (91)
A solution of 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoic acid (108) (500 mg, 
1.63 mmol), 1-hydroxybenzotriazole (330 mg, 2.45 mmol), l-(3-dimethylaminopropyl)-3-
o N = /
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ethyl carbodiimide (345 mg, 1.80 mmol), 5-aminotetrazole monohydrate (168 mg, 1.63 
mmol) and jV-methylmorpholine (363 mg, 3.59 mmol) in dimethylformamide (16 mL) was 
stirred at room temperature for 18 h. Water (15 mL) was added and the white precipitate 
collected by filtration. The crude product was washed with ethyl acetate then recrystallised 
from dimethylformamide-water. The white solid was triturated with diethyl ether to give the 
title compound (371 mg, 61 %) as a white solid, mp 270 °C dec.; IR (cm 1) 3377, 2844, 
1672, 1586, 1023. ]H-NMR ((CD3)2SO, 300 MHz) 5 12.34 (1H, brs, NH), 9.22 (1H, s, ),
N, 32.42. Found: C, 57.04; H, 3.99; N, 32.63.
4-((4-(Pyridin-3-yl)pyrimidin-2-yIamino)methyl)-Ar-(l,3,4-thiadiazol-2-yl)benzamides
A solution of 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoic acid (108) (500 mg,
1.63 mmol), 1-hydroxybenzotriazole (330 mg, 2.45 mmol), 1-(3-dimethyl aminopropyl)-3- 
ethyl carbodiimide (345 mg, 1.80 mmol), 2-amino-1,3,4-thiadiazole (165 mg, 1.63 mmol) 
and A-methylmorpholine (363 mg, 3.59 mmol) in dimethylformamide (16 mL) was stirred 
at room temperature for 18 h. Water (20 mL) was added and the solution cooled to 5 °C. 
The white precipitate was collected by filtration and recrystallised from 
dimethylformamide-water. The white solid was washed with methanol to give the title 
compound (391 mg, 62 %) as a white solid, mp 258-9 °C; IR (cm '1) 3240, 3047, 1663, 1527, 
1296. ’H-NMR ((CD3)2SO, 300 MHz) 5 13.01 (1H, brs, CONH), 9.21 (2H, m, 4-pyridyl, 2- 
thiadiazolyl), 8.67 (1H, m, 6-pyridyl), 8.40 (2H, m, 4-pyrimidyl, 4-pyridyl), 8.04 (3H, m, 2,
6-aryl, NH), 7.52 (3H, m, 3, 5-aryl, 5-pyridyl), 7.26 (1H, d, 7=5.1 Hz, 5-pyrimidyl), 4.66
(2H, d, 7=5.5 Hz, CH2); 13C-NMR ((CD3)2SO, 75 MHz) 5 165.02 (CO), 162.03 (2- 
pyrimidyl), 159.46 (4, 6-pyrimidyl), 151.21 (6-pyridyl), 148.88 (2, 5-thiadiazolyl), 147.97 
(2-pyridyl), 145.97 (4-aryl), 134.12 (4-pyridyl), 132.27 (3-pyridyl), 129.83 (1-aryl), 128.38
8.67 (1H, d, 7=3.2 Hz, ), 8.40 (2H, m, ), 8.02 (3H, m, ), 7.53 (3H, m, ), 7.26 (1H, d, 7=5.2 
Hz, ), 4.66 (2H, d, 7=5.7 Hz, CH2). Anal.Calcd for C mH l5N9Q + V2U20  C, 57.14; H, 4.28;
(92)
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(2, 6 -aryl), 127.09 (3, 5-aryl), 123.72 (5-pyridyl), 106.21 (4-pyrimidyl), 43.93 (CH2). Anal. 
Calcd for C 19H 15N7OS C, 58.60; H, 3.88; N, 25.18. Found: C, 58.45; H, 3.85; N, 25.53.
4-((4-(Pyridin-3-yl)pyrimidin-2-ylamino)methyl)-7V-(5-thioxo-4,5-dihydro-l,3,4- 
thiadiazol-2-yl)benzamides (93)
s
A solution of 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoic acid (108) (500 mg,
1.63 mmol), 1-hydroxybenzotriazole (330 mg, 2.45 mmol), 1-(3-dimethyl aminopropyl)-3- 
ethyl carbodiimide (345 mg, 1.80 mmol), 5-amino-1,3,4-thiadiazole-2-thiol (217 mg, 1.63 
mmol) and A-methylmorpholine (363 mg, 3.59 mmol) in dimethylformamide (16 mL) was 
stirred at room temperature for 18 h. Water (20 mL) was added to the pale yellow solution 
and the pale yellow precipitate collected by filtration. The product was washed with water, 
methanol and diethyl ether to give the title compound (339 g, 49 %) as a yellow solid, mp 
175 °C dec.; IR (cm'1) 3299, 2905, 1655, 1563, 1527, 1061.1H-NMR ((CD3)2SO, 300 MHz) 
5 13.26 (1H, brs, CONH), 9.21 (1H, brs, 2-pyridyl), 8 . 6 6  (1H, d, J= 3.1 Hz, 6 -pyridyl), 8.38 
(2H, m, 4-pyridyl , 4-pyrimidyl), 8.01 (3H, m, 2, 6 -aryl, NH), 7.52 (3H, m, 3, 5-aryl, 5- 
pyridyl), 7.24 (1H, d, .7=5.1 Hz, 4-pyrimidyl), 4.66 (2H, d, .7=5.7 Hz, CH2); Anal. Calcd for 
C 19H15N7 0 S2 + V2H2O C, 53.01; H, 3.75; N, 22.77. Found: C, 52.71; H, 3.59; N, 22.45.
(2-(l-Benzoyl-17/-imidazol-2-yl)-2//-imidazole-l,3-diyl)bis(phenylmethanone) (118)2
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Benzoyl chloride (20.65 g, 146.89 mmol) was added slowly to a suspension of imidazole 
(5.0 g, 73.44 mmol) and triethylamine (14.85 g, 146.89 mmol) in acetonitrile (75 mL) at 0 
°C. The ensuing white suspension was stirred for a further 2 h at room temperature then 
water (300 mL) and diethyl ether (75 mL) added. The mixture was shaken and the white 
precipitate collected by filtration and washed with diethyl ether to give the title compound 
(14.30 g, 43% ) as a white solid, mp 191-2 °C; IR (cm'1) 3149, 1720, 1390, 1280, 1156, 867. 
’H-NMR ((CD3)2SO, 300 MHz) 8  7.75 (4H, m, Ar), 7.57 (11H, m, Ar), 7.30 (1H, brs, Ar),
7.03 (1H, s, Ar), 6.50 (2H, brs, Ar); 13C-NMR ((CD3)2SO, 75 MHz) 8  167.60 (CO), 164.68 
(CO), 146.83 (2-imidazolyl), 133.71 (Ar), 133.37 (Ar), 132.98 (Ar), 131.11 (Ar), 130.67 
(Ar), 128.57 (3, 5-aryl), 127.86 (2, 6 -aryl), 120.80 (Ar), 114.64 (3, 4-imidazolyl).LRMS 
(Cl) m/z 449 (M+H, 11 %), 343 (29 %), 277 (100 %), 105 (99 %).
(l//-Imidazol-2-yl)methanamine dihydrochloride (119)3
HN A
' 2 H a
Propan-2-ol saturated with HC1 (25 mL) was added to a solution o f (2-(l-benzoyl-1H- 
imidazol-2-yl)-2i/-imidazole-l,3-diyl)bis(phenylmethanone) (118) (10.0 g, 22.30 mmol) in 
methanol (100 mL) and the yellow solution refluxed for 4 h. The solvent was removed in 
vacuo and the residue triturated with cold acetone to give the title compound (1.42 g, 37 %) 
as an off-white solid, mp 237-8 °C (lit.3 240-42 °C); IR (cm’1) 3108, 2957, 2585, 1604, 
1389, 1058. 'H-NMR ((CD3)2SO, 300 MHz) 8  9.48 (2H, brs, NH2), 7.71 (2H, s, Ar), 7.61 
(1H, s, NH), 7.44 (1H, s, NH), 7.27 (1H, s, NH), 4.40 (2H, s, CH2); 13C-NMR ((CD3)2SO, 
75 MHz) 8  139.65 (NCNH), 119.68 (C=C), 32.91 (CH2). LRMS (Cl) m/z 98 (M+H, 46 %), 
81 (100%), 69 (25 %).
7V-((lJT-Imidazol-2-yl)methyl)-4-((4-(pyridin-3-yI)pyrimidin-2- 
ylamino)methyl)benzamides (94)
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A solution of 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoic acid (108) (400 mg, 
1.31 mmol), 1-hydroxybenzotriazole (264 mg, 1.96 mmol), l-(3-dimethylaminopropyl)-3- 
ethyl carbodiimide (276 mg, 1.44 mmol), (17/-imidazol-2-yl)methanamine dihydrochloride 
(444 mg, 2.61 mmol) and A-methylmorpholine (726 mg, 7.18 mmol) in dimethylformamide 
(13 mL) was stirred at room temperature for 18 h. The solvent was removed in vacuo and 
replaced with water (10 mL). Saturated aqueous sodium hydrogen carbonate solution (5 
mL) was added and the white precipitate collected by filtration. The crude product was 
recrystallised from ethanol to give the title compound (180 mg, 36 %) as a white crystalline 
solid, mp 236-9 °C dec.; IR (cm'1) 3253, 3054, 1636, 1563, 1403, 1108. JH-NMR 
((CD3)2SO, 300 MHz) 5 11.77 (1H, s, NH imidazolyl), 9.23 (1H, s, 4-pyrimidyl), 8.90 (1H, 
t, 7= 5.3 Hz, NH), 8.67 (1H, d, 7= 3.7 Hz, 2-pyridyl), 8.39 (2H, m, 4, 6 -pyridyl), 7.98 (1H, t, 
.7=6.0 Hz, NH), 7.85 (2H, d, 7=8.1 Hz, 2, 6 -aryl), 7.48 (3H, m, 3, 5-aryl, 5-pyridyl), 7.24 
(1H, d, 7=5.1 Hz, 5-pyrimidyl), 6.98 (1H, s, 4-imidazolyl), 6.80 (1H, s, 5-imidazolyl), 4.63 
(2H, d, 7=5.8 Hz, CH2-Ph), 4.47 (2H, d, 7=5.5 Hz, CONHC7/2); ,3C-NMR ((CD3)2SO, 75 
MHz) 5 166.12 (CO), 162.33 (2-pyrimidyl), 159.41 (6 -pyridyl), 151.20 (2-pyridyl), 147.96 
(4-pyrimidyl), 144.97 (Ar), 143.92 (Ar), 134. 10 (4-pyridyl), 127.33 (2, 6 -aryl), 126.76 (3,
5-aryl), 123.71 (5-pyridyl), 116.19 (Ar), 106.08 (5-pyrimidyl), 43.89 (CH2-PI1), 37.01 
(CONHCH2). LRMS (Cl) m/z 386 (M+H, 100 %). Anal. Calcd for C2 iH 19N70  C, 65.44; H, 
4.97; N, 25.44. Found: C, 65.17; H, 4.97; N, 25.31.
2-(Tritylthio)benzenamine (112) 4
STrt
To a solution of triphenylmethanol (2.08 g, 7.99 mmol) in TFA (14 mL) was added a 
solution of 2-aminothiophenol (1.0 g, 7.99 mmol) in dichloromethane (1.5 mL) and the 
reaction stirred for 3 h. The solvent was removed in vacuo and the residue stirred in 
saturated aqueous sodium hydrogen carbonate solution for 2  h to give an off-white, powdery 
suspension. The solid was collect by filtration an recrystallised from a large volume of 
methanol to give the title compound (2.50 g, 85 %) as a pale yellow crystalline solid, mp 
143-144 °C; IR (cm 1) 3463, 3369, 3055, 1605, 1478, 1444, 743. JH-NMR (CDC13, 300
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MHz) 5 7.44 (5H, m, Ar), 7.27 (10H, m, Ar), 7.06 (2H, m, Ar), 6.47 (2H, m, Ar), 3.58 (2H, 
brs, NH2); ,3C-NMR (CDC13, 75 MHz) 5 151.42 (2-thiophenyl), 144.54 (1-aryl), 137.91 (6 - 
thiophenyl), 130.81 (4-thiophenyl), 130.02 (3, 5-aryl), 127.67 (2, 6 -aryl), 126.80 (4-aryl),
117.98 (5-thiophenyl), 116.29 (1-thiophenyl), 115.19 (3-thiophenyl), 70.93 (C(Ph)3). LRMS 
(Cl) m/z 390 (M+Na, 4 %), 329 (34 %), 286 (32 %), 243 (75 %), 176 (100 %).
4-((4-(Pyridin-3-yI)pyrimidin-2-ylamino)methyI)-J/V-(2-(tritylthio)phenyl)benzamides
(124)
To a suspension of 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoic acid (108) (300 
mg, 0.98 mmol) in dichloromethane (10 mL) was added oxalyl chloride (497 mg, 3.92 
mmol) and dry dimethylformamide (3 drops) and the resultant suspension stirred for 3 h at 
room temperature. The solvent was evaporated and chloroform (10 mL) added, followed by 
A,A-dimethylaminopyridine (132 mg, 1.08 mmol) and 2-(tritylthio)benzenamine (360 mg, 
0.98 mmol). The solution was stirred for 2 d at room temperature then the solvent removed 
in vacuo. The crude product was purified by column chromatography (ethyl acetate, 
increasing to 10 % methanol-ethyl acetate) to give the title compound (167 mg, 26 %) as a 
yellow oil; IR (cm 1) 3343, 3054, 1674, 1575, 1501, 1430, 1300, 733. ]H-NMR (CDC13, 300 
MHz) 5 9.23 (1H, d, 7=1.3 Hz, 2-pyridyl), 8.82 (1H, s, NH), 8.63 (1H, dd, 7=1.2, 4.7 Hz, 6 - 
pyridyl), 8.46 (1H, dd, 7=1.2, 8.3 Hz, 3-thiophenyl), 8.35 (1H, d, 7=5.1 Hz, 4-pyrimidyl),
8.28 (1H, td, 7=1.9, 8.0 Hz, 4-pyridyl), 7.54 (2H, d, 7=8.3 Hz, 2, 6 -aryl), 7.42 (2H, d, 7=8.3 
Hz, 3, 5-aryl), 7.35 (2H, m, 4, 6 -thiophenyl), 7.27 (7H, m, 3, 5-trityl, 5-pyridyl), 7.14 (9H, 
m, 2, 6 -trityl, 4-trityl), 7.02 (1H, d, 7=5.2 Hz, 5-pyrimidyl), 6.81 (1H, dt, 7=1.3, 7.6 Hz, 5- 
thiophenyl), 6.10 (1H, brs, NH), 4.79 (2H, d, 7=6.1 Hz, CH2); 13C-NMR (CDC13, 75 MHz) 5
164.28 (CO), 162.55 (2-pyrimidyl), 159.07 (4-pyrimidyl), 151.36 (6 -pyridyl), 148.52 (2- 
pyridyl), 1433.67 (6 -pyrimidyl), 143.29 (1-trityl, 4-aryl), 142.42 (2-thiophenyl), 137.54 (6 - 
thiophenyl), 134.39 (4-pyridyl), 133.81 (3-pyridyl), 132.87 (1-aryl), 131.29 (5-pyridyl), 
129.64 (3, 5-trityl), 127.83 (2, 6 -trityl), 127.47 (2, 6 -aryl), 127.36 (3, 5-aryl), 127.20 (4-
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trityl), 123.57 (4-thiophenyl), 123.30 (5-thiophenyl), 120.68 (1-thiophenyl), 119.57 (3- 
thiophenyl), 106.92 (5-pyrimidyl), 71.80 (C(Ph)3), 45.17 (CH2). LRMS (Cl), mlz 678 
(M+Na, 77 %), 656 (M+H, 42 %), 299 (35 %), 243 (100 %). HRMS (M+H) calcd for 
C42H33N5OS 656.24786. Found: 656.24612.
_/V-(2-Mercaptophenyl)-4-((4-(pyridm-3-yl)pyrimidin-2-ylammo)methyI)benzamides
(95)
Trifluoroacetic acid (0.5 mL) was added to a solution o f 4-((4-(pyridin-3-yl)pyrimidin-2- 
ylamino)methyl)-A-(2-(tritylthio)phenyl)benzamide (124) (160 mg, 0.24 mmol) in 
dichloromethane (0.25 mL), developing a bright red colour. Triethylsilane (112 mg, 0.96 
mmol) was then added to the reaction and stirring continued for 1 0  min at room 
temperature. The solvent was evaporated and the residue subjected to column 
chromatography (5 % methanol-ethyl acetate). A white precipitate formed in the eluted 
solvent which would not re-dissolve. The white solid was filtered and washed with 
methanol and dichloromethane to give the pure title compound (44 mg, 44 %) as a 
crystalline white solid, mp 206-209 °C dec.; ]H-NMR ((CD3)2SO, 300 MHz) 5 9.23 (1H, s,
2-pyridyl), 8.67 (1H, d, J=4.2 Hz, 6 -pyridyl), 8.40 (2H, m, 4-pyridyl, 4-pyrimidyl), 8.12 
(1H, d, J= 7.8 Hz, 3-thiophenyl), 8.04 (4H, m, 2, 6 -aryl, 6 -thiophenyl, NH), 7.51 (5H, m, 3,
5-aryl, 4, 6 , 5-thiophenyl), 7.26 (1H, d, .7=5.1 Hz, 5-pyrimidyl), 4.67 (2H, d, J=5.3 Hz, 
CH2). Anal.Calcd for C23H 19N5OS C, 66.81; H, 4.63; N, 16.94. Found: C, 66.81; H, 4.43; N,
To a cooled solution of sodium hydroxide (25.3 g, 633.2 mmol) in water (72 mL) was added 
hydroxylamine hydrochloride (40.0 g, 575.6 mmol) portionwise and the solution stirred for
16.98.
(lE,2E)-ATl^V’2-Dihydroxyoxalimidamide (121)5
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10 min at 0 °C. Glyoxal (20.9 mL of a 40 % aqueous solution, 143.9 mmol) was added and
night. The product (3.26 g, 19 %) was collected by filtration as brown needles, mp 203-204 
°C (lit.5 203 °C); IR (cm*1) 3420, 3333, 3208, 2828, 1639, 1576, 1431, 933. ‘H-NMR 
((CD3)2SO, 300 MHz) 5 9.76 (2H, brs, OH), 5.17 (4H, brs, NH2); 13C-NMR ((CD3)2SO, 75 
MHz) 5 145.26 (CN). LRMS (Cl) mlz 199 (M+H, 100 %), 8 6  (27 %), 59 (24 %).
[1,2,5] Thiadiazolo[3,4-c] [l,2,5]thiadiazole (122)6
©
(lE,2E)-7/’l,7/,2-Dihydroxyoxalimidamide (121) (2.50 g, 21.17 mmol) in dry DMF (30 mL) 
was added dropwise to a stirred solution of SC12 (13.08 g, 127.02 mmol) in dry DMF (50 
mL) at 0 °C. After the mixture had been heated to 55 °C for 14 h, it was cooled to 5 °C and 
poured onto ice (80 g) to give a yellow suspension. The sludgy, aqueous suspension was 
extracted with diethyl ether (10 x 30 mL) and the combined pale yellow extracts washed 
with water (3 x 25 mL) and brine (25 mL). The organic phase was dried over Na2SC>4 and 
evaporated to leave a yellow solid which was recrystallised from methanol to give pale 
yellow platelets (1.05 g, 35 %), mp 113 °C (lit.6 115-116 °C); IR (cm 1) 916, 806, 6 8 6 . 13C- 
NMR ((CD3)2SO, 75 MHz) 6  169.35 (CN). LRMS (El) m/z 144 (M+, 100 %), 128 (48 %), 
96 (36 %), 78 (35 %).
1,2,5-Thiadiazole-3,4-diamine (123)6
A suspension of [l,2,5]thiadiazolo[3,4-c][l,2,5]thiadiazole (122) (800 mg, 5.55 mmol) in 3 
M N H 4O H  (16 mL) was heated to 100 °C for 10 min to give a pale yellow solution. The 
solution was cooled to room temperature and approximately half the solvent removed in 
vacuo, the remaining suspension was heated to dissolve the precipitate and allowed to 
recrystallise to give the product (477 mg, 74 %) as pale yellow prisms, mp 178-179 °C (lit.
stirring continued at 0 °C for another 10 min before heating to 95 °C for 5 h. The volume of 
the red/brown solution was reduced by approximately 1/3 in vacuo and cooled to 5 °C over
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181-182 °C); IR (cm'1) 3277, 3134, 2807, 1676, 1614, 1027. *H-NMR ((CD3)2SO, 300 
MHz) 5 6.28 (4H, s, NH2); ,3C-NMR ((CD3)2SO, 75 MHz) 6  148.97. LRMS (Cl) m/z 117 
(M+H, 100 %), 90 ( 6  %), 74 (15 %).
7V-(4-Nitrobenzylidene)qumolin-3-amine
Acetic acid (99 mg, 1.65 mmol) was added to a solution o f 3-aminoquinoline (2.39 g, 16.54 
mmol) and 4-nitrobenzaldehyde (2.50 g, 16.54 mmol) in methanol (180 mL) and the 
colourless solution stirred for 18 h at room temperature. The solvent was reduced in volume 
and the yellow crystalline product (3.68 g, 80 %) collected by filtration, washed with cold 
methanol and used directly in the next step.
A-^-Nitrobenzytyquinolin-S-amine (127)
Sodium borohydride (312 mg, 8.26 mmol) was added to a yellow suspension of N-(4- 
nitrobenzylidene)quinolin-3-amine (2.29 g, 8.26 mmol) in methanol (70 mL). After stirring 
for 1 h at room temperature, the reaction was warmed to dissolve the orange suspension and 
then cooled on ice. The suspension was filtered and the solid washed with water to give the 
product (2.19 g, 95 %) as a yellow crystalline solid, mp 151-152 °C; IR (nujol) (cm*1) 3246, 
1610, 1515, 1344, 1224. 'H-NMR ((CD3)2SO, 300 MHz) 6  8.58 (1H, d, 7=2.8 Hz, 2-
13C-NMR ((CD3)2SO, 75 MHz) 6  147.68 (4-aryl), 146.48 (1-aryl), 143.52 (2-quinolyl),
141.81 (10-quinolyl), 141.05 (3-quinolyl), 129.21 (5-quinolyl), 128.44 (9-quinolyI), 128.16 
(3, 5-aryl), 126.55 (7-quinolyl), 125.71 (6 -quinolyl), 124.09 (8 -quinolyl), 123.51 (2, 6 -aryl),
quinolyl), 8.19 (2H, d, 7=8.8 Hz, 2, 6 -aryl), 7.78 (1H, d, 7=7.1 Hz, 9-quinolyl), 7.66 (2H, d, 
7=8.8 Hz, 3, 5-aryl), 7.54 (1H, d, 7=7.4 Hz, 6 -quinolyl), 7.32 (2H, m, 7, 8 -quinolyl), 7.11 
(1H, d, 7=6.1 Hz, NH), 6.94 (1H, d, 7=2.5 Hz, 4-quinolyl), 4.56 (2H, d, 7=6.0 Hz, CH2);
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108.38 (4-quinolyl), 45.45 (CH2). LRMS (Cl) m/z 280 (M+H, 100 %), 234 (9 %). 
Anal.Calcd for C16H,5N3 + ^H 20  C, 67.71; H, 4.79; N, 14.81. Found: C, 67.88; H, 4.73; N, 
14.75.
AL(4-Aminobenzyl)quinolin-3-amine (128)
.N
NH2
To a stirred suspension of ethyl A-(4-nitrobenzyl)quinolin-3-amine (127) (2.04 g, 7.30 
mmol) in ethanol (70 mL), was added 5 % palladium on carbon (30 mg) under nitrogen. The 
system was evacuated and replaced with hydrogen at atmospheric pressure. After stirring 
for 18 h, the catalyst was removed by filtration and the solvent evaporated to yield a pale 
brown solid which was recrystallised from ethanol-water to give the title compound (1.08 g, 
59 %) as off-white crystals, mp 150-152 °C; IR (nujol) (cm '1) 3402, 3300, 3179, 1612, 
1560. *H-NMR ((CD3)2SO, 300 MHz) 6  8.56 (1H, d, .7=2.7 Hz, 2-quinolyl), 7.78 (1H, d, 
7=8.0 Hz, 9-quinolyl), 7.59 (1H, dd, 7=1.3, 8.0 Hz, 6 -quinolyl), 7.39-7.25 (2H, m, 7, 8 - 
quinolyl), 7.09 (2H, d, .7=8.3 Hz, 2, 6 -aryl), 6 . 6 6  (1H, t, 7=5.5 Hz, NH), 6.57 (2H, d, 7=8.4 
Hz, 3, 5-aryl), 5.00 (2H, s, NH2), 4.17 (2H, d, 7=5.5 Hz, CH2); 13C-NMR ((CD3)2SO, 75 
MHz) 8  147.61 (1-aryl), 143.82 (2-quinolyl), 142.47 (10-quinolyl), 140.78 (3-quinolyl),
129.49 (Ar), 128.41 (3, 5-aryl, 9-quinolyl), 126.43 (7-quinolyl), 125.66 (6 -quinolyl), 125.58 
(Ar), 123.66 (8 -quinolyl), 113.83 (2, 6 -aryl), 107.80 (4-quinolyl), 46.09 (CH2). LRMS (Cl) 
m/z 250 (M+H, 6 8  %), 173 (27 %), 145 (100 %), 106 (67 %). Anal.Calcd for C ]6Hi5N3 C, 
77.08; H, 6.06; N, 16.85. Found: C, 77.11; H, 6.07; N, 16.65.
iV-(4-((l//-Imidazol-5-yl)methylamino)benzyl)quiiioIiii-3-amine (96)
L»N
A solution of A-(4-aminobenzyl)quinolin-3-amine (128) (200 mg, 0.80 mmol), 4(5)- 
imidazole carboxaldehyde (77 mg, 0.80 mmol) and acetic acid (5 mg, 80 pmol) in methanol
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( 8  mL) was stirred for 1 h at room temperature. Sodium borohydride (30 mg, 0.80 mmol) 
was then added and stirring continued for 3 d, then the solvent removed in vacuo. The 
residue was suspended in saturated aqueous sodium hydrogen carbonate solution (15 mL) 
and the aqueous phase extracted with dichloromethane ( 3 x 1 5  mL). The combined organics 
were washed with brine then dried (Na2S0 4 ) and the solvent removed in vacuo. The orange 
oil was purified by column chromatography (CHCl3 :acetone:ethanol, 100:40:8) to give the 
title compound (81 mg, 31 %) as off-white crystals, mp 190-192 °C; IR (nujol) (cm'1) 3377, 
1612, 1517, 1279, 1126. ]H-NMR ((CD3)2SO, 300 MHz) 5 11.92 (1H, brs, NH), 8.54 (1H, 
d, 7=2.6 Hz, 2-quinolyl), 7.77 (1H, d, 7=7.9 Hz, 9-quinolyl), 7.59 (2H, m, 6 -quinolyl, 3- 
imidazolyl), 7.32 (2H, m, 7, 8 -quinolyl), 7.14 (2H, d, 7=8.3 Hz, 3, 5-aryl), 7.00 (1H, d, 
7=2.4 Hz, 5-imidazolyl), 6.93 (1H, s, NH), 6.65 (3H, d, 7=8.4 Hz, 3, 5-aryl, 4-quinolyl),
5.76 (1H, s, NH), 4.17 (2H, d, 7=5.4 Hz, quinoline-NHCH2), 4.12 (2H, d, 7=4.7 Hz, aniline- 
CH2); 13C-NMR ((CD3)2SO, 75 MHz) 6  147.86 (1-aryl), 143.80 (2-quinolyl), 142.46 (10- 
quinolyl), 140.77 (3-quinolyl), 134.75 (3-imidazolyl), 129.48 (Ar), 128.42 (9-quinolyl), 
128.34 (3, 5-aryl), 126.42 (7-quinolyl), 125.65 (6 -quinolyl, Ar), 123.64 (8 -quinolyl), 112.27 
(2, 6 -aryl), 107.78 (4-quinolyl), 46.05 (quinoline-NHCH2), 40.32 (aniline-CH2). LRMS (Cl) 
m/z 252 (M+Na, 9 %), 329 (82 %), 199 (22 %), 176 (100 %), 154 (79 %). Anal. Calcd for 
C2oH,9N5 C, 72.93; H, 5.81; N, 21.26. Found: C, 72.84; H, 5.78; N, 21.12.
(2-PhenyI-li/-imidazoI-5-yl)methanol (130)
A mixture of benzamidine (767 mg, 6.39 mmol), dihydroxyacetone dimmer (1.21 g, 6.71 
mmol) and ammonium chloride (1.37 g, 25.56 mmol) in ammonium hydroxide (10 mL) was 
heated to 80 °C for 40 min. The orange suspension was allowed to cool to room temperature 
then extracted with ethyl acetate ( 8  x 10 mL), the combined extracts dried (MgSO.*) and 
evaporated to leave an orange oil. The crude product was purified by column 
chromatography (5 % methanol-ethyl acetate) to give a yellow solid which was 
recrystallised from ethanol-diethyl ether, providing the title compound (150 mg, 13 %) as a 
crystalline white solid, mp 146-7 °C; IR (cm'1) 3042, 2929, 2723, 2614, 1574, 1455, 1353,
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1137, 1026, 988, 772. LRMS (Cl) m/z 175 (M+H, 52 %), 157 (100 %), 145 (13 %), 104 (16 
%). Anal.Calcd for CioH,oN20  C, 68.95; H, 5.79; N, 16.08. Found: C, 68.94; H, 5.81; N, 
16.00.
l-(4-Cyanobenzyl)guanidine (132)
NH
A solution of 4-(aminomethly)benzonitrile hydrochloride (2.0 g, 11.86 mmol), pyrazole-1- 
carboxamidine hydrochloride (1.91 g, 13.05 mmol) and diisopropylethylamine (3.37 g,
26.09 mmol) in dimethylformamide (60 mL) was stirred for 7 h at room temperature. The 
solvent was removed in vacuo and saturated aqueous sodium hydrogen carbonate solution 
(20 mL) added. The white suspension was filtered and washed with water and diethyl ether 
to give the product (1.61 g, 78 %) as a white solid; IR (cm-1) 3416, 3343, 2890, 2234, 1694, 
1608, 1359, 830. ‘H-NMR ((CD3)2SO, 300 MHz) 6  8.67 (4H, brs, NH), 7.80 (2H, d, J=8.3 
Hz, 2, 6 -aryl), 7.44 (2H, d, J=8.2 Hz, 3, 5-aryl), 4.41 (CH2); ,3C-NMR ((CD3)2SO, 75 MHz) 
6  160.54 (CNH2), 143.79 (4-aryl), 132.29 (3, 5-aryl), 127.73 (2, 6 -aryl), 118.71 (CN),
109.88 (1-aryl), 43.11 (CH2).
4-((4-(Pyridin-3-yl)pyrimidin-2-ylamino)methyI)benzonitrile (133)
CN
A suspension of l-(4-cyanobenzyl)guanidine (132) (2.65 g, 15.21 mmol) and (E)-3- 
(dimethylamino)-l-(pyridin-3-yl)prop-2-en-l-one (2.68 g, 15.21 mmol) in propan-2-ol (40 
mL) was refluxed for 18 h. The orange solution was evaporated to dryness and the yellow 
solid triturated with cold ethyl acetate to give the product (2.79 g, 64 %) as an off-white 
crystalline solid, mp 169-170 °C; IR (cm 1) 3261, 2228, 1584, 1407, 799. 1H-NMR 
((CD3)2SO, 300 MHz) 6  9.20 (1H, s, 6 -pyridyl), 8 . 6 6  (1H, d, J= 3.6 Hz, 2-pyridyl), 8.39 (2H, 
m, 4-pyrimidyl, 4-pyridyl), 8.02 (1H, t, J= 6.2 Hz, NH), 7.76 (2H, d, J=8.2 Hz, 2, 6 -aryl),
7.54 (3H, m, 3, 5-aryl, 5-pyridyl), 7.25 (1H, d, J=5.1 Hz, 5-pyrimidyl), 4.64 (2H, d, J=5.5
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Hz, CH2); 13C-NMR ((CD3)2SO, 75 MHz) 5 162.24 (Ar), 159.38 (4-pyrimidyl), 151.22 (2- 
pyridyl), 147.95 (6 -pyridyl), 146.56 (4-aryl), 134.10 (4-pyridyl), 132.22 (3-pyridyl), 132.12 
(2, 6 -aryl), 127.84 (3, 5-aryl), 123.71 (5-pyridyl), 118.89 (CN), 109.22 (1-aryl), 106.30 (5- 
pyrimidyl), 43.93 (CH2). Anal.Calcd for C 17Hi3N5 C, 71.06; H, 4.56; N, 24.37. Found: C, 
70.66; H, 4.49; N, 24.19.
AT-Hydroxy-4-((4-(pyridin-3-yl)pyrimidin-2-yIamino)methyl)benzimidamide (99)
N
H
NOH
Hydroxylamine hydrochloride (726 mg, 10.45 mmol) was dissolved in a solution o f DIEA 
(1.62 g, 12.54 mmol) in methanol (10 mL)and the colourless solution stirred for 30 min. 4- 
((4-(Pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzonitrile (133) (600 mg, 2.09 mmol) was 
added and the white suspension stirred for 3 d at room temperature. The solvent was 
removed in vacuo and replaced with water (200 mL). The white precipitate was filtered and 
recrystallised from 10 % methanol-ethyl acetate to give the title compound (499 mg, 75 %) 
as white crystals, mp 200-1 °C; IR (cm'1) 3421, 3318, 1636, 1579, 1408, 933, 798. 1H-NMR 
((CD3)2SO, 300 MHz) 6  9.56 (1H, s, OH), 9.23 (1H, s, 6 -pyridyl), 8.67 (1H, d, 7=3.7 Hz, 2- 
pyridyl), 8.39 (2H, m, 4-pyrimidyl, 4-pyridyl), 7.92 (1H, t, 7=6.1 Hz, NH), 7.60 (2H, d, 
7=8.2 Hz, 2, 6 -aryl), 7.51 (1H, dd, 7=4.9, 7.6 Hz, 5-pyridyl), 7.35 (2H, d, 7=7.6 Hz, 3, 5- 
aryl), 7.23 (1H, d, 7=5.1 Hz, 5-pyrimidyl), 5.74 (2H, s, NH2), 4.58 (2H, d, 7=5.9 Hz, CH2); 
,3C-NMR ((CD3)2SO, 75 MHz) 5 162.24 (2-pyrimidyl), 159.34 (4-pyrimidyl), 151.89 (2- 
pyridyl), 150.68 (C(NH2)NOH), 147.96 (6 -pyridyl), 141.20 (4-aryl), 134.10 (4-pyridyl), 
132.33 (3-pyridyl), 131.66 (1-aryl), 126.77 (3, 5-aryl), 125.22 (2, 6 -aryl), 123.72 (5- 
pyridyl), 105.98 (5-pyrimidinyl), 43.83 (CH2). LRMS (Cl) m/z 343 (M+Na, 100 %), 321 (84 
%), 303 (26 %), 286 (22 %), 185 (14 %), 173 (18 %). Anal.Calcd for Ci7H)6N60  C, 63.74; 
H, 5.03; N, 26.23. Found: C, 63.78; H, 5.06; N, 26.32.
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4-Cyano-7V-phenylbenzamide (137)
4-Cyanobenzoic acid (200 mg, 1.36 mmol) was dissolved in thionyl chloride (4 mL) and the 
solution heated to 90 °C for 1 h. The solution was then evaporated and the pale yellow solid 
dissolved in dichloromethane (15 mL) and cooled to 0 °C. Aniline (139 mg, 1.50 mmol) was 
added slowly to the cooled solution, followed by pyridine (119 mg, 1.50 mmol). The 
reaction was stirred at 0 °C for 1 h then washed with 2 M HC1 (15 mL) and saturated 
aqueous sodium hydrogen carbonate solution (15 mL) before drying over MgSC>4 . The 
solvent was evaporated to leave a white solid which was recrystallised from ethyl acetate- 
petroleum ether (40 - 60) to give the title compound (254 mg, 84 %) as white crystals, mp 
176-178 °C; IR (cm'1) 3354, 2232, 1655, 1600, 1531, 1440, 854. 1H-NMR ((CD3)2SO, 300 
MHz) 5 10.48 (1H, s, NH), 8.10 (2H, d, 7=8.5 Hz, Ar(o-CN)), 8.02 (2H, d, 7=8.6 Hz, Ar(m- 
CN)), 7.76 (2H, d, 7=7.7 Hz, Ar(o-NH)), 7.36 (2H, t, 7=7.9 Hz, Ar(m-NH)), 7.12 (1H, t, 
7=7.4 Hz, Ar(p-NH)); 13C-NMR ((CD3)2SO, 75 MHz) 5 164.08 (CO), 138.92 (Ar), 138.67 
(Ar), 132.40 (Ar(m-CN)), 128.63 (Ar), 128.47 (Ar), 124.04 (Ar(p-NH)), 120.38 (Ar(o- 
NH)), 118.26 (Ar(p-NH)), 113.76 (CN). LRMS (Cl) m/z 223 (M+H, 100%), 130(6% ), 104 
(3 %).
4-(7V*-Hydroxy carbamimidoyl)-7V-phenylbenzamide (100)
NOH
Hydroxylamine hydrochloride (312 mg, 4.50 mmol) was dissolved in a solution of methanol 
(4.5 mL) and DIEA (605 mg, 4.68 mmol) and the colourless solution stirred for 30 min. 4- 
Cyano-TV-phenylbenzamide (137) (200 mg, 0.90 mmol) was added and stirring continued 
for 20 h at room temperature. The white suspension was filtered washed with a small 
amount of ethyl acetate to give the title compound (94 mg, 41 %), requiring no further 
purification, as a crystalline white solid, mp 273 °C; IR (cm '1) 3452, 3359, 3270, 1648, 927.
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1 H-NMR ((CD3)2SO, 300 MHz) 5 10.25 (1H, s, OH), 9.84 (1H, s, NH), 7.91 (2H, d, 7=8.3 
Hz, Ar(o-CNOH)), 7.80 (4H, m, Ar(m-CNOH), Ar(o-NH)), 7.34 (2H, t, 7=7.8 Hz, Ar(m- 
NH)), 7.09 (1H, t, 7=7.3 Hz, Ar(/?-NH)), 5.94 (2H, s, NH2); ,3C-NMR ((CD3)2SO, 75 MHz) 
5 164.99 (CO), 150.06 (CNOH), 138.67 (Ar(/-NH)), 136.09 (Ar(p-CNOH)), 134.92 (Ar(/- 
CNOH)), 128.55 (Ar(m-NH)), 127.45 (Ar(m-CNOH)), 125.11 (Ar(o-CNOH)), 123.63 
(Ar(p-NH)), 120.29 (Ar(o-NH)). LRMS (Cl) m/z 256 (M+H, 100 %). Anal.Calcd for 
C 14H13N30 2 C, 65.87; H, 5.13; N, 16.46. Found: C, 65.46; H, 5.12; N, 16.25.
4-((Phenylamino)methyl)benzonitrile (140)
Aniline (448 mg, 4.81 mmol) was added to a solution o f 4-cyanobenzaldehyde (631 mg,
4.81 mmol) in methanol (45 mL) and the pale yellow solution stirred at room temperature 
for 24 h. Sodium borohydride (260 mg, 6.87 mmol) was then added and the solution stirred 
for a further 18 h. The solvent was evaporated and replaced with ethyl acetate (20 mL) and 
the suspension washed with water (2 x 20 mL). The organic phase was dried over M gS04 
and evaporated to leave a yellow oil which solidified on standing. The crude product was 
recrystallised from diethyl ether to give the title compound (557 mg, 56 %) as a crystalline 
pale yellow solid, mp 87-88 °C; IR (cm'1) 3426, 2219, 1600, 1507, 1266. 1H-NMR (CDC13, 
300 MHz) 6  7.61 (2H, d, 7=8.3 Hz, Ar(o-CN)), 7.48 (2H, d, 7=8.3 Hz, Ar(m-CN)), 7.20 
(2H, dd, 7=7.4, 8.5 Hz, Ar(m-NH)), 6.77 (1H, t, 7=7.3 Hz, Ar(/?-NH)), 6.61 (2H, dd, 7=0.9, 
8.5 Hz, Ar(o-NH)), 4.43 (2H, s, CH2), 4.30 (1H, brs, NH); 13C-NMR (CDC13, 75 MHz) 5
147.54 (Ar(/-NH)), 145.59 (Ar(p-CN)), 132.47 (Ar(o-CN)), 129.43 (Ar(w-NH)), 127.78 
(Ar(m-CN)), 119.04 (CN), 118.07 (Ar(p-NH)), 112.95 (Ar(o-NH)), 110.82 (Ar(/-CN)), 
47.76 (CH2). LRMS (Cl) m/z 209 (M+H, 100 %), 118 (26 %), 94 (15 %). Anal.Calcd for 
Ci4H 12N2 + V8H20  C, 79.88; H, 5.87; N, 13.31. Found: C, 80.20; H, 5.77; N, 13.26.
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7V,-Hydroxy-4-((phenylamino)methyI)benzimidamide (101)
NOH
4-((Phenylamino)methyl)benzonitrile (140) (331 mg, 1.59 mmol) was dissolved in a 1M 
methanolic solution of hydroxylamine (7.95 mL, 7.95 mmol) and the colourless solution 
stirred for 3 d at room temperature. The solvent was evaporated, water (10 mL) added and 
the aqueous suspension extracted with ethyl acetate ( 3 x 1 0  mL). The combined extracts 
were dried (MgSCU) and evaporated to leave a yellow oil which solidified on standing. The 
crude product was purified by column chromatography (65 % ethyl acetate-petroleum ether 
(40 - 60)) to give the title compound (177 mg, 46 %) as a white solid, mp 132-133 °C; IR 
(cm'1) 3469, 3351, 2831, 1672, 1601, 1502, 939. ‘H-NMR ((CD3)2SO, 300 MHz) 5 9.59 
(1H, s, OH), 7.62 (2H, d, J=8.3 Hz, Ar(o-CNOH)), 7.34 (2H, d, J=8.3 Hz, Ar(m-CNOH)),
7.03 (2H, m, Ar(m-NH)), 6.52 (3H, m, Ar(o-NH), Ar(p-NH)), 6.24 (1H, t, 6.1 Hz, NH),
5.77 (2H, s, NH2), 4.27 (2H, d, J=6.1 Hz, CH2); 13C-NMR ((CD3)2SO, 75 MHz) 6  150.73 
(CNOH), 148.50 (Ar(Z-NH)), 141.12 (Ar^-CNOH)), 131.72 (Ar(/-CNOH)), 128.76 (Ar(m- 
NH)), 126.77 (Ar(m-CNOH)), 125.30 (Ar(o-CNOH)), 115.73 (Ar(/?-NH)), 112.25 (Ar(o- 
NH)), 46.10 (CH2). LRMS (Cl) m/z 242 (M+H, 100 %). Anal.Calcd for C]4Hi5N30  + 
V10H2O C, 69.17; H, 6.30; N, 17.29. Found: C, 69.28; H, 6.27; N, 17.18.
4-Cyano-JV-(quinolin-3-yI)benzamide (138)
4-Cyanobenzoic acid (200 mg, 1.36 mmol) was dissolved in SOCl2 (4 mL) and the solution 
heated to 90 °C for 1 h. The solution was then evaporated and the pale yellow solid 
dissolved in dichloromethane (15 mL) and cooled to 0 °C. 3-Aminoquinoline (287 mg, 1.99 
mmol) was added to the solution to give a yellow precipitate. Pyridine (157 mg, 1.99 mmol) 
was added slowly and the reaction was stirred at 0 °C for 2 h. The solvent was evaporated
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and the residue washed with 2 M HC1, water and methanol to leave the title compound (286 
mg, 77 %) as a yellow solid which was used without further purification.
4-(7V’-Hydroxycarbamimidoyl)-Ar-(quinolin-3-yl)benzamide (102)
NOH
Hydroxylamine hydrochloride (381 mg, 5.49 mmol) was dissolved in a solution of methanol 
(5.5 mL) and DIEA (738 mg, 5.71 mmol) and the colourless solution stirred for 30 min. 4- 
Cyano-iV-(quinolin-3-yl)benzamide (138) (300 mg, 1.10 mmol) was added and stirring 
continued for 18 h at room temperature. The white suspension was filtered washed with a 
small amount of methanol to give the title compound ( 2 1 0  mg, 62 %) requiring no further 
purification as a white solid, mp 262-263 °C dec; IR (cm 1) 3404, 3300, 2820, 1640, 1530, 
1490, 1369, 1277, 752. 'H-NMR ((CD3)2SO, 300 MHz) 5 10.71 (1H, s, OH), 9.88 ( 1H, s, 
NH), 9.16 (1H, d, .7=2.4 Hz, 2-quinolyl), 8 . 8 6  (1H, d, 7=2.1 Hz, 4-quinolyl), 8.05 (2H, d, 
7=8.4 Hz, 2, 6 -aryl), 7.97 (2H, t, 7=7.3 Hz, 5, 8 -quinolyl), 7.88 (2H, d, 7=8.4 Hz, 3, 5-aryl), 
7.66 (1H, m, 7-quinolyl), 7.58 (1H, m, 6 -quinolyl), 5.97 (2H, s, NH2); 13C-NMR ((CD3)2SO, 
75 MHz) 5 165.65 (CO), 150.06 (C(NH2)NOH), 145.43 (2-quinolyl), 144.32 (9-quinolyl),
136.50 (3-quinolyl), 134.27 (1-aryl), 132.83 (4-aryl), 128.51 (8 -quinolyl), 127.98 (6 - 
quinolyl), 127.75 (7-quinolyl), 127.70 (5-quinolyl), 127.60 (2, 6 -aryl), 126.99 (6 -quinolyl),
125.25 (3, 5-aryl), 123.34 (4-quinolyl). LRMS (Cl) m/z 307 (M+H, 100 %). Anal.Calcd for 
C,7Hi4N40 2 C, 6 6 .6 6 ; H, 4.61; N, 18.29. Found: C, 66.47; H, 4.61; N, 18.00.
AL(4-Cyanobenzyl)benzamide (141)
o
Benzoyl chloride (366 mg, 2.61 mmol) was added slowly to a solution of 4- 
(aminomethyl)benzonitrile hydrochloride (400 mg, 2.37 mmol) and triethylamine (503 mg,
4.98 mmol) in dichloromethane (20 mL) at 0 °C. The solution was stirred at 0 °C for 3 h
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then washed with 2 M HC1 (10 mL) and saturated aqueous sodium hydrogen carbonate 
solution (10 mL) before drying over MgSC>4 . The solvent was evaporated to leave a white 
solid which was recrystallised from ethyl acetate-petroleum ether (40 - 60) to give the title 
compound (459 mg, 82 %) as a white crystalline solid, mp 157-158 °C; IR (cm'1) 3249, 
3072, 2229, 1634, 1546, 794. 1H-NMR (CDC13, 300 MHz) 5 7.80 (2H, dt, .7=1.8, 7.0, Hz, 
Ar(o-CO)), 7.60 (2H, d, 7=8.4 Hz, Ar(m-CO)), 7.53 (1H, tt, 7=1.4, 7.3, Hz, Ar(p-CO)), 7.43 
(4H, m, Ar), 6.75 (1H, brs, NH), 4.68 (2H, d, 7=6.1 Hz, CH2); ,3C-NMR (CDC13, 75 MHz) 
5 167.64 (CO), 143.95 (Ar(p-CN)), 133.80 (Ar(z-CO)), 132.49 (Ar(o-CN)), 131.94 (Ar(p- 
CO)), 128.72 (Ar), 128.22 (Ar), 127.02 (Ar), 118.72 (CN), 111.27 (Ar(/-CN)), 43.51 (CH2). 
LRMS (Cl) m/z 237 (M+H, 100 %), 122 (44 %), 104 (13 %). Anal.Calcd for C 15Hi2N20  C, 
76.25; H, 5.12; N, 11.86. Found: C, 75.87; H, 5.13; N, 11.77.
AL(4-(A’-Hydroxycarbamimidoyl)benzyl)benzamide (103)
o
NOH
Hydroxylamine hydrochloride (397 mg, 5.71 mmol) was dissolved in a solution o f methanol 
(5.7 mL) and DIEA (766 mg, 5.93 mmol) and the colourless solution stirred for 30 min. N- 
(4-Cyanobenzyl)benzamide (141) (270 mg, 1.14 mmol) was added and stirring continued 
for 20 h at room temperature. The solution was evaporated and water (10 mL) added to the 
colourless oil. The aqueous solution was extracted with ethyl acetate ( 3 x 1 0  mL) and the 
combined organics dried (MgSO^ and evaporated. The white solid was recrystallised from 
methanol to give the title compound ( 2 1 0  mg, 6 8  %) as a crystalline white solid, mp 188- 
190 °C; IR (cm 1) 3452, 3347, 3309, 3047, 1630, 1531, 1313, 942. 1H-NMR ((CD3)2SO, 300 
MHz) 5 9.60 (1H, s, OH), 9.07 (1H, t, 7=±5.9Hz, NH), 7.89 (2H, m, Ar(o-CO)), 7.62 (2H, d, 
7=8.3 Hz, Ar(o-CNOH)), 7.49 (3H, m, Ar(m,p-CO)), 7.30 (2H, d, 7=8.3 Hz, Ar(m-CNOH)), 
5.80 (2H, s, NH2), 4.89 (2H, d, 7=5.9 Hz, CH2); 13C-NMR ((CD3)2SO, 75 MHz) 5 166.16 
(CO), 150.67 (CNOH), 140.39 (Ar(p-CNOH)), 134.22 (Ar(z-CO)), 131.80 (Ar), 131.20 
(Ar), 128.27 (Ar), 127.18 (Ar), 126.84 (Ar), 125.30 (Ar), 42.33 (CH2). LRMS (Cl) m/z 270 
(M+H, 100 %). Anal.Calcd for C15H 15N30 2 C, 66.90; H, 5.61; N, 15.60. Found: C, 66.83; 
H, 5.63; N, 15.48.
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7-Bromoheptanoic acid (145)7
o
HO Br
To a solution of ethyl 7-bromoheptanoate (1.0 g, 4.22 mmol) in methanol (30 mL) was 
added 2 M aqueous LiOH (5.06 mL) and the solution stirred for 18 h at room temperature. 
The methanol was removed in vacuo to leave a white slurry and ethyl acetate (30 mL) was 
added. The mixture was washed with 2 M HC1 ( 2 x 1 5  mL) and brine (15 mL} before drying 
over MgSC>4 . The colourless solution was evaporated to leave a colourless oil which 
solidified on standing to give the product (861 mg, 98 %) as a white solid which was 
spectroscopically identical to the literature; *H-NMR (CDCI3, 300 MHz) 6  11.33 (1H, brs, 
OH), 3.38 (2H, t, J= 6 . 8  Hz, CH2Br), 2.34 (2H, t, J=7.4 Hz, COCH2), 1.84 (2H, m, 
C//2CH2Br), 1.62 (2H, m, COCH2CH2), 1.40 (4H, m, COCH2CH2C //2, C //2CH2CH2Br); 
13C-NMR (CDCI3, 75 MHz) 5 180.32 (COOH), 33.95 (COOHCH2), 33.78 (CH2Br), 32.50 
(CH2CH2Br), 28.14 (CH2CH2CH2Br), 27.76 (COCH2CH2CH2), 24.41 (COCH2CH2).
7-Bromo-iV-phenylheptanamide (146)7,8
H
7-Bromoheptanoic acid (145) (840 mg, 4.02 mmol) in thionyl chloride (10 mL) was heated 
to 70 °C for 1 h. The solution was evaporated to leave a pale yellow oil which was dissolved 
in dichloromethane (40 mL) and cooled to 0 °C. Aniline (412 mg, 4.42 mmol) was added 
dropwise followed by pyridine (350 mg, 4.42 mmol) also dropwise and stirring continued 
for 3 h at 0 °C. The suspension was washed with 2 M HC1 (20 mL) and saturated aqueous 
sodium hydrogen carbonate solution (20 mL) then dried (MgSO.4). The solvent was 
removed in vacuo to leave a peach coloured solid which was purified by column 
chromatography (petroleum ether (40 - 60)-ethyl acetate, 2:1) to give the title compound 
(790 mg, 69 %) as white needles, mp 98-99 °C, which were spectroscopically identical to 
the literature; 1 H-NMR (CDC13, 300 MHz) 6  7.51 (2H, d, J=1.7 Hz, 2, 6 -aryl), 7.30 (2H, t, 
J= 7.8 Hz, 3, 5-aryl), 7.09 (1H, t, J=7.3 Hz, 4-aryl), 3.39 (2H, t, J=6.7 Hz, CH2Br), 2.35 (2H, 
t, J=1A Hz, COCH2), 1.89-1.68 (4H, m, COCH2CH2, C tf2CH2Br), 1.44 (4H, m, 
COCH2CH2CH2, C //2CH2CH2Br); 13C-NMR (CDC13, 75 MHz) 6  171.34 (CO), 137.96 (1-
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aryl), 128.98 (3, 5-aryl), 124.24 (4-aryl), 119.89 (2 , 6 -aryl), 37.51 (COCH2), 33.89 (CH2Br), 
32.51 (CH2CH2Br), 28.31 (COCH2CH2CH2), 27.84 (CH2CH2CH2Br), 25.36 (COCH2CH2). 
LRMS (Cl) m/z 284 (M+H, 85 %), 204 (100 %), 93 (37 %). Anal.Calcd for C 13H18NOBr C, 
54.94; H, 6.38; N, 4.93. Found: C, 55.30; H, 6.43; N, 4.81.
7-Cyano-iV-phenylheptanamide (147)
o
H
7-Bromo-JV-phenylheptanamide (146) (770 mg, 2.71 mmol) was added to a solution of KCN 
(212 mg, 3.25 mmol) in dry ethanol (13 mL) and the solution heated to 75 °C for 19 h. The 
reaction was quenched by addition of 2 M HC1 (5 mL) (caution: HCN evolved). The 
inorganic precipitates were removed by filtration and the filtrate evaporated to give a pale 
yellow solid. The solid was re-dissolved in ethanol and filtered to remove remaining 
inorganics, then evaporated. The crude solid was purified by column chromatography 
(petroleum ether (40 - 60)-ethyl acetate, 1:1) to give the title compound (458 mg, 73 %) as a 
white crystalline solid, mp 99-101 °C; IR (cm 1) 3300, 3260, 2944, 2247, 1664, 1599. 1H- 
NMR (CDC13, 300 MHz) 6  7.64 (1H, s, NH), 7.52 (2H, d, 7=7.8 Hz, 2, 6 -aryl), 7.29 (2H, t, 
7=7.9 Hz, 3, 5-aryl), 7.08 (1H, t, 7=7.4 Hz, 4-aryl), 2.33 (4H, t, 7=7.2 Hz, , CH2CN), 1.77- 
1.58 (4H, m, COCH2CH2, C //2CH2CN), 1.41 (4H, m, COCH2CH2C7/2, C //2CH2CH2CN); 
13C-NMR (CDCI3, 75 MHz) 5 171.32, (CO), 138.05 (1-aryl), 128.97 (3, 5-aryl), 124.20 (4- 
aryl), 119.86 (2, 6 -aryl, CN), 37.29 (COCH2), 28.33 (COCH2CH2CH2), 28.28 
(CH2CH2CH2CN), 25.13 (COCH2CH2), 25.09 (CH2CH2CN), 17.07 (CH2CN). LRMS (Cl) 
m/z 231 (M+H, 100 %), 138 (26 %), 94 (37 %). Anal. Calcd for C 14H 18N20  C, 73.01; H, 
7.88; N, 12.16. Found: C, 73.01; H, 7.98; N, 11.87.
8 -Ammo-8 -(hydroxyimino)-iV-phenyloctanamide (104)
NHg 
NOH
To a solution of 7-cyano-JV-phenylheptanamide (147) (1.50 g, 6.51 mmol) was added a 1 M 
methanolic solution of hydroxylamine (32.46 mL, 32.56 mmol) and the resultant solution
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stirred for 2 d at room temperature. The solvent was evaporated to leave a white solid which 
was purified by column chromatography (50 % ethyl acetate-petroleum ether (40 - 60) 
increasing to 1 0 0  % ethyl acetate) and recrystallisation from ethyl acetate-petroleum ether 
(40 - 60) to give the starting material (800 mg, 53 %) and the title compound (233 mg, 14 
%) as a pale-grey crystalline solid, mp 127 °C; IR (cm '1) 3290, 2940, 1662, 1601, 1544, 
1444. 1H-NMR ((CD3)2SO, 300 MHz) 6  9.84 (1H, s, OH), 9.30 (1H, s, NH), 8.22 (1H, s, 
NH), 7.88 (1H, s, NH), 7.57 (2H, d, 7=7.7 Hz, 2, 6 -aryl), 7.26 (2H, t, 7=7.9 Hz, 3, 5-aryl), 
7.00 (1H, t, 7=7.4 Hz, 4-aryl), 2.28 (2H, t, 7=7.4 Hz, , COCH2), 2.16 (2H, t, 7=7.5 Hz, 
CH2C(NH2)NOH), 1.62-1.46 (4H, m, COCH2CH2, CH2CH2CNH2), 1.29 (4H, m, 
COCH2CH2CH2, C //2CH2CH2CNH2); 13C-NMR ((CD3)2SO, 75 MHz) 5 171.19, (CO),
157.26 (C(NH2)NOH), 139.28 (1-aryl), 128.56 (3, 5-aryl), 122.84 (4-aryl), 118.96 (2, 6 - 
aryl), 36.35 (COCH2), 28.53 (CH2CH2CH2CNH2), 28.42 (COCH2CH2CH2), 27.69 
(CH2CNH2), 25.80 (COCH2CH2), 25.03 (CH2CH2CNH2), 17.07 (CH2CN). LRMS (El) m/z 
263 (M+, 7 %), 249 (12 %), 231 (13 %), 190 (24 %), 135 (27 %), 93 (100 %). HRMS calcd 
for C14H21N30 2263.16283. Found: 263.16266.
6.3 Analogues of SAHA
Oxonane-2,9-dione (157)9
Suberic acid (5.0 g, 28.7 mmol) was refluxed at 150 °C in acetic anhydride (10 mL) for 1 
h. The solution was then evaporated to. leave a white solid which was recrystallised from 
ethyl acetate-petroleum ether (40 - 60) to give a crystalline white solid (5.40 g, 83 %), mp 
50-52 °C (lit.9 51-52 °); IR (cm'1) 1799, 1740, 1473, 1415, 1077, 910. ‘H-NMR (CDC13, 300 
MHz) 6  2.43 (4H, t, 7=7.3 Hz, CH2CO), 1.64 (4H, m, CH2CH2CO), 1.36 (4H, m, 
C //2CH2CH2CO); 13C-NMR (CDC13, 75 MHz) 5 169.41 (CO), 35.07 (CH2CO), 28.38 
(CH2CH2CO), 23.89 (CH2CH2CH2CO). LRMS (Cl) m/z 157 (M+H, 100%), 111(12 %).
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8-Oxo-8-(phenylamino)octanoic acid (158)9
N'
H
CQ2H
Aniline (1.48 g, 15.88 mmol) was added to a white suspension of oxonane-2,9-dione (157) 
(2.48 g, 15.88 mmol) in dry tetrahydrofuran (25 mL) and the resultant yellow solution 
stirred for 45 min at room temperature. The white suspension was then poured onto water 
(200 mL) and the precipitate filtered then recrystallised form methanol-water to give the 
product (3.12 g, 79 %) as a white crystalline solid, mp 123-124 °C (lit.9 122-123 °C); IR 
(cm'1) 3304, 2936, 1690, 1659, 1598, 1442, 1250, 1178. ’H-NMR ((CD3)2SO, 300 MHz) 6
C//2C//2CH2CH2COO); 13C-NMR ((CD3)2SO, 75 MHz) 6  174.43 (COOH), 171.17 
(CONH), 139.26 (1-aryl), 128.54 (3, 5-aryl), 122.84 (4-aryl), 118.97 (2, 6 -aryl), 36.29 
(NHCOCH2), 33.55 (CH2COO), 28.33 (CH2CH2CH2COO), 28.26 (NHCOCH2CH2CH2), 
24.92 (NHCOCH2CH2), 24.32 (CH2CH2COO). LRMS (Cl) m/z 250 (M+H, 82 %), 232 (100 
%), 157 (16 %), 93 (53 %).
A1 -hydroxy-A8-phenyloctanediamide (SAHA)9
Ethyl chloroformate (5.69 mg, 5.24 mmol) and triethylamine (611 mg, 6.04 mmol) were 
added to a solution of 8 -oxo-8 -(phenylamino)octanoic acid (158) (1.0 g, 4.03 mmol) in dry 
tetrahydrofuran at 0 °C. The mixture was stirred for 20 min then the solid filtered and the 
filtrate added to a methanolic solution of hydroxylamine (prepared by addition of a solution 
of hydroxylamine hydrochloride (476 mg, 6.85 mmol) in methanol (10 mL) to a solution of 
KOH (384 mg, 6.85 mmol) in methanol (10 mL) at 0 °C, stirring for 15 min then filtration 
of the precipitate). The solution was stirred for 20 min then evaporated to leave a white 
solid which was recrystallised from 1 % methanol-acetonitrile to give the title compound 
(685 mg, 65 %) as a white crystalline solid, mp 159-160 °C (lit.9 159.5-160 °C); IR (cm 1)
12.01 (1H, brs, OH), 9.84 (1H, s, NH), 7.58 (2H, d, 7=7.8 Hz, 2, 6 -aryl), 7.26 (2H, d, 7=7.8 
Hz, 3, 5-aryl), 7.00 ( 1H, t, 7=7.3 Hz, 4-aryl), 2.28 (2 H, t, 7=7.4 Hz, NHCOC//2), 2.18 (2 H, 
t, 7=7.3 Hz, CH2COO), 1.53 (4H, m, NHCOCH2C7/2, CH2CH2COO), 1.28 (4H, m,
NHOH
O
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3193, 2935, 1655, 1598, 1527, 1443, 1317, 1248. 1 H-NMR ((CD3)2SO, 300 MHz) 6  10.34 
(1H, brs, NH), 9.86 (1H, s, NH), 8 . 6 6  (1H, s, OH), 7.57 (2H, d, 7= 8.4 Hz, 2, 6 -aryl), 7.26 
(2H, t, 7= 7.8 Hz, 3, 5-aryl), 7.00 (1H, t, 7=7.3 Hz, 4-aryl), 2.27 (2H, t, 7=7.4 Hz, 
PhNHCOC//2), 1-92 (2H, t, 7=7.3 Hz, C7/2CONHOH), 1.52 (4H, m, PhNHCOCH2C //2, 
CH2CH2CONHOH), 1.26 (4H, m, CH2CH2CH2CH2CONHOH, C/72CH2CH2CONHOH); 
,3C-NMR ((CD3)2SO, 75 MHz) 5 171.16 (PhNHCO), 169.04 (CONHOH), 139.28 (1-aryl),
128.55 (3, 5-aryl), 122.83 (4-aryl), 118.95 (2, 6 -aryl), 36.30 (PhNHCOCH2), 32.18 
(CH2CONHOH), 28.34 (CH2CH2CH2CONHOH, PhNHCOCH2CH2CH2), 24.96 
(PhNHCOCH2CH2, OH2CH2CONHOH). LRMS (Cl) m/z 287 (M+Na, 78 %), 265 (M+H, 
100%), 232 ( 8  %).
l-(terf-Butoxycarbonyl)piperidine-4-carboxylic acid (163)10
o
NBoc
Isonipecotic acid (5.0 g, 38.71 mmol) was added to a solution o f potassium carbonate (10.70 
g, 77.42 mmol) in water (80 mL) at 0 °C. To the resultant solution was added a solution of 
di-ter/-butyl dicarbonate (16.90 g, 77.42 mmol) in tetrahydrofuran (80 mL) dropwise at 0 
°C. After stirring for 4 h at room temperature the tetrahydrofuran was evaporated and the 
aqueous solution washed with diethyl ether (2 x 30 mL). The aqueous phase was then 
acidified with 1 M HC1 and extracted with ethyl acetate (4 x 20 mL). The combined extracts 
were washed with brine (20 mL) and dried (MgS0 4 ). The solvent was removed in vacuo to 
give the product (7.45 g, 84 %) as a white crystalline solid, mp 148-150 °C; IR (cm’1) 3217, 
2974, 1732, 1651, 1431, 1286.1H-NMR (CDC13, 300 MHz) 5 11.21 (1H, s, COOH), 3.99 
(2H, d, 7=11.8 Hz, 2-piperidyl), 2.83 (2H, t, 7=11.4 Hz, 2-piperidyl), 2.45 (1H, tt, 7=3.8,
10.8 Hz, 4-piperidyl), 1.87 (2H, dd,7=2;5, 13.1, Hz, 3-piperidyl), 1.61 (2H, m, 3-piperidyl),
1.42 (9H, s, C(CH3)3); 13C-NMR (CDC13, 75 MHz) 5 180.73 (COOH), 154.82 (NCOO), 
79.86 (C(CH3)3), 42.99 (4-piperidyl), 40.81 (2, 6 -piperidyl), 28.40 (C(CH3)3), 27.71 (3, 5 - 
piperidyl). LRMS (Cl) m/z 230 (M+H, 36 %), 202 (48 %), 174 (100 %), 156 (97 %), 139 
(79%), 112(82%).
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tert-Butyl 4-(phenyIcarbamoyI)piperidine-l-carboxylate (164)11
NBoc
A solution of l-(/ert-butoxycarbonyl)piperidine-4-carboxylic acid (163) (4.63 g, 20.19 
mmol), 1-hydroxybenzotriazole (4.09 g, 30.29 mmol), l-(3-dimethylaminopropyl)-3-ethyl 
carbodiimide (4.26 g, 22.21 mmol), aniline (1.88 g, 20.19 mmol) and A-methylmorpholine 
(4.49 g, 44.42 mmol) in dimethylformamide (100 mL) was stirred at room temperature for 
18 h. The reaction was acidified with 0.5 M HC1 (90 mL) and extracted with ethyl acetate (4 
x 20 mL). The combined extracts were washed with saturated aqueous sodium hydrogen 
carbonate solution (20 mL) and brine (20 mL) before drying (MgS0 4 ). The solvent was 
removed in vacuo to leave a brown oil which was triturated with diethyl ether to give a 
white solid. The crude product was recrystallised from ethanol-water to give the title 
compound (4.20 g, 6 8  %) as a white crystalline solid, mp 154-6 °C; IR (cm '1) 3316, 2848, 
1698, 1663, 1603, 1546, 760. 'H-NMR (CDC13, 300 MHz) 5 7.51 (2H, d, .7=7.2 Hz, 2, 6 - 
aryl), 7.29 (2H, m, 3, 5-aryl), 7.10 (1H, t, .7=7.0 Hz, 4-aryl), 4.17 (2H, d, .7=12.3 Hz, 2, 6 eq- 
piperidyl), 2.75 (2H, t, .7=12.3 Hz, 2, 6 ax-piperidyl), 2.38 (1H, m, 4-piperidyl), 1.87 (2H, d, 
.7=12.3 Hz, 3, 5eq-piperidyl), 1.74 (2H, m, 3, 5ax-piperidyl), 1.46 (9H, s, C(CH3)3); 13C- 
NMR (CDC13, 75 MHz) 5 172.78 (NHCO), 154.71 (NCOO), 137.84 (1-aryl), 129.02 (3, 5- 
aryl), 124.40 (4-aryl), 119.95 (2, 6 -aryl), 79.78 (C(CH3)3), 44.26 (2, 6 -piperidyl), 43.26 (4- 
piperidyl), 28.61 (3, 5-piperidyl), 28.45 (C(CH3)3). LRMS (Cl) m/z 327 (M+Na, 100 %), 
227 (63 %). Anal.Calcd for C n ^ ^ C T *  C, 67.08; H, 7.95; N, 9.20. Found: C, 67.04; H, 
7.93; N, 9.00.
A-Phenylpiperidine^-carboxam ide (165)12
tert-Butyl 4-(phenylcarbamoyl)piperidine-l-carboxylate (164) (3.0 g, 9.86 mmol) was 
dissolved in a 1 :1  solution of dichloromethane-trifluoroacetic acid and the resultant solution 
stirred for 17 h. The reaction was quenched with saturated aqueous sodium hydrogen
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carbonate solution and the organic layer separated. The aqueous phase was further extracted 
with ethyl acetate (10 x 50 mL) and the combined organics dried with MgSC>4 . The solvent 
was removed in vacuo to give the product (1.37, 6 8  %) without further purification as a 
viscous white oil; IR (cm 1) 3268, 2940, 1645, 1527, 1440, 731. ]H-NMR (CD3OD, 300 
MHz) 5 7.55 (2H, d, 7= 7.6 Hz, 2, 6 -aryl), 7.27 (2H, t, 7=7.9 Hz, 3, 5-aryl), 7.05 (1H, t, 
7=7.4 Hz, 4-aryl), 3.11 (2H, d, 7=12.5 Hz, 2, 6 eq-piperidyl), 2.67 (2H, dt, 7=3.0, 12.3 Hz, 2, 
6 ax-piperidyl), 2.53 (1H, m, 4-piperidyl), 1.76 (4H, d, 7=12.3 Hz, 3, 5-piperidyl); 13C-NMR 
(CD3OD, 75 MHz) 5 175.83 (CO), 139.96 (1-aryl), 129.89 (3, 5-aryl), 125.56 (4-aryl),
121.42 (2, 6 -aryl), 45.86 (2, 6 -piperidyl), 44.25 (4-piperidyl), 29.46 (3, 5-piperidyl). LRMS 
(El) m/z 204 (M+, 54 %), 148 (100 %), 92 (93 %). HRMS calcd for C 12H ]6N20 204.12626. 
Found: 204.12588.
Ethyl 3-(4-(phenylcarbamoyl)piperidin-l-yl)propanoate (166)
o
Ethyl acrylate (0.66 g, 6.56 mmol) was added to a solution o f 7V-phenylpiperidine-4- 
carboxamide (165) (1.34 g, 6.56 mmol) in ethanol (30 mL) and the solution stirred for 4 d. 
The solvent was removed in vacuo to leave a white solid which was purified by column 
chromatography (ethyl acetate) and recrystallisation from ethyl acetate-petroleum ether (40- 
60) to give a white crystalline solid (1.34 g, 67 %), mp 115-116 °C; IR (cm'1) 3281, 2962, 
1730, 1653, 1525, 1249, 730. *H-NMR (CDC13, 300 MHz) 5 7.51 (2H, d, 7=7.8 Hz, 2, 6 - 
aryl), 7.30 (2H, t, 7=7.9 Hz, 3, 5-aryl), 7.08 (1H, t, 7=7.4 Hz, 4-aryl), 4.14 (2H, q, 7=7.1 Hz, 
C //2CH3), 3.02 (2H, d, 7=11.5 Hz, 2, 6 eq-piperidyl), 2.75 (2H, t, 7=7.3 Hz, C //2CH2COO), 
2.53 (2H, t, 7=7.3 Hz, CH2COO), 2.30-2.10 (3H, m, 4-piperidyl, 2, 6 ax-piperidyl), 1.97- 
1.85 (4H, m, 3, 5-piperidyl), 1.25 (3H, s, CH3); ,3C-NMR (CDC13, 75 MHz) 5 173.05 
(COO), 172.30 (NHCO), 137.91 (1-aryl), 129.00 (3, 5-aryl), 124.29 (4-aryl), 119.90 (2, 6 - 
aryl), 60.60 (CH2CH3), 53.56 (CH2CH2COO), 52.65 (2, 6 -piperidyl), 43.73 (4-piperidyl),
32.10 (CH2COO), 28.50 (3, 5-piperidyl), 14.22 (CH3). LRMS (Cl) m/z 327 (M+Na, 100 %),
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305 (63 %), 217 (46 %), 212 (27 %). Anal.Calcd for Ci7H24N20 3.!/2H20  C, 65.15; H, 8.04; 
N, 8.94. Found: C, 65.59; H, 7.73; N, 8.71.
l-(3-(Hydroxyamino)-3-oxopropyl)-7V-phenylpiperldine-4-carboxamide (148)
Ethyl 3-(4-(phenylcarbamoyl)piperidin-l-yl)propanoate (166) (513 mg, 1.69 mmol) in 
tetrahydrofuran (3 mL) was added to a 1M solution of hydroxylamine in methanol (16.9 mL,
16.9 mmol) and to the solution was added a 1M solution o f KOH (3.37 mL, 3.37 mmol). 
After stirring over night at room temperature, the orange suspension was neutralised with 2 
M HC1 and evaporated. The pale orange solid dissolved in 10 % methanol-ethyl acetate and 
an insoluble white solid removed by filtration. The filtrate was evaporated to leave a pale 
orange solid which was recrystallised from 5 % methanol-acetonitrile to give the title 
compound (247 mg, 42 %) as white crystals, mp 118-120 °C; IR (cm '1) 3463, 3232, 2949, 
2714, 1657, 1446, 947. ’H-NMR ((CD3)2SO, 300 MHz) 6  10.79 (1H, s, NH), 10.52 (1H, brs,
1.98 (4H, m, 3, 5-piperidyl); 13C-NMR ((CD3)2SO, 75 MHz) 6  171.78 (PhNHCO), 165.70 
(CONHOH), 139.07 (1-aryl), 128.56 (3, 5-aryl), 123.13 (4-aryl), 119.16 (2, 6 -aryl), 51.92 
(NGH2), 50.89 (2, 6 -piperidyl), 39.89 (4-piperidyl), 26.80 (CH2CO), 25.62 (3, 5-piperidyl). 
IR (nujol) (cm'1) 3238, 2588, 1654, 752. LRMS (Cl) m/z 292 (M+H, 100 %), 217 (19 %), 
154 (74 %). Anal.Calcd for C ,5H2 iN30 3.H20 .HCl C, 52.10; H, 7.00; N, 12.15. Found: C, 
52.15; H, 7.10; N, 12.09.
NHOH
.h c i .h 2o  o
OH), 10.27 (1H, s, NH), 8.93 (1H, s, NH), 7.62 (2H, d, 7=7.8 Hz, 2, 6 -aryl), 7.27 (2H, t, 
7=7.7 Hz, 3, 5-aryl), 7.01 (1H, t, 7=7.2 Hz, 4-aryl), 3.48 (2H, d, 7=9.6 Hz, 2, 6 eq-piperidyl), 
3.27 (2H, m, NCH2), 2.91 (2H, m, 2, 6 ax-piperidyl), 2.59 (3H, m, CH2CO, 4-piperidyl),
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Ethyl 3-(bis(2-hydroxyethyl)amino)propanoate (168)
o
A solution of di ethanol amine (10.42 g, 99.11 mmol) and ethyl acrylate (9.92 g, 99.11 mmol) 
in ethanol (250 mL) was refluxed at 120 °C for 5 h. The solvent was removed in vacuo and 
the colourless oil purified by column chromatography ( 1 0 % methanol-ethyl acetate) to give 
the product (18.14 g, 90 %) as a colourless oil; IR (cm 1) 3371, 2967, 1728, 1187, 1042. ]H- 
NMR (CDCI3, 300 MHz) 6  4.10 (2H, q, .7=7.1 Hz, C //2CH3), 3.55 (4H, t, 7=5.2 Hz, 
C //2OH), 3.25 (2H, brs, OH), 2.80 (2H, t, 7= 6.5 Hz, CH2COO), 2.59 (4H, t, 7=5.1 Hz, 
NC7/2CH2OH), 2.43 (2H, t, 7=6.5 Hz, N C//2CH2COO), 1.21 (3H, t, 7=7.1 Hz, CH2C //3); 
,3C-NMR (CDC13, 75 MHz) 6  173.25 (COO), 60.67 (CH2CH3), 59.49 (CH2OH), 56.06 
(NCH2CH2OH), 49.66 (NCH2CH2COO), 32.65 (CH2COO), 14.10 (CH2CH3). LRMS (Cl) 
m/z 228 (M+Na, 74 %), 206 (M+H, 43 %), 188 (100 %).
Ethyl 3-(bis(2-bromoethyI)amino)propanoate (169)
bO
N OEt
Br O
To a solution of ethyl 3-(bis(2-hydroxyethyl)amino)propanoate (168) (3.0 g, 14.62 mmol) in 
dichloromethane (150 mL) was added triphenylphosphine (8.05 g, 30.70 mmol) followed by 
iV-bromosuccinamide (5.46 g, 30.70 mmol) slowly and the pale yellow solution stirred for 6  
h at room temperature. The solvent was removed in vacuo to leave an off-white solid which 
was recrystallised from acetone-petroleum ether (40 - 60). The white, crystalline 
triphenylphosphine oxide was filtered off and washed with 1 0  % ethyl acetate-petroleum 
ether (40 - 60). The filtrate was then evaporated to give a pale yellow solid which was 
purified by column chromatography (10 % ethyl acetate-petroleum ether (40 - 60)) to give 
the title compound (2.97 g, 61 %) as a colourless oil; ]H-NMR (CDC13, 300 MHz) 8  4.12 
(2H, q, 7=7.1 Hz, C //2CH3), 3.32 (4H, t, 7=7.4 Hz, CH2Br), 2.89 (6 H, m, (CH2)3N), 2.42 
(2H, t, 7=6.9 Hz, CH2COO), 1.25 (3H, t, 7=7.1 Hz, CH2CH3); ,3C-NMR (CDC13, 75 MHz) 8
172.01 (COO), 60.48 (CH2CH3), 56.27 (CH2CH2Br), 49.95 (NCH2CH2COO), 33.56 
(CH2COO), 30.13 (CH2Br), 14.26 (CH2CH3). LRMS (Cl) m/z 330 (M+H, 39 %), 282 (77
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%), 252 (53 %), 236 (70 %), 202 (100 %). HRMS (M+H) calcd for C9H,7N0 2Br2 
329.97042. Found: 329.96970.
Di-tert-butyl l-(3-ethoxy-3-oxopropyl)piperidine-4,4-dicarboxylate (170)
A suspension of di-/ert-butyl malonate (2.61 g, 12.09 mmol) and sodium hydride (725 mg 
of a 60 % dispersion in mineral oil, 18.14 mmol) in dry dimethyl form amide was stirred at 
room temperature for 30 min before addition o f ethyl 3-(bis(2- 
bromoethyl)amino)propanoate (169) (4.00 g, 12.09 mmol). The reaction was stirred at 70 °C 
for 18 h then further sodium hydride (725 mg of a 60 % dispersion in mineral oil, 18.14 
mmol) added and stirring continued for 24 h at 70 °C. Water (200 mL) was added slowly 
and the solution extracted with ethyl acetate (60 mL then 3 x 30 mL). The combined 
extracts were washed with brine and dried with MgSC>4 before evaporation to leave an 
orange oil. The crude material was purified by column chromatography (30 % ethyl acetate- 
petroleum ether (40 - 60) increasing to 100 % ethyl acetate) to give a pale yellow oil (2.51
CH2C //3); 13C-NMR (CDCI3, 75 MHz) 6  172.50 (COOEt), 170.40 (COO'Bu), 81.12 
(C(CH3)3), 60.33 (CH2CH3), 53.81 (4-piperidyl), 53.66 (CH2CH2COOEt), 50.20 (2 , 6 - 
piperidyl), 32.44 (CH2COO), 30.71 (3, 5-piperidyl), 14.20 (CH2CH3). LRMS (El) m/z 385 
(M+, 13 %), 298 (93 %), 228 ( 8 6  %), 186 ( 6 8  %), 96 (100 %). HRMS calcd for C2oH35N0 6 
385.24643. Found: 385.24581.
o
g, 54 %); IR (cm'1) 2978, 1730, 1257, 1168, 850. 'H-NMR (CDC13, 300 MHz) 5 4.09 (2H, 
q, 7=7.1 Hz, C //2 C H 3 ) ,  2.61 (2H, t, 7=7.4 Hz, CH2CH 2C O O ) ,  2.42 (6 H, m, 3, 5-piperidyl, 
C H 2C O O ) ,  1.99 (4H, 2 , 6 -piperidyl), 1.40 (18H, s, C ( C H 3) 3) ,  1.21 (3H, t, 7=7.1 Hz,
l-(3-Ethoxy-3-oxopropyl)piperidine-4,4-dicarboxylic acid (171)
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Trifluoroacetic acid (5 mL) was added dropwise to a solution of di-terf-butyl l-(3-ethoxy-3- 
oxopropyl)piperidine-4,4-dicarboxylate (170) (2.23 g, 5.79 mmol) in dichloromethane (5 
mL) and the brown solution stirred for 3 d. The solvent was evaporated to leave a brown oil 
which was triturated with diethyl ether to give a white powder which was recrystallised 
from ethanol to give the product (1.57 g, 99 %) as colourless crystals which were used 
without further purification.
Ethyl 3-(4,4-bis(phenylcarbamoyl)piperidin-l-yl)propanoate hydrochloride (172)
OEt
.HCI
l-(3-Ethoxy-3-oxopropyl)piperidine-4,4-dicarboxylic acid (171) (750 mg, 2.74 mmol) in 
thionyl chloride (9 mL) was heated to 80 °C for 2 h then evaporated to give a light brown 
solid. The crude acyl chloride was dissolved in dichloromethane and cooled to 0 °C before 
dropwise addition of aniline (537 mg, 5.76 mmol). The orange suspension was stirred for 5 
min at 0 °C then pyridine (477 mg, 6.03 mmol) added dropwise. Stirring was continued at 0 
°C for 3 h then the solvent removed in vacuo. The orange solid was washed with 0.5 M 
H2SO4 (20 mL) and water (10 mL) then dried. The pale orange solid was recrystallised from 
ethanol to give the product (637 mg, 51 %) as white crystals, mp 231-233 °C; IR (cm'1) 
3224, 2549, 1736, 1668, 1528, 1191. ‘H-NMR ((CD3)2SO, 500 MHz) 8  10.73 (1H, brs, 
NH), 10.03 (1H, s, NH), 9.72 (1H, s, NH), 7.69 (4H, brs, 2, 6 -aryl), 7.29 (4H, t, > 7 .5  Hz, 3,
5-aryl), 7.08 (2H, t, > 7 .1  Hz, 4-aryl), 4.09 (2H, q, > 7 .1  Hz, C tf2CH3), 3.55 (2H, d, > 7 .3  
Hz, 2, 6 ax-piperidyl), 3.31 (2H, t, > 7 .5  Hz, N C //2CH2COO), 3.03 (4H, m, 3, 5ax-piperidyl, 
2, 6 eq-piperidyl), 2.92 (2H, t, > 7 .7  Hz, CH2COO), 2.25 (2H, brs, 3, 5eq-piperidyl), 1.19 
(3H, t, > 7 .1  Hz, CH3); l3C-NMR ((CD3)2SO, 75 MHz) 8  169.95 (COO), 168.04 (CONH),
167.03 (CONH), 138.40 (1-aryl), 128.38 (3, 5-aryl), 124.08 (4-aryl), 121.06 (2, 6 -aryl), 
120.78 (2, 6 -aryl), 60.54 (CH2CH3), 52.76 (4-piperidyl), 50.56 (NCH2), 49.17 (2, 6 - 
piperidyl), 28.49 (CH2COO), 27.61 (3, 5-piperidyl), 13.93 (CH3). LRMS (Cl) m/z 424
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(M+H, 100 %), 287 ( 6  %). Anal.Calcd for C24H29N3O4 .HCI C, 62.67; H, 6.57; N, 9.14. 
Found: C, 62.49; H, 6.52; N, 8.87.
Ethyl 7-(l//-benzo[</]imidazol-2-yl)heptanoate (176)
Q ^n
N
H
O
A solution of oxonane-2,9-dione (157) (3.0 g, 19.21 mmol) in tetrahydrofuran (15 mL) was 
added dropwise to a solution of 1,2-phenylenediamine (2.08 g, 19.21 mmol) in 
tetrahydrofuran (30 mL) and the brown solution stirred for 45 min. The solvent was 
removed in vacuo and the crude product dissolved in a 4 % solution o f concentrated sulfuric 
acid in ethanol (190 mL). The orange solution was heated to 90 °C for 16 h then quenched 
with saturated aqueous sodium hydrogen carbonate solution and evaporated. Water (20 mL) 
was added and the mixture extracted with ethyl acetate (3 x 20 mL). The combined extracts 
were dried (MgS0 4 ) and evaporated to leave a brown oil which was purified by column 
chromatography (20 % ethyl acetate-petroleum ether (40 - 60)) to give an off-white solid. 
Recrystallisation from diethyl ether gave the title compound (1.52 g, 29 %) as white 
needles, mp 95-97 °C; IR (cm 1) 2934, 1720, 1175, 1026, 747. *H-NMR ( C D C I3 ,  300 MHz) 
5 10.78 ( 1H, brs, NH), 7.54 (2H, dd, 7= 3.2, 6.0 Hz, 4, 7-benzimidazolyl), 7.20 (2H, dd, 
7=3.2, 6.0 Hz, 5, 6 -benzimidazolyl), 4.10 (2H, q, 7=7.1 Hz, C //2CH3J, 2.93 (2H, t, 7=7.6 Hz, 
NCCH2), 2.21 (2H, t, 7=7.4 Hz, CH2COO), 1.84 (2H, m, C //2CH2COO), 1.54 (2H, m, 
NCCH2C //2), 1.39-1.19 (7H, m, NCCH2CH2Ctf2, C77>CH2CH2COO, CH3); l3C-NMR 
(C D C I3 ,  75 MHz) 5 173.96 (COO), 155.49 (2-benzimidazolyl), 138.64 (4, 9- 
benzimidazolyl), 122.03 (6 , 7-benzimidazolyl), 114.60 (5, 8 -benzimidazolyI), 60.31 
(CH2CH3), 34.17 (CH2COO), 29.18 (NCCH2), 28.84 (NCCH2CH2), 28.63
(CH2CH2CH2COO), 28.13 (NCCH2CH2CH2), 24.70 (CH2CH2COO), 14.23 (CH3). LRMS 
(Cl) m/z 275 (M+H, 100 %), 229 ( 6  %), 187 (4 %). Anal. Calcd for C ,6H22N20 2 C, 70.04; 
H, 8.08; N, 10.21. Found C, 69.87; H, 8.07; N, 10.12.
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7-(l/f-Benzo[</|iinidazol-2-yl)-J/V-hydroxyheptanamide (151)
o
To a solution of ethyl 7-(l//-benzo[d]imidazol-2-yl)heptanoate (176) (1.20 g, 4.37 mmol) in 
tetrahydrofuran (40 mL) was added hydroxylamine (2.89 mL of a 50 % aqueous solution, 
43.74 mmol) followed by slow addition o f a 1 M methanolic solution of potassium 
hydroxide (6.56 mL). The solution was stirred for 2 h at room temperature then evaporated 
to leave a yellow residue. Water (60 mL) was added and the solution acidified with 2 M 
HC1 to give a white precipitate which was collected by filtration. The product was washed 
with water, methanol and diethyl ether to give the title compound (696 mg, 61 %) as a white 
solid, mp 226-227 °C; IR (cm'1) 3284, 2930, 2324, 1642, 1443, 1275, 727. ]H-NMR 
((CD3)2SO, 300 MHz) 6 10.33 (1H, s, NH), 8.67 (1H, s, NH), 7.34 (2H, m, 8, 5- 
benzimidazolyl), 7.09 (2H, m, 6, 7-benzimidazolyl), 2.77 (2H, t, .7=7.5 Hz, NNCCH2), 1.92 
(2H, t, .7=7.3 Hz, CH2CO), 1.74 (2H, m, NNCCH2C772), 1.48 (2H, m, C/72CH2CO), 1.29 
(4H, m, C //2CH2CH2CH2CO, CH2CH2CH2CO); 13C-NMR ((CD3)2SO, 75 MHz) 5 174.24 
(CO), 160.23 (2-benzimidazolyl), 148.39 (9-benzimidazolyl), 139.37 (4-benzimidazolyl),
126.42 (7-benzimidazolyl), 125.86 (6-benzimidazolyl), 123.11 (8-benzimidazolyl), 115.77 
(5-benzimidazolyl), 37.33 (NNCCH2), 33.55 (CH2CO), 33.47 (NNCCH2CH2), 33.37 
(CH2CH2CH2CO), 32.54 (CH2CH2CH2CH2CO), 30.10 (CH2CH2CO). LRMS (Cl) m/z 262 
(M+H, 100 %), 242 (57 %), 201 (9 %). Anal. Calcd for C ,4H 19N 3 0 2 C, 64.35; H, 7.33; N, 
16.08. Found C, 64.36; H, 7.51; N, 15.89.
3-terf-Butoxy-3-oxopropanoic acid (178)13
o
o o
A solution of dicyclohexycarbodiimide (32.72 g, 158.6 mmol) in acetonitrile (150 mL) was 
added to a solution of malonic acid (15.0 g, 144.2 mmol) and tert-butyl alcohol (21.37 g,
288.3 mmol) in acetonitrile (380 mL). The resultant white suspension was stirred for 2 h at
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room temperature then filtered and evaporated. The colourless oil was dissolved in diethyl 
ether (75 mL) and extracted with saturated aqueous sodium hydrogen carbonate solution (4 
x 50 mL). The combined aqueous phases were acidified with 2 M HC1 and extracted with 
ethyl acetate (4 x 50 mL). The combined organics were dried (M gS04) and evaporated to 
give the pure title compound (20.05 g, 87 %) as a colourless oil; IR (cm'1) 2937, 1732, 
1371, 1150, 837. *H-NMR (CDC13, 300 MHz) 5 11.02 (1H, brs, COOH), 3.31 (2H, s, CH2), 
1.44 (9H, s, (CH3)3); ,3C-NMR (CDC13, 75 MHz) 5 172.02 (COOH), 166.22 (COOBu'),
82.88 (C(CH3)3), 42.01 (CH2), 27.84 ((CH3)3). LRMS (Cl) m/z 161 (M+H, 47 %), 145 (14 
%), 133 (46 %), 115 (33 %), 105 (100 %).
tert-Butyl 3-oxo-3-(phenylamino)propanoate (179)
Method 1
A solution of 3-ter/-butoxy-3-oxopropanoic acid (178) (2.05 g, 12.80 mmol), EDCI.HC1 
(2.70 g, 14.08 mmol), HOBt (1.90 g, 14.08 mmol), triethylamine (2.85 g, 28.16 mmol) and 
aniline (1.19 g, 12.80 mmol) in DMF (60 mL) was stirred for 3 h at room temperature. The 
yellow solution was evaporated and the residue suspended in 2 M HC1 (50 mL) and 
extracted with ethyl acetate (3 x 1 5  mL). The combined extracts were washed with saturated 
aqueous sodium hydrogen carbonate solution (20 mL) and brine (20 mL) before drying over 
MgS04. The solvent was removed in vacuo to leave the pure title compound (2.03 g, 63 %) 
as a peach-coloured solid.
Method 2
A solution of DCC (25.17 g, 122 mmol) in MeCN (180 mL) was added to a solution of 3- 
ter/-butoxy-3-oxopropanoic acid (178) (17.86 g, 111 mmol) and aniline (11.40 g, 122 
mmol) in MeCN (450 mL). The solution was stirred for 3 h then filtered and the filtrate 
evaporated. The pale pink oil was dissolved in ethyl acetate (100 mL) and washed with 2 M 
HC1 (2 x 30 mL) and saturated aqueous sodium hydrogen carbonate solution (30 mL) and
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brine (30 mL). The organic phase was dried (MgS0 4 ) and evaporated to leave a pale peach- 
coloured solid which was purified by column chromatography (30 % ethyl acetate- 
petroleum ether (40 - 60)) to give the title compound (21.51 g, 77 %) as a white, crystalline 
solid.
Method 3
Oxalyl chloride (11.72 g, 92.34 mmol) was added slowly to a solution of 3-fer/-butoxy-3- 
oxopropanoic acid (178) (4.93 g, 30.78 mmol) in DCM (300 mL) followed by DMF (10 
drops). The reaction was warmed to 40 °C for 2 h then evaporated. The red oil was 
dissolved in DCM (300 mL) and aniline (3.09 g, 33.86 mmol) added to give a precipitate. 
DMAP (4.14 g, 33.86 mmol) was added and the resultant solution stirred for 2 h at room 
temperature. The solvent was evaporated and the residue dissolved in ethyl acetate (50 mL). 
The organic phase was washed with 2 M HC1 (2 x 30 mL) and saturated aqueous sodium 
hydrogen carbonate solution (30 mL), then dried (MgSO-O. The solvent was evaporated to 
leave a red oil which was purified by column chromatography (30 % ethyl acetate- 
petroleum ether (40 - 60)) to give the title compound (6.92 g, 89 %) as a white, crystalline 
solid, mp 72-74 °C; IR (cm'1) 3308, 3267, 1721, 1556, 1146, 860. ’H-NMR (CDC13, 300 
MHz) 5 9.35 (1H, s, NH), 7.55 (2H, dd, 7=0.9, 8.5 Hz, 2, 6 -aryl), 7.29 (2H, t, 7=7.9 Hz, 3,
5-aryl), 7.08 ( 1H, t, 7=7.4 Hz, 4-aryl), 3.36 (2H, s, CH2), 1.48 (9H, s, C(CH3)3); ,3C-NMR 
(CDC13, 75 MHz) 5 168.89 (COOBu'), 163.83 (CONH), 137.70 (1-aryl), 128.93 (3, 5-aryl),
124.42 (4-aryl), 120.12 (2, 6 -aryl), 82.90 (C(CH3)3), 42.87 (CH2), 28.00 ((CH3)3). LRMS 
(El) m/z 235 (M+, 41 %), 179 (81 %), 162 (17 %), 119(19 %), 93 (100 %). Anal. Calcd for 
C 13H17N 0 3 C, 66.36; H, 7.28; N, 5.95. Found C, 66.35; H, 7.34; N, 5.98.
1-terf-Butyl 8 -ethyl 2-(phenylcarbamoyl)octanedioate (180)
Sodium hydride (773 mg of a 60 % dispersion in oil, 19.33 mmol) was added slowly to a 
solution of ter/-butyl 3-oxo-3-(phenylamino)propanoate (179) (4.45 g, 17.57 mmol) in dry
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tetrahydrofuran (175 mL) at 0 °C. After stirring for 20 min at room temperature, ethyl 6 - 
bromohexanoate (3.92 g, 17.57 mmol) was added and the reaction heated to 70 °C for 18 h. 
The white suspension was allowed to cool to room temperature and the solvent removed in 
vacuo. The residue was taken up in ethyl acetate (50 mL) and washed with 2 M HC1 (2 x 20 
mL) and brine (20 mL) before drying over MgSd*. The crude product was purified by 
column chromatography (10 % ethyl acetate-petroleum ether (40 -  60)) to give the title 
compound (4.94 g, 74 %) as a crystalline, pale yellow solid, mp 65-66 °C; IR (cm 1) 3307,
(4H, m, C //2CH2CH2COO, CHCH2C//2), 1.24 (3H, t, 7=7.1 Hz, CH2C //3); 13C-NMR 
(CDCI3, 75 MHz) 5 173.62 (COOEt), 171.95 (CONH), 166.96 (COOBu'), 137.76 (1-aryl).
128.96 (3, 5-aryl), 124.33 (4-aryl), 119.89 (2, 6 -aryl), 82.68 (C(CH3)3), 60.22 (CH2CH3), 
54.40 (CH), 34.16 (CH2COO), 31.45 (CHCH2), 28.64 (CH2CH2CH2CHOO), 27.99 (CH3)3), 
26.86 (CHCH2CH2), 24.63 (CH2CH2COO), 14.24 (CH2CH3). LRMS (El) m/z ' i l l  (M+, 13 
%), 322 (12 %), 258 (11 %), 179 (53 %), 161 (37 %), 93 (100 %). Anal. Calcd for 
C21H 31NO5 C, 66.82; H, 8.28; N, 3.71. Found C, 66.72; H, 8.32; N, 3.69.
tert-Butyl 8 -(hydroxyamino)-8 -oxo-2 -(phenylcarbam oyl)octanoate (181)
To a solution of \-tert-buXy\ 8 -ethyl 2-(phenylcarbamoyl)octanedioate (180) (300 mg, 0.79 
mmol) in tetrahydrofuran ( 8  mL) was added hydroxylamine (0.53 mL of a 50 % aqueous 
solution, 7.95 mmol) and 1 M KOH/methanol (2.37 mL, 2.37 mmol) dropwise. The solution 
was stirred for 1 h at room temperature then acidified with 2 M HC1. The solvent was 
evaporated to approximately 5 mL in volume and water (20 mL) added. The aqueous 
solution was extracted with ethyl acetate ( 4 x 1 5  mL) and the combined yellow extracts 
dried over Na2S0 4 . The solvent was removed in vacuo to leave a yellow oil which was
2944, 1726, 1656, 1554, 1154, 758. ]H-NMR (CDC13, 300 MHz) 5 8.75 (1H, s, NH), 7.54 
(2H, d, 7=8.3 Hz, 2, 6 -aryl), 7.32 (2H, t, 7=7.9 Hz, 3, 5-aryl), 7.10 (1H, t, 7=7.4 Hz, 4-aryl),
4.11 (2H, q, 7=7.1 Hz, CH2CH3), 3.24 (1H, t, 7=7.3 Hz, CH), 2.28 (2H, t, 7=7.4 Hz, 
CH2COO), 1.95 (2H, m, CHC//2), 1.62 (2H, m, CH2CU2COO), 1.49 (9H, s, (CH3)3), 1.38
NHOH
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purified by column chromatography (ethyl acetate) to give the title compound (84 mg, 29 
%) as a yellow oil; *H-NMR (CDC13, 300 MHz) 5 9.02 (1H, s, NH), 7.52 (2H, d, 7=7.7 Hz, 
2, 6 -aryl), 7.26 (2H, t, J= l.l  Hz, 3, 5-aryl), 7.06 (1H, t, 7=7.3 Hz, 4-aryl), 3.27 (t, 7=7.0 Hz, 
CH), 2.08 (2H, m, C //2CONHOH), 1.86 (2H, m, CHCH2), 1.54 (C //2CH2CONHOH), 1.44 
(9H, s, C(CH3)3), 1.28 (4H, m, CHCH2C//2, CHCH2CH2C//2); ,3C-NMR (CDC13, 75 MHz) 
5 171.65 (COOC(CH3)3), 171.32 (CONHOH), 167.82 (CONHPh), 137.67 (1-aryl), 128.94 
(3, 5-aryl), 124.57 (4-aryl), 120.28 (2, 6 -aryl), 82.68 (C(CH3)3), 54.20 (CH), 32.52 
(CH2CONHOH), 30.51 (CHCH2), 28.27 (CHCH2CH2CH2), 27.97 (C(CH3)3), 26.59 
(CH2CH2CONHOH), 25.02 (CHCH2CH2). LRMS (Cl) m/z 387 (M+Na, 100 %), 365 (M+H, 
45 %), 328 (22 %), 309 (35 %). HRMS calcd for C i9H28N20 5 (M+H) 365.20710. Found: 
365.20792.
8-(Hydroxyamino)-8-oxo-2-(phenylcarbamoyl)octanoic acid (149)
o
HO O
To a solution of ter/-butyl 8-(hydroxyamino)-8-oxo-2-(phenylcarbamoyl)octanoate (181) 
(170 mg, 0.47 mmol) in DCM (2 mL) was added trifluoroacetic acid (2 mL) and the 
resultant solution stirred for 30 min. The solvent was evaporated to leave a pale yellow solid 
which was washed with cold diethyl ether and DCM to leave the pure title compound (116 
mg, 80 %) as a white solid, mp 150-152 °C; IR (cm'1) 2931, 2856, 1733, 1597, 1547, 1172. 
*H-NMR (CD3OD, 300 MHz) 5 7.55 (2H, d, 7=7.6 Hz, 2, 6 -aryl), 7.30 (2H, t, 7=7.3 Hz, 3,
5-aryl), 7.09 (1H, t, 7=7.1 Hz, 4-aryl), 3.44 (1H, t, 7=7.1* Hz, CH), 2.07 (2H, t, 7=6.8 Hz, 
C //2CONH), 1.92 (2H, m, CHCH2), 1.61 (2H, m, C/72CH2CONH), 1.38 (4H, m, 
CHCH2CH2, CHCH2CH2C //2); 13C-NMR (CD3OD, 75 MHz) 5 173.39 (COOH), 172.95 
(CONHPh), 170.37 (CONHOH), 139.58 (1-aryl), 129.85 (3, 5-aryl), 125.53 (4-aryl), 121.40 
(2, 6 -aryl), 54.43 (CH), 33.66 (CH2CONH), 30.17 (CHCH2), 29.88 (CHCH2CH2CH2), 
28.11 (CH2CH2CONH), 26.53 (CHCH2CH2). LRMS (Cl) m/z 331 (M+Na, 100 %), 309 
(M+H, 83 %). Anal. Calcd for C ,5H2oN20 5 C, 58.43; H, 6.54; N, 9.09. Found C, 58.16; H, 
6.51;N, 8.75.
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8-Ethoxy-8-oxo-2-(phenylcarbamoyl)octanoic acid (182)
Trifluoroacetic acid (9 mL) was added to a solution o f l-ter/-butyl-8-ethyl-2- 
(phenylcarbamoyl)octanedioate (180) (1.33 g, 3.52 mmol) in DCM (9 mL) and the solution 
stirred for 6  h. The solvent was removed in vacuo and the residue washed with a 1:1 
solution of petroleum ether (40 - 60)-diethyl ether to give the title compound (0.91 g, 80 %) 
as a white powder, mp 108-110 °C; IR (cm'1) 3426, 3340, 2933, 1730, 1600, 1174. *H-NMR 
(CDC13, 300 MHz) 5 10.17 (1H, brs, OH), 9.05 (1H, s, NH), 7.50 (2H, d, 7=7.8 Hz, 2, 6 - 
aryl), 7.30 (2H, t, 7=7.7 Hz, 3, 5-aryl), 7.14 (1H, t, 7=7.3 Hz, 4-aryl), 4.12 (2H, q, 7=7.1 Hz, 
C //2CH3), 3.47 (1H, t, 7=6.2 Hz, CH), 2.29 (2H, t, 7=7.3 Hz, CH2COO), 1.99 (2H, m, 
CHC//2), 1-59 (2H, m, C //2CH2COO), 1.36 (4H, m, C //2CH2CH2COO, CHCH2C //2), 1.24 
(3H, t, 7=7.1 Hz, CH3); ,3C-NMR (CDC13, 75 MHz) 6  175.11 (COOH), 174.56 (COOEt), 
169.13 (CONH), 136.72 (1-aryl), 129.07 (3, 5-aryl), 125.47 (4-aryl), 120.84 (2, 6 -aryl),
60.94 (CH2CH3), 52.18 (CH), 34.14 (CH2COO), 31.06 (CHCH2), 28.32
(CH2CH2CH2COO), 26.50 (CHCH2CH2), 24.37 (CH2CH2COO), 14.08 (CH3). LRMS (El) 
m/z 321 (M+, 8  %), 277 (43 %), 232 (54 %), 179 (36 %), 135 (97 %), 93 (100 %). Anal. 
Calcd for C17H23NO5 + V5H2O C, 62.83; H, 7.26; N, 4.31. Found C, 63.08; H, 7.18; N, 3.92.
Ethyl 7-(hydroxymethyl)-8-oxo-8-(phenylamino)octanoate (183)
H II
S  O
HO
To a solution of 8-ethoxy-8-oxo-2-(phenylcarbamoyl)octanoic acid (182) (300 mg, 0.94 
mmol) in dry tetrahydrofuran (3 mL) at 0 °C was added triethylamine (114 mg, 1.13 mmol) 
and ethyl chloroformate (152 mg, 1.40 mmol). The reaction was stirred at 0 °C for 30 min 
then filtered. The solid was washed with tetrahydrofuran ( 2 x 3  mL) and the combined 
filtrate cooled to 10 °C. Sodium borohydride (107 mg, 2.82 mmol) was added in one 
portion, followed by dropwise addition of methanol (0.6 mL) over a period of 1 h. After 
stirring for a further 30 min the reaction was quenched by dropwise addition of 2 M HC1
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and extracted with DCM (10 mL). The organics were dried (MgSC^) and evaporated, the 
crude product being purified by column chromatography (60 % ethyl acetate-petroleum 
ether (40 - 60)) to give the title compound (222 mg, 77 %) as a crystalline white solid, mp 
132-134 °C; IR (cm'1) 2935, 2669, 1684, 1408, 1250, 1188, 923. 'H-NMR (CDC13, 300 
MHz) 5 8.73 (1H, s, NH), 7.53 (2H, d, J=7.7 Hz, 2, 6 -aryl), 7.23 (2H, t, J=1.9 Hz, 3, 5-aryl), 
7.04 (1H, t, J= 7.4 Hz, 4-aryl), 4.08 (2H, q, 7=7.1 Hz, CH2CH3), 3.95 (1H, brs, OH), 3.73 
(1H, t, 7=9.0 Hz, C //2OH), 3.62 (1H, m, CH2OH), 2.45 (1H, m, CH), 2.22 (2H, t, 7=7.4 Hz, 
CH2COO), 1.56 (3H, CHCH//, C //2CH2COO), 1.30 (8 H, m, CHCH//, CH2CH2CH2COO, 
CHCH2C//2, C //3); ,3C-NMR (CDC13, 75 MHz) 5 174.13 (COOEt), 174.05 (CONH),
138.09 (1-aryl), 128.84 (3, 5-aryl), 124.24 (4-aryl), 120.20 (2, 6 -aryl), 63.51 (CH2OH), 
60.35 (CH2CH3), 49.71 (CH), 34.18 (CH2COO), 28.95 (CH2CH2CH2COO), 28.74 
(CHCH2), 26.88 (CHCH2CH2), 24.61 (CH2CH2COO), 14.21 (CH3). LRMS (Cl) m/z 308 
(M+H, 100 %), 262 (53 %), 197 (63 %), 169 (51 %). Anal. Calcd for C ,7H25N0 4  C, 66.43; 
H, 8.20; N, 4.56. Found C, 66.49; H, 8.34; N, 4.65.
A^-hydroxy^-fhydroxymethylJ-A^-phenyloctanediamide (150)
To a solution of ethyl 7-(hydroxymethyl)-8-oxo-8-(phenylamino)octanoate (183) (600 mg, 
1.95 mmol) in tetrahydrofuran (20 mL) was added hydroxylamine (0.64 mL of a 50 % 
aqueous solution, 9.76 mmol) and 1 M methanolic potassium hydroxide solution (3.9 mL,
3.9 mmol) and the resultant solution stirred for 1.5 h. The yellow solution was evaporated 
and 0.5 M HC1 (10 mL) added. The title compound (70 mg, 12 %) crystallised from the 
aqueous solution as an off-white solid, mp 150-151 °C; IR (c m 1) 3398, 3291, 3185, 2920, 
1626, 1543, 1446, 968. 'H-NMR ((CD3)2SO, 300 MHz) 6  10.30 (1H, s, NH), 9.83 (1H, s, 
NHOtf), 8.62 (NH), 7.62 (2H, d, 7=7.8 Hz, 2, 6 -aryl), 7.27 (2H, t, 7=7.9 Hz, 3, 5-aryl), 7.00 
(1H, t, 7=7.4 Hz, 4-aryl), 4.71 (1H, t, 7=5.0 Hz, OH), 3.58 (1H, m, C7/HOH), 3.45 (1H, td, 
7=5.1, 10.2 Hz, CH//OH), 2.50 (1H, m, CH), 1.90 (2H, t, 7=7.3 Hz, C f/2CONH), 1.42 (4H, 
m, C //2CH2CONH, CHC//2), 1.24 (4H, m, CHCH2CH2C //2, CHCH2C //2); n C-NMR 
((CDj)2SO, 75 MHz) 8  173.02 (PhNHCO), 169.03 (CONHOH), 139.29 (1-aryl), 128.50 (3,
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5-aryl), 122.87 (4-aryl), 119.09 (2, 6 -aryl), 62.89 (CH2OH), 49.75 (CH), 32.18 
(CH2CONH), 28.67 (CHCH2CH2CH2), 28.57 (CHCH2), 26.60 (CHCH2CH2), 24.96 
(CH2CH2CONH). LRMS (Cl) m/z 317 (M+Na, 100 %), 285 (17 %), 276 (15 %), 242 (13 
%), 217(13 %). Anal.Calcd for C ,5H22N20 4 + '/5H20  C, 60.47; H, 7.46; N, 9.40. Found: C, 
60.71; H, 7.49; N, 9.39.
tert-Bnty\ 2 -aminophenylcarbamate (185)
H
A solution of di-/er/-butyl dicarbonate (10.09 g, 46.24 mol) in tetrahydrofuran (20 mL) was 
added to a solution of 1,2-phenylenediamine (5.0 g, 46.24 mmol) in tetrahydrofuran (80 
mL) and the solution stirred for 2 h. The solvent was evaporated and the crude solid purified 
by column chromatography (20 % ethyl acetate-petroleum ether (40 - 60)) to give the title 
compound (7.30 g, 76 %) as a white, crystalline solid, mp 112-116 °C; *H-NMR (CDCI3, 
300 MHz) 6  7.26 (1H, d, 7=7.6 Hz, 6 -aryl), 6.99 (1H, dt, 7=1.4, 7.7 Hz, 4-aryl), 6.76 (2H, 
m, 3, 5-aryl), 6.36 ( 1H, brs, NH), 3.74 (2H, brs, NH2), 1.51 (9H, s, C(CH3)3); 13C-NMR 
(CDC13, 75 MHz) 5 153.93 (CO), 140.01 (2-aryl), 126.13 (4, 1-aryl), 124.79 (6 -aryl), 
119.56 (5-aryl), 117.57 (3-aryl), 80.50 (a C H 3)3), 28.37 (C(CH3)3). LRMS (El) m/z 208 
(M+, 11 %), 152 (28 %), 108 (100 %).
Ethyl 8-(2-(tert-butoxycarbonylamino)phenyIamino)-8-oxo-7- 
(phenylcarbamoyl)octanoate (186)
OEt
HN
BocHN
To a solution of 8-ethoxy-8-oxo-2-(phenyIcarbamoyl)octanoic acid (182) (1.0 g, 3.11 
mmol) in DMF (30 mL) was added /er/-butyl 2-aminophenylcarbamate (648 mg, 3.11
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mmol), triethylamine (692 mg, 6.84 mmol), EDC.HC1 (657 mg, 3.42 mmol) and HOBt (462 
mg, 3.42 mmol). The solution was stirred for 18 h then the solvent evaporated and water (50 
mL) added. The solution was extracted with ethyl acetate (2 x 25 mL) and the combined 
extracts washed with water (15 mL), saturated ammonium chloride solution (15 mL) and 
saturated aqueous sodium hydrogen carbonate solution (15 mL). The organic phase was 
dried over MgSC>4 and evaporated to leave a yellow oil which was purified by column 
chromatography (33 % petroleum ether (40 - 60)-ethyl acetate) to give the title compound 
(1.05 g, 6 6  %) as a white solid, used without further purification.
Ethyl 7-(l//-benzo[7]imidazol-2-yl)-8-oxo-8-(phenylamino)octanoate (187)
From ethyl 8-(2-aminophenylamino)-8-oxo-7-(phenylcarbamoyI)octanoate:
A solution of ethyl 8-(2-aminophenylamino)-8-oxo-7-(phenylcarbamoyl)octanoate (620 mg,
1.36 mmol) in glacial acetic acid (6 .8  mL) was heated to 100 °C for 1 h. The solvent was 
evaporated and the crude product recrystallised from ethyl acetate-petroleum ether (40 - 60) 
to give the title compound (410 mg, 77 %) as a crystalline white solid, mp 211-212 °C; IR 
(cm 1) 3284, 2926, 1734, 1666, 1430, 1186, 730. 'H-NMR (CDC13, 300 MHz) 5 11.95 (1H, 
s, NH), 11.47 (1H, s, NH), 7.66 (2H, d, m, 2, 6 -aryl, 7-benzimidazolyl), 7.48 (1H, m, 6 - 
benzimidazolyl), 7.25 (4H, m, 3, 5-aryl, 5, 8 -benzimidazolyl), 7.10 (1H, t, ,7=7.4 Hz, 4-aryl), 
4.65 (1H, t, 7=7.7 Hz, CH), 4.02 (2H, q, 7=7.1 Hz, CH2CH3), 2.32 (1H, m, CHC//H), 2.15 
(1H, m, CHCH//), 1.99 (2H, t, 7=7.5 Hz, CH2COO), 1.36 (4H, m, CHCH2C7/2, 
C7/2CH2COO), 1.19 (5H, m, C //2CH2CH2COO, CH2C //3); ,3C-NMR (CDC13, 75 MHz) 5 
173.52 (COO), 170.84 (NHCO), 153.32 (2-benzimidazolyl), 142.08 (9-benzimidazolyl),
138.16 (1-aryl), 134.20 (4-benzimidazolyl), 128.99 (3, 5-aryl), 124.70 (4-aryl), 123.15 (8 - 
benzimidazolyl), 122.43 (5-benzimidazolyl), 120.41 (2, 6 -aryl), 118.34 (7-benzimidazolyl), 
111.69 (6 -benzimidazolyl), 60.12 (CH2CH3), 48.26 (CH), 33.95 (CH2COO), 33.60 
(CHCH2), 28.52 (CH2CH2CH2COO), 27.21 (CHCH2CH2), 24.54 (CH2CH2COO), 14.21
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(CH2CH3). LRMS (Cl) m/z 394 (M+H, 100 %), 293 (58 %), 274 (23 %). Anal. Calcd for 
C23H27N3O3 C, 70.21; H, 6.92; N, 10.68. Found C, 70.17; H, 7.01; N, 10.79.
From ethyl S-(2-(tert-butoxycarbonyIamino)phenylamino)-8-oxo-7-
(phenylcarbamoyl)octanoate (186):
To a solution of ethyl 8-(2-(tert-butoxycarbonylamino)phenylamino)-8-oxo-7- 
(phenylcarbamoyl)octanoate (186) (0.88 g, 1.72 mmol) in DCM (9 mL) was added 
trifluoroacetic acid (9 mL) and the solution refluxed for 2 h. The solvent was evaporated 
and the residue recrystallised from ethyl acetate-petroleum ether (40 - 60) to give the title 
compound (505 mg, 75 %).
tert-Butyl 2-(8-ethoxy-l,8-dioxo-l-(phenyIamino)octan-2-yl)-l//-benzo[</Jimidazole-l- 
carboxylate (188)
OEt
NBoc
Di-/er/-butyl dicarbonate (403 mg, 1.85 mmol) was added to a solution of ethyl 
benzo[7]imidazol-2-yl)-8-oxo-8-(phenylamino)octanoate (187) (484 mg, 1.23 mmol) in 
tetrahydrofuran (12 mL) and the colourless solution stirred for 7 d at room temperature. The 
solvent was evaporated and the product purified by column chromatography ( 2 0  % ethyl 
acetate-petroleum ether (40 - 60)) to give the starting material (220 mg, 45 %) and the title 
compound (210 mg, 35 %) as a colourless oil; IR (cm'1) 3319, 2936, 1732, 1600, 1152, 744. 
^-N M R  (CDCI3, 300 MHz) 5 9.46 (1H, s, NH), 7.89 (1H, m, 8 -benzimidazolyl), 7.77 (1H, 
m, 5-benzimidazolyl), 7.57 (2H, d, 7=8.5 Hz, 2, 6 -aryl), 7.31 (4H, m, 6 , 7-benzimidazolyl, 
3, 5-aryl), 7.04 (1H, t, .7=7.4 Hz, 4-aryl), 4.82 (1H, t, 7=7.2 Hz, CH), 4.07 (2H, q, 7=7.1 Hz, 
C //2CH3), 2.28 (4H, m, CHC772, CH2COO), 1.72 (9H, s, C(CH3)3), 1.61 (2H, m, 
C //2CH2COO), 1.43 (4H, m, CHCH2C //2, CHCH2CH2C7/2), 1.21 (3H, t, 7=7.1 Hz, 
CH2C //3); ,3C-NMR (CDCI3, 75 MHz) 6  173.65 (COOEt), 168.09 (CONH), 154.12 
(COO'Bu), 149.18 (2-benzimidazolyl), 141.71 (9-benzimidazolyl), 138.19 (1-aryl), 132.63
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(4-benzimidazolyl), 128.89 (3, 5-aryl), 124.99 (7-benzimidazolyl), 124.52 (6 -
benzimidazolyl), 124.06 (4-aryl), 119 93 (8 -benzimidazolyl), 119.75 (2, 6 -aryl), 115.18 (5- 
benzimidazolyl), 86.71 (C(CH3)3), 60.15 (CH2CH3), 48.13 (CH), 34.21 (CH2COO), 33.48 
(CHCH2), 28.86 (CHCH2CH2CH2), 28.08 (C(CH3)3), 26.99 (CHCH2CH2), 24.69 
(CH2CH2COO), 14.25 (CH2CH3). LRMS (Cl) m/z 516 (M+Na, 49 %), 494 (M+H, 92 %), 
394 (28 %), 335 (100 %), 276 (19 %). HRMS (M+H) calcd for C28H35N 30 5 494.26550. 
Found: 494.26504.
2-(lFf-Benzo[finimidazol-2-yl)-A^-hydroxy-V-phenyloctanediamide (152)
NHOH
NH
To a solution of tert- butyl 2-(8-ethoxy-l,8-dioxo-l -(phenyl amino)octan-2-yl)-IH- 
benzo[J]imidazole-l-carboxylate (188) (210 mg, 0.43 mmol) in tetrahydrofuran (4 mL) was 
added hydroxylamine (0.28 mL of a 50 % aqueous solution, 4.25 mmol) followed by 
dropwise addition of 1 M methanolic KOH (1.29 mL). The pale yellow solution was stirred 
for 6  h the evaporated. Water (10 mL) was added followed by saturated aqueous ammonium 
chloride solution (10 mL) and the white precipitate collected by filtration. The crude 
product was recrystallised from ethanol to give the title compound (81 mg, 50 %) as a 
crystalline white solid, mp 184-185 °C; IR (cm'1) 3261, 3093, 2924, 1637, 1437, 1133. *H- 
NMR (CD3OD, 300 MHz) 8  7.58 (4H, m, 2, 6 -aryl, 5, 8 -benzimidazolyl), 7.27 (2H, t, J=7.7 
Hz, 3, 5-aryl), 7.19 (2H, m, 6 , 7-benzimidazolyl), 7.06 (1H, t, <7=7.3 Hz, 4-aryl), 4.09 (1H, 
m, CH), 2.13 (4H, m, CHGH2, C //2CONH), 1.58 (2H, m, C //2CH2CONH), 1.37 (4H, m, 
CHCH2GH2, CHCH2CH2C //2); l3C-NMR ((CD3)2SO, 125 MHz) 5 169.29 (PhNHCO), 
169.25 (CONHOH), 152.66 (2-benzimidazolyl), 142.65 (benzimidazolyl), 138.92 (1-aryl), 
134.60 (benzimidazolyl), 128.74 (3, 5-aryl), 123.51 (4-aryl), 121.80 (benzimidazolyl), 
121.01 (benzimidazolyl), 119.28 (benzimidazolyl), 118.33 (benzimidazolyl), 111.25 
(benzimidazolyl), 47.79 (CH), 32.22 (CH2CONHOH), 31.14 (CHCH2), 28.36
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(CHCH2CH2CH2), 26.79 (CHCH2CH2), 24.95 (CH2CH2CONHOH). Anal. Calcd for 
C21H24N4O3 + V3H2O C, 65.27; H, 6.43; N, 14.50. Found C, 65.18; H, 6.36; N, 14.13.
tert-Butyl 3-(2-aminophenylamino)-3-oxopropanoate (189)
NH-
O
To a solution o f 3-fer£-butoxy-3-oxopropanoic acid (178) (200 mg, 1.25 mmol) and 1,2- 
phenylenediamine (135 mg, 1.25 mmol) in acetonitrile (5 mL) was added a solution of D C C  
(283 mg, 1.37 mmol) in acetonitrile (2 mL) and the reaction stirred for 20 min. The white 
suspension was filtered and evaporated to leave a pale yellow/brown oil which was purified 
by column chromatography (ethyl acetate-petroleum ether (40 - 60), 1:1) followed by 
recrystallisation from ethyl acetate-petroleum ether (40 - 60) to give the title compound 
(155 mg, 50 %) as a white, crystalline solid, mp 122-123 °C; IR (cm '1) 3428, 3318, 1718, 
1655, 1353, 750. ‘H-NMR (CDC13, 300 MHz) 6  8.89 (1H, s, NH), 7.26 (1H, m, 3 -aryl), 7.05 
(1H, m, 5-aryl), 6.78 (2H, m, 4, 6 -aryl), 3.59 (2H, brs, NH2), 3.40 (2 H, s, CH2), 1.50 (9H, s, 
(CH3)3); 13C-NMR (C D C I3 ,  75 MHz) 6  169.08 (COOBu'), 164.18 (CONH), 140.59 (2-aryl),
127.17 (4-aryl), 125.26 (6 -aryl), 123.75 (1-aryl), 119.26 (5-aryl), 117.69 (3-aryl), 83.07 
(C(CH3)3), 42.40 (CH2), 28.03 ((CH3)3). Anal. Calcd for C 13H ,8N20 3 C, 62.38; H, 7.25; N,
11.19. Found C, 62.29; H, 7.28; N, 11.13.
terf-Butyl 2-(l//-benzo{</jimidazoI-2-yl)acetate (190)
o
tert-Butyl 3-(2-aminophenylamino)-3-oxopropanoate (189) (70 mg, 0.28 mmol) was 
dissolved in acetic acid (0.15 mL) and the solution heated to 90 °C for 1 h. The solvent was 
removed in vacuo and the crude product recrystallised from ethyl acetate-petroleum ether
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(40 - 60) to give the title compound (62 mg, 96 %) as a white, crystalline solid, mp 158-161 
°C; IR (cm'1) 2984, 1722, 1435, 1270, 1156, 755. 1H-NMR (CDC13, 300 MHz) 5 10.01 (1H, 
brs, NH), 7.56 (2H, dd, J— 3.2, 6.0 Hz, 4, 7-benzimidazolyl), 7.22 (2H, dd, J= 3.2, 6.0 Hz, 5,
6 -benzimidazolyl), 3.99 (2H, s, CH2), 1.46 (9H, s, (CH3)3); ,3C-NMR (CDC13, 75 MHz) 5 
168.99 (COOBuf), 147.79 (2-benzimidazolyl), 138.27 (4, 9-benzimidazolyl), 122.45 (6 , 7- 
benzimidazolyl), 114.98 (5, 8 -benzimidazolyl), 82.69 (C(CH3)3), 35.65 (CH2), 28.01 
((CH3)3). Anal. Calcd for C 13H,6N20 2 C, 67.22; H, 6.49; N, 12.06. Found C, 67.10; H, 6.97; 
N, 11.97.
ferf-Butyl 2-(2-tert-butoxy-2-oxoethyl)-l//-benzo[*/limidazoIe-l-carboxylate (191)
o
To a solution of /erf-butyl 2-(l//-benzo[d]imidazol-2-yl)acetate (190) (3.37 g, 14.52 mmol) 
in tetrahydrofuran (33 mL) was added di-/er/-butyl dicarbonate (3.80 g, 17.43 mmol) and 
the solution stirred for 3 d at room temperature. The solvent was evaporated and the product 
subjected to column chromatography (20 % ethyl acetate-petroleum ether (40 - 60)) to give 
the title compound (4.68 g, 97 %) as a viscous, colourless oil which solidified on standing to 
a white solid, mp 82-83 °C; IR (cm'1) 2979, 1750, 1729, 1361, 1258, 1127. 1H-NMR 
(CDCI3, 300 MHz) 5 7.87 (1H, m, 7-benzimidazolyl), 7.67 ( IH, m, 4-benzimidazolyI), 7.30 
(2 H, m, 5, 6 -benzimidazolyl), 4.19 (2H, s, CH2), 1.68 (9 H, s, (CH3)3), 1.43 (9 H, s, (CH3)3); 
13C-NMR (CDC13, 300 MHz) 5 167.87 (NCOO), 149.67 (CH2COO), 148.91 (2- 
benzimidazolyl), 142.07 (4-benzimidazolyl), 132.90 (9-benzimidazolyl), 124.63 (6 - 
benzimidazolyl), 124.12 (7-benzimidazolyl), 119.84 (5-benzimidazolyl), 114.93 (8 - 
benzimidazolyl), 85.66 (C(CH3)3), 81.72 (C(CH3)3), 39.10 (CH2), 28.02 ((CH3)3), 27.99 
((CH3)3). Anal. Calcd for CI8H24N20 4 C, 65.04; H, 7.28; N, 8.43. Found C, 65.02; H, 7.26; 
N, 8.30.
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1-terf-butyl 8-ethyl 2-(l-(tert-butoxycarbonyl)-l//-benzo[7]imidazol-2-yl)octanedioate 
(192)
OEt
Sodium hydride (337 mg of a 60 % dispersion in mineral oil, 14.03 mmol) was added to a 
solution of ter/-butyl 2-(2-tert-butoxy-2-oxoethyl)-l//-benzo[7]imidazole-l-carboxylate 
(191) (4.24 g, 12.76 mmol) in dry tetrahydrofuran (130 mL). The suspension was stirred for 
30 min to give a pale yellow, clear solution, then ethyl 6 -bromohexanoate (3.13 g, 14.03 
mmol) added and the solution stirred at 60 °C for 18 h. A further portion o f sodium hydride 
(337 mg, 14.03 mmol) was added to the reaction (with effervescence) and stirring continued 
at 60 °C for 4 h. The solvent was evaporated and replaced with ethyl acetate (80 mL). The 
suspension was washed with saturated aqueous ammonium chloride solution (40 mL), dried 
over MgSC>4 and evaporated to leave a brown oil. The crude product was purified by 
column chromatography (15 % ethyl acetate-petroleum ether (40 - 60)) to give the title 
compound (2.01 g, 33 %) as a yellow oil; IR (cm'1) 2978, 1731, 1453, 1333, 1152, 745. *H- 
NMR (CDCI3, 300 MHz) 6  7.83 (1H, m, 7-benzimidazolyl), 7.69 (1H, m, 4- 
benzimidazolyl), 7.26 (2H, m, 5, 6 -benzimidazolyl), 4.39 (1H, dd, .7=6.1, 8.3 Hz, CH), 4.05 
(2H, q, .7=7.1 Hz, C772CH3), 2.36-2.09 (4H, m, CHCH2, CH2COO), 1.61 (11H, m, (CH3)3, 
CH2CH2COO), 1.44 (13H, m, CHCH2CH2, CHCH2CH2C772, (CH3)3), 1.18 (3H, t, 7=7.1 Hz, 
CH2C//3); 13C-NMR (CDC13, 75 MHz) 5 173.64 (COOEt), 170.50 (CHCOOBu'), 153.50 
(NCOO), 149.07 (2-benzimidazolyl), 142.08 (4-benzimidazolyl), 132.83 (9-
benzimidazolyl), 124.44 (6 -benzimidazolyl), 123.98 (7-benzimidazolyl), 120.00 (5- 
benzimidazolyl), 114.95 (8 -benzimidazolyl), 85.53 (C(CH3)3), 81.19 (C(CH3)3), 60.05 
(CH2CH3), 48.23 (CH), 34.21, (CH2COO), 29.82 (CHCH2), 28.89 (CHCH2CH2CH2), 28.05 
((CH3)3), 27.83 ((CH3)3), 27.45 (CHCH2CH2), 24.72 (CH2CH2COO), 14.22 (CH2CH3). 
LRMS (El) m/z 497 (M+H, 34 %), 441 (33 %), 397 (57 %), 297 (100 %), 251 ( 8 6  %). 
HRMS (M+H) calcd for C26H38N206 497.26276. Found: 497.26199.
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tert-Butyl 2-(Lflr-benzo[71imidazol-2-yI)-8-(hydroxyamino)-8-oxooctanoate (153)
NHOH
To a solution of 1 -tert-bu\y\ 8 -ethyl 2-(l-(/er/-butoxycarbonyl)-177-benzo[7]imidazol-2- 
yl)octanedioate (192) (1.0 g, 2.11 mmol) in tetrahydrofuran (20 mL) was added 
hydroxylamine (1.39 mL of a 50 % aqueous solution, 21.07 mmol) followed by dropwise 
addition of 1 M methanolic potassium hydroxide (6.33 mL). The solution was stirred for 30 
min and the solvent evaporated to leave a yellow oil. Water (15 mL) was added and the 
solution neutralised with saturated aqueous ammonium hydroxide solution. On cooling, the 
product precipitated from the solution and was collected by filtration. The crude product 
was recrystallised from ethanol-water to give the title compound (508 mg, 67 %) as a white 
crystalline solid, mp 110-115 "C; IR (c m 1) 3341, 2934, 1704, 1650, 1438, 1274, 1151. 'H- 
NMR ((CD3)2SO, 300 MHz) S 12.31 (1H, brs, OH), 10.32 (1H, brs, NH), 8.65 (1H, brs, 
NH), 7.54 (1H, d, 7=7.6 Hz, 5-benzimidazolyl), 7.44 (1H, d, .7=7.0 Hz, 8 -benzimidazolyl)
7.12 (2H, m, 6 , 7-benzimidazolyl), 3.80 (1H, t, 7=7.7 Hz, CH), 1.98 (2H, m, CHC772), 1.90 
(2H, t, 7=7.3 Hz, C7/2CONH), 1.45 (2H, m, C772CH2CONH), 1.37 (9H, s, C(CH3)3), 1.24 
(4H, m, CHCH2C//2, CHCH2CH2C7/2); l3C-NMR ((CD3)2SO, 75 MHz) 5 170.18 (COO),
168.97 (CONH), 151.73 (2-benzimidazolyl), 142.80 (4-benzimidazolyl), 134.35 (9- 
benzimidazolyl), 121.78 (7-benzimidazolyl), 120.93 (6 -benzimidazolyl), 118.44 (5- 
benzimidazolyl), 111.08 (8 -benzimidazolyl), 80.81 (C(CH3)3), 46.79 (CH), 32.13 
(CH2CONH), 30.46 (CHCH2), 28.19 (CHCH2CH2CH2), 27.56 (C(CH3)3), 26.52 
(CH2CH2CONH), 24.86 (CHCH2CH2). LRMS (El) m/z 384 (M+Na, 100 %), 362 (54 %), 
329 (79 %), 306 (36 %), 176 (99 %), 154 (99 %). HRMS (M+Na) calcd for C 19H27N30 4  
384.18992. Found: 384.19056.
6 -Ethyl l,l-bis(terf-butyl) hexane-1,1,6-tricarboxylate (194)
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To a solution of di-ter/-butyl malonate (5.0 g, 23.13 mmol) in dry tetrahydrofuran 230 mL) 
was added sodium hydride (1.02 g of a 60 % dispersion in mineral oil, 25.44 mmol). After 
stirring for 20 min at room temperature, ethyl-6 -bromohexanoate (5.16 g, 23.13 mmol) was 
added and the reaction refluxed at 85 °C for 16 h. The solvent was then evaporated and 
water (50 mL) added. The aqueous phase was extracted with diethyl ether (2 x 30 mL) and 
the combined organics dried (MgSO,*) and the solvent removed in vacuo leaving a pale 
yellow oil. The crude product was purified by column chromatography (10 % ethyl acetate- 
petroleum ether (40 - 60)) to give the product (6.11 g, 74 %) as a colourless oil; IR (cm 1) 
2935, 1732, 1369, 1138, 847. *H-NMR (CDC13, 300 MHz) 6  4.04 (2H, q, 7=7.1 Hz, CH20), 
3.02 (2H, t, 7=7.6 Hz, CH2COOEt), 2.20 (2H, t, 7=7.49 Hz, CHCH2), 1.71 (2H, m, 
CH2CH2COOEt, 1.55 (2 H, m, CHCH2CH2C //2), 1.38 (18H, s, C(CH3)3), 1.26 (4H, m, 
CHCH2, CHCH2CH2% 1.17 (3H, t, 7=7.1 Hz, CH2CH3); 13C-NMR (CDC13, 75 MHz) 6  
173.51 (COOEt), 168.80 (COOC(CH3)3), 81.09 (C(CH3)3), 60.06 (CH2CH3), 53.80 (CH),
34.12 (CH2COOEt), 28.70 (CHCH2), 28.30 (CH2CH2CH2COOEt), 27.84 (C(CH3)3), 26.78 
(CHCH2CH2), 24.62 (CH2CH2COOEt), 14.16 (CH3CH2). LRMS (Cl) m/z 381 (M+H, 100 
%), 269 (25 %), 247 (75 %), 201 (13 %). HRMS (M+Na) calcd for CnHjgOe 381.22530. 
Found: 381.22599.
2-Carboxy-octanedioic acid 8-ethyl ester (195)
o
,OE\
HO Y
°
To a solution of 6 -ethyl 1,1 -bis(terJ-butyl) hexane-1,1,6-tricarboxylate (194) (6.09 g, 16.99 
mmol) in DCM (170 mL) was added trifluoroacetic acid (11.62 g, 101.9 mmol) and the 
solution stirred for 1 d. The volatile material was then removed in vacuo, leaving the acid 
(4.14 g, 99 %) as a white, crystalline solid without further purification, mp 71-73 °C; IR 
(cm-1) 2939, 2613, 1705, 1183, 916. 'H-NMR (CDC13, 300 MHz) 8  4.12 (2H, q, 7=7.1 Hz, 
C //2CH3), 3.42 (1H, t, 7=7.4 Hz, CH), 2.30 (2H, t, 7=7.4 Hz, CH.COOEt), 1.93 (2H, m, 
C //2CH2COOEt), 1.61 (2H, m, CHC7/,), 1.37 (4H, m, CHCH2CH2, CHCH2CH2C //2), 1.24 
(3H, t, 7=7.1 Hz, CH2C //3); l3C-NMR (CDC13, 75 MHz) 8  174.62 (COOH), 174.55 
(COOEt), 60.69 (CH2CH3), 51.46 (CH), 34.21 (CH2COOEt), 28.59 (CHCH2CH2CH2),
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28.46 (CHCH2), 26.82 (CHCH2CH2), 24.53 (CH2CH2COOEt), 14.16 (CH2CH3). LRMS 
(Cl) m/z 247 (M+H, 31 %), 201 (21 %), 185 (100 %), 157 (27 %). Anal.Calcd for C n H180 6 
C, 53.65; H, 7.37; N, 0.00. Found: C, 53.48; H, 7.41; N, 0.00.
6-Ethyl l,l-bis(2,4,6-trichIorophenyl) hexane-1,1,6-tricarboxylate (196)
OEt
Cl
A solution of 2-carboxy-octanedioic acid 8-ethyl ester (195) (1.34 g, 5.44 mmol) and 
trichlorophenol (2.15 g, 10.88 mmol) in phosphorusoxychloride (2.17 g, 14.4 mmol) was 
heated to 100 °C for 5 h, then water (10 mL) added. The aqueous solution was extracted 
with ethyl acetate (2 x 10 mL) and the combined extracts washed with saturated aqueous 
sodium hydrogen carbonate solution (10 mL) and brine (10 mL). The solution was dried 
(MgSCU) and the solvent removed in vacuo leaving a brown oil which was purified by 
column chromatography (5 % ethyl acetate-petroleum ether (40 - 60)) to yield a colourless 
oil (1.61 g, 49 %); IR (cm 1) 2937, 1769, 1731, 1566, 1446, 1231. 'H-NMR (CDC13, 300 
MHz) 5 7.38 (4H, m, 3, 5-aryl), 4.13 (2H, q, .7=7.1 Hz, C772CH3), 4.05 (1H, t, 7=7.4 Hz, 
COCHCO), 2.29 (4H, m, CHC772, CH2C 02Et), 1.65 (4H, m, CH2CU2CO2EX, CHCH2CH2), 
1.47 (2H, m, CHCH2CH2C //2), 1.25 (3H, t, 7=7.1 Hz, CH2C //3). 13C-NMR (CDC13, 75 
MHz) 5 173.52 (COOEt), 164.61 (COOAr), 142.44 (1-Ar), 132.56 (4-Ar), 129.53 (Ar)
128.75 (Ar), 60.30 (CH2CH3), 50.72 (CH), 34.12 (CH2COOEt), 29.24 (CHCH2), 28.62 
(CH2CH2CH2COOEt), 26.97 (CHCH2CH2), 24.60 (CH2CH2COOEt), 14.12 (CH3CH2). 
LRMS (Cl) m/z 626 (18 %), 211 (26 %), 176 (100 %). HRMS calcd for C23H20Cl6O6 
(M+Na) 624.92887, found 624.92751.
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Ethyl 6-(4-hydroxy-6-oxo-2-phenyl-l,6-dihydropyrimidin-5-yl)hexanoate (197)
OEt
HN
OH
Benzamidine (361 mg, 3.01 mmol) was added to a solution of 6 -ethyl l,l-bis(2,4,6- 
trichlorophenyl) hexane-1,1,6 -tricarboxylate (196) (1.82 g, 3.01 mmol) in DCM (10 mL) 
and the resultant solution stirred for 30 min at 40 °C. The solvent was evaporated, the 
residue washed with diethyl ether (30 mL) and filtered to give the title compound (805 mg, 
81 %) as a yellow solid, mp 272-273 °C; IR (cm'1) 2921, 2640, 1738, 1611, 1500, 1185. 1H- 
NMR ((CD3)2SO, 300 MHz) 6  11.71 (1H, brs, OH), 8.05 (2H, m, 2, 6 -aryl), 7.51 (3H, m, 3, 
4, 5-aryl), 4.02 (2H, q, J=7.1 Hz, CH2CH3), 2.29 (4H, m, CCH2, CH2COO), 1.59-1.36 (4H, 
m, CCH2CH2, CH2CH2COO), 1.28 (2H, m, CCH2CH2CH2), 1.15 (3H, t, J=7.1 Hz, 
CH2C //3); 13C-NMR ((CD3)2SO, 75 MHz) 5 172.87 (COO), 165.13 (4, 6 -pyrimidyl), 153.94 
(2-pyrimidyl), 132.11 (1-aryl), 131.33 (4-aryl), 128.49 (3, 5-aryl), 127.41 (2, 6 -aryl), 101.00 
(5-pyrimidyl), 59.55 (CH2CH3), 33.43 (CH2COO), 28.32 (CCH2CH2CH2), 27.20 
(CCH2CH2), 24.34 (CH2CH2COO), 21.96 (CCH2), 14.02 (CH2CH3). LRMS (Cl) m/z 411 
(M+Na, 100 %), 389 (M+H, 64 %), 321 (17 %), 192 (70 %). Anal.Calcd for C 18H22N20 4 + 
!/4H20 C, 64.56; H, 6.77; N, 8.37. Found: C, 64.83; H, 6.60; N, 8.24.
vV-Hydroxy-6-(4-hydroxy-6-oxo-2-phenyI-l,6-dihydropyrimidin-5-yl)hexanamide (154)
o
NHOH
HN'
OH
Benzamidine (361 mg, 3.01 mmol) was added to a solution of 6 -ethyl l,l-bis(2,4,6- 
trichlorophenyl) hexane-1,1,6 -tricarboxyl ate (197) (1.82 g, 3.01 mmol) in DCM (10 mL) 
and the resultant solution stirred for 30 min at 40 °C. The solvent was evaporated, the 
residue washed with diethyl ether (30 mL) and filtered to give the title compound (805 mg, 
81 %) as a yellow solid, mp 272-273 °C; ‘H-NMR ((CD3)2SO, 300 MHz) 8  11.71 (1H, brs, 
OH), 8.05 (2H, m, 2, 6 -aryl), 7.51 (3H, m, 3, 4, 5-aryl), 4.02 (2H, q, 7=7.1 Hz, C //2CH3), 
2.29 (4H, m, CCH2, CH2COO), 1.59-1.36 (4H, m, CCH2C //2, C //2CH2COO). 1.28 (2H, m,
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CCH2CH2C//2), 1.15 (3H, t, J=1A Hz, CH2C //3); ,3C-NMR ((CD3)2SO, 75 MHz) 5 172.87 
(COO), 165.13 (4, 6 -pyrimidyl), 153.94 (2-pyrimidyl), 132.11 (1-aryl), 131.33 (4-aryl), 
128.49 (3, 5-aryl), 127.41 (2 , 6 -aryl), 101.00 (5-pyrimidyl), 59.55 (CH2CH3), 33.43 
(CH2COO), 28.32 (CCH2CH2CH2), 27.20 (CCH2CH2), 24.34 (CH2CH2COO), 21.96 
(CCH2), 14.02 (CH2CH3). LRMS (Cl) m/z 411 (M+Na, 100 %), 389 (M+H, 64 %), 321 (17 
%), 192 (70 %). Anal.Calcd for C18H22N20 4  + ^H 20 C, 64.56; H, 6.77; N, 8.37. Found: C, 
64.83; H, 6.60; N, 8.24.
Diethyl-cyanamide (200)14
A solution of cyanogen bromide (2.0 g, 18.9mmol) in dry diethyl ether (9 mL) was added 
drop-wise to a solution o f diethylamine (2.76 g, 37.8 mmol) in dry diethyl ether (7.5 mL) at 
0 °C. The reaction was stirred for a further 30 min at 0 °C then the white precipitate 
removed by filtration and washed with diethyl ether. The combined organic phases were 
dried (MgSCU) and the solvent removed in vacuo to leave the product (1.40 g, 75 %) as a 
pale yellow oil requiring no further purification; *H-NMR (CDC13, 300 MHz) 5 2.89 (4H, 
q, J=7.2 Hz, CH2), 1.11 (6 H, t, J=7.3 Hz, CH3); 13C-NMR (CDC13, 75 MHz) 5 117.16 
(NCN), 45.77 (CH2), 12.72 (CH3). LRMS (Cl) m/z 99 (M+H, 100 %).
A^A-Diethyl-iV-phenyl-guanidine (201)
A solution of diethyl cyanamide (200) (3.37 g, 34.3 mmol) and aniline hydrochloride (4.45 
g, 34.3 mmol) in dry toluene (50 mL) was refluxed for 3 d. The solution was allowed to 
cool to room temperature and water (20 mL) added. The organic layer was separated and the 
aqueous phase extracted with diethyl ether (20 mL) before being made basic by the addition 
o f sodium hydroxide. The basic aqueous solution was extracted with diethyl ether (2 x 20 
mL). The combined organics were dried (MgSO,*) and the solvent removed in vacuo leaving 
a brown oil which was purified by column chromatography ( 1 0  % methanol-ethyl acetate, 1
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% triethylamine) to give the product as a brown oil (0.94 g, 15 %); *H-NMR (CDCI3, 300 
MHz) 8  7.23 (2H, t, 7=7.1 Hz, 2, 6 -aryl), 6.89 (3H, m, 3, 4, 5-aryl), 3.89 (1H, brs, NH), 3.35 
(4H, q, 7=7.1 Hz, C //2CH3), 1.18 (6 H, t, 7=7.1 Hz, CH2C //3); 13C-NMR (CDC13, 75 MHz) 8  
151.03 (CNH), 150.89 (1-aryl), 129.22 (3, 5-aryl), 123.52 (2, 6 -aryl), 121.35 (4-aryl), 41.82 
(CH2), 13.71 (CH3). LRMS (Cl) m/z 192 (M+H, 100 %), 175 (19 %), 119 (21 %).
Ethyl 6-(2-(diethylamino)-4-hydroxy-6-oxo-l-phenyl-l,6-dihydropyrimidin-5- 
yl)hexanoate (2 0 2 )
A mixture of 6 -ethyl l,l-bis(2,4,6-trichlorophenyl) hexane-1,1,6-tricarboxylate (196) (1.40 
g, 2.31 mmol) and A^V-diethyl-iV’-phenyl-guanidine (443 mg, 2.31 mmol) was heated to 150 
°C with stirring for 5 min. On cooling to room temperature, the viscous brown oil was 
purified by column chromatography (50 % ethyl acetate-hexane) to give the product (635 
mg, 6 8  %) as a pale yellow oil; IR (cm'1) 2935, 1730, 1595, 1524, 1243, 752. ]H-NMR 
(CDC13, 300 MHz) 8  7.36 (2H, t, 7=7.4 Hz, 3, 5-aryl), 7.28 (1H, t, 7=7.3 Hz, 4-aryl), 7.19 
(2H, d, 7=7.1 Hz, 2, 6 -aryl), 4.02 (2H, q, 7=7.1 Hz, CH2CU3), 2.97 (4H, q, 7=6.9 Hz, 
N(C//2CH3)2), 2.33 (2H, t, 7=7.5 Hz, CCH2), 2.20 (2H, t, 7=7.6 Hz, C //2COOEt), 1.56 (2H, 
m, Ci/2CH2COOEt), 1.44 (2H, m, CCH2CH2), 1.29 (2H, m, CCH2CH2CH2), 1.15 (3H, t, 
7=7.1 Hz, CH2CH3), 0.75 (6 H, t, 7=7.0 Hz, N(CH2C //3)2). 13C-NMR (CDC13, 75 MHz) 8  
174.05 (COOEt), 165.08 (4-pyrimidyl), 163.69 (6 -pyrimidyl), 155.45 (2-pyrimidyl), 138.07 
(1-aryl), 128.91 (3, 5-aryl), 128.80 (2, 6 -aryl), 128.01 (4-aryl), 95.11 (5-pyrimidyl), 60.06 
(CH2CH3), 44.60 (N(CH2CH3)2), 34.38 (CH2COOEt), 29.14 (CCH2CH2CH2), 27.89 
(CHCH2CH2), 24.89 (CH2CH2COOEt), 23.05 (CCH2), 14.19 (CH2CH3), 12.37
(N(CH2CH3)2). LRMS (El) m/z 401 (M+, 2 %), 291 (27 %), 171 (59 %), 125 (100 %). 
HRMS calcd for C22H3iN3O4401.23144. Found: 401.23108.
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6-(2-(Diethylamino)-4-hydroxy-6-oxo-l-phenyl-l,6-dihydropyrimidm-5-yl)-7V- 
hydroxyhexanamide (155)
To a solution of ethyl 6-(2-(diethylamino)-4-hydroxy-6-oxo-l -phenyl-1,6- 
dihydropyrimidin-5-yl)hexanoate (202) (250 mg, 0.62 mmol) in tetrahydrofuran ( 6  mL) was 
added hydroxylamine (0.41 mL of a 50 % aqueous solution, 6.23 mmol) followed by
min then evaporated and water (20 mL) added. The solution was neutralised with 1 M HC1 
and the aqueous phase extracted with ethyl acetate (4 x 20 mL). The combined organics 
were dried (Na2S0 4 ) and evaporated to leave an orange oil. The crude product was purified 
by column chromatography (ethyl acetate) to give the title compound (124 mg, 51 %) as an 
orange oil; IR (cm 1) 3192, 2932, 1616, 1522, 1202, 708. *H-NMR (CD3OD, 300 MHz) 6
7=7.5, 15.0 Hz, C//2CH2CG), 1.40 (4H, m, C //2CH2CH2CH2CO, C //2CH2CH2CO), 0.80 
(6 H, t, 7= 7.0 Hz, N(CH2C //3)2); i3C-NMR (CD3OD, 75 MHz) 6  173.15 (4-pyrimidyl), 
167.68 (CONHOH), 167.22 (6 -pyrimidyl), 160.00 (2-pyrimidyl), 139.88 (1-aryl), 130.28 (3, 
5-aryl), 130.21 (2, 6 -aryl), 129.33 (4-aryl), 95.84 (5-pyrimidyl), 45.96 (N(CH2CH3)2), 33.74 
(CH2CO), 30.00 (CH2CH2CH2CO), 29.03 (CH2CH2CH2CH2CO), 26.65 (CH2CH2CO),
23.94 (CCH2), 12.88 (N(CH2CH3)2). LRMS (Cl) m/z 411 (M+Na, 100 %), 389 (M+H, 65 
%), 321 (17 %), 192 (70 %). HRMS calcd for C2oH28N40 4 (M+H) 389.21833, found 
389.21984.
Bis(2,4,6-trichlorophenyl) malonate (198)15
o
NHOH
dropwise addition of 1 M methanolic KOH (1.87 mL). The yellow solution was stirred for 5
7.46 (3H, m, 3, 5-aryl, 4-aryl), 7.27 (2H, d, 7=7.1 Hz, 2, 6 -aryl), 3.08 (4H, q, 7= 7.0 Hz, 
N (C //2CH3)2), 2.36 (2H, t, 7=7.5 Hz, CH2CO), 2.07 (2H, t, 7=7.4 Hz, CCH2), 1.62 (2H, td,
ci ci
A mixture of malonic acid (2.0 g, 19.22 mmol) and 2,4,6-trichlorophenol (7.59 g, 38.44 
mmol) in phosphorus oxychloride (7.66 g, 49.97 mmol) was heated to 100 °C for 2.5 h. The
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reaction was then allowed to cool to room temperature and water (50 mL) added slowly. 
The off-white precipitate was filtered and suspended in a saturated aqueous sodium 
hydrogen carbonate solution (20 mL). After stirring for 1 h, the solid was collected by 
filtration, washed with water (3 x 20 mL), dried and recrystallised from ethyl acetate- 
petroleum ether (40 - 60) to give the title compound (6.81 g, 77 %), mp 152-155 °C (lit. 15 
154-156 °C); ‘H-NMR (CDC13, 300 MHz) 5 7.40 (4H, s, Ar), 4.06 (2H, s, CH2); 13C-NMR 
(CDC13, 75 MHz) 5 161.48 (COO), 142.38 (1-aryl), 132.72 (4-aryl), 129.50 (2, 6 -aryl),
128.76 (3, 5-aryl), 39.72 (CH2). LRMS (CI) m/z 463 (46 %), 265 (98 %), 197 (100 %).
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